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Abstract
Spinal cord injury in adult mammals commonly leads to the permanent loss of 
motor and sensory function in regions of the body below the level of injury. 
The inability of the central nervous system to regenerate is, in part, due to the 
presence of growth-inhibitory agents surrounding the lesion site. This thesis 
presents a previously unreported, inhibitory interaction between ephrinB2 
expressed on reactive astrocytes and the EphA4 receptor present on lesioned 
corticospinal tract axons. This interaction appears to mediate the unusually 
large retraction of the corticospinal tract away from spinal cord injury sites. An 
attempt to interfere with this interaction by implanting a cell line secreting the 
ephrinA5 receptor binding domain is reported. While this approach induced 
improvements in regenerative sprouting from the corticospinal tract, 
complications with immune rejection and cell proliferation stopped further 
investigation. A second intervention using a small peptide with high affinity 
and specificity for the EphA4 receptor is also reported. Intrathecal infusion of 
this peptide for 14 or 28 days after injury reversed the retraction of the 
corticospinal tract and induced improvements in regenerative sprouting from 
corticospinal and rubrospinal tracts following dorsal or lateral white matter 
transection injuries. Sprouts were seen to migrate long distances, often to the 
astrocyte margin of the lesion cavity. Astrocyte behaviour following injury was 
also altered with the formation of astrocytic ‘bridges’ into the lesion cavity 
along which regenerating axons grew. Functional recovery was also 
enhanced with improvements in the paw reaching assay within 10 days of a 
unilateral dorsal column lesion with a 30% recovery of function at 28 days 
post-operation. The simplicity of this intervention and direct translation to 
human application make it a promising candidate for use in combinatorial 
approaches to human spinal cord injury treatment.
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Chapter I
Introduction
Time Line of Spinal Cord Injury Development 
Acute Phase
The initial mechanical insult of a spinal cord injury (SCI) commonly spares the 
peripheral white matter with a propensity for damage to the grey matter. The 
most likely explanation for this phenomenon is the greater vascularisation of 
the grey matter as well as its inherently softer consistency1. Within minutes of 
injury, the central grey matter microvasculature begins to develop scattered 
punctuate haemorrhages with localised oedema and serum and erythrocyte 
extravasation. This develops rostrally and caudally over the following eight 
hours through much of the grey matter and to a limited extent into the white 
matter2 with anterior structures presenting changes first. With time this 
induces haemorrhagic necrosis in these areas that affects both neurons and 
glial cells to a similar extent and with a similar time scale2. The extent of 
haemorrhagic necrosis that develops appears to correlate closely with the 
severity of the injury3 and anterior spinal artery damage is common at later 
time points. Typical observations of necrotic tissue include cellular atrophy, 
nuclear disorganisation, granulation of chromatin and disorganisation of the 
endoplasmic reticulae. Under these conditions, estimates of the timescale of 
irreversible damage to neural tissue following injury suggest that white matter 
may survive up to 72 hours following injury whereas the more susceptible grey 
matter is likely to be unrecoverable within an hour.
Sub-Acute Phase
This phase, also referred to as secondary injury, is typified by recruitment and 
invasion of cells into the lesion vicinity as well as reactive responses to injury 
by surviving cells. The main phenotypic change common to most CNS (central 
nervous system) injuries is reactive gliosis, comprising microglia and astroglia. 
However, while the pathophysiology of spinal cord injury develops relatively 
predictably over a period of weeks to months, different injury types do evolve 
distinctly and involve a wide range of cell types and signalling mechanisms.
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The progression of secondary injury leads to expansion of the initial damage 
and hence incomplete lesions may often develop such that they are 
functionally equivalent to a transection4.
Blood Flow Changes, Ischaemia
Injury to vasomotor output pathways commonly induces neurogenic shock 
through the loss of vasoregulation. Clinically this is observed in the form of 
bradycardia and hypotension. This vasospasm, combined with the primary 
insult damage to the microcirculation and other complications such as 
intravascular thrombosis, leads to the formation of hypoxic and ischaemic 
conditions in the injured cord. Furthermore, release of cytokines, serotonin, 
endogenous opioids and platelet-activating factor (PAF) in the secondary 
phase of injury may also induce vasoconstriction and hence limit perfusion. 
This hypoperfusion of the grey matter subsequent to injury is a common 
occurrence and probably expands to the white matter also, although some 
studies suggest that white matter may be more tolerant of the hypoxic and 
ischaemic consequences5. Ischaemic conditions develop rapidly and 
contribute to the formation of a depressed metabolic state relying mostly on 
anaerobic respiration for the first few hours post-injury. The uncoupling of 
cellular metabolism through free radical damage and sodium/calcium overload 
that occurs after injury (discussed below) is likely to combine with the 
ischaemic state of the tissue to induce this metabolic depression. 
Mitochondrial function, already diminished through secondary hypoxic and 
ischaemic damage, is further impaired by this build-up of intracellular calcium. 
However, a semblance of metabolic recovery occurs within 24 hours in 
surviving tissue6.
The accumulation of lactate and other acidic metabolites during the ischaemic 
period has been proposed to reduce perivascular pH and hence induce 
hyperaemia7. As is typical for any ischaemia-reperfusion injury, oxygen- 
derived free radical generation in excess of the cellular antioxidant capacity 
occurs in the form of superoxide, nitric oxide, etc. These high-energy oxidants 
place oxidative stress on the injured nervous tissue and induce the oxidation 
of cellular components such as proteins and lipids. Action on mitochondrial
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and metabolic enzymes, as well as ion channels and lipid peroxidation all 
contribute to secondary damage and other forms of secondary injury such as 
apoptosis and excitotoxicity.
Excitotoxicity
Accumulation of excitatory neurotransmitters induces damage to the injured 
cord8 and the release of glutamate and aspartate occurs within minutes of 
injury9,10. Much research has focussed on the role of glutamate in this context 
and glutamate-induced excitotoxicity appears to play a central role in the 
secondary ischaemic phase of CNS injury11. Activation of NMDA (N-methyl-D- 
aspartate) and AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-propionate- 
kainate) receptors leads to the accumulation of sodium within neural cells with 
subsequent development into calcium overload through the Na+-Ca2+ 
exchanger. Sodium overload within the cell induces cytotoxic oedema and 
acidosis which is exacerbated by inactivation of the Na+-K+ ATPase by 
reactive oxygen species. Calcium-dependent enzymes such as calpains, 
cyclooxygenase and phospholipase A2 (PLA2) degrade structural components 
of the cell such as neurofilaments and also axon-myelin proteins. Calcium- 
dependent lipoxygenase, cyclooxygenase and lipase also induce the 
production of cytokines such as prostaglandins, leukotrienes and 
thromboxanes. As well as their role in disruption of blood flow secondary to 
injury and formation of reactive lipid species, these cytokines are known to 
mediate astrocyte reactivity and the formation of the glial scar12.
Free Fatty Acid Release and Free Radical Formation 
Excessive activation of calcium-dependent phospholipases leads to hydrolysis 
of phospholipids and free fatty acid (FFA) release. FFA accumulation occurs 
rapidly after injury and also in a later phase between four and 24 hours that 
mirrors metabolic depression13. The severity of tissue damage apparent in the 
stable long-term injury correlates well with the extent of FFA build-up that 
occurs during secondary injury, highlighting the importance of these mediators 
of secondary damage. FFA metabolism leads to the formation of 
thromboxanes and other cytokines released from arachindonic acid, as well
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as PAF derived from activated PLA2, that will contribute to diminished local 
blood flow and inflammation.
Numerous components of the secondary phase of injury contribute to the 
formation of free radicals. Metabolism of arachindonic acid by cyclooxygenase 
can lead to free radical release. Invading cytotoxic neutrophils release oxygen 
free radicals to kill target cells and the excessive release of ROS (reactive 
oxygen species) and the high numbers of neutrophils within the lesion area 
leads to free radical levels beyond the ability of surviving tissue to cope. 
Furthermore, calcium overload induces the formation of free radical species 
as do glutamate excitotoxicity, inflammation and ischemia, and catecholamine 
autoxidation. Under less pathological conditions endogenous defence 
mechanisms such as anti-oxidants, superoxide dismutase and peroxidases 
sequester and inactivate ROS. However, the diminished viability of large 
quantities of spared tissue in the secondary phase of injury, combined with 
the high levels of free radicals means that free radical-mediated cell death is 
common. Furthermore, sequestration of iron to prevent the propagation of 
oxygen and lipid free radical formation is impaired as the ready availability of 
haemoglobin following haemorrhage provides a source of iron to overcome 
cellular defences.
Electrolyte Balance
As discussed, the initial primary insult results in local rupture of the 
vasculature and blood-brain barrier that induces radially spreading vasogenic 
oedema that is likely to imbalance the precise electrolytic homeostasis of the 
CNS tissue for at least the first week after injury. Disruption to the electrolyte 
balance is one leading candidate for the development of spinal shock 
following injury. Spinal shock occurs transiently following damage to the spinal 
cord with flaccid paralysis below the level of the damage and a loss of stretch 
and flexor reflexes. Loss of impulse conduction in intact fibres in spinal shock 
is common and rapid accumulation of intra-axonal calcium14 and extra-cellular 
potassium15 would be expected to interfere with normal conduction. 
Intracellular calcium accumulation might deregulate sodium and potassium 
electrochemical gradients. Extracellular potassium would be expected to
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induce excessive depolarisation of surviving fibres and neurons hence 
diminishing their function15.
Inflammation
The inflammatory response to SCI occurs rapidly (within hours) and develops 
over days2. Inflammatory cell invasion commences with polymorphonuclear 
granulocytes and this is followed by infiltration of monocytes and 
macrophages with a phagocytic role. At later time points, a minor influx of 
lymphocytes has also been observed.
The leukocyte response following injury initially involves the invasion of 
neutrophils that release lytic enzymes, potentially inducing secondary damage 
to surviving neuronal and circulatory tissue16. These neutrophils, whose 
primary role is anti-bacterial, still invade lesions (experimental or clinical) that 
are closed, sterile wounds. Subsequent recruitment of macrophages leads to 
large-scale phagocytosis of damaged tissue. The microglial response is 
graded in a well-controlled manner to the extent of injury and cellular 
regulation appears to be relatively precise as only moderate invasion of 
healthy, non-degenerative tissue is apparent2. Microglial activation involves 
upregulation of major histocompatibility complex class I and II antigens (MHCI 
and II) and the activated macrophage marker ED1 as well as an increase in 
the number of processes. Full transformation into phagocytic brain 
macrophages can occur with associated cytotoxic activity, however it appears 
that these cells attack healthy as well as necrotic tissue and contribute to 
inflammatory damage. Macrophage and neutrophil overreaction to injury 
results in destruction of spared tissue through release of granule components 
and formation of oxygen free radicals. These two immune system agents are 
proposed to induce the rapid demyelination of spared axons seen ~24hrs after 
injury16. Oligodendrocyte lysis through secretion of tumour necrosis factor-a 
(TNFa) and nitric oxide (NO) production is a likely mediator of this.
The role of the immune system in the secondary phase of spinal cord injury is 
controversial with components proposed to be both beneficial and detrimental 
to recovery17. Macrophages and microglia highlight the duality of the role the
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immune system can play following injury to neural tissue. Further to their 
negative influence on the recovery process, macrophages have been shown 
to secrete a wide range of pro-recovery molecules that contribute to the 
destruction of myelin, aid tissue repair, stimulate Schwann cell proliferation 
and promote tissue homeostasis. The massive influx of macrophages to the 
distal stump of severed PNS (peripheral nervous system) axons is credited 
with the rapid clearance of myelin debris within days and subsequent 
regeneration. Poor macrophage recruitment in the CNS is likely to blame for 
persistence of myelin debris for months after injury. It should be noted 
however that other work suggests that the Schwann cell-derived myelin 
sheaths of the PNS are more amenable to macrophage degradation than 
oligodendrocyte myelin in the CNS18.
Glial Cells
Following CNS injury glial cells play a variety of roles, positive and negative. 
Some secrete neurotrophic factors that can modulate regenerative sprouting 
either positively or negatively19. Others that have a phagocytic role play a 
detrimental role as either oxidative or enzymatic functions overreact to the 
injury, as discussed above. In many cases the homeostatic role of glial cells 
often becomes uncoupled following injury facilitating the excitotoxic and 
acidosis processes.
Following injury astrocytes typically become hypertrophic and upregulate the 
expression of intermediate filament proteins such as GFAP (glial fibrillary 
acidic protein), nestin and vimentin within hours. The extent of astrocyte 
reactivity is remarkable with a gradient of GFAP expression visible rostral and 
caudal to the injury over millimetres in the adult rat, while nestin and vimentin 
appear localised to the lesion margin. In addition to the hypertrophic 
response, glial cell oxidative and lysosomal activity is increased as well as the 
production of inhibitory extracellular matrix20 (ECM). Limited division of 
astrocytes occurs within the first few days after injury often restricted to the 
margin of the lesion site. However, ablating these mitotic astrocytes21 has 
been shown to diminish repair of the blood brain barrier (BBB) leaving the 
spinal cord without effective homeostasis or protection leading to extensive
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inflammation and degeneration21. The BBB is permeable for as long as two 
weeks following spinal cord injury and extensive scarring is observed in those 
areas where the BBB is most heavily damaged as reactive astrocytes work to 
restore it.
Roughly a week following injury a flexible intermixed aggregation of cells 
develops at the lesion margin, comprising reactive astrocytes, meningeal cells 
and endoneural tissue. Interactions between meningeal cells and astrocytes 
appear to regulate the formation of the glial scar and the new glial limitans 
and this interaction appears to be ephrin mediated, as discussed below. 
Injuries that do not damage the dural layers significantly, and hence do not 
have a meningeal cell component, develop a scar without these interactions. 
Reactive astrocytes around the lesion penumbra form the bulk of the glial 
scar22 and begin to develop connexin-43-based junctional complexes similar 
to those found in the tightly-knit BBB. The development of the glial scar 
begins around one week after injury, similar in time-scale to the reformation of 
the BBB, and this astrocyte response continues for weeks after injury. As 
discussed later, cytokine signalling through transactivation of the EphA4 
receptor appears to mediate this astroglial response to injury12. The close 
association between scar astrocytes develops into a mechanically strong 
lining, probably developed to permit the reformation of the glial limitans and to 
exclude invading meningeal cells such as fibroblasts. Invading meningeal 
fibroblasts in both brain and spinal cord injuries23,24 proliferate rapidly in the 
basic fibroblast growth factor (bFGF)-rich spinal cord environment25. These 
invading cells often divide extensively hence a mechanically strong barrier is 
required to maintain the integrity of surviving neural tissue. However, the tight 
interaction between reactive astrocytes at the lesion penumbra and their 
expression of anti-regenerative agents presents a formidable barrier to 
regeneration. The astrocyte response to CNS injury is well conserved 
throughout evolution and hence must provide some benefit to the animal. 
However, the procreative capacity of any animal following severe spinal cord 
injury is likely to be minimal; hence the astrocyte response has evolved to 
ensure survival of an animal following a minor CNS injury where such a 
response can be inherited. Preventing massive secondary inflammation and
14
damage following minor injury is evolutionarily preferable to permitting 
regeneration of lesioned axons through more extensive areas of damage.
With time the glial scar stabilises and segregation of astrocytes and fibroblasts 
occurs with deposition of a new basal lamina that develops into the reformed 
glial limitans26. Deposition of new ECM by invading cells such as Schwann 
cells, macrophages and fibroblasts will also contribute to the development of 
the cavity and scar. Laminin, collagen and fibronectin are all produced and 
may contribute to wound closing, reformation of the basal lamina or providing 
a permissive environment for regeneration.
Apoptosis and Axons
Apoptosis in the secondary phase of injury results from free radical damage, 
excitotoxicity, cytokine exposure and inflammation; all extensive following 
spinal cord damage. Neuronal apoptosis leads to a significant reduction in 
functional outcome27, while microglial apoptosis has been suggested to 
contribute to the inflammatory component of secondary injury28. 
Demyelination, already in progress through immune cell activity, is increased 
by apoptosis within the oligodendrocyte population29.
A rim of spared peripheral white matter is common in many patients once the 
lesion site has stabilised, however these patients often score as suffering a 
complete spinal cord transection injury in functional and sensory tests. In 
some cases the tracts that are spared do not mediate motor or sensory 
function, but in many others demyelination or necrosis of spared fibres and 
supporting cells appears to be responsible. Demyelination begins within 24 
hours of injury and continues throughout the injury process, completely baring 
some axons within a week. Demyelination exacerbates the post-injury loss of 
function significantly as spared axons with little or no myelin are typically 
unable to conduct or at best will be unstable in their conduction properties. 
Haemorrhagic necrosis induces separation of the axon from its myelin sheath 
with axonal swelling30 that will further disrupt function.
15
Late Phase
Despite differing subacute and late stages of development, most spinal cord 
injuries develop into similar stable lesions with cavitation walled off by a scar 
and the Wallerian degeneration of white matter distal to the lesion. Following 
the immediate inflammatory phase, macrophages migrate away from the 
centre of the lesion to leave a cerebrospinal fluid (CSF)-filled cavity that is 
surrounded by scar tissue. In some cases slow development of syringomyelia 
in the months following injury can lead to the formation of an extensive cavity 
that induces further functional loss.
The Neuronal Response to CNS Injury
Unlike the perinatal response to injury, where many injured neurons die, adult 
spinal and supraspinal neurons survive axotomy as long as the injury is not 
too proximal. In some cases an axotomised neuron will die through lack of 
target-derived neurotrophic factors31, but this is often dependent on the 
neuronal population in question. Similarly the intrinsic ability of neurons to 
regenerate varies significantly between tracts32. The neurons of the 
corticospinal and rubrospinal tracts, often studied for their obvious functional 
role, ease of access, established anatomy and simple labelling, have both 
been shown to survive for significant periods after injury, despite neuronal 
atrophy33.
The initial intrinsic response to CNS injury is encouraging with upregulation of 
regeneration-associated genes and moderate sprouting of lesioned 
processes. Sprouts from lesioned axons have been seen in many animal 
models of CNS injury and generally follow a similar morphology and time 
frame of behaviour. Thin, unmyelinated sprouts are put out from lesioned 
axon stumps for short distances (often less than 1 mm34) and persist for a few 
weeks35. However, these sprouts do not elongate and within a week 
regeneration-associated genes have been downregulated and axotomised 
neurons become atrophied31. Subsequent to this period of sprouting, sprout 
regression occurs (termed die-back) in nearly all cases such that only minimal 
functional recovery typically occurs36, 37. The extent of this retraction has not 
been conclusively defined34, 38 but retraction from the initial mechanical
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disruption of over 2mm is standard for the corticospinal tract (CST). During 
and subsequent to retraction, sprouts and axonal stumps develop retraction 
bulbs (also termed termination bulbs or end bulbs) with a highly characteristic 
swollen morphology37 -  large swellings similar to growth cones filled with 
mitochondria, neurofilaments and other organelles39. While these structures 
have traditionally been viewed as stagnant attempts at sprouting that hold 
little regenerative potential, recent evidence suggests that they are 
remarkably flexible and have been shown to respond to favourable changes in 
their environment with impressive regeneration despite long periods of 
stability40. Furthermore, damage to spinal roots permits the slow invasion of 
the lesion site by Schwann cells and these have been found to secrete 
neurotrophic factors and permit the formation of myelinated sprouts from 
endbulbs in chronic injuries over a period of years36,41.
After PNS lesion, rapid degeneration of the distal stump occurs with myelin 
breakdown. Local proliferation of Schwann cells occurs concomitantly with 
synthesis of growth-promoting substrates and neurotrophic factors. 
Subsequently sensory and motor fibres regenerate through the cleared lesion 
site, often close to their previous paths, and grow for long distances, usually 
resulting in target reinnervation with good specificity. Over a longer period 
Schwann cells remyelinate the newly grown axons to restore near-normal 
conduction. While extrinsic factors such as neurotrophic support and the 
presence of scar-associated growth-inhibitors in the CNS are likely to be 
important differentiating factors (discussed below), intrinsic differences should 
not be ignored. It is important to consider that the mechanism of CNS 
regeneration, whether endogenous or treated, is likely to be different to that 
seen in the PNS as the usual substrates for PNS regeneration and 
development, such as laminin, fibronectin and collagen, are not present in 
great quantities in CNS injury. PNS regeneration is characterised by 
upregulation in tubulin and actin mRNAs (messenger ribonucleic acid) with 
downregulation in neurofilament mRNAs42,43. In contrast, the growth rate for 
CNS neurites is around ten percent of their peripheral counterparts44 and they 
appear to be neurofilament-dense, with little of the F-actin seen in other 
growth cones45. It is likely therefore that the CNS does not use the standard
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actin-filopodial approach to regeneration but may be driven by neurofilament 
polymerisation inside the growth cone. Furthermore, microtubule-associated 
proteins, required for stable axon growth, may also contribute to the 
differences in regeneration rate and capacity: isoforms expressed in the adult 
are different to those in development and expression does not revert following 
injury46.
It is a well-accepted phenomenon that embryonic and newborn CNS tissue 
regenerates significantly better than the equivalent adult tissue. Analysis of 
CST regeneration in the newborn hamster following pyramidotomy showed 
extensive plastic growth into spared tissue with subsequent growth down 
distal spinal cord47. While targetting of regenerating axons was imperfect, 
functional improvements were readily apparent47. Subsequent work identified 
late developing axons to be a major constituent of this recovery process, but 
the presence of regenerating axons was also confirmed48. While embryonic 
neurons implanted into adult CNS tissues can put forward processes that can 
successfully navigate the inhibitory glial environment, adult processes are 
unable to do so49. The ability of embryonic neurons to modify their expression 
of integrins such that they can navigate the adult spinal cord ECM appears to 
be the differentiating factor. Adult neurons have lost this capacity50 and hence 
the mature CNS appears to be more sensitive to growth-inhibitory 
mediators51. Occasional reports have identified some moderately successful 
regenerative sprouting in the untreated CST34 but no progress into the lesion 
site has ever been reported in the untreated adult animal.
Regeneration of long myelinated tracts in the adult mammal is limited to only a 
few specific tracts52,53. However, significant functional recovery can be made 
following stroke, partial SCI and other CNS injuries. Plasticity of the remaining 
nervous structure is probably responsible for this long-term functional 
improvement and extensive reorganisation has been observed in all CNS 
regions associated with spinal cord injuries54. This plasticity usually takes the 
form of activation of ‘silent’ pathways, collateral sprouting from injured or 
uninjured pathways and reorganisation of neural networks and pattern 
generators. Silent synapses, often inhibited by GABAergic (gamma-
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aminobutyric acid) interneurons, become active shortly after injury and the 
presence of numerous vacated post-synaptic densities stimulates sprouting of 
local spared fibres to fill these sites. However, in a similar manner to the ability 
of tracts to regenerate, the plasticity response diminishes with age but even in 
humans over eighty years of age recovery from stroke is still readily apparent.
Gene Expression
Some studies comparing recovery from injury in the PNS and CNS indicate 
that the main differentiating factor is the presence of the inhibitory glial 
environment within the CNS55. This was initially highlighted by the pioneer 
peripheral nerve transplant experiments where brainstem axons were seen to 
regenerate into a peripheral nerve implant in the spinal cord but not beyond 
it56,57. However, subsequent experiments by Richardson58 demonstrated that 
the cell body response was also critical. DRG (dorsal root ganglion) neuron 
central processes were only able to regenerate into peripheral nerve grafts in 
the dorsal columns of the spinal cord if a pre-conditioning lesion of their 
peripheral processes had been performed. The cell body response elicited by 
this pre-conditioning lesion involves expression of a range of regeneration- 
associated genes59 (RAGs). These studies have been extended and more 
recently central DRG processes have been observed to regenerate strongly 
following dorsal column injury subsequent to a preconditioning lesion60. This 
result, combined with similar studies in the rat optic nerve61, have shown that 
the intrinsic growth state of the neuron is as important as the extrinsic 
microenvironment to the extent that strong neurotrophic support may facilitate 
regeneration through growth-inhibitory sites.
The genetic cell body response to injury of PNS neurons with central 
processes comprises upregulation of a range of RAGs encompassing ion 
channels, trophic factors and their receptors, neuropeptides, cytoskeletal and 
cytoskeletal regulatory proteins, axon guidance and cell adhesion mediators, 
cytokines and their receptors and transcription factors. Transgenic 
approaches to determine the role of these RAGs individually have shed some 
light on the topic suggesting that proteins such as integrin a-7 receptors62 and 
galanin63 are important in regeneration. However, as these studies are not in
19
conditional or targetted transgenic animals, it is hard to determine whether 
changes in extrinsic (i.e. non-neuronal cell) expression may also be 
influencing the regeneration phenotype. For example, knocking out a 
cytoskeletal regulating protein could readily alter microglial or astroglial 
behaviour and hence give the impression of diminished regeneration 
attributed to the absence of a neuronal RAG.
Re-expression of developmental proteins is a common response to CNS 
injury with numerous immediate-early genes expressed64. Different neurons 
show different transcriptional responses to injury and different primary and 
secondary injury pathologies induce varying expression patterns as well. 
However, a number of genes are commonly upregulated in the immediate- 
early response. A comparison between gene expression changes following 
spinal cord injury and sciatic nerve injury in mice65 identified a range of 
interesting genes that may be responsible for the remarkable difference in 
regenerative capacity of these two tissues. Immediate-early and heat shock 
proteins (HSPs) are well represented in this population and probably act to 
stabilise surviving neural tissue. Growth-associated protein of 43kDa (GAP- 
4366) and CAP-2367 show dramatic upregulation following PNS injury and 
have received much attention68, 69. GAP-43 is expressed in developing 
neuronal growth cones and regenerating axons70,71 and has been correlated 
with the rapid growth cone progress that initiates regeneration72. GAP-43 
mediates the interaction between membrane rafts and actin73 and appears to 
promote sprouting of the axon terminal through directed mobilisation of actin, 
a mechanism that appears to be shared by CAP-2373. The gene expression 
pattern of CNS neurons following injury differs significantly from their PNS 
counterparts, not just in the individual proteins expressed but, as mentioned 
previously, in the duration and degree of expression. For instance, while CNS 
neuron expression of GAP-43 correlates with the ability of transected fibres to 
successfully sprout into peripheral nerve grafts, this expression is typically 
transient and only occurs in descending tracts when the injury is sufficiently 
proximal74,75. Proximal injuries also induce the expression of a wider range of 
RAGs in CNS neurons; in addition to GAP-43, L1 and c-jun are also
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upregulated under these conditions76 and are likely to be at least partially 
responsible for the regenerative response seen after proximal injury.
Targetted overexpression of RAGs has revealed an interesting requirement 
for synergy between these proteins for successful regeneration. Attempts to 
promote regeneration into peripheral nerve grafts in the thalamic77 and 
Purkinje cell78 systems by overexpression of GAP-43 resulted in no 
improvement. However, co-overexpression of CAP-23 and GAP-43 increased 
sprouting of dorsal column axons into peripheral nerve grafts79 but still 
significantly less than that seen with preconditioning lesions suggesting that a 
more suitable target for manipulation may be an upstream expression 
regulator capable of turning on the whole battery of RAGs seen following 
preconditioning PNS lesions. This conclusion fits well with analysis of the 
intrinsic regenerative capacity of CNS neurons when compared to their RAG 
expression80: neurons expressing more than one RAG following injury 
demonstrate better regeneration. Hence, synergy between the RAGs appears 
to be necessary for effective regeneration and this requirement for more than 
one growth-associated gene for successful regeneration is common.
Neurotrophic Deficiency
Changes in the expression of neurotrophins and their receptors, as well as 
atypical secretion of neurotrophins from endogenous and invading/recruited 
cells, play a significant role in the post-injury survival and response of most 
cells affected by injury. Considering the differences in intrinsic CNS and PNS 
regeneration it is unsurprising that neurotrophic factors and their receptors are 
also differentially regulated and expressed in these tissues following injury. 
Target- or glial cell-derived neurotrophic support following PNS injury is 
required for maintenance of the neuron -  administering anti-NGF (nerve 
growth factor) antibodies leads to PNS neuron atrophy where usually none 
occurs81. A similar phenomenon appears to occur in the CNS as the initial 
rapid cell death of retinal ganglion cells following injury can be reversed by the 
application of neurotrophic factors82. Hence the observed atrophy and cell 
death of CNS neurons following axotomy is likely to be due to insufficient 
autocrine or paracrine neurotrophic support. The downregulation in
21
expression of neurotrophin and growth factor receptors in adult neurons, and 
the lack of re-expression following injury is also likely to exacerbate the loss of 
regenerative capacity. However, upregulation in the Trk family of neurotrophin 
receptors does occur. Penetrating lesions to adult rat spinal cord induce 
upregulation in the glial expression of TrkB receptor mRNA and that is 
localised to the glial scar33. Lateral column injuries have shown TrkC 
upregulation in transected fibres84 while contusion injuries in the rat induce 
TrkA upregulation and the expression of bFGF25, 85,86. Expression of bFGF 
appears to be localised to motor and grey matter neurons as well as peri- 
lesion astrocytes. However, a lack of expression of appropriate receptors for 
available neurotrophins may be the critical factor -  rubrospinal axons show a 
downregulation in the FGF receptor FGFR-1 after axotomy and signalling 
through this receptor may be required for regenerative growth87.
The corticospinal tract illustrates this neurotrophic dependency well: lesion of 
the CST at the level of the internal capsule leads to death of over half of the 
corticospinal neurons88. However, this response can be rescued by 
exogenous BDNF (brain-derived neurotrophic factor) in sufficient quantities89, 
while application of anti-BDNF antibodies exacerbates the cell death. Hence, 
the endogenous supply of BDNF following injury is sufficient to maintain the 
survival of a proportion of the BDNF-sensitive CST neuron population but not 
all of it. The complex neurotrophic requirements of CNS neurons is also likely 
to require considerable work to unravel. In the adult rat CST, quantification of 
sprouting following lesion showed a significant response to injury that was 
enhanced by NT3 (neurotrophin), unaffected by BDNF and impaired by 
NGF90. Hence, broad-range application of neurotrophic factors to encourage 
neuronal survival and regenerative outgrowth is unlikely to resolve the 
impaired CNS recovery. Implantation of embryonic rat spinal cord tissue into 
adult animal spinal cord permits good regeneration and recovery91 suggesting 
that an approach based on developmental expression of neurotrophins may 
have some merit.
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Myelin-based Inhibitors of Regeneration
In vitro neurite outgrowth is inhibited by CNS myelin and this activity appears 
to be mediated by a range of myelin-associated inhibitors92,93. Nogo, OMgp 
(Oligodendrocyte myelin glycoprotein) and MAG (Myelin Associated 
Glycoprotein) will be discussed here although other molecules are known and 
others are likely to be discovered. These proteins are expressed in the intact 
CNS94,95, where they are likely to play a role in preventing aberrant plasticity 
and sprouting, and at the site of CNS injury22,96 where they present a strong 
growth-inhibitory obstacle.
The Nogo proteins comprise three members: Nogo-A (the largest), Nogo-B 
and Nogo-C (the smallest). The common inhibitory domain, Nogo-66, induces 
growth cone collapse and neurite retraction97. Nogo-A contains a further N- 
terminal inhibitory domain that enhances its potency98 and is found in CNS 
myelin oligodendrocytes. OMgp, also known as arretin", is a GPI-linked 
(glycosylphosphatidylinositol) inhibitory extract from CNS myelin capable of 
causing growth cone collapse and inhibiting axonal regeneration100, 101. 
Recent evidence suggests an expression of OMgp by glial cells that 
contribute to nodes of Ranvier102; whether this protein is found on reactive 
astrocytes at the lesion margin is unknown. MAG is a sialic acid-binding Ig- 
family lectin that binds glycoconjugates, predominately two major axonal 
gangliosides, GD1a and GT1b103. MAG has a wide growth-inhibitory spectrum 
that includes action on adult DRG cells, cerebellar granule cells and many 
other neurons99,104. However, despite compelling in vitro data, regeneration 
studies using both MAG105 and OMgp102 knock-out mice show no 
improvement in regeneration.
NgR1 mediates signalling for all three of these molecules and acts as a co­
receptor with LINGO-1 and either p75 or TROY106. The Nogo receptor 
homologues NgR2 and NgR3 may also play a role in inhibitory signalling - 
NgR2 binds MAG in a sialic acid-dependent manner and acts as a functional 
receptor for that protein107.
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Knock-out of Nogo isoforms in mice have resulted in mixed regenerative 
responses following injury108. Nogo-A'7' mice show a slight improvement in 
CST sprouting after injury109 while Nogo-A'/'B'7' mice demonstrated no 
regeneration of the hemisected CST110 nor impressive anatomical and 
functional recovery111. Genetic background or compensatory expression could 
account for these differences, although further investigation is required to 
resolve the disparity. One safe conclusion is that Nogo-A cannot be the only 
mediator of growth inhibition in CNS injury. The best evidence to date for the 
role of Nogo as a key growth-inhibitory mediator is derived from experiments 
using antibodies that neutralise Nogo signalling112, 113, notably IN-1. 
Expression of NgR1 and Nogo-A on corticospinal neurons and axons make 
the CST an obvious target for regenerative studies. IN-1 administration to 
midthoracic dorsal column injuries in young rats114 led to remarkable CST 
regeneration beyond the lesion site. However, the presence of the 
regenerating axons in the normal anatomical location for the CST and the 
impressive regeneration seen in control animals (2.5mm beyond the lesion 
site) suggests that some fibres recorded as regenerating may have been 
spared. A separate study on IN-1 treatment of adult rat pyramidotomies 
demonstrated increased regeneration (2mm) and in this study regenerated 
axons were found everywhere but the degenerating CST115. Other 
approaches using anti-Nogo antibodies have found similar results116. 
Functional recovery has also been demonstrated following partial lesions of 
the cord117, 118 but acute administration is required for full anatomical and 
functional benefits -  an eight week delay in treatment significantly diminishes 
the regenerative response119.
As discussed previously, combinatorial approaches combining IN-1 antibodies 
with neurotrophic support90 or embryonic spinal cord implants34 led to 
enhancement of the regenerative response above that observed for IN-1 
alone. Further evidence that neutralisation of Nogo alone does not lead to 
successful regeneration comes from studies of more severe injuries involving 
extensive scarring or cyst formation116,118. The presence of numerous other
q c  120  121inhibitors of regeneration at these lesions is the likely explanation 1 *u’ .
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The sum of current literature on Nogo neutralisation suggests that the 
functional improvements seen following injury stem predominately from 
sprouting and plasticity of injured122,123 and spared122 fibres, although some 
regeneration of CST fibres into spared tissue may also contribute to motor 
functions. The most telling experiment to highlight this demonstrated that 
rostral relesioning of the corticospinal tract after functional recovery was 
induced by IN-1 administration had no significant effect on the recovered 
function124. Hence, sprouting from fibres very rostral to the primary injury into 
spinal cord tissue untouched by the secondary injury, must have mediated the 
functional recovery. The expression of Nogo-A on regenerating CST and 
other cell bodies and access to the cell body by neutralising antibodies 
suggests that plasticity may be induced by an antibody-mediated cell body 
response. However, regardless of the source of regeneration, neutralisation of 
Nogo appears to be strongly pro-regenerative. Primate experiments125 have 
found similar functional recovery to that seen in rodent studies which is very 
encouraging for clinical initiatives.
Endogenous antibodies to myelin can be generated by immunisation with 
CNS myelin preparations. Pre-immunised animals show improved CST 
regeneration following injury126 and the presence of regenerating axons in the 
dorsal white matter suggests that myelin breakdown following injury may be 
more rapid, similar to PNS regeneration. Similar techniques involving 
immunisation against MAG and Nogo-66127 or AminoNogo, Nogo-66, MAG 
and tenascin-R128 have reported improved regeneration but not to the extent 
seen with whole-myelin immunisation. Knock-out experiments aimed at the 
NgR1 receptor have produced ambiguous results, suggesting either slightly 
enhanced129 or unimproved130 regeneration; neither study demonstrated CST 
regeneration however. Pharmacological approaches using the Nogo-66 
blocking peptide NEP1-40 have shown regeneration and sprouting of 
descending spinal tracts following injury after either immediate97 or seven day 
delayed131 administration. NgRecto, the NgR1 ectodomain, also encourages 
CST regeneration and functional recovery132 but significantly more than that 
seen with NEP1-40 despite it’s wider range of pharmacological action 
(blockade of Nogo-66, MAG and OMgp activity). Interestingly these
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pharmacological studies report CST regeneration unlike the genetic 
approaches to NgR1 inactivation discussed above; compensatory changes in 
gene expression may account for this discrepancy however.
As already discussed, DRG neurons microtransplanted into the spinal cord 
white matter133 or the corpus callosum134 successfully put out growing 
processes. This occurred whether in undamaged spinal cord or white matter 
undergoing Wallerian degeneration subsequent to dorsal column injury. The 
rate of regeneration was similar to that found in peripheral nerve regeneration 
(approximately 2mm per day) despite the presence of numerous myelin- 
associated growth-inhibitory molecules. Growth stopped upon arrival at the 
chondroitin sulphate proteoglycan (CSPG)-rich lesion scar suggesting that 
scar- rather than myelin-associated inhibitory molecules may prove to be 
more potent. The lack of expression of NgR1135,136 and p75137 in many DRG 
neurons may account for part of this behaviour, however.
Other Inhibitors at the Lesion Site
Semaphorins
The semaphorin family of proteins share a conserved 500 amino acid motif 
termed the sema domain. Semaphorins are classified based on membrane 
topology (transmembrane, secreted or GPI-linked) and primary sequence. 
The vertebrate semaphorins include secreted (class 3) and membrane- 
anchored (classes 4 to 7) family members, however Sema 3A has received 
most attention in spinal cord injury to date. Recent research into other family 
members has identified strong Sema4D expression in myelin and 
upregulation by oligodendrocytes around an injury138. Sema4D is a potent 
inhibitor of DRG and cerebellar granule cell neurite outgrowth and hence is 
likely to contribute to myelin-associated inhibition. Plexins and neuropilins act 
as co-receptors for Sema3A as well as further accessory proteins such as the 
L1 adhesion molecule. Complex intracellular signalling mechanisms develop 
from many of the developmental guidance proteins and semaphorin signalling 
is no different. Currently recognised mediators of growth cone guidance 
include cyclic nucleotides, redox signalling139, kinases, Rho family guanosine 
trisphosphatases140 (GTPases) and eicosanoids141.
26
Expression of Sema3A depends on the type of damage sustained by the 
spinal cord (or any other CNS tissue). Meningeal fibroblasts express Sema3A 
and hence transection and stab wound injuries are SemaSA-positive96. 
Contusion injuries where meningeal cell invasion does not occur do not 
contain SemaSA96, 142. These injuries are still highly inhibitory however, 
suggesting that Sema3A may not be a significant growth-inhibitory mediator. 
However, regenerating ascending dorsal column axons avoid areas of 
Sema3A expression 96, suggesting further work on semaphorins in spinal cord 
injury is warranted.
Slits and Netrins
Slit and Netrin family members are pathfinding proteins that play critical roles 
in CNS development. Depending on cyclic nucleotide levels and neuron type 
either repulsion or attraction can result from Netrin signalling and midline 
expression of Netrin in mammals preserves left-right integrity of various 
nervous tracts. Adult rat and mouse Netrin-1 expression is localised to 
neurons and oligodendrocytes as well as ECM surrounding these cells143. 
Recent research indicates that Netrin-1 is strongly expressed in mouse spinal 
cord lesions144 but no regenerative studies have yet been reported. Vertebrate 
Slit proteins play a role as repulsive guidance markers for developing spinal 
cord axons145 and the retina146 through the Robo family of receptors. Slit-1 
and -3 are expressed in mouse spinal cord lesions by macrophages and/or 
meningeal fibroblasts144 and would be expected to repel regenerating axons 
from Robo-positive tracts such as the CST147. While no studies have yet to 
confirm the role of slits and Netrins in spinal cord injury, they clearly require 
further study in this context as potential mediators of growth-inhibitory 
signalling.
Scar Formation and Approaches to Overcome Scar-Associated 
Inhibition
As discussed, the glial scar begins to develop at the physical margin of the 
lesion site around a week following injury. The main components are reactive 
astrocytes as well as invading meningeal fibroblasts and endoneural tissue
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(when dural or spinal root damage has occurred, respectively). These 
astrocytes are predominately derived by migration from surviving tissue 
although limited division of astrocytes occurs within the first few days after 
injury. Meningeal fibroblasts rapidly invade both brain and spinal cord 
injuries23, 24 and proliferate in the bFGF-rich spinal cord environment25. At 
early time points oligodendrocyte precursors are also major constituents of the 
scar; the limited migration of these cells during injury suggests that the 
majority of the precursors present in the scar must be derived from 
proliferation, probably driven by the presence of FGF and PDGF (platelet- 
derived growth factor) in the lesion vicinity.
Depending on the cellular composition of the lesion margin, the interactions 
that mediate the development of the scar vary. In the case of the most 
common human injuries where dural and spinal root tissues are disrupted, 
ephrin-mediated interactions appear to contribute to cell sorting and the 
deposition of a new basal lamina that develops into the reformed glial 
limitans148. In all cases however, reactive astrocytes develop connexin-43- 
based junctional complexes and form a tightly-knit physical barrier. Not only 
does this barrier prevent any further invasion of surviving spinal cord tissue by 
fibroblasts, it restricts the migration of parencyhmal astrocytes such that the 
scar rapidly evolves into an astrocyte-free zone149. Further to the deposition of 
ECM molecules that contribute to the reformation of the blood-brain barrier, 
growth-inhibitory substrates are expressed throughout the scar -  both on cells 
and deposited in the ECM.
Hence, the lesion scar appears to prevent regeneration in three main ways:
- A physical barrier to regeneration of axons into the lesion cavity
- Preventing migration of astrocytes into the cavity
- Expression of growth-inhibitory agents
While the strength of the tight junctions between scar astrocytes is beneficial 
to repel the pressure of proliferating meningeal fibroblasts, axons are unable 
to penetrate this physical blockade. Hence, even those axons with sufficient 
regenerative capacity to overcome the numerous growth-inhibitory molecules
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surrounding the scar are unable to regenerate through it. Sprouting into 
spared white and grey matter presents navigation difficulties and successful 
growth around lesion scars is unlikely without strong neurotrophic support. 
However, the scar developed following injury to the mediobasal hypothalamus 
is permissive for growth and has few gap junctions and expresses some PSA- 
NCAM (Polysialic Acid-Neural Cell Adhesion Molecule) and laminin150. Hence 
in some cases the glial scar can be permeable to axons and permit 
regeneration. Furthermore, NGF-responsive neurons may be able to put 
forward processes onto reactive astrocytes151, 152 and neurotrophic factors 
such as NGF, bFGF and TGF-p (transforming growth factor) may, under the 
right circumstances, be able to modulate the expression of some astroglial 
growth-inhibitory proteins such as L1 and tenascin153. Hence, modification of 
the glial scar such that it becomes permissive for growth is likely to be a 
component of any successful approach to inducing regeneration.
The role of astrocytes in CNS injury is unresolved with robust evidence for 
both growth-promoting and -inhibitory roles. Approaches to diminish the 
formation of the glial scar by ablating mitotic astrocytes21 have shown 
diminished repair of the blood brain barrier leaving the spinal cord without 
effective homeostasis or protection leading to extensive inflammation and 
degeneration. Furthermore, migrating astrocytes aid wound closure and 
provide a substrate upon which other cells and axons may repopulate 
disrupted tissue and provide reinnervation133, 134. However, generic 
approaches aimed at minimising the formation of the scar and astrocyte 
gliosis have reported some improvements in regeneration. Administration of 
7p-hydroxy-cholesterol-oleate appears to improve serotonergic axon 
sprouting154 while transgenic animals without GFAP and vimentin demonstrate 
improved regeneration following injury155. Other experiments have shown that 
removing hyperplasic astrocytes with low-dose X-irradiation or ethidium 
bromide injection reduces secondary injury156 and improves functional 
recovery157, 158. Targetting the cytokines that mediate gliosis, i.e. with anti- 
TGF-p antibodies or IL-10 (interleukin) application to prevent cytokine 
synthesis, also appears to minimise the overall CNS damage159. Elegant 
implant studies by the Silver laboratory highlight the dual role played by
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astrocytes. Microtransplantation of adult DRG neurons into the spinal cord 
white matter such that no local reaction occurs permit sensory processes to 
regenerate long distances at rates of 1mm per day or more, implying that 
quiescent astrocytes are growth-supportive. Implantation into white matter of a 
spinal cord that had received a distal (caudal) lesion also results in good 
regeneration of DRG processes through oligodendrocytes, damaged myelin 
and reactive astrocytes. Hence, reactive astrocytes also appear to be growth- 
permissive. However, upon reaching the growth inhibitor-dense scar the 
processes rapidly terminated to produce typical dystrophic endbulbs133, 134. 
Hence, reactive astrocytes expressing moderate levels of growth-inhibitors 
are permissive for regeneration but, when a critical expression level is 
reached, are highly effective inhibitors of growth.
While astrocytes do express growth-promoting molecules, numerous 
experiments have highlighted the inhibitory nature of the ECM developed by 
reactive astrocytes160,161, despite the fact that it contains laminin. Expression 
of ECM proteoglycans by astrocytes in the glial scar is upregulated following 
CNS injury in adult animals120,1611162 Proteoglycans consist of a protein cord 
linked to a sulphated glycosaminoglycan (GAG) chain. Four classes of 
proteoglycan are expressed by astrocytes; heparin, dermatan, karatan and 
chondroitin sulphate proteoglycans. The CSPG family includes brevican, 
aggrecan and NG2 and these differ in their protein core as well as their side 
chain composition (reviewed by Carulli et al., 2005, Hartmann and Maurer, 
2001). Some CSPGs are neurotrophic163 while others appear to minimise 
astrogliosis and scarring164, 165, although the majority are thought to be 
growth-inhibitory and induce retraction166,167. Both the protein core168 and the 
GAG side chains are thought to be inhibitory169. CSPG expression and 
secretion appears to be a common mechanism within CNS injuries170,171 with 
CSPGs secretion by astrocytes within 24hrs and a maintained presence in the 
lesion vicinity for months120,161 ’ 162. The distribution and time-course of CSPG 
expression varies with the subtype in question120 and different cells express 
different CSPGs. Reactive astrocytes predominately express neurocan while 
NG2 and phosphacan are present on meningeal fibroblasts. Significantly, 
early mammalian embryos and cold-blooded species where effective
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regeneration occurs following central injury do not express CSPGs172, 173. 
Furthermore, in vitro hippocampal neuron cultures regenerate better on ‘scar- 
in-a-dish’ cultures from neonatal animals than on those derived from adult 
animals, with evidence that neonatal cultures are in fact supportive and 
promote growth174. Similarly, astrocyte cultures derived from adult lesioned 
optic nerve are strongly growth-inhibitory towards adult DRG regeneration in 
vitro whereas those from neonatal injuries promote outgrowth175. Adult CNS 
and PNS responses to CSPG exposure in vivo appear to be varied with 
sensory neurons capable of growing further into a proteoglycan-positive lesion 
site than motor processes176. In a similar manner to the repulsion of DRG 
processes by a CSPG-positive spinal cord scar133, central DRG processes are 
repelled from the CSPG-dense DREZ (dorsal root entry zone) following spinal 
nerve transection, even when the DREZ is free from injury177.To date, there 
are no published reports suggesting significant regeneration into a 
proteoglycan-positive spinal cord lesion site without intervention.
Application of the Proteus vulgaris enzyme chondroitinase selectively cleaves 
GAG side chains from CSPGs and hence diminishes the glycoprotein 
inhibitory activity. Regeneration of retinal ganglion cells in ‘scar-in-a-dish’ 
experiments is substantially improved by the application of chondroitinase167 
and chondroitinase has been applied to contusion injuries with significant 
reductions in CSPG immunoreactivity178 that persist for weeks179. The precise 
mechanism of chondroitinase action -  i.e. improvements in plasticity or 
regeneration -  has not been fully elucidated180. Regardless, chondroitinase 
has been found to encourage the regeneration of various ascending and 
descending spinal tracts following lesion181, 182 including spinocerebellar183 
and rubrospinal184 tract axons. Growth into peripheral nerve grafts following 
injury185 is also enhanced as well as regeneration in a range of other CNS 
injuries181. Improvements in functional recovery have also been demonstrated 
-  intrathecal chondroitinase ABC injections induced moderate functional 
recovery following dorsal column injury181 or forcep compression of the 
cord186. However, the remaining protein core and digested GAG stubs from 
chondroitinase digestion retain inhibitory activity187 and approaches to 
minimise this further show improved regeneration188.
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Approaches to Improve CNS Regeneration 
Neurotrophic Support
Most experiments aimed at neurotrophic supplementation have used the 
neurotrophin family members NGF, BDNF and NT3 as well as GDNF (glial 
cell-derived neurotrophic factor). Signalling for the neurotrophins is through 
the TrkA, B and C receptors and in some cases the p75 receptor. GDNF acts 
through the RET tyrosine kinase and an accessory subunit. Most spinal 
pathways appear to express TrkB and TrkC, motoneurons have been found to 
express RET and different subpopulations of DRG neurons express varying 
Trk receptors. In culture neurotrophins and GDNF have been shown to 
promote neurite outgrowth189,190 and to facilitate growth on inhibitory myelin 
substrates191. Convergence of signalling on RhoA is a likely mechanism of 
action for the neurotrophic ability to facilitate growth over inhibitory substrates. 
The p75 receptor is involved in transmitting both neurotrophin and myelin- 
based inhibitor signalling to induce either growth or retraction of growth cones. 
Inactivation of RhoA by neurotrophin-mediated p75 signalling prevents growth 
cone collapse and retraction mediated by myelin-induced activation of RhoA 
byP75192,193.
NGF, GDNF and various cytokines are upregulated in the PNS following 
injury194,195. These growth-promoting factors undoubtedly contribute to PNS 
recovery. Furthermore, inhibition of Jak2 (Janus kinase 2, a cytokine 
signalling mediator) prevents axon growth following preconditioning lesion196 
and leukaemia inhibitory factor (LIF) or IL-6 knock-out mice show reduced 
regeneration197,198. Sensory axons have been found to regenerate into the 
spinal cord and provide functional improvements following NGF or FGF2 
delivery via an adenoviral vector199 or intrathecal neurotrophin delivery200. 
Similarly, long regenerative sprouts from the central processes of DRG 
neurons similar to those found following a preconditioning lesion occur 
following application of NT3, NGF and GDNF200-203.
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Neurotrophic support does not just promote regeneration from severed axons 
but also appears to play a neuroprotective and cell-survival role following 
injury such that neuronal apoptosis can be counteracted by neurotrophic 
factors. Lesion of adult rat or mouse facial or sciatic nerves leads to 
motoneuron atrophy and death and this effect is counteracted by NT3, CNF 
(ciliary neurotrophic factor) and GDNF204. Various neurotrophins have been 
found to enhance motor neuron regeneration205,206 and an alternative method 
of neurotrophic delivery through genetically modified fibroblasts has also 
yielded encouraging results. Lesioned RST (rubrospinal tract) axons were 
seen to regenerate towards an implant of BDNF-secreting cells with 
subsequent navigation through the implant or into spared tissue207. Axons 
able to grow into cord distal to the injury site were seen to regenerate for 
remarkable distances and behavioural testing suggested the formation of 
useful nervous connections. Similarly, NGF-secreting fibroblasts induced 
some regeneration208 following injury, although motor axon recovery was not 
seen to improve. However, most reports of neurotrophic intervention alone 
have documented only moderate regeneration. Combinatorial therapy 
however, whether with embryonic spinal cord implants or anti-Nogo 
antibodies, induces good growth. Regeneration of descending fibres have 
also been found to improve following embryonic spinal cord implants 
combined with intrathecal BDNF209, 210 and the combination of NT3 and 
neutralisation of myelin-associated growth-inhibitors also results in improved 
spinal cord regeneration90.
The diverse roles of neurotrophins during development include cell survival, 
axon guidance, plasticity, neurotransmitter release and synapse/dendritic 
arbour formation211; hence it should be expected that neuronal sensitivity and 
response will vary. BDNF appears to encourage chronically injured spinal cord 
axons to grow into a peripheral nerve graft212 but in the acute injury plays a 
neuroprotective role for CST axons while not inducing regeneration213. This 
change in activity as the lesion develops is not uncommon -  BDNF and NT3 
induce greater RST neuron survival and regeneration when administered non- 
acutely209,214.
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Filling the Lesion Site
Numerous approaches to fill the lesion site with synthetic materials have been 
used (for reviews see references 215 and 216). These materials are usually 
seeded with growth-promoting neurotrophic factors or cells such as Schwann 
cells. In some cases astrocytic rejection of the implant as a ‘foreign body’ 
results in rapid exclusion of the implant from the spinal cord similar to that 
seen with normal scarring. However fibronectin-based conduits appear to offer 
a good balance of properties215 including effective resorption, no immune 
rejection and orientation for regenerating axons. Fibrin gels present another 
synthetic material with similar properties216 and also appears to prevent 
excessive scar and cavity formation.
Schwann cells have been found to promote the regeneration of the CST when 
injected into spinal cord217 and their incorporation into implanted materials 
enhances regeneration of a range of CNS tracts218. Implantation of 
exogenous or endogenous neural stem cells or neuron and oligodendrocyte 
precursors has been investigated213, 219’ 220. Ventral horn motoneurons 
produced by expansion and targetted differentiation in culture of rodent 
embryonic stem cells successfully integrated with endogenous ventral horn 
tissue and extended axons that successfully synapsed on muscle221. Other 
studies have found successful myelination and neuronal repopulation by 
embryonic stem cells when implanted into a contusion injury219,222. However, 
the neurotrophic environment of the spinal cord following injury appears to 
promote differentiation into glial lineages, rather than neuronal223.
Olfactory ensheathing glia (OEGs) present one of the best current implant 
treatments for a range of CNS injuries. OEGs have been found to migrate into 
spared neural tissue rostral and caudal to a spinal cord injury and, following 
alignment of their processes to provide regenerative channels, facilitate the 
growth of CNS tracts through the lesion site, shielded from potential growth- 
inhibitory factors224, 225. The regenerative drive induced by these cells stems 
from their expression and deposition of growth-permissive substrates and 
secretion of numerous neurotrophic factors. Following CST injury OEGs have 
been found to promote long distance regeneration with limited plastic
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sprouting that led to moderate recovery of locomotor function. The ability of 
OEGs to elicit a regenerative response when implanted into chronic injuries 
highlights the promise of this developing field.
Ephrins in Spinal Cord Injury 
Introduction
The Eph family of receptor tyrosine kinases226 and their membrane-bound 
ligands, the ephrins, are critical regulators of development, particularly 
neuronal pathfinding227"229. The ligands are grouped into two sub-families226 -  
the A-subclass (ephrinA1-A6) that are glycosylphosphatidylinositol coupled 
and the B-subclass (ephrinB1-B3) that are integral membrane proteins with 
one transmembrane domain and a short cytoplasmic region. To date, 16 Ephs 
have been found in vertebrates and are divided into A- and B-subclasses on 
the basis of ligand affinity and sequence similarity. Ephs and ephrins bind 
promiscuously with most members of the corresponding subclass interacting 
in the nM affinity range229. Some promiscuity exists between subclasses230-232, 
in particular EphA4 binds ephrinB ligands with high affinity233-236. The Eph 
extracellular domain is composed of the ligand-binding globular domain, a 
cysteine rich region and two fibronectin type III repeats -  a 90 amino acid long 
stretch repeated 15-17 times in the fibronectin molecule, commonly found in 
many cell-surface proteins. The cytoplasmic domain of the Eph receptor 
family is divided into 4 parts -  a juxta-membrane (JM) domain containing two 
conserved tyrosines, a classical protein tyrosine kinase domain, a sterile a- 
motif thought to participate in protein-protein interactions and a PDZ-domain 
(postsynaptic density-95/Discs large/zona occludens-1) binding motif in the 
last 4-5 residues important in protein scaffolding237. As is the case with 
classical RTKs238 (receptor tyrosine kinases), Eph receptor kinase activity is 
autoinhibited by the JM domain239, 240 Ligand-induced autophosphorylation 
relieves this conformational inhibition, permitting kinase activity and adaptor 
protein recruitment, required for most signalling241.
Ephrin Signalling with relation to Spinal Cord Injury
Soluble monomeric ephrin ligands do not induce functional signalling, instead 
artificial preclustering or membrane attachment is required242-245, indicating a
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requirement for cell-cell contact in vivo. The single transmembrane nature of 
the Eph family necessitates receptor dimerisation for activation through 
clustering of ephrins and leads to phosphorylation of 10 or more specific Eph 
tyrosine residues, several of which are involved in upregulation of the tyrosine 
kinase activity246. Phosphorylation also permits phosphotyrosine-binding 
proteins to bind to the 4 or more phosphotyrosines that are docking sites for 
SH2 (Src homology-2)-domain containing proteins. This regulatory 
mechanism is highly reminiscent of that proposed for the platelet-derived 
growth factor receptor p and the TrkB receptor. X-Ray crystallographs show 
that Ephs and ephrins form a cyclic heterotetramer with a 2:2 stoichiometry247, 
this planar arrangement is necessary for binding to occur between two cell 
surfaces. The complexity of Eph signalling means that the receptor modulates 
many pathways and cell responses, many of which affect growth cone 
guidance or cell migration248. The principal mediators of ephrin-induced 
repulsion and morphogenesis are the Rho family of small GTPases, RhoA, 
Rac1, and Cdc42, through modulation of actin cytoskeleton dynamics249-252. 
These signalling mediators permit repulsive or adhesive interactions between 
cells230, 253_258) partially mediated by differential activation of the Rho, Rac1 
and Cdc42 GTPase pathways, which regulate actin depolymerisation 
(repulsion) and polymerization (adhesion), respectively248, 259 Further 
signalling diversity comes from PDZ-binding domains in ephrin and Eph family 
members that can induce protein clustering260-263 and hence specify 
regulation.
Recruitment of Src family kinases (SFKs) is a common Eph receptor theme264, 
265 and recent work suggests that EphA4-mediated growth cone collapse 
requires the phosphorylation of ephexinl by SFKs266, 267. Ephrin signalling 
through ephexinl (Eph-interacting exchange protein, a Rho GTPase guanine 
nucleotide exchange factor, GEF), a member of the Dbl family of exchange 
factors has been shown to activate RhoA to induce growth cone collapse and 
inhibit cdc42 and Rad to inhibit filopodial and lamellipodial outgrowth, 
respectively259,268. This interaction appears to be required for EphA-receptor- 
mediated repulsive guidance. Similarly, EphB receptors interact with other 
GEF proteins, e.g. kalirin269 and intersectin270, that exhibit exchange activity
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towards Rac1 and Cdc42. The ability of the ephrin system to signal in either 
direction is now a common theme with reverse, ephrin-based, signals acting 
through PDZ domains to activate SFKs230,243,244,255,2601271-273 For example, 
A-class ephrin signalling274 has been implicated in vomeronasal axon 
mapping to the accessory olfactory bulb275 and B-class signalling mediates 
commissural axon repulsion276 and attraction241. Ephrin signalling is 
complicated by emerging data that ligand co-expression can modulate 
receptor sensitivity277, 278; increasing evidence for co-expression of ligands 
and receptors on neurons279, 280 suggests this may play a significant 
developmental role. As well as their well-defined role in the regulation of 
cytoskeletal dynamics, there is also evidence for transcriptional modulation by 
ephrin signalling. Examples include the NMDA receptor264, 281 and, 
interestingly, ephrinA2 itself282. Furthermore, Eph-mediated activation of the 
MAP (mitogen-activated protein) kinase pathway283, 284 and the Rho 
GTPases285,286 would be expected to have further transcriptional roles.
Many of the Eph receptor signalling roles require differential responses to 
gradients of ligand expression. A number of studies suggest that, unlike 
classical RTKs, activation of Eph receptor kinase activity is not sufficient for 
signalling287 but clustering is also required. Furthermore, increasing densities 
of ephrin ligand lead to further oligomerisation of receptors and hence 
recruitment of different cytoplasmic effectors288.
Developmental Functions and Expression of Ephrins relevant to Spinal 
Cord Injury
Ephrins represent major contact-dependent guidance molecules in 
development of the nervous system. A selective list of their roles would 
encompass the guidance of corticospinal tract fibres down the spinal cord to 
their terminal field235,236,289,29°, thalmocortical291"293 and hippocamposeptal294, 
295 fibres, spinal motoneuron outgrowth296, 297, target selection279, 296-301 and 
neuromuscular junction formation and maintenance302. Other critical roles 
involve the visual system303"307, the segmental organization of spinal 
nerves308,309, selective bundling (fasciculation) and dispersal (defasciculation) 
of axons310, the formation of the anterior commissure241,311 and spinal central
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pattern generators290,300,312> 313, local neuronal networks within the spinal cord 
that mediate locomotion314.
Ephrin Expression in the Adult CNS
Ephrin family member expression is most prominent during development; 
following birth most tissues downregulate ephrin expression and it is only 
preserved in selected areas where it performs maintenance and regulatory 
roles in the adult. Adult human315, 316 and non-human primate317 studies 
indicate substantial Eph and ephrin expression in adult brain and spinal cord, 
with particularly strong expression in cortical and hippocampal neurons. This 
staining pattern appears to be similar or identical to that highlighted in mouse 
and rat318"325 suggesting that data from rodents is relevant to human studies. 
Of particular interest is the evolutionary conserved expression of EphA4 in 
cortical neurons315 suggesting a conserved guidance mechanism for the 
CST235,236,289 In the rodent, extensive neuronal expression in adult brain has 
been found, in particular in the hippocampus, cortex, striatum, thalamus, and 
cerebellum321, 326-329 and studies have highlighted expression of ephrins in 
both motor330 and sensory26, 281 systems. Furthermore, supporting cell types 
such as astrocytes26,321 and oligodendrocyte331 in both brain and spinal cord 
and the surrounding meningeal fibroblasts26 have been shown to express 
ephrin family members. Expression of Eph receptors and ligands in 
complementary systems such as axons321 and myelin331 or hippocampal 
dendrites and supporting astrocytes332'335 suggest in the adult system ephrins 
may act to constrain and modulate plasticity. This role has been highlighted in 
both learning265 and sensory281 scenarios.
Ephrin Functions in the Adult CNS
Accumulating evidence suggests that the ephrin family plays a significant role 
in the adult animal, discarding the conventional view of these proteins as 
solely developmental. Recent evidence has revealed a complex ephrin- 
mediated regulation of hippocampal plasticity with multiple EphB receptors 
acting via Rho to regulate the actin-based cytoskeleton249,269,270,336 required 
for dendritic spine morphogenesis337, development and maturation338. B-class 
ephrin signalling is essential for dendritic spine morphogenesis, neuronal-glial
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communication335 and plasticity in synaptic signalling264, 334, 339, 340 
Furthermore, sensory plasticity in the spinal cord regulated by EphB-ephrinB 
interactions may contribute to sensory abnormalities in persistent pain 
states281.
Complementary to this role in regulating plasticity, the more typical repulsive 
role of ephrin signalling235,341 is employed in constraining plasticity of ‘fixed’ 
neural connections where ectopic connections would be unwanted. Evidence 
suggests that continued expression of EphA4 in adult cortical neurons giving 
rise to the CST315, 321 may be required to maintain specificity -  localised 
expression of ephrinB3 in myelinating oligodendrocytes around the adult 
CST331 would prevent aberrant sprouting. Similarly, EphA5 may constrain 
hippocamposeptal and olfactory system plasticity in the adult mouse295. This 
model is similar to that proposed for the non-pathological function of Nogo, 
MAG, and OMgp342 and is supported by the observation that aberrant 
sprouting occurs when EphA receptors are not expressed234"236,343.
Other critical adult roles of ephrin signalling include neural stem cell migration, 
proliferation and function290,344-346, immune system functions such as T- and 
B-cell signalling, immunoregulation and costimulation347"349, ECM attachment 
through integrin receptor signalling350"352 and chemokine responses263. All of 
these may be important in the response of the CNS to injury, furthermore it is 
possible that Eph receptor activation may play a trophic role in cell survival353, 
although solid evidence for this is lacking.
The Role of Ephrins in Spinal Cord Injury
The presence of ephrin family members in the uninjured animal, particularly 
within the spinal cord, means that following injury ephrin-mediated 
pathological interactions will occur that are likely to be detrimental to 
regeneration. These interactions are not restricted to typical growth cone 
repulsion but are fundamentally involved in the acute and long-term post­
injury environment.
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As discussed, astrocyte proliferation and gliosis following injury leads to the 
formation of glial scar354 that protects surviving neural tissue from invasion by 
meningeal fibroblasts148,355, 35e. While this process is essential for restoring 
the blood-brain barrier356, astrocytes in the scar not only present a mechanical 
barrier to regeneration but also induce the expression of numerous scar- 
associated neurite growth-inhibitory molecules in the basal lamina deposited 
during this astrocytic-fibroblast interaction. Bundesen et al. have shown that, 
in mouse SCI, upregulated expression of ephrinB2 in reactive astrocytes and 
EphB2 in fibroblasts following injury26 mediates these astrocyte-meningeal 
fibroblast interactions. Their results suggest that bidirectional signalling 
prevents cell population intermingling in a manner similar to that found during 
ephrin-regulated rhombomere boundary formation230, 271 ■ 357 The authors 
suggest that astrocytes and fibroblasts are initially repelled via cell contact- 
mediated ephrin signalling and subsequent segregation is maintained by the 
basal lamina. This interaction may also regulate cellular morphology to induce 
the well-documented parallel-lesion orientation of astrocytic processes. 
Activation of Rho in astrocytes, as well as in neurons and oligodendrocytes, 
has also recently been reported in spinal cord after injury358. Ephrin signalling 
is likely to regulate Rho activity and may be the mechanism behind the 
reactive astrocyte morphogenesis. The juxtaposition of ephrinB2-positive 
astrocytic end feet onto EphB2-positive fibroblasts at the newly formed glia 
limitans suggests these proteins may play a role in the deposition of this basal 
lamina or the cellular attachment to it through integrin signalling350"352,359. The 
presence of ephrinB2 throughout the extent of the glial scar will present a 
further regenerative barrier to Eph-positive axonal tracts. As discussed, the 
disruption of this non-permissive glial environment154,156 is likely to contribute 
to CST regeneration and the recovery of motor function, as shown 
previously157,158.
Further work by Goldshmit et al.12 has identified astrocytic EphA4 as a major 
constituent of the post-SCI signalling cascade. The authors report that EphA4 
null mice regain significant functional capacity following a dorsal hemisection. 
Importantly, the hemisected spinal cord showed almost no astrocytic gliosis 
with minimal glial scarring and the authors demonstrate that astrocytic EphA4
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may be required for gliosis following cytokine exposure12. The inhibition of this 
pathway may be the basis of the attenuated astroglial reaction360 and 
improved SCI environment159 following IL-10 administration (an inhibitor of 
microglial cytokine synthesis). The EphA^' mice also show decreased CSPG 
expression at the lesion site suggesting that EphA4-mediated reactivity may 
be a crucial component of the formation of the growth-inhibitory basal lamina. 
However, reactive astrocytes play numerous beneficial roles following SCI 
including phagocytosis21,3611362 to remove degenerated material114, 363, the 
production of growth-promoting molecules364,365 and other roles21. A transient 
increase in astrocytic ephrinB expression has been seen following 
hippocampal deafferentation332,366 and the temporal profile of the expression 
suggests a potential role in denervation-induced reorganization events and 
regulation of Rho-mediated astrocytic phagocytosis367, 368. In the EphA4_/' 
mouse, it appears that astrocytic gliosis is not entirely abrogated which may 
permit growth-enhancing properties of gliosis such as phagocytosis and 
growth factor secretion while limiting negative effects such as the formation of 
the glial scar. Similarly, GFAP and vimentin double null mice present a mild 
gliosis following entorhinal cortex lesion and these animals demonstrate 
improved regeneration155.
EphrinB3, well established as the midline developmental guidance marker for 
EphA4-expressing CST axons235, 289, is also expressed in adult myelin331. 
Adult cortical neurons continue to express EphA4323 which is activated by 
ephrinB3369 and induces growth cone collapse370. In culture the cortical 
neuron repulsion/retraction response was equivalent to that of all three of the 
p75-mediated inhibitors combined331. EphrinB3 was also shown to induce a 
repulsive reaction in cerebellar granule neurons through an EphB-mediated 
mechanism331. The CST, unlike other axonal tracts which may extend short 
sprouts into or around a lesion, undergoes a progressive retraction in the 
months following a lesion38,97,176. The continued expression of EphA4 in the 
adult CST and its interaction with astrocytic ephrinB2 and myelin-based 
ephrinB3 is a likely cause of this phenomenon. One emerging aspect of 
ephrin signalling following SCI is that, due to the huge range of expression 
profiles, different cellular and axonal populations respond in different manners
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to unique combinations of inhibitory molecules. This may be the basis for 
differential regeneration of rubrospinal, raphespinal and corticospinal tracts in 
NgR1 knockout mice111 where ephrinB2/3-responsive CST axons cannot take 
advantage of the improved SCI environment. Furthermore, regeneration 
approaches aimed at Rho signalling371,372 might benefit from the abrogation of 
ephrin signalling as well as that mediated by p75-mediated inhibitors.
Contrary to the larger body of work on the ephrin proteins, some interactions 
do favour axonal growth373"378. Wang et a/.332 propose that dendritic EphB- 
astrocytic ephrinB neuroglial crosstalk may mediate dendritic spine regrowth 
in the hippocampus after entorhinal deafferentation, perhaps though 
mechanisms seen in adult plasticity334. Furthermore, there is evidence that 
ephrins may be re-expressed to supply their developmental role as guidance 
molecules for appropriate reinnervation of targets. During optic nerve 
regeneration in goldfish, specific EphAs and ephrin-As are up-regulated 
coincident with restoration of retino-tectal topography282, 379. Ephrin family 
members also appear to be transcriptional regulators, and in the goldfish 
EphA/ephrin-A interactions appear to regulate ephrin-A2 expression in the 
tectum282.
Other studies have implicated changes in ephrin expression in the post-injury 
CNS environment. Thoracic contusion models have shown an upregulation in 
A318 and B380 family Eph receptors and EphB3 upregulation in astrocytes has 
been implicated in the astrocytic gliosis that contributes to scar formation in 
adult rat SCI12, 381. Furthermore the expression of Eph family members is 
upregulated in adult animals following central neural damage282,382_385. An as 
yet unresolved role for ephrin signalling post-SCI in inflammation is probable: 
perivascular mononuclear cells express numerous A-class ligands and 
receptors315 where they may regulate migration349, cytokine production386 and 
T-cell adhesion387. In multiple sclerosis tissue, EphA3 staining indicated 
expression in microglia315. Considering the similarity315,318 in expression of 
ephrin family members in MS (multiple sclerosis) and SCI, this suggests a 
possible role for ephrin signalling in post-injury regulation of activated 
microglia. This correlation also suggests a common injury mechanism.
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The concept of developmental proteins being re-employed following injury is 
not limited to ephrins388. Many regenerative processes parallel prior 
ontogenesis and frequently the molecular mechanisms involved seem to 
resemble development. The upregulation and re-expression of ephrins 
following CNS injury might be an attempt to re-implement developmental 
expression profiles that promote neuron survival, neurite outgrowth and 
reorganisation/guidance. Enhanced expression might supply some 
topographic guidance information for re-establishing organisation and 
connections, but these signals will invariably inhibit regrowth. Approaches to 
specifically target ephrin signalling in vivo with synthetic peptides and chimera 
proteins have been successful344, 345, 389 suggesting the ephrin system is 
amenable to intervention to improve regeneration. Evidence to date suggests 
that a careful modulation of ephrin signalling could bring about significant 
improvements in glial scarring and astrocytic gliosis.
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Chapter II
Expression of Ephrin Family Member Protein and mRNA 
following Spinal Cord Injury
ABSTRACT
It is likely that a number of factors combine to make the injured spinal cord a 
non-permissive environment for axonal growth. Most cut axons, including 
those of the corticospinal tract, generate sprouts in the days following lesions 
of the adult mammalian spinal cord217. However, in the absence of other 
manipulation, no sprouts successfully grow back to their synaptic targets. 
Indeed, axons within the corticospinal tract undergo an usually large degree of 
retraction or ‘die-back’ in the months following a lesion38, 39°. The results 
presented in this chapter suggest that a significant, previously unreported, 
factor inhibiting the regeneration of corticospinal tract axons is ephrin: Eph 
receptor interaction. Two events combine to cause this inhibition. First, 
following a lesion, ephrinB2 is upregulated in white matter astrocytes, such 
that the distal stumps of the cut corticospinal tract, and any sprouts they 
generate, are invariably surrounded by high levels of ephrinB2 expression. 
Second, continued transport of the EphA4 receptor down corticospinal tract 
axons causes the accumulation of the receptor at the axonal termination bulbs 
where it interacts with ephrinB2 and generates an inhibitory, retraction- 
evoking response. In contrast neighbouring rubrospinal axons, which do not 
express EphA4, retract less following spinal cord injury and can advance 
some way towards the lesion before they are stopped by other inhibitory 
factors391'393. Regrowth of corticospinal tract axons through and across a 
lesion is markedly enhanced in mice lacking EphA412. In normal mice EphA4 
was present at only low levels in descending axons, and it was suggested that 
the major mechanism by which EphA4 inhibited growth after spinal cord 
lesions was by encouraging the formation of a glial scar. Further to this 
finding, our results indicate that in the rat transected CST axons express 
significant amounts of EphA4 and that this may allow a direct inhibitory action 
on the axons by ephrinB2-positive reactive astrocytes.
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METHODS
Animal Housing and Surgery
Animals were housed at the UCL Biological Services Central Facility. Adult 
female 200-220g Sprague-Dawley rats were housed in groups of one to four 
animals with food and water available ad libitum. A 12/12h light/dark cycle 
was used with the lights on at 7.00am. Housing conditions were identical for 
all animals discussed in this thesis. Professor Anderson (Department of 
Anatomy, UCL) assisted in the majority of the surgical procedures discussed 
and helped develop the techniques used.
All surgical procedures were approved by the UCL ethical committee and 
licensed by the Home Office. Before surgery rats were anaesthetised with a 
mixture of halothane, nitrous oxide, and oxygen. Microsurgical scissors were 
used to transect part of the left dorsal column, the entire right dorsal column 
and part of the dorsal horn of grey matter at C6, or to transect the lateral 
column at C6. In other experiments the spinal cord was compressed with a 50 
gram weight applied at C6 for 5 minutes using an apparatus derived from that 
used by Nystrom and Berglund394. In each case, animals were sacrificed 
seven or ten days after injury by overdose with halothane.
For qRT-PCR (quantitative reverse transcriptase polymerase chain reaction) 
experiments, up to 100pg tissue was taken from the region encompassed by, 
and including, the lesion site. For immunohistochemical procedures, the 
animal was either transcardially perfused with 4% paraformaldehyde before 
removal of the spinal cord or, following exsanguination, approximately 2cm of 
spinal cord tissue was removed and fresh-frozen in OCT Compound (Tissue- 
Tek), cooled by dry ice followed by storage at -20°C until use. Perfused tissue 
was stored at 4°C in 30% sucrose, 10% Thiermesol in phosphate buffer until 
use.
Anterograde Tracing of Nerve Tracts
Where anterograde labelling of the CST was required, 5pl of 10% biotinylated 
dextran amine (BDA, Molecular Probes, Oregon, USA) was injected into the 
motor cortex using standard coordinates395. Labelling of the rubrospinal tract
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was carried out by stereotaxic injection into the red nucleus of 3pl of a 
replication-deficient human immunodeficiency virus (HIV) vector encoding 
enhanced green fluorescent protein (EGFP, 6.5 x 108 
EGFP transfecting units/ml) 10 days before spinal cord injury. The HIV vector 
was produced using transfer plasmid pHR'SIN-cPPT-CE and following 
standard procedures. In this vector EGFP is driven by the CMV 
(cytomegalovirus) promotor396. The viral vector injected in this way only 
infected midbrain neurons, so that only rubrospinal axons were labelled with 
EGFP. This was done because BDA injection into the red nucleus has in 
some cases in the Anderson laboratory been found to produce some 
corticospinal labelling in addition to rubrospinal labelling.
Quantitative RT-PCR
Tissue dissection was performed using sterile instruments, the tissue was 
then cleaned in RNase-free PBS (ribonuclease, phosphate buffered saline) 
and homogenised in TRIzol (Invitrogen) or QIAzol (Qiagen), RNA (ribonucleic 
acid) stabilisation agents. When the tissue under study was of CNS or PNS 
origin the Qiagen RNeasy Lipid Tissue Extraction Kit was used. Otherwise, 
the material was then cleared of sediment and phase-separated using 
chloroform. An upper, aqueous, phase that contained the tissue RNA was 
precipitated at -80°C with isopropanol overnight, washed with ethanol and 
resuspended in RNase-free distilled water. RNA samples were treated with 
DNase I (deoxyribonuclease, Qiagen DNase Free kit) to remove any genomic 
contamination. 20pl of complete cDNA (complementary deoxyribonucleic 
acid) was prepared from 1pg of each RNA using random hexamers (500ng, 
Promega) and AMV reverse transcriptase (avian myeloblastosis virus, 20U, 
Promega) for 45min at 42°C. Primers for qRT-PCR were designed using the 
Applied Biosystems Primer Express software due to the stringency of the 
parameters required for effective PCR in the system. Primers were designed 
based on either the published rat sequence of each gene, where available, or 
the mouse sequence in all other cases. 96 parallel 25pL PCRs were set up, 
each containing 0.5pL (approx. 25ng) cDNA and 300nM of each primer. Forty 
cycle PCR was performed on the Applied Biosystems LightCycler™ with a 30 
second denaturation step at 94°C followed by 30 seconds at 59°C for primer
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annealing and 30 seconds at 72°C for polymerase extension. At the end of 
this amplification phase, a slow dissociation step was performed starting at 
60°C and finishing at 85°C that permitted analysis of the DNA 
(deoxyribonucleic acid) product from the PCR for purity. As the temperature 
rose and double-stranded DNA species began to denature, the SYBR Green 
fluorescence reduced. As each species has a different denaturation 
temperature depending on length and GC base percentage, the fluorescence 
change peak corresponding to that species differed in temperature to other 
PCR products. Hence, a single DNA product in each PCR produced only one 
peak and indicated a highly specific PCR with minimal background signal. 
DNA synthesis was monitored using the fluorescent AmpliGOLD compound 
(Applied Biosystems). Following the selection of a suitable threshold DNA 
concentration, the PCR cycle (Ct) at which each PCR breached this threshold 
was used to determine the original cDNA concentration for each mRNA (See 
Figure 2.M1). Normalising each cDNA with (3-actin expression permitted 
comparison between cDNAs (see Results), hence the Ct for 0-actin 
expression was analysed for each cDNA as well. Each PCR was performed in 
triplicate with a parallel well containing a cDNA preparation that lacked 
reverse transcriptase. This eliminated the occasional spurious PCR result and 
allowed an analysis of genomic, or other, contamination in the assay.
The efficiency of each primer pair is a numerical representation of the efficacy 
of each pair to amplify specific DNA amplicons. Theoretically each cycle 
should generate one copy of each existing amplicon, giving an efficiency of 2. 
However, experimentally Ct values of correctly designed primer pairs range 
from 1.7 to 2.1. Primer efficiencies were calculated using a 20-fold dilution 
series (from 1 to 1:2000) of one cDNA that strongly expressed the amplicon of 
interest. The Ct value for each of these dilutions was then plotted against the 
log (base 10) of the relative cDNA concentration. As shown in Figure 2.1, this 
gives a linear plot, the gradient of which (termed m) can be used to derive the 
primer efficiency (Eff) using the equation:
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Mathematical manipulation of the qRT-PCR data was performed to normalise 
expression of each gene in each cDNA sample to p-actin expression 
independently of all other samples. Direct comparison between genes and 
tissue treatments was then possible. The original cDNA concentration of an 
amplicon can then be derived by placing the primer efficiency for that 
amplicon to the power of the Ct for any cDNA (i.e. E f f^ n A Ctpadin)• Due to the 
inverse relationship between Ct values and the starting cDNA expression of 
the amplicon of interest, the normalised expression of any gene in a given 
cDNA preparation (ft) is calculated inversely (i.e. p-actin expression / EphA4 
expression). Hence the following equation397 was used to calculate the final 
normalised mRNA expression values for each tissue of interest:
This gives a normalised value for gene expression based on |3-actin 
expression in the cDNA analysed to account for variations in tissue collection 
and processing, cDNA production and PCR efficiency. Typically the values 
are less than one due to the high level of expression of p-actin in many 
tissues.
EphA, EphrinA and EphrinB expression following spinal cord injury
Two spinal injuries have been investigated. In the first, a dual dorsal 
hemisection was performed at C5 and tissue taken from the region 
encompassed by, and including, the lesion sites. In the second injury a 
50gram weight application was performed at C5 and an equivalent volume of 
tissue removed from the injury site. Control animals underwent a laminectomy 
but no spinal cord injury and were treated identically to the injured animals. In 
all cases tissue was excised 7 days after injury and limited to 100pg.
Primers were designed to minimise the likelihood of cross-amplification due to 
the high sequence homology in the Eph and ephrin family (see Figures 2.M2-
ySactin
Eph
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4). Thermal dissociation analysis and agarose gel electrophoresis of qRT- 
PCR products revealed distinct DNA species without splice variants (Figure 
2.3). BLAST searches of the rat genome also confirmed that each primer pair 
would only anneal to their intended targets and that there would be no cross­
priming.
Immunocytochemistry
Fresh frozen samples of brain and spinal cord from operated and unoperated 
animals were sectioned in the horizontal or para-sagittal planes at 12pm 
thickness on a cryostat. Fixed tissue was cut at 40pm thickness on a freezing 
microtome. Samples were rinsed three times in TNT buffer (Tris Buffered 
Saline (TBS) with 0.05% Tween-20, Sigma) prior to incubation for one hour at 
room temperature in blocking solution (TBS, 1% BSA, 0.1% Triton X-100) 
supplemented with 10% normal serum as appropriate for the secondary 
antibody in use. Where biotinylated secondary antibodies were used, 2% 
normal horse serum was also included in the blocking solution. The samples 
were then incubated with primary antibodies, diluted appropriately in blocking 
solution, at 4°C. The samples were rinsed three times with TNT buffer and 
incubated with fluorophore- or biotin-conjugated secondary antibodies, diluted 
in blocking solution for two hours at room temperature. Again, the samples 
were rinsed several times in TNT solution before being stained with 
bisbenzamide (1pg/ml) for 5min. Primary antibodies used included rabbit anti- 
EphA4 antibody (1:5000, kindly provided by David Wilkinson, National 
Institute for Medical Research, UK), goat anti-ephrinB2 antibody (1:750, R & D 
Systems), goat anti-EphA4 antibody (1:750, R & D Systems) and mouse anti- 
GFAP (1:400, Sigma) in blocking medium overnight at 4°C. Secondary 
antibodies used were goat anti-rabbit-Alexa 488 (1:400, Molecular Probes), 
rabbit anti-goat-FITC (Fluorescein, 1:200, Sigma), chicken anti-mouse-Alexa 
594 (1:400, Molecular Probes) and biotinylated horse anti-goat (1:200, Vector 
Labs.). Visualisation of either biotinylated secondary antibodies or 
anterogradely labelled corticospinal tract axons was performed using either 
streptavidin-Alexa 568 (1:200 in 0.1 M TBS, Molecular Probes) or avidin-HRP 
reagent (horse radish peroxidase, Vectastain ABC kit, Vector Labs.) followed 
by exposure to tyramide-Cy3 (1:400 in 0.1M Tris Buffer, New England
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Nuclear) for 30min at room temperature. Where tyramide-Cy3 enhancement 
was used sections were exposed to 0.3% H2O2 for 15min at room 
temperature followed by three washes in TNT buffer before application of 
blocking solution. The samples were rinsed three more times in TNT buffer 
before being coated with 1,4- diazabicyclo[2.2.2]octane (DABCO) and sealed 
under a coverslip with nail-vamish. Control sections, which were not incubated 
with primary antibodies but otherwise processed identically, were used to 
ensure signal specificity.
Generation of digoxigenin-labelled riboprobes
Primers were designed against the 364-1282bp region of the mouse EphA4 
gene (GenBank Accession NM_007936) that encompassed the C-terminal 
end of the ligand binding domain and the N-terminal end of the fibronectin 
type-3 repeat region. The 5’ primer was designed to contain a T7 RNA 
polymerase recognition sequence and similarly, the 3’ primer was designed 
to contain a T3 RNA polymerase recognition sequence.
Primer sequences used were:
5'-EphA4 AATTAACCCTCACTAAAGGGAGCGCTTCATCAGAGAGAGCC 
3-EphA4 TAATACGACTCACTATAGGGGGTCCGGGCTAGGGTTATACT 
with sequence-specific regions in bold font.
Antisense probes were generated by gel purification of the ~950bp PCR 
product and phenol:chloroform precipitation of the DNA fragment followed by 
in vitro transcription with T7 RNA polymerase (Roche Applied Science). 
Sense probes were produced from the same purified DNA fragment but in 
vitro transcription was performed with T3 RNA polymerase (Roche Applied 
Science). Antisense and sense cRNA (complementary ribonucleic acid) 
probes labelled with digoxigenin (DIG) were generated according to the 
manufacturer’s recommendations using a DIG-UTP (uracil trisphosphate) 
RNA labelling kit (Roche Applied Science). Unincorporated digoxigenin was 
removed from the probe using a Sephadex column (Roche Quickspin).
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In situ hybridisation
In situ hybridisation was carried out using published methods398,399 In brief, 
cryostat sections of brain and spinal cord were cut at a nominal thickness of 
12pm, thaw-mounted onto slides coated with 3-aminopropyltriethoxy silane, 
and fixed with RNase-free 4% paraformaldehyde in PBS overnight at 4°C. 
After being washed in PBS, sections were treated with 0.1M hydrochloric acid 
and washed in PBS, incubated in 0.1M triethanolamine containing 0.25% 
acetic anhydride, and then washed with PBS, dehydrated in an ascending 
ethanol series, and air dried. Prehybridisation was carried out at 37°C 
overnight with a mixture of prehybridisation buffer/deionised formamide 1:1 
(containing 50% formamide, 25mM ethylenediaminetetraacetic acid (EDTA), 
50mM, pH7.6, Tris-HCI, Denhardt’s solution (Sigma), 0.25mg/ml tRNA 
(Boehringer Mannheim), and 20mM NaCI). The digoxigenin labelled sense 
and antisense probes were prepared at a concentration of approximately 
1pg/ml with hybridisation buffer containing 50% formamide, 20mM Tris-HCI 
(pH7.5), 1mM EDTA, 1x Denhardt’s solution, 0.5mg/ml tRNA, 0.1 mg/ml polyA 
RNA (Sigma), 0.1 M dithiothreitol and 10% dextran sulphate. Hybridisation 
was performed overnight at 65°C. After hybridisation, sections were washed 
in 0.2x standard saline citrate (SSC, containing 30mM NaCI and 3mM Na- 
citrate, pH7.0) and then three times in 0.1x SSC/50% formamide at the 
hybridization temperature. Sections were equilibrated with buffer 1 (100mM 
Tris-HCI, 150mM NaCI, pH7.5) and then incubated in buffer 2 (1% Boehringer 
blocking reagent, 0.5% BSA fraction V (Sigma) in buffer 1) and incubated with 
alkaline phosphatase-coupled antibodies to digoxigenin (Roche Applied 
Science, UK) at a dilution of 1:1500 in buffer 2 overnight at 4°C. Sections 
were washed in buffer 1, equilibrated in buffer 3 (100mM Tris-base, 100mM 
NaCI, 50mM MgCI2, adjusted to pH9.5), and developed in the dark with buffer 
3 containing 0.34 mg/ml 4-nitroblue tetrazolium chloride (Roche Applied 
Science, UK), 0.175 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (Roche 
Applied Science, UK), and 0.25 mg/ml levamisol (Sigma). Development was 
stopped by washing with buffer 4 (10mM Tris-HCI, 1mM EDTA, pH 8.0), 
following which the sections were air dried and mounted in DPX beneath 
glass coverslips. The specificity of the hybridisation signal was verified by 
comparison with the sections processed with the sense probe under identical
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conditions. Comparison between tissues pre- and post-injury was performed 
using sections developed on the same slide.
Digital image capture and analysis
Fluorescence images were acquired on a Zeiss 510 confocal microscope 
using conventional filter based fluorescence optics. Excitation and emission 
wavelengths were, respectively: Hoechst = 351 nm, 385 - 490nm; FITC, Alexa 
488 and EGFP = 488nm, 505 - 550nm; Cy 3, Alexa 568 and Alexa 594 = 
543nm, >560nm. Imaging of slides labelled with multiple dyes was always 
sequential, that is, the preparation was only illuminated with light of one 
wavelength at any one time. Transmitted light images were acquired on the 
same microscope using bright field illumination.
RESULTS
Quantitative RT-PCR was used to initially pan a range of possible ephrins and 
Eph receptors to define which family members were mostly likely to be 
important in spinal cord injury and hence warranted further investigation. 
Following selection of interesting genes (specifically the ephrinB2 ligand and 
the EphA4 receptor), in situ hybridisation and immunohistochemistry were 
employed to localise the expression of the corresponding proteins.
qRT-PCR for EphrinA1-5, EphrinB2-3 and EphA3-4,6-7
Primer Efficiency Calculations
Primer pairs were accepted for use in the qRT-PCR study only if their 
efficiency resided within the range of 1.8-2.05 and the linear regression 
coefficient for the dilution graph was R2 > 0.99. The efficiency assays for all 
primer pairs used showed that the qRT-PCR assay is responsive to a range of 
PCR cDNA concentrations with a good regression fit potentially as low as 
0.1 pg/pl (for examples see Figure 2.1). Negative control assays using 
preparations without reverse transcriptase revealed no genomic signal or 
other background expression suggesting that DNase treatment of RNA 
preparations was successful and background PCR signal was not significant. 
Details of primer pairs used in this investigation are included in Figure 2.2.
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Thermal Dissociation of qRT-PCR Products
Subsequent to each complete qRT-PCR, a thermal dissociation step was 
performed to assess the quality of DNA product produced. As shown in Figure 
2.3, nearly all dissociation profiles for the qRT-PCR products showed a single, 
well-defined fluorescence change peak indicating a single DNA product with 
little or no background. Hence the primers used in this study appear specific 
for the cDNA sequence to which they are designed, the use of low-homology 
regions permitting differentiation between family members. Furthermore the 
dissociation profiles suggest there are no splice variants produced within 
these amplicon regions in the tissues of interest.
N.B. The thermal dissociation profile for ephrinA2 produces a double peak. 
This matter was not pursued further as ephrinA2 expression was seen to be 
negligible in control or injured tissue.
Matrix Metalloprotease-2 mRNA expression as a reporter for experimental 
confidence
RNA extraction from nervous tissue is often complicated by the presence of 
high lipid content. A lipid-specific RNA extraction kit (Qiagen RNeasy Lipid 
Tissue Extraction Kit) was used for all extractions. However, to ensure that the 
qRT-PCR technique was accurately reporting changes in gene expression, 
matrix metalloproteinase-2 (MMP-2) expression, an inflammation-associated 
protein that is known to be upregulated following some spinal injuries400,401, 
was examined. As shown in Figure 2.4A, the quantitative RT-PCR technique 
reported that expression of MMP-2 mRNA was significantly upregulated after 
crush injury, indicating that the technique is giving valid results. Hence, the 
changes in Eph and ephrin family member expression can be confidently 
interpreted as real and not an artefact due to complications with post-injury 
tissue.
Eph A Receptor mRNA expression following Spinal Cord Injury 
EphA3 and EphA7 show limited expression in control cord and there is little 
change in expression following either injury type. However, EphA4 and EphA6 
show significant expression in control spinal cord and this is downregulated 
significantly following both injury types performed, the dual dorsal column
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transection and controlled weight compression (Figure 2.4A). The degree of 
mRNA downregulation also appears to correlate with the extent and severity 
of the injury. Crush injuries reduce levels of EphA4 by ~90% and nearly 
abolish expression of EphA6.
EphrinA1-5 mRNA expression following Spinal Cord Injury 
EphrinA expression following spinal cord injury has not been investigated to 
date. EphrinA4 was the only significantly expressed ligand subtype in the 
spinal cord tissue, either before or after injury (Figure 2.4B). In a similar 
manner to that seen in the EphA receptor data, the expression trend was 
negative with ephrinA4 expression reduced by around 95% following 
controlled compression injury. Unfortunately, the expression of ephrinA 
protein in adult rat or mouse spinal cord tissue has not been investigated to 
date so no comparison with the current literature can be performed.
EphrinB2 and B3 mRNA expression following Spinal Cord Injury 
Of B class ephrins, only B2 and B3 have been reported to be expressed at 
significant levels in spinal cord26,236. Quantitative RT-PCR indicated that the 
levels of ephrinB2 mRNA increased after spinal cord injury, consistent with 
previous findings (Figure 2.5, Bundesen et al., 200326). Upregulation of 
ephrinB3 following dorsal transection injury was not statistically significant. 
However, downregulation of ephrinB2 expression following crush injury was 
significant.
Immunohistochemistry and In Situ Hybridisation to Detect the EphA4 
Receptor in Normal and Injured Spinal Cord
Immunocytochemical investigation of EphA4 expression following spinal cord 
injury
Horizontal sections of spinal cord from uninjured Sprague-Dawley rats 
revealed low levels of EphA4 expression (when compared to secondary 
antibody-only controls) in grey matter at all spinal levels and throughout the 
dorsal and ventral extent of the cord. Immunoreactivity was undetectable in 
white matter in these control animals (Figure 2.6A and B), or in lesioned 
axons remote from the lesion site (Figure 2.6C). However, strong EphA4
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immunoreactivity was observed in dorsal and lateral white matter tracts just 
proximal to a transection injury 3-14 days following injury (Figures 2.6C, 2.6D 
and 2.7A). The anatomical location of the immunostaining was suggestive of a 
corticospinal expression. To confirm the identity of the EphA4 positive axons, 
a subpopulation of corticospinal tract axons was labelled by injection of 
biotinylated dextran amine into the motor cortex at the time of spinal cord 
lesion. Ten days later anterogradely transported BDA was seen to colocalise 
with EphA4 immunoreactivity in axon stumps and immediate intact axonal 
material (Figure 2.7B-D).
In addition to its appearance in CST axon terminations, EphA4 expression 
was present in blood vessels associated with GFAP-positive astrocytes 
(Figure 2.7E) as well as in GFAP-positive astrocytes in white and grey matter 
(Figure 2.8). Interestingly, a time course of EphA4 expression at 28 and 42 
days following injury did not reveal EphA4 expression at or near the lesion 
site, although grey matter astrocytic staining was preserved.
Caudal to a spinal cord transection injury, punctate EphA4 immunostaining 
was observed in the central white matter (Figure 2.9A). OX-42 staining for 
macrophages and microglia did not reveal any colocalisation with EphA4 
suggesting these are not invading immune system cells (Figure 2.9B-D). 
Bisbenzamide staining indicated the absence of a nucleus in these puncta 
and they appeared to be closely associated with astrocytic processes (Figure 
2.9E). These puncta are therefore likely to be the swollen EphA4-filled 
remains of damaged CST axons or perhaps the termination bulbs of 
ascending dorsal column axons. The absence of any axonal EphA4 caudal to 
the lesion site would argue against the presence of EphA4 in ascending 
tracts, however.
In Situ Hybridisation for EphA4 mRNA expression in control and post-injury 
tissue
Localisation of EphA4 receptor protein to the injured CST suggests that either 
the protein is accumulating passively in the termination bulbs through 
continuing anterograde transport following injury, or the cell bodies of the CST
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axons are actively upregulating expression of EphA4. To examine whether 
EphA4 transcription is increased in cortical pyramidal neurones following CST 
lesion in rats, in situ hybridisation was performed using a probe for EphA4 
mRNA. Consistent with previous reports from the mouse323, brains from 
uninjured animals showed EphA4 expression in layers ll-VI of the hindlimb 
cortical region together with a particularly strong expression in the 
hippocampus (Figure 2.10). Seven days after a CST lesion, EphA4 mRNA 
expression in these regions was comparable to control (Figure 2.10C), 
consistent with previous findings that these neurons show little cell body 
response in the first 2 weeks following a remote axotomy74. Local axotomy, 
however, has been shown to induce an upregulation in EphA receptor 
expression in the hippocampus385. To investigate the expression of EphA4 
following local neural damage, a stab wound was performed in the motor 
cortex and coronal sections through the cortex processed for EphA4 mRNA 
expression. Very local to the insult, EphA4 mRNA was clearly upregulated 
(Figure 2.11 A). EphA4 mRNA was also detected in the CA1 and CA3 regions 
of the hippocampus (Figure 2.10) and the lining of the lateral and fourth 
ventricles (Figure 2.11B).
EphA4 mRNA in control spinal cord showed the expected pattern of staining 
indicative of astrocytic localisation (Figure 2.11C). White matter staining was 
weaker and more striated with EphA4-positive puncta aligned in small discrete 
groups. Grey matter staining was more intense and uniformly distributed in 
agreement with immunohistochemical staining of astrocytic EphA4. Around 
the lesion site, EphA4 mRNA staining is clearly visible in the white matter 
suggesting either an upregulation of EphA4 mRNA in surviving white matter 
astrocytes or the invasion of reactive EphA4-positive astrocytes from the grey 
matter (Figure 2.11D). Also of interest is the highly centralised staining of 
each astrocyte with close association of mRNA with the nucleus in each cell 
and little staining of processes.
56
Immunohistochemistry to detect the ephrinB2 ligand in normal and 
injured spinal cord
The qRT-PCR data indicated an upregulation of ephrinB2 mRNA in the lesion 
site (Figure 2.5). Previous studies have also reported this ephrinB2 
upregulation at spinal cord lesions, particularly in reactive astrocytes at the 
glial scar margin26. The presence of ephrinB2 in the lesion site may present a 
further barrier to the regeneration of EphA4-positive CST axons following 
injury hence the probability of this interaction occurring at the astrocyte-axon 
interface was investigated. Remote from the lesion site, ephrinB2 
immunoreactivity was relatively weak and was predominately in GFAP- 
positive grey matter astrocytes, with low levels of staining in white matter 
astrocytes (Figure 2.12). Consistent with existing reports, strong ephrinB2 
immunoreactivity was observed in astrocytes of both grey matter and white 
matter at the lesion site (Figure 2.13). These astrocytes were observed to 
orient their processes perpendicular to the lesion margin (Figure 2.14). The 
effect of the continued expression of ephrinB2 in grey matter together with its 
upregulation in astrocytes at the lesion site is that EphA4-positive CST 
termination bulbs are completely surrounded by tissue expressing this 
inhibitory ligand (Figure 2.15). EphrinB2 immunoreactivity was also seen in 
small and medium dorsal root ganglion neurones and their unmyelinated 
processes (Figure 2.16), as previously reported281.
EphA4 expression correlates with retraction after lesion
In the lateral white matter, axons of the lateral CST run alongside axons of the 
rubrospinal tract. The red nucleus, where the cell bodies of the rubrospinal 
axons are located, has no detectable expression of EphA4 in adult rodents321, 
323. In order to compare the responses of neighbouring EphA4-expressing 
corticospinal axons and non-expressing rubrospinal axons to a spinal injury, a 
lentiviral vector encoding EGFP was injected into the red nucleus. Ten days 
later BDA was injected into the motor cortex to label corticospinal axons and a 
lateral column injury was performed. When the animals were killed, ten days 
following the spinal injury, EGFP-expressing neuronal perikarya were found 
only in the midbrain, indicating that there was no retrograde transfection of 
neurons by the viral vector via axons of passage (Figure 2.17A). In the
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cervical spinal cord bright EGFP labelling of the rubrospinal axons was 
observed, without any EGFP labelling of dorsal CST axons (Figure 2.17B). 
Lentiviral delivery of EGFP therefore allowed complete separation of 
rubrospinal and corticospinal axons, unlike most conventional tracing 
techniques. This is clearly seen in coronal brain sections with separate zones 
of tracer expression and no colocalisation (Figure 2.17A). In the lateral white 
matter, BDA positive CST axons terminated well proximal to the lesion site, 
indicating that, as in the dorsal CST, they had retracted following the injury. In 
contrast the terminations of EGFP-positive RST axons were located closer to 
the lesion (Figure 2.18A). 63 CST axons in three cords terminated an average 
of 307±19pm (± SEM, standard error in the mean) from the boundary of the 
lesion, while in the same cords 209 RST axons terminated 103±7pm from the 
boundary (Figure 2.18B, p<0.0001, t test).
DISCUSSION
EphA Receptor qRT-PCR
The data indicates that expression of both A-class Eph receptors and ephrins 
is reduced in the tissue around a lesion site. Most, if not all, axonal EphA 
receptor mRNA will be located in the cell body some distance from the lesion 
site. Hence, the reduction in EphA mRNA expression around a spinal cord 
injury seen in the qRT-PCR study does not detract from the hypothesis that 
neuronal EphA receptors may play an important role in preventing axonal 
regeneration. However, the downregulation observed does imply that EphA 
receptors are not significantly expressed in surviving or invading cells local to 
the lesion. In apparent disagreement with this finding, published data 
suggests that EphA4 upregulation in astrocytes may contribute to their 
reactive behaviour following injury and to the formation of the glial scar12. One 
means to resolve the data presented here with the existing literature would be 
to consider the extensive loss of astrocytes following spinal cord injury. 
Uninjured grey matter tissue appears to express moderate amounts of EphA4 
(see Figure 2.6) and this may be localised to astrocytes (Figure 2.8 and 
Willson et a/.318). In contrast EphA4 appears in white matter astrocytes in a 
highly localised region at the lesion site itself. Hence, following an injury, the 
overall level of EphA4 expression (as seen in the qRT-PCR data) may fall due
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to astrocytic loss, but the remaining astrocytic upregulation of EphA4 results in 
a positive result in published immunohistochemistry and in situ hybridisation 
studies presented here. This hypothesis is supported by Bundensen et a/.26 
who note a similar downregulation in expression of ephrinB2 and EphB2 in 
injured spinal cord following an injury, despite increases in expression at later 
time points.
Data from Willson et al. indicates a two-fold or greater upregulation in EphA3, 
4 and 7 receptors seven days following spinal cord injury318. This is in 
disagreement with the qRT-PCR data presented here regarding EphA 
receptor expression. There are some differences in experimental technique 
regarding the comparable data sets -  i.e. spinal cord crush injury. Willson et 
al. make use of the New York University (NYU) Impactor injury to perform a 
12.5mm 10gram weight drop whereas we used a controlled (non-impact) 
50gram weight application to perform our crush injuries. It is likely that the 
NYU Impactor injury will induce a different type and location of injury to our 
controlled crush approach -  an impact would be expected to induce more 
cavitation and possibly an injury close to the central canal whereas a 
controlled crush might induce the injury epicentre closer to the site of weight 
contact and produce less cavitation. Another possible cause of differences 
stems from the quantification used in the two studies. Whereas Willson et al. 
have used a semi-quantified approach looking at the intensity of PCR bands, 
we have used p-actin expression-normalised RT-PCR quantification based on 
fluorescence of the DNA-reporter SYBR Green. Such a deleterious tissue 
treatment as spinal cord injury could easily cause complications in expression 
quantification without some form of normalisation, due to tissue death and 
other confounding factors. These complex pathological changes include the 
invasion of meningeal fibroblasts and immune system cells, hypertrophy and 
death of astrocytes and for formation of a new glial limitans. Importantly, our 
data regarding ephrinB2 and MMP-2 expression agrees with that expressed in 
the literature26, 40°. Identical cDNA preparations and qRT-PCR techniques 
were used in all gene expression studies, hence the data presented here is 
well founded. Nevertheless, work from another laboratory to confirm these 
findings would provide good grounding for future expression studies.
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EphrinA qRT-PCR
Published data suggests a developmental expression of ephrinA4 in the 
hippocampus and cortex402 but this is thought to disappear in the adult. 
However, as Figure 2.4B shows, ephrinA4 expression appears to be retained 
in the adult rat spinal cord. The severe downregulation in mRNA expression 
seen in Figure 2.4B implies there is no active upregulation in expression in 
surviving neural tissue subsequent to injury suggesting that ephrinA4 is 
unlikely to be significant in the post-injury environment. Without further data 
on adult expression and ligand localisation it is hard to postulate a possible 
role for ephrinA4 in the adult, however the fact that expression diminishes 
following both injury types suggests it is not expressed on an invading cell line 
such as meningeal fibroblasts or immune cells. Most likely it is expressed on 
astrocytes (where co-expression with ephrinB2 and EphA4 would open up a 
whole range of regulatory c/s-interactions), oligodendrocytes or dorsal horn 
neurones, all of which suffer extensive cell death following injury. Further 
investigation of this ligand is warranted as it may play a role in constraining 
plasticity in the normal spinal cord. Ephrin signalling has also been shown to 
be supportive or trophic in nature in some cases353, hence downregulation in 
the expression of some ephrins and Eph receptors may diminish the trophic 
support available to surviving tissue following injury. Neurotrophic deficiency 
following injury is a major factor in the lack of regeneration and approaches to 
replenish this growth support should consider trophic factors such as ephrins 
that may not act through the standard p75 receptor mediated signalling 
pathway.
EphrinB qRT-PCR
Both ephrinB2 and ephrinB3 have been implicated as major contact-repellent 
agents in the injured spinal cord environment. Our qRT-PCR analysis of 
ephrinB ligand expression in rat spinal cord demonstrated significant 
expression of ephrinB2 and ephrinB3 in control tissue, in agreement with 
published work26,236. Furthermore, the qRT-PCR data indicates that ephrinB2 
is upregulated following injury in agreement with the Western blot experiments 
of Bundensen et al.26. As ephrinB2 expression appears to be upregulated in
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reactive astrocytes, ephrinB2 mRNA expression would be expected to be 
highest in tissues undergoing a crush injury where the degree of inflammation 
and astrocytic gliosis was greatest. However, as outlined above and in 
agreement with the data of Bundensen et al.26, cell death following the more 
deleterious crush injury will mask a large extent of the increase in ephrinB2 
expression. This is the likely cause of the smaller ephrinB2 mRNA expression 
upregulation seen seven days following crush injuries compared to dual 
dorsal hemisection injuries.
Immunohistochemistry and in situ hybridisation for EphA4 expression 
following spinal cord injury
EphA4 protein is not detectable in uninjured corticospinal tract axons, even 
though EphA4 transcription is proceeding in the cell body (Figures 2.6A-B and 
2.10A). In contrast, EphA4 protein accumulates at the cut ends of 
corticospinal tract axons after injury, with distinct axonal ‘tails’ tracking 
rostrally from termination bulbs. The most likely explanation for these data is 
that uninjured pyramidal neurones of the motor cortex synthesize EphA4 and 
transport it down the axon to their presynaptic terminals, where it may play a 
role in synaptic plasticity345. In this model, although EphA4 is present in 
uninjured axons, the concentration is too low for immunological detection. 
Axotomy does not increase the rate of EphA4 synthesis as no increase in in 
situ hybridisation signal is apparent after injury, but as transport out of the cell 
body and down the axon continues the protein accumulates at the severed 
axon stump. In the non-pathological situation, EphA4 may act at CST termini 
to prevent axonal sprouting in the developed animal. At the injury site, 
however, the presence of high levels of EphA4 at the sites of potential neurite 
regeneration in the spinal cord is likely to be strongly inhibitory to any 
regenerative activity.
Expression of EphA4 in, and proximal to, termination bulbs of the CST is 
strong three days following injury and does not appear to strengthen over the 
subsequent 11 days. This is not surprising, as previous studies403, 404 using 
transfected cell lines in vitro have shown that rapid uptake of ligand-receptor 
complexes occurs into both ligand- and receptor-expressing cells. This
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process not only attenuates signalling to downstream processes (although 
some is likely to persist inside the endocytotic cell) but will also lead to rapid 
protein turnover -  hence preventing excessive build-up of EphA4 at CST 
termination bulbs. However, at 4 and 6 weeks following injury, EphA4 
expression disappeared from the dorsal or lateral white matter but is retained 
in the grey matter. While proximal injuries appear to induce a robust change in 
EphA expression in the cortex385 (also see Figure 2.11 A), cortical neuron 
responses to distal injury are generally negligible74. Death of cortical neurons 
may explain this change in expression, or perhaps a long-term decline in 
overall transcription as the axotomised neurons atrophy.
The recent discovery of ephrinB3 in myelin and evidence for its strong growth- 
inhibitory properties in v/fro331 suggests that the interaction between myelin 
ephrinB3 and CST EphA4 may also prove significant in the post-injury 
response. While the interaction with astrocytic ephrinB2 may diminish as the 
lesion scar becomes more stable and the majority of the CST fibers die back 
from the lesion site, the interaction with ephrinB3 will be maintained as 
damaged myelin will be present throughout the vicinity of the injury. EphrinB3 
may prove to be the ligand which prevents regenerative sprouting of the CST 
from its final, retracted, position.
In addition to the axonal and astrocytic EphA4 discussed above, punctate 
EphA4 immunostaining caudal to the lesion site in the central white matter 
was also noted (Figures 2.6C and 2.9A). This did not colocalise with OX-42 
staining (Figure 2.9B-D) arguing against a role for EphA4 in activated 
macrophages and microglia invading the lesion site. This was confirmed by 
the apparent absence of genetic material within the puncta following 
bisbenzamide staining (Figure 2.9E). GFAP staining suggested a close 
association with reactive astrocytic processes suggesting these strongly 
EphA4-positive puncta are likely to be the swollen remains of damaged CST 
axons undergoing Wallerian degeneration. As noted previously, the absence 
of any axonal EphA4 caudal to the lesion site would argue against the 
presence of EphA4 in ascending tracts.
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The in situ hybridisation staining for EphA4 revealed astrocytic staining in the 
spinal cord in agreement with the immunohistochemical data (Figures 2.11C 
and 2.8). EphA4 staining in the lesion site is significantly stronger than that 
found in control white matter and injured white matter some distance from the 
lesion. However, mRNA expression of EphA4 in cells in the lesion site was not 
visibly higher than control or injured grey matter expression suggesting that 
either:
• Reactive grey matter astrocytes invading the lesion site do not increase 
their expression of EphA4 significantly.
• Reactive surviving white matter astrocytes near the lesion site greatly 
upregulate their EphA4 expression.
Both of these phenomena may occur but differentiating between them -  and 
hence elucidating the source of EphA4-positive astrocytes in the lesion site -  
is difficult. When one considers the loss of white matter astrocytes subsequent 
to a lesion centred on the white matter, the most likely source of invading 
astrocytes would be from the grey matter. Hence, local upregulation of EphA4 
mRNA is unlikely to be extensive. This conclusion is in agreement with the 
qRT-PCR data that suggests that, overall, the expression of EphA4 mRNA 
decreases following injury.
Immunohistochemistry for EphrinB2 expression following Spinal Cord 
Injury
The upregulation of ephrinB2 in reactive astrocytes (Figures 2.5 and 2.13) is 
proposed to interact with EphB2 expressed on invading meningeal fibroblasts 
following spinal cord injury26. In this context it is likely to play a role in the 
formation of the new glial limitans, limiting the invasion of meningeal 
fibroblasts into surviving tissue, and permitting the reformation of a stable 
CNS environment. However, an unexpected side-effect of this physiological 
mechanism is the possible interaction between astrocytic ephrinB2 and CST- 
based EphA4. EphA4 binds with high affinity to ephrinB2 and transduces a 
repulsive signal to the growth cone of any developing CST axon235,236, 405. 
Hence, a similar response is likely in the context of spinal cord injury. As 
shown in Figure 2.12B, ephrinB2 expression is strong in the uninjured grey
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matter surrounding the lesion site, preventing any regenerative sprouting into 
spared grey matter. It is also strongly expressed in reactive astrocytes (either 
from surviving white matter or invading grey matter) around the lesion centre. 
In this location there is an unavoidable interaction between astrocytic 
ephrinB2 and EphA4 strongly expressed in CST termination bulbs (Figure 
2.15). The time-course of ephrinB2 expression26 and CST retraction38 are also 
closely interlinked with the period of greatest CST retraction occurring 
between 5 and 14 days after injury and rapid upregulation of ephrinB2 
expression between 3 and 10 days after injury. This interaction is therefore 
likely to be a major contributor to the increased retraction seen in the CST 
response to injury when compared to other axonal tracts.
One question raised by the presence of ephrinB2 and EphA4 on reactive 
astrocytes is whether any form of c/s-interaction occurs. Binding of ephrin 
ligands and receptors in c/s has been documented278 and, while it appears to 
not mediate any intracellular signalling, does interfere with frans-activation of 
the receptor (and mostly likely the ligand also). However, while astrocytic 
EphA4 is most likely to be important in the one to three day period post-injury 
when cytokine release from invading immune cells appears to induce 
astrogliosis via a mechanism involving EphA412, ephrinB2 expression is 
upregulated between the three and seven day period when it interacts with 
fibroblastic EphB2. Hence these two proteins are unlikely to be strongly co­
expressed during their period of critical signalling and hence c/'s-interactions 
are unlikely to prove significant.
Comparing Corticospinal and Rubrospinal Tract responses to Lateral 
Column Injury
Evaluating the role of any single protein in a process as complex as spinal 
cord injury is difficult. Fortunately, the rubrospinal tract does not express 
EphA4321, 323 and, to date, has not been found to be developmental^ 
regulated by ephrin signalling of any kind. In all other respects the two 
descending motor tracts should respond to lesion in an identical manner. The 
lateral CST (LCST) and the RST also run in close proximity within the lateral 
white matter, often with interspersed fibers (Figure 2.17B) hence they can be
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transected by a single injury with confidence that they will experience very 
similar post-lesion conditions. Hence a direct comparison of the post-injury 
response of the LCST and the RST should identify the role of EphA4 
expressed on LCST termination bulbs (Figure 2.7A). As shown in Figure 2.18, 
transected lateral CST axons terminated with intensely BDA-positive 
termination bulbs on average ~200pm more rostral than their EGFP-stained 
RST counterparts. No other differences in gene expression or post-injury 
response published to date explain this difference in behaviour following 
lateral white matter injury. Hence, the likely cause is the presence of growth- 
inhibitory EphA4 present on CST axons that interacts with astrocytic ephrinB2 
and myelin-based ephrinB3
CONCLUSION
An increasingly common theme in spinal cord injury is the emergence of 
developmental guidance proteins as major regulators of the spinal cord 
response to injury. EphA4, the critical regulator of repulsive developmental 
guidance of the CST down the spinal cord around embryonic day 1 7 234*236> 319 
appears to be yet another member of this growing group of proteins. 
Manipulation of the environment within the injured spinal cord to allow useful 
recovery in humans is likely to require a combinatorial approach to overcome 
a number of different inhibitory cues. Indeed, even within the field of operation 
of ephrins and Eph receptors at spinal cord lesions, more complex 
interactions, such as a backwards signalling in which Ephs evoke effects upon 
ephrin expressing cells, may play a role12. Nevertheless, our results suggest 
that blockade or modification of ephrin:Eph receptor interactions may be a 
useful component of a successful treatment strategy.
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Figure 2. Ml
Sample qRT-PCR readout showing Ct analysis
Fluorescence from each well is plotted against the PCR cycle number. A threshold is 
defined that intersects all fluorescence traces in the linear phase. The corresponding 
PCR cycle number (termed Ct) is taken as a quantitative representation of the cycles 
required for that PCR to reach the threshold. Therefore a high Ct value implies more 
cycles were required to reach the expression threshold and hence the initial cDNA 
(and therefore by implication the mRNA and tissue) contained low levels of the gene 
of interest.
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Figure 2. M2
Multiple Sequence Alignment of investigated EphA receptors
Alignment of EphA receptor sequences used for qRT-PCR amplification 
demonstrating the use of primers in DNA regions that demonstrate less conservation. 
In this Multiple Sequence Alignment red characters indicate exact homology between 
all aligned sequences, blue show partially homologous areas and black characters 
represent those bases with no homology between aligned gene family members. 
Dashed regions show that insertions and deletions during evolution of the gene family 
have led to regions that do not correspond between family members.
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EphA3 ATGGATTGTCA---------CCTCTCCATCCTCATCCTGTTCGGCTGCTGCGTCCTCAGCTGCTCCAGGGAACTGAGTCCACAGCCTTCCAACGAAG
EphA7 ATGGTTGTTCAAACTCGGTACCCTTCGTGGATTATTTTGTGTTACATCTGGCTGCTTGGCTTTGCACACACGGGGGAGGCGCAGGCTGCGAAGGAAG
EphA4 ATGGCTGGGATT------TTCTATTTCATCCTCTTTTCGTTTCTCTTTGGAATTTGCGACGCTGTCACCGGTTCTAGGGTATACCCGGCGAATGAAG
EphA6 ATGGGGGGCTGCGAAGTCCGGGAATTTCTTTTGCAATTTGGTTTCTTCTTGCCCCTGCTGACAGCTTGGACCGGCGACTGCAGTCACGTCTCCAACCAAG
TTAATCTACTAGATTCAAAAACGATTCAAGGAGAGCTGGGCTGGATCTCCTACCCATCCCACGG-- GT GGGAAGAGATCAGTG|GTGT TGATGAGCATT ACACACCAjTCAG
TACTGT: A|CTGGACTCGAAAGCACAACAAA|C. -GAATTGGAATGGATTTCCTCTCCACCCAGTGG GTGGGAAG^KTTAGTGGTTTGGATGAGAACTACAflACCAATAAG
TTACTTTATTGGATTCCAGATCTGTTCAGGGAGAGCTTGGGTGGATAGCAAGCCCTCTG|GAAG AAGGG T ■■ GGAGGAAGTAA|3CATTATGGATGAGAAAAATACACCGATCCG 
TTGTGTTGCTTGATACAACTA :|AGTGATGGGAGAACTAGGATGGAA1aA ATATCCACTGAATGG GTGGGATGCCAT| a CTGAAATGGATGAACACAACAGG|ICCATACA
gacttaccaggtatgcaatgtcatggatcacagccaaaataattggctga gg[acaaactgggtgccgagaa^|ctcagctcagaagatc 
AACATACCAGGTGTGCCAGGTCATGGAGCCCAACCAGAACAACTGGCTTCGGACTAACTGGATTTCTAAAGGCAACGCACAAAGGATT
AACCTACCAG|GTATGCAACGT(SATGGAAfldgAGTCAGAACAACTGGCTGCGAACTGACTGGATCACCCGAGAAGGGGCGCAGAGGGTG
TACATACCAGGTATGCAATGTCATGGAACCAAACCAGAACAACTGGCTTCGTACTAACTGGATCTCTCGTGATGCTGCTCAGAAAATC
|5f Primerj [g* primerj
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Figure 2. M3
Multiple Sequence Alignment of investigated ephrinA proteins
Alignment of ephrinA sequences used for qRT-PCR demonstrating the use of primers 
in DNA regions that demonstrate less conservation. In this Multiple Sequence 
Alignment red characters indicate exact homology between all aligned sequences, 
blue show partially homologous areas and black characters represent those bases 
with no homology between aligned gene family members. Dashed regions show that 
insertions and deletions during evolution of the gene family have led to regions that 
do not correspond between family members.
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ephrinAl
ephrinA2
ephrinA5
ephrinA4
ephrinA3
|5' Primer|
ATGGAGTTCCTTTGGGCCCCTCTCTTGGGTCTGTGCTGCAGTCTG-------------------------------------- GCCGCTGTTGACCGCC
ATGGCGCCCGCGCAGCGCCCGCTGCTGCCGCTGCTGCTGTTGCTGCTGCCGCTGCGTGCGCGCAACGAGGACCCGG CCCGTGCCAACGCTGACCGCT
ATGTTGCACGTGGAGA----- TGTTGACGCTGCTCTTT.CTGGTGCTCTGGATGTGTGTGTTCAGCCAGGACCCGGGCTCCAAAGTCGTCGCCGACCGCT
ATGCGGCTGTTGCCCCTGCTGCGGACTGTGCTCTGGGCCGCGCTGCTCGGCTCGCGCCTGCGGGGGTGCTCCAGCCT CCGCC
ACATCGTCTTCTGGAACAGTTCAAATCCCAAGTTCCGAGAG----------------- GAGGACT AC ACCGT GCACGT GCAGCT GAAT GACT AT CT GGA
ACGC^GXCTACTGGAACCGCAGCAalcCCCAGGTTTCAGGTGAGCGCTGTGGfii!iftf®i£iG£0OGfl|p CACCGTGGAGGTCAGCATCAATGACTACCTGGA
ACGCCGTCTACTGGAACAGCAGCAACCCCAGATTCCAGAGG----------------- GGTGACTACCACATCGATGTCTGTATCAATGACTACCTGGA
ACTCTATCTACTGGAACTCCACTAACCCCAGGTTGCT----------------- TCGAGGAGATGCCGTGGTGGAGCTGGGCCTCAACGATTACCTAGA
c a t c a t c t g|c c c a c a t t a c g a g g a c g a c t c t|g t g g c a g a t g c t g c c a t g g a g a g a t a c t c g c t g t a c a t g g t g g a a c a c c a g |g a g t a t g t g a c a i GCGAGj
CATCTATTGCCCGCACTATGGGGCGCCACTGCCCCCGGCAGAGCGCATGGAACGGTACATCCTATACATGGTGAACGGCGAGGGCCATGCCTCCTGTGAC
TGTTTTCTGCCCTCACTATGAGGACTCTGTACCAGAGGATAAG ACTGAG{CGCTATGTCCTGTACATGGTGAA|TTTTGAT : AGTG
CATCTTCTGCCCACATTATGAGAGCCCAGGGCCCCCAG AGGGCCCGGAAACGTTTGCATTATACATAGTGGACTGGTCAGGCTACGAGGCCTGCAAG
ATGGTGAACCTGAGCGGCTACCGCACCTGCAAC
ICCCjCA GTCCAAGGACCAGGTTCGCGTTAAGTGCAACCAGCCCAGTGCCAAGCACGGCCCGGAGAAGCTGTCTGAGAAATTCCAGCGCTTCACGCCTT
C ACCGGCAGCGAGGCTTCAAGCGCTGGGAATGCAACCGGCCCGCTGCGCCTGGGGGACCCCTCAAATTCTCCGAGAAGTTCCAACTCTTCACCCCCT
C ACACATCjCAAAGGGTTCAAGA-ATGGGAJ|TGTAACCGGCCTCACTCTCCAAACGGACCGCTGAAGTTCTCGGAGAAATTCCAGCTCTTCACTCCCT
GCAGAGGGGGCAAAT -CCTTCCAGClGCTGGAATTGCACGCTACCTlTTTGCGCCTTTTGTCCCTGTTCGATTCTCCGAAAAGATTCAGCGCTlTCACACCGTl 
GCCAGCC------ AAGGCTCCAAGCGCTGGGAATGCAACCGG 'AGCACGCCTCGCACAGCCCCATCAAGTTCTCCGAGAAGTTCCAGCGCTACAGCGCCT
T CAC C T T GGG CAAGGAGT T CAAGGAAGGACACAGC T AC TAC TACAT C T C CAAAC C TAT C T ACCATCAGGAAACCCAGTGCCTGAAGTTGAAGGTGAC
TTTCCCTGGGCTTTGAGTTCCGACCTGGACACGAGTACTACTACATCTCTGCCACACCCCCCAACCTTGTGGACCGACCCTGCCTGCGGCTGAAAGTTTA
TTTCTTTAGGATTTGAATTCAGGCCAGGCCGAGAGTATTTCTACATCTCCTCTGCAATCCCAGACAATGGAAGAAGATCCTGCCTAAAGCTCAAAGTCTT
|TCCCGCTG|GGCTTCGAGTTCTTGCCTGGAGAGACTTACTACTACATCTCGGTGCCAACTCCGGAGAGTCCTGGCCAG TGCCTGAGACTCCAGGTGTC
TCTCGCTGGGCTATGAATT|CCATGCCGGCCAAGAA|. .CTACTATATCTCCACGCCCACTC ACAACCTGCA|TtG^AGTGTCTGAGGAT^AGG|TGTT
|3^ Primed
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Figure 2.M4
Multiple Sequence Alignment of investigated ephrinB proteins
Alignment of ephrinB sequences used for qRT-PCR demonstrating the use of primers 
in DNA regions that demonstrate less conservation. In this Multiple Sequence 
Alignment red characters indicate exact homology between all aligned sequences, 
blue show partially homologous areas and black characters represent those bases 
with no homology between aligned gene family members. Dashed regions show that 
insertions and deletions during evolution of the gene family have led to regions that 
do not correspond between family members.
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ephrinB2 ATGGCCATGGCCCGGTCCAGGAGGGACTCTGTGTGGAAGTACTGTTGGGGACTTTTGATGGTTTTGTGCAGAACTGCGATCTCCAGATCGATAGTTTTAG 
ephrinB3 ATGGGGGGCCCCCATTTTGGGCCAGGGGGTGTGCAAGT----------------------------------------------------------
AGCCTATCTACTGGAATTCCTCGAACTCCAACCACACGGGATCTACAGGCACCTGGTGGTGCCAGAAGGCGCCTGGCTGGGATCTGAGCGCTGCAGCCTT 
--------------------------------------------CGGGGCCCTGCTGCTGTTAGGTTTTGCGGGGCTGGTGTCTGG------------
c t t c a c t c a g a c t g g g g c c c t g g t g g t g g c t g c t g c t g a c g c t c g c c g t g|c c t a c a g a g c a c a t g g a a a c g a|c c a g g a c a a c a a a g g g c t c c g t g c a t g c
 ACTCAGCCTGGAGCCT------------------    —
TCTGTTCCTG|GAATTGATGGGATCT€lfCTGGC|ATGCCCAATAAACCAGATGCCAATGGTTAAAAAAATAACAAACAGGTGGGACGGTCTGACTCACCACC
GGGGGAAGAGTTGTAAAATCCGCACAAAAGAGTACTGGAGTATTGCAAGGGCAAGATTTCTACCCGGACAAGGCCTGGTACTATACCCACAGATAGGAGA 
---------------------------- GTCTACTGGAACTCGGCGAATAAGAGGTTCCAGGCAGAGGGTGGTTACGTGCTTTACCCTCAGATCGGGGA
CAAAT T GGATAT TAT T T GC CC CAAAGT G-------- GACTCTAAAACTGTTGGCCAGTATGAATATTATAAAGTTTATATGGTTGATAAAGAGCAAGCC
CCGGCTAGATCTACTTTGTCCCCGGGCCCGGCCTCCTGGCCCCCACTCCTCTCCTAGTTATGAGTTCTACAAACTGTACCTGGTAGGGGGTGCCCAGGGT
GACAGAT G CAC TAT TAAGAAG GAAAATAC C C CAC T GC T CAAC T G T G C CAGAC CAGAC CAAGAT GT GAAAT T CAC CAT CAAG T T C CAAGAAT T CAGC C C TA 
CGGCGTTGTGAGGCACCCCCTGCCCCAAACCTTCTTCTCACATGTGACCGGCCAGACCTGGACCTCCGCTTCACCATCAAGTTCCAGGAATACAGCCCTA
ACCTCTGGGGTCTAGAGTTTCAGAAGAACAAAGATTACTACATTATATCTACATCAAATGGGTCTTTGGAGGGCCTGGATAACCAGGAGGGAGGGGTGTG
ACCTCTGGGGCCACGAGTTCAGATCCCACCACGATTACTACATAATTGCCACATCAGATGGGACCCGGGAAGGCCTGGAGAGCTTGCAGGGAGGTGTGTG
CCAGACAAGAGCCATGAAGATCCTCATGAAAGTTGGACAAGATGCAAGTTCTGCTGGATCAACCAGGAATAATGATCCAACAAGACGTCCAGAGCTAGAA 
CCTAACCAGAGGCATGAAGG' G [TTCTGCGAGTGGGACAAAGTC| CCGAGGAGGAGCTGTACCCCGAAAACCTGTGTCTGBfi/TGCCCATG . AGi -.Cl
GCTGGTACGAATGGGAGAAGTTCAACAACAAGTCCCTTTGTGAAGCCA— AATCCAGGTTCTAGCACCGATGGCAACAGCGCGGGGCATTCCGGGAACAA 
CGAGGGGCAGCTC---------- ACAGCCAGGAGCCTGGGAAGGACAGCATACCAGGTGACCCCAACAGCAATGCAACCTCCCGGGGTGCTGAAGGCCC
|5' Primer! [3f Primer]
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Figure 2.1
Example primer efficiency plots
Typical serial dilution graphs for primer efficiency calculations (EphA4 and EphA6 
receptors shown). Ct values for the EphA4 and EphA6 receptors in serially diluted 
hippocampal cDNA plotted against the log (base 10) of the relative cDNA 
concentration. Starting cDNA concentrations were approximately 0.2ng/jjl and good 
data was obtained from dilutions of O.lpg/pl. As shown, regression analysis of the 
best-fit lines was good, indicating a good assay sensitivity for a range of cDNA 
concentrations.
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EphA4 and EphA6 Receptor Example Efficiencies
■ EphA4 o EphA6
EphA4 Receptor EphA6 Receptor
y = -3.4849X + 20.21 
R2 = 0.9976
y = -3.3078x + 19.977 
R2 = 0.9979
-0.5 -1.5 -2 -3 -3.50 ■1 -2.5
Log (Relative cDNA Concentration)
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Figure 2.2
Table of primers used in the qRT-PCR study
Primers were designed using the Primer Express Software (Ambion) due to the 
stringent conditions required for the LightCycler qRT-PCR machine. Primer annealing 
temperatures (Tm) were designed to be as close to the optimum of 59°C as possible 
and amplicons were maintained in the 60-120bp range to facilitate reliable and rapid 
replication.
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Figure 2.3
Thermal dissociation graphs for qRT-PCR products
A-C. Plot of the thermal dissociation curve analysis for EphA (A), ephrinA (B) and ephrinB 
(C) qRT-PCR products. All but one RT-PCR product yielded a single fluorescence 
change peak indicating a highly specific PCR with minimal background signal. Control 
PCR dissociation profiles using control cDNA preparations where no reverse 
transcriptase was included yielded no DNA product, as shown, indicating the absence 
of genomic, or other, contamination.
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Figure 2.4
Relative EphA and ephrinA mRNA expression from qRT-PCR data
A-B. EphA receptor (A), ephrinA ligand (B) and Matrix Metalloprotease-2 (A) mRNA 
expression in spinal cord 7 days following control laminectomy, dual dorsal 
hemisection or controlled weight crush injuries. Mean ± SEM, n = 4 for each data set. 
* p < 0.05; unpaired f-test.
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Figure 2.5
Relative ephrinB mRNA expression from qRT-PCR data
EphrinB mRNA expression in adult rat spinal cord 7 days following control 
laminectomy, dual dorsal hemisection or controlled weight injuries. Mean ± SEM, n = 
4 for each data set. * p < 0.05, ** p < 0.001; unpaired f-test.
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Figure 2.6
Immunohistochemical localisation of EphA4 receptor expression
A. EphA4 staining of control, uninjured adult Sprague-Dawley rat spinal cord tissue.
Horizontal section taken through the dorsal corticospinal tract (*) showing no EphA4 
expression with EphA4-positive dorsal horn grey matter (#) on either side. Scale bar 
150pm.
B. EphA4 staining (green) of control, uninjured adult Sprague-Dawley rat spinal cord
tissue. Horizontal section taken though the dorsal CST (*) with EphA4-positive dorsal 
horn grey matter visible (#). BDA labelling of the CST with streptavidin-Alexa568 
processing (red) indicates that the CST in this region of cord is EphA4-negative. 
Scale bar 150pm.
C. Horizontal section through the dorsal corticospinal tract showing EphA4 staining. The 
lesion centre is highlighted by the dotted line and the retraction of the EphA4-positive 
CST (arrow) is clearly visible. White matter rostral and caudal to the lesion site is 
EphA4-negative (*) unlike the grey matter which shows minimal change in EphA4 
expression proximal or distal to the injury (#). Punctate EphA4 expression is also 
visible caudal to the lesion site (triangle). Negative control immunohistochemistry 
using an identical protocol but excluding the primary antibody shows only normal 
tissue autofluorescence (square indentation). Scale bar 500pm.
D. Higher magnification image of Figure 2.8C highlighting the axonal appearance of the
EphA4 staining (arrows) with the EphA4-dense termination bulbs closer to the lesion 
(triangles). Scale bar 150pm.
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Figure 2.7
Immunohistochemical localisation of EphA4 receptor expression
A. Lesioned lateral white matter axons expressing EphA4. Horizontal 14pm fresh frozen
section taken through the lateral corticospinal tract seven days following dorsal 
hemisection. Lateral corticospinal tract fibres with strong EphA4 expression are 
sparse but this axon demonstrates a clear EphA4-poisitive process with obvious 
termination bulbs at the end of abortive sprouts (arrows). Scale bar 50pm.
B-D. EphA4 receptor expression (A) colocalises with BDA labelling of the CST (C).
Horizontal 14pm fresh frozen section taken through the dorsal corticospinal tract. To 
preserve the EphA4 antigen only a brief fixation was performed hence BDA labelling 
appears diffuse. Hence, some diffusion of BDA from the CST fibres occurs. However, 
it is apparent that EphA4 appears to be predominately located in the main part of the 
lesioned CST, rather than the smaller off-shoots and processes (arrows). Scale bars 
50pm.
E. Fresh frozen 14pm section through the dorsal grey matter showing EphA4-positive
blood vessels (green) associated with GFAP-positive astrocytes (red). Scale bar 
50pm.
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Figure 2.8
The EphA4 receptor is expressed in GFAP-positive astrocytes
A-C Fresh frozen 14|jm section through the dorsal grey matter showing GFAP-positive 
grey matter astrocytes (red, A) expressing the EphA4 receptor (green, B). Merging 
these images with bisbenzamide staining for DNA (blue, C) demonstrates that EphA4 
is present throughout most of the astrocytic processes (arrows) and the cell body 
(triangle). Scale bars 50pm.
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Figure 2.9
EphA4 positive puncta rostral to a spinal cord injury are not microglial but do 
associate strongly with astrocytes
A. EphA4-positive puncta present in the caudal region of the lesion site (arrows) do not
have any distinct morphology by which they can be identified. Scale bar 100pm.
B-D. OX-42 staining for macrophages and microglia (red, B) shows no colocalisation with
the EphA4-positive puncta (green, C and D). Scale bars 50pm.
E. GFAP staining (red) reveals reactive astrocytes closely associated with these EphA4
positive puncta (green). Bisbenzamide staining (blue) indicates the puncta contain no 
genetic material suggesting they are either termination bulbs from ascending tracts or 
degenerating EphA4-positive CST axon fragments. Scale bar 50pm.
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Figure 2.10
Pyramidal cells do not upregulate EphA4 expression following spinal cord injury
A-B. Coronal 14pm fresh frozen section from a control adult rat brain. In situ hybridisation 
for EphA4 mRNA expression using antisense (A) and control, sense (B) probes. 
EphA4 mRNA is localised to the hippocampus (h) and layers ll-VI of the motor cortex 
(m). Non-specific probe binding is negligible (B). Scale bars 750pm.
C. Coronal 14pm fresh frozen section from an adult rat brain seven days following a 
dorsal hemisection that fully transected the dorsal and lateral corticospinal tract. In 
situ hybridisation for EphA4 mRNA expression reveals EphA4 mRNA localised to the 
hippocampus (h) and layers ll-VI of the motor cortex (m). Scale bar 750pm.
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Figure 2.11
EphA4 receptor localisation by in situ hybridisation
A. Coronal 14pm fresh frozen section from an adult rat brain highlighting the site of a
needle puncture. In situ hybridisation for EphA4 mRNA expression reveals an 
upregulation in the expression of EphA4 in motor cortex nuclei local to the injury. 
Scale bar 50pm.
B. Coronal 14pm fresh frozen section from an adult rat brain highlighting the lateral 
ventricle. EphA4 mRNA is strongly expressed in unidentified cells in the lining and 
plexus of the ventricle and a similar expression pattern is seen in other ventricles. 
Scale bar 150pm.
C. Horizontal fresh frozen 14pm section of the control adult rat spinal cord showing
EphA4 mRNA localised to strongly expressing grey matter (#) cells and more weakly 
expressing white matter (*) cells. The in situ staining pattern and
immunohistochemical data suggests these cells are likely to be astrocytes. Scale bar
200pm.
D. Horizontal fresh frozen 14pm section of the adult rat spinal cord seven days following 
injury demonstrating how the lesion epicentre becomes strongly EphA4 mRNA- 
positive with a likely combination of white matter astrocytes upregulating expression 
and reactive grey matter astrocytes invading the lesion site. Scale bar 200pm.
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Figure 2.12
Grey matter astrocytes express ephrinB2
A-C. Horizontal 14pm fresh-frozen section through the uninjured dorsal corticospinal tract 
showing that GFAP-positive grey matter (#) astrocytes (red, A) strongly express 
ephrinB2 (green, B) while the less GFAP-positive white matter (*) astrocytes do not. 
Some weak staining of dorsal horn grey matter neurons was also apparent (arrows, 
C). Scale bars 200pm.
D-E. Higher magnification images of uninjured spinal cord confirm this colocalisation of 
GFAP (red, D) and EphA4 (green, E). Interestingly, merged images with 
bisbenzamide staining for DNA (blue, F) indicate that while GFAP expression is 
strongest close to the nucleus, EphA4 staining appears to extend throughout all the 
astrocyte processes with comparable intensity (arrows, E). Scale bars 50pm.
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Figure 2.13
Astrocytes upregulate ephrinB2 expression following spinal cord injury
A-B. Low magnification image of a horizontal 14pm fresh frozen section through the dorsal 
corticospinal tract seven days following dorsal column transection. GFAP-positive 
astrocytes (green, A) strongly upregulate GFAP expression when undergoing gliosis 
in the vicinity of the lesion site. EphrinB2 in these astrocytes is similarly upregulated 
(red, B). Expression of both antigens is strong in the white (*) and grey (#) matter 
rostral and caudal to the injury although the spread of ephrinB2 expression does not 
appear as extensive. Scale bars 500pm
C-E. Higher magnification images of the grey/white matter margin near the lesion site. The 
expression margin of GFAP (red, C) and ephrinB2 (green, D) between the grey (#) 
and white (*) matter near the lesion site has become indistinct. The two proteins still 
strongly colocalise but expression in the white matter is now comparable to that seen 
in the grey matter. A combination of invading ephrin-B2 positive reactive grey matter 
astrocytes and upregulation of GFAP and ephrinB2 in surviving white matter 
astrocytes is likely to cause this expression change. Scale bars 200pm.
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Figure 2.14
EphrinB2-positive astrocytes surround the lesion site
A-C. Horizontal 14pm fresh frozen section showing the margin of the grey matter 
astrocytes at the lesion cavity (*) seven days following dorsal column injury. GFAP- 
positive reactive astrocytes orient their processes towards the lesion epicentre (red, A 
and D) and ephrinB2 expression in these cells and their processes is clear (green; B 
and C, E and F). Scale bars 100pm.
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Figure 2.15
The EphA4-positive CST is surrounded by ephrinB2-positive astrocytes after injury
A-C. Horizontal 14|jm fresh frozen section through the transected dorsal corticospinal tract 
seven days following injury. EphA4 in the corticospinal tract (green, A) is clearly in 
close proximity to ephrinB2-positive astrocytes (B) at the lesion margin (C). Scale 
bars 150pm.
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Figure 2.16
Immunohistochemical localisation of the ephrinB2 protein
A-C. Horizontal 14pm fresh frozen section though a dorsal root entry zone in the thoracic 
region. Sensory neuron axons originating in the dorsal root ganglion are ephrinB2- 
positive (green, A) although this expression diminishes as they approach the GFAP- 
positive DREZ (red, B and C). Scale bar 200pm.
D. Horizontal 14pm fresh frozen section though a dorsal root ganglion in the thoracic 
region. Small- and medium-sized DRG neurons are strongly ephrinB2-positive, as are 
their processes. Scale bar 200pm.
104
105
Figure 2.17
The CST and RST tracing methods do not co-label any axonal tracts
A. Coronal 40|jm section through the perfused rat brain following corticospinal tract 
labelling by BDA injection to the motor cortex and rubrospinal tract labelling by EGFP- 
expressing lentivirus injection to the red nucleus. The section is taken just caudal to 
the level of red nucleus injection and the distinct expression domains of the BDA (red) 
and EGFP (green) are clear. Scale bar 500pm.
B. Transverse section of the lateral white matter from an animal receiving EGFP- 
expressing lentivirus to the red nucleus and BDA to the motor cortex. Lateral CST 
(red, arrows) and RST (green) fibres intermingle and occupy similar fields of the 
lateral white matter. Scale bar 100pm.
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Figure 2.18
The EphA4-positive CST retracts further following injury than the EphA4-negative RST
A-B. EGFP-positive RST axons (green) are seen to retract to a smaller extent than BDA- 
positive CST axons (red). Hence the mean distance of RST termination bulbs from 
the lesion margin (delineated by the dotted line) is less than that for the lateral CST. 
Quantifying these regeneration distances for a series of animals (n = 3) highlights this 
difference in regenerative capacity (B, mean ± SEM). Scale bar 250pm.
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Comparing CST and RST Retraction following Lesion
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Chapter III
Production and Implantation of CHO Cell Lines Secreting 
Blockers of Ephrin Signalling
Abstract
Given the likely role of ephrin signalling in spinal cord injury as a negative 
regulator of regeneration and a possible mediator of the formation of the 
growth-inhibitory basal lamina, a method of neutralising ephrin signalling to 
encourage spinal cord regeneration was pursued. The aim of the project was 
to produce stably-transfected cell lines secreting monomeric ephrin/Eph 
ectodomains that would be capable of binding endogenous ligand and 
receptors. Implantation of these cell lines would permit a continuous supply of 
blocking protein to a lesion site and hence interrupt any ephrin signalling. 
EphrinBI, EphB3, EphA7 and ephrinA5 were selected for their ability to bind 
promiscuously and with high affinity to many Eph/ephrins identified as 
potentially important in the damaged spinal cord. An in vitro collapse assay 
using E6 chick retinal ganglion cell growth cones exposed to dimerised 
ephrinA5-Fc showed that the ephrinAS and EphA7 ectodomains worked 
effectively and rapidly to prevent ephrinA5-Fc induced collapse. Preliminary 
implant studies using an EGFP-expressing cell line identified complications 
with immune rejection, proliferation of implanted cells and meningeal fibroblast 
invasion of the collagen gelfoam implant support. A pilot study using a stable 
cell line secreting ephrinA5 ectodomain or a control cell line demonstrated 
encouraging improvements in the regeneration of the corticospinal tract 
through increased termination bulb sprouting and the formation of 
regenerative sprouts that reached as far as the lesion margin. However, 
proliferation of the implanted cell line led to deformation of undamaged 
regions of spinal cord. Hence, while the approach of inhibiting ephrin 
signalling in the post-injury spinal cord environment appears to be beneficial, 
the use of implanted cell lines is not a viable long-term means of 
administration.
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METHODS
Design of PCR Primers
To produce the desired protein ectodomains that would bind to endogenous 
ephrin ligands and Eph receptors, primers were designed to incorporate the 
entire ligand or receptor binding domain as appropriate. Each primer 
consisted of 6 bases of random sequence (ATGGAT) to permit binding of the 
Taq polymerase to the DNA followed by the desired digestion enzyme 
recognition sequences for subsequent ligation into pEF-BOS. In the 3' 
primers, a TTA STOP codon was introduced and in the case of the ephrinA 
ligand this was placed before the GPI attachment sequence406 to ensure the 
translated product was not retained at the cell membrane. 16 to 19 bases of 
gene-specific sequence were then attached to the end of this non-specific 
sequence. In all cases, the locations of the digestion enzyme recognition sites 
were held in frame with the coding sequence to permit fusion protein 
production.
Primer sequences were based on published rat sequences or were derived 
from n-BLAST searches of rat genome using published mouse sequences.
EphrinBI primers were designed based on the published mRNA sequence for 
Rattus norvegicus ephrinBI [GenBank: gi 8393301; ref NM_017089.1]. 
Forward primer sequence
ATCGATTCTAGAACGCGTACGCCGTTGGCCAAGA 
Reverse primer sequence
ATCGATACGCGTTTAGGAGTTAAAGAAGCTGTCG
EphB3 primers were designed using a BLAST search of the published NCBI 
rat genome using the published mRNA sequence for the Mus musculus 
EphB3 receptor [GenBank: gi 20892082; ref XM_148146.1].
Forward primer sequence
AT CGAT GAATT CACGCGTT GCT GGGCGCT GGAAG 
Reverse primer sequence
AT CGATACGCGTTTAAGT GGT GGATGCACACTT C
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EphrinA5 primers were designed based on the published mRNA sequence for 
Rattus norvegicus ephrinA5 [GenBank: gi 16758777; ref NM_053903.1]. 
Forward primer sequence
AT CGAT GGAT CCACGCGTAAAGT CGT CGCCGACC 
Reverse primer sequence
ATCGATACGCGTTTATGGCTCGGCTGACTCA
EphA7 primers were designed based on the published mRNA sequence for 
the Rattus norvegicus EphA7 receptor [GenBank: gi 19705436; ref 
NM_134331.1].
Forward primer sequence
AT CGAT GGAT CCACGCGT GAGGCGCAGGCT GCG A 
Reverse primer sequence
AT CGATACGCGTTTAGGACCAGCACTT CTT GTAG
PCR and cloning
Rat whole brain RNA was made from the complete brain of an adult female 
200g Sprague-Dawley rat dissected using sterile instruments. The tissue was 
cleaned in RNase-free PBS and homogenised in TRIzol (Invitrogen). The 
material was then centrifuged at 3500rpm for 10min to clear remaining 
sediment and phase-separated using 20% chloroform. An upper, aqueous, 
phase that contained the tissue RNA was precipitated at -80°C with 
isopropanol overnight, washed with ethanol and resuspended in RNase-free 
distilled water. Complete cDNA was prepared from 1 pg of RNA using random 
hexamers (25mM, Promega), dNTPs (500pM, Promega), RNasin (2U, 
Promega) and AMV reverse transcriptase (20U, Promega) for 45min at 42°C. 
Initial cloning PCRs were performed using rat whole brain cDNA and 
subsequent PCR used the appropriate PCR product for second-round 
amplification. PCR products were analyzed on 1% agarose gels to ensure the 
presence of product. The product was gel purified and then digested with the 
appropriate digestion enzymes (all from Promega), as was purified vector 
DNA. Gel purification to select the appropriate digestion product was followed 
by ligation and transformation of ultracompetent E. coli (JM-109, Promega).
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Colony selection and clone analysis through Mini-Prep (Qiagen Mini-Prep Kit) 
and restriction enzyme digestion permitted the production of large DNA 
quantities that were sent for sequencing analysis (DNA Sequencing Facility, 
Biochemistry Department, University of Cambridge) to confirm successful 
cloning (Figures 3.M1-3.M8).
Initially ectodomain inserts were cloned into pEF-BOS, a mammalian 
expression vector407, to add immunorecognition and secretion signal tags to 
the eventual translation product. The enlarged insert was then cloned into 
pCS2+ to permit high level expression in transfected cells. Inserts were 
cloned into the Mlul IL-3/c-myc cloning site of pEF-BOS (Figure 3.M9A). This 
provides an N-terminal domain secretion signal derived from the lnterleukin-3 
(IL-3) gene that induces strong mammalian expression407 and is cleaved 
subsequent to secretion of the protein. The vector also encodes a c-myc C- 
terminal domain tag that permits tracing and purification through 
immunorecognition at this c-myc domain. Following successful insertion of 
correctly-oriented inserts into pEF-BOS, the ~750bp Xbal digestion fragment 
containing the DNA coding for the complete fusion protein was inserted into 
the Xbal cloning site of pCS2+, a high-level transient mammalian expression 
vector408 (Figure 3.M9B). The calcium phosphate precipitation method 
(Calcium Phosphate Transfection Kit, Promega) was used to transiently 
transfect Human Embryonic Kidney (HEK) and Chinese Hamster Ovary 
(CHO) cells with the pEF-BOS and pCS2+ vectors at each cloning stage to 
check for successful expression. 96 hours post-transfection the medium was 
harvested, centrifuged for 1min at 2000g to pellet cell debris and then 
centrifuged for 15min at 2000g at room temperature through 10kDa NWM 
size-exclusion filters (Millipore). This yielded roughly 1ml supernatant per 
10ml growth medium.
Cell Culture Media and Techniques
Standard aseptic cell culture techniques were used throughout. All work was 
performed in a class II laminar flow tissue culture hood. HEK and CHO cells 
were maintained at 37°C, 5% CO2 in culture flasks containing supplemented 
DMEM medium (Dulbecco’s Modified Eagle’s Medium, High Glucose, with
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FBS (foetal bovine serum), 10%; and occasionally also penicillin/streptomycin, 
1%; final concentrations 5,000 units/ml and 5 mg/ml, respectively) or serum- 
free and protein-free medium for CHO cells transfected with ectodomains for 
use on SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis) gels.
Transfection of HEK and CHO cells
24hr before transfection HEK or CHO cells were split and plated (at 106 cells 
per dish) onto 10cm diameter cell culture dishes. Following 24hr incubation 
(37°C, 5% C02), 20pg of DNA was used to transiently transfect the cells 
(using the calcium phosphate precipitation method). 24 hours post­
transfection cells were washed twice in sterile PBS and returned to the 
incubator with fresh pre-warmed medium for a further 48 hours. Cytoplasmic 
(3-galactosidase (in pCS2+) was used in a control transfection dish to assess 
the transfection ratio. The (3-galactosidase plate was washed with PBS 24hrs 
post-transfection then fixed (2% w/v formaldehyde in PBS, 5min, 4°C), rinsed 
with PBS and stained (X-gal 1 mg/ml, potassium ferricyanide 5mM, potassium 
ferrocyanide 5mM, magnesium chloride 2mM) for p-galactosidase expression 
for 30min at 37°C. Transfections producing a transfection ratio of less than 
25% after 24hrs were discarded.
Alkaline Phosphatase-tagged Eph and Ephrin ectodomains
The RAP (Receptor Affinity Probe or Receptor Alkaline Phosphatase) staining 
method304, 409, 410 uses soluble protein ectodomains fused to secreted 
placental alkaline phosphatase (SEAP411) to locate binding sites within cells or 
tissues. APtag-1 vector (alkaline phosphatase, Figure 3.M10A) containing 
EphA3 or ephrinA5a was used to transiently transfect HEK cells via the 
calcium phosphate precipitation method. The APtag-1 vector induces 
secretion of the EphA3 or ephrinA5a extracellular domain fused to SEAP, 
which can be visualised chromatogenically following binding and fixation412.
To assay the level of ephrinA5 or EphA7 protein ectodomain expression 
EphA3-AP or ephrinA5a-AP fusion proteins were used as detection agents. 
The full method used is published on the Science STKE website413; briefly,
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HEK293 cells are transfected with one AP-tag construct (or an empty 
construct for negative controls) using the calcium phosphate method. 96 
hours post-transfection the medium is harvested, centrifuged for 1min at 
2000g to pellet cell debris and then centrifuged for 15min at 2000g at room 
temperature through 10kDa NWM size-exclusion filters. The AP-tagged 
protein concentration in any sample was assayed using serial dilutions and 
addition of p-Nitro phenyl phosphate substrate (pNPP, Sigma) with detection 
at 405nm. The known rate constant of SEAP means that a change of 15 OD 
units over a 30 minute time period corresponds to 1pmol of AP-tagged 
protein.
Detection of Secreted Eph/Ephrin Ectodomains
Semi-purified supernatant derived from size-exclusion spin preparations was 
applied for 2hrs to 96-well plates coated in anti-c-myc antibody (Sigma), wells 
were then washed three times in PBS-0.1T PBS containing 0.1% Tween-20, 
Sigma). 2.5nM ephrinA2-AP fusion protein was then applied to each well for 
2hrs, following three washes in PBS-0.1T, bound alkaline phosphatase was 
detected using the p-Nitro phenyl phosphate substrate system (pNPP) with 
detection at 405nm.
Immunoprecipitation and Coomassie Staining
Protein A (0.2g, Invitrogen) was resuspended in 40ml of distilled water and 
allowed to swell for 2 hours followed by two washes in distilled water. Beads 
were then spun at 1500rpm and resuspended in immunoprecipitation (IP) 
buffer (50mM Tris HCI, 150mM NaCI, pH 7.0). Ectodomain protein samples 
were adjusted to 0.5ml with IP Buffer and anti c-myc antibody added at 
1:2000. Samples were rocked gently for one hour at 4°C when 50pl of Protein 
A slurry in prechilled IP Buffer was added. Samples were gently rocked for a 
further hour at 4°C and then spun at 10,000g for 30sec at 4°C. The 
supernatant was removed and the remaining protein A material was washed 
three times with IP Buffer at 4°C with gentle rocking. Following a further spin 
at 10,000g for 30sec, gel loading buffer was added and the sample was boiled 
for 10min. The supernatant from a final centrifugation at 10,000g was loaded 
onto a 10% Tris-HCI SDS-PAGE (Bio-Rad pre-cast gels) and electrophoresed
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at 200V with constant current. Coomassie staining was performed with 
BioSafe Coomassie (Bio-Rad) for one hour with gentle rocking followed by 
extensive washing with distilled water.
Anti-c-myc Western Blotting
Samples were placed at 95°C in Laemmli Buffer for five minutes before being 
loaded onto 10% Tris-HCI SDS-PAGE pre-cast gels (Bio-Rad) and 
electrophoresed at 200V with constant current. Electrophoresed protein was 
then transferred onto nitrocellulose (Amersham) by semi-dry transfer blotting. 
Polyacrylamide gels were equilibrated in semi-dry transfer buffer for 20 
minutes before being transferred for one hour at 15V. Nitrocellulose 
membranes were washed three times for five minutes in PBS-0.05T (PBS 
containing 0.05% Tween-20) before being blocked for one hour at room 
temperature in PBST containing 5% non-fat dried milk powder (Sainsbury’s, 
UK). Membranes were then incubated overnight at 4°C in PBS-0.05T 
containing 1% milk supplemented with rabbit anti-c-myc antibody (1:5000, 
Covance). Three washes in PBS-0.05T were performed followed by two hour 
incubation in goat anti-rabbit-HRP secondary antibody (1:25,000, Autogen 
Bioclear) at room temperature. Following three washes in PBS-0.05T, 
membranes were developed in ECL Plus Western Detection reagent 
(Amersham Biosciences) and visualised using photosensitive film (Kodac).
Stripe Assays
The stripe assay, an axon pathfinding assay based on the chick retinotectal 
mapping system where EphA3-expressing retinal ganglion cells (RGCs) are 
guided by repulsive gradients of ephrinA5414, was investigated as a possible 
assay of the efficacy of the secreted ectodomains in blocking ephrin 
signalling. The assay involves the production of alternating 90pm width stripes 
of substrate with/without ephrinA5 such that axons growing out from RGCs 
are faced with a choice of substrate301, 3051 363, 415' 416. Previous work has 
indicated that RGCs avoid the ephrin-containing lanes, growing solely on the 
lanes of control substrate. Addition of soluble ephrinA5 or EphA7 ectodomains 
would be expected to block ephrin signalling and permit growth on either 
lane417"419
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Two different types of stripe substrate were used. When soluble proteins were 
used as the test substrate, stripes were deposited on a glass substrate. When 
cell membranes were used as the source of the test agent, the stripes were 
created on 0.1pm pore size filters.
Glass coverslips were treated with 1% acid alcohol for 2hrs, rinsed twice in 
sterile water and maintained in 70% ethanol at 4°C until used. Before use, 
coverslips were placed on 3MM filter paper (Whatman) and autoclaved, 
cooled and coated with poly L-lysine. Following aspiration and two rinses in 
sterile water, coverslips were dried and pressed onto silicone matrices (Figure 
3.M10B; Bonhoeffer laboratory, Max-Planck Institute, Tubingen, Germany).
The primary stripe agent, 10pg/ml anti-human Fc antibody (~10pl, Sigma) was 
injected into the matrices and incubated at 37°C for 1 hr. Sterile PBS was then 
injected through the matrices to wash the stripes. Coverslips were removed 
from the matrices and natural mouse laminin (5pg/ml, Invitrogen) was applied 
to the whole coverslip to provide a general growth-supporting layer against 
which any repulsion or avoidance behaviour could be observed. Each 
coverslip was then incubated with growth medium containing 10% foetal calf 
serum (FCS, Sigma) to block any non-specific binding. The coverslips were 
then washed in PBS and incubated with either homodimeric human Fc-tagged 
ephrinA5 or human IgG (both 20pg/ml, Sigma) at 37°C for one hour. 
Coverslips were placed in growth medium consisting of F12, 86%; FCS, 10%; 
chicken serum, 2%; 200mM L-Glutamine, 1%; and penicillin/streptomycin, 1% 
(final concentrations 5000 units/ml and 5 mg/ml, respectively) supplemented 
with 0.4% methylcellulose (all from Sigma)
Filter-based stripes were made in a two-step process420; a 0.1pm Whatman 
polycarbonate filter was placed onto a polymerised silicone rubber ‘grill’ 
consisting of horizontal channels 90pm in diameter and 9mm in length. This 
grill was then placed on a porous glass frit support through which a vacuum 
was applied to the microchannels (Figure 3.M11A). 150pL of the primary 
stripe agent was applied to the surface of the filter. The concentration of
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primary stripe agent was calibrated to fully block the filter after 10OpL of the 
suspension had been sucked through. 0.03bar suction was applied until the 
filter was blocked and then surplus liquid was removed and the filter placed on 
a nylon grid supported on another porous glass frit (Figure 3.M11B). 150pL of 
the secondary stripe agent was applied and 0.03bar suction applied to fill the 
alternating stripes. The filter was rinsed in PBS solution and then placed in 
culture medium (without methylcellulose) until use.
Resolution between the two stripes was good with both methods (See Figure 
3.M11C) and this was preserved regardless of the substrate type and period 
of incubation.
Retinal Ganglion Cell Culture and Visualisation of Axons on Stripe Substrates 
Retinas were dissected from 6-day-old chick embryos in Hank’s Buffered 
Saline Solution (HBSS, Sigma). After removal of the pigment epithelium and 
vitreous body, the retina was spread on a 0.4pm Whatman nucleopore filter. 
Retina and filter were chopped together in a Mcllwain tissue chopper into 
250pm width strips and placed inverted on either glass coverslip or filter 
stripes. RGC/filter strips were held in place with platinum weights and 
incubated at 37°C and 5% CO2 in the minimum volume of medium required to 
cover the explant in order to enhance adhesion of the explant to the stripes. 
After 1hr, 250pL of pre-warmed medium (containing methylcellulose) was 
added and explants were incubated at 37°C and 5% CO2 for 40-48hrs.
Cultures were then fixed (2% w/v formaldehyde, 0.33M sucrose in PBS) for 
4hrs at 4°C, washed twice in PBS, permeabilised with Triton X-100 (0.1% w/v 
in PBS, Sigma), washed twice in PBS and stained with phalloidin-Alexa 488 
(1:40, Molecular Probes) for 20min at room temperature. After being washed 
twice in PBS, stripes were visualised using a goat anti-human Fc primary 
antibody (1:1000, Sigma) and a rabbit anti-goat secondary antibody coupled 
to Alexa-594 (1:400, Molecular Probes). Coverslips could be viewed directly 
under a fluorescence microscope. Filter-based cultures were inverted onto 
Petri-perm dishes and then analysed.
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Neurite Outgrowth Assay
The neurite outgrowth assay421 is based on in vitro assays used to assess the 
effects of astrocytes on dendrite or axon outgrowth from neuronal explants422. 
HEK cells or HEK cells transiently transfected with full-length ephrinA5a were 
grown to near-confluency (-85% , to permit further growth of cells during the 
experiment without reaching over-confluency). Culture medium was then 
replaced with RGC culture medium (this change induced no obvious 
phenotypic change in the HEK cells). An E6 chick retina was then dissected 
as normal and then dispersed with collagenase and repeated pipetting. RGCs 
were seeded onto the HEK cell monolayer, maintained in position by surface 
tension, and allowed to adhere. 48hrs later plates were fixed and 
immunocytochemically stained with a mouse anti-neurofilament antibody 
(1:500, Sigma) and Alexa 594 coupled goat anti-mouse secondary (1:400, 
Molecular Probes). Ectodomains were added in the co-culture stage where 
necessary and the average axonal lengths for neurons were assessed under 
a fluorescence microscope.
Collapse Assay
10mm diameter glass coverslips were treated with 20pg/ml poly-L-lysine for 
30min at room temperature, washed in sterile PBS and then incubated with 
25pg/ml mouse laminin for 1 hr at 37°C. Following two washes in PBS 1ml of 
RGC medium was added to each well and placed at 37°C in 5% CO2 until 
addition of primary retinal cultures. Temporal E6 chick retinas were chopped 
into -1mm2 squares and then triturated manually in Ca2+/Mg2+-free HBSS 
(Sigma) approximately 10 times to produce clumps of 10-20 cells that were 
still viable and extended axons in culture. Roughly 4 squares of tissue were 
added per coverslip and cultures were left for 24hrs at 37°C, 5% C 02.
Once robust axon outgrowth was underway and axons of roughly 100-200pm 
length were visible, cultures were exposed to either ephrinA5-Fc (20nM, R & 
D Systems), NOC-7 (500pM, positive control, Sigma) or PBS (control) for 
30mins at 37°C, 5% C 02. In those cases where an ectodomain was co-added 
to the culture, a 4:1 molar ratio of blocker to collapsing agent was applied. 
Cultures were then fixed with warm 4% w/v paraformaldehyde at 37°C, 5%
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C 02, permeabilised with 0.1% Triton-X100 (5min) and stained with phalloidin- 
Alexa 488 (1:40, Molecular Probes) to identify F-actin. NOC-7, a nitric oxide 
donor, is known to induce strong growth cone collapse and hence acts as a 
positive control in this context423. Fluorescence images were acquired on a 
Zeiss 510 confocal microscope with both the experimental procedure and the 
analysis being performed blind. Analysis of randomised fluorescence images 
permitted a quantification of the percentage of growth cone collapse.
Stable Cell Line Production for EphrinA5-cm/c and EphA7-cmyc
For initial investigation the EphA7-c/77yc and EphrinA5-cmyc ectodomains 
were selected. pC1-neo and pCS2+EphrinA5-cmyc or pCS2+EphA7-cmyc 
vectors were used to co-transfect CHO cells for subsequent clonal selection 
for neomycin resistance and ectodomain expression. Clonal selection in 
600pg/ml neomycin for one week resulted in well-defined and isolated clones 
of neomycin resistant CHO cells. 384 clones were selected per ectodomain 
and grown in 600pg/ml neomycin for ~two weeks until nearly confluent. 
Colonies were assayed for ectodomain expression for each cell line using the 
c-myc capture assay; this identified numerous expressing clones of each line. 
Those colonies that were secreting at the highest levels and showed a normal 
cell morphology under a light microscope were selected for further large-scale 
growth and assessment. Following further selection in 600pg/ml neomycin for 
2-3 weeks, the colony with the best combination of good secretion of 
ectodomain, normal cell morphology and standard growth rate in culture was 
selected to be used in the in vivo experiments.
Production of the EGFP-expressing Cell Line
CHO cells were grown to 50% confluency in CHO growth medium in a 6-well 
plate. On the day of transduction, one well was trypsinised and the cell 
number counted. Typically 2x105 cells were present in this well. A non- 
replicative integrating HIV virus was used that contained EGFP driven by a 
CMV promoter396. The HIV vector was produced using transfer plasmid 
pHR'SIN-cPPT-CE and following standard procedures. This virus was diluted 
in CHO growth medium supplemented with polybrene (hexadimethrine 
bromide, 8pg/ml, Sigma) at 1x106 Transforming Units (TU) to produce a
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multiplicity of infection (MOI) of 5. Typically with this virus an MOI of one 
would suffice for >95% transduction but to ensure >99% of cells were EGFP- 
positive, an MOI of 5 was used. CHO culture medium was replaced with virus- 
containing medium overnight at 37°C, cells were then washed twice in sterile 
37°C PBS before being returned to normal CHO culture medium. Some 
variability was apparent in EGFP expression but few cells developed 
aggregated protein clusters. Furthermore, growth rate and morphology 
appeared unaffected by EGFP transduction. Cells were observed for one 
month in standard culture conditions to ensure no loss of EGFP expression 
occurred.
Surgical Procedures and CST Labelling
All surgical procedures were approved by the UCL ethical committee and 
licensed by the Home Office. Adult female 200-220g Sprague-Dawley rats 
were anaesthetised with a halothane, nitrous oxide, and oxygen mixture. A 
number of surgical approaches were pursued to obtain the optimal cell 
implantation procedure but the spinal cord injury and CST labelling techniques 
remained the same. Microsurgical scissors were used to transect part of the 
left dorsal column, the entire right dorsal column and part of the dorsal horn of 
grey matter at C6. In each case, animals were sacrificed two weeks after 
surgery by overdose with halothane. Where anterograde labelling of the CST 
was required, 5pl of 10% biotinylated dextran amine (Molecular Probes, 
Oregon, USA) was injected into the left motor cortex using standard 
coordinates (Paxinos and Watson, 1986). Animals were injected 
subcutaneously with FK-506 (1 mg/kg body weight) every day for three days 
prior to surgery to provide sufficient immunosuppression. Animals received 
further FK-506 injections daily for a further three days after surgery and then 
injections every other day until the end of the experiment. For 
immunohistochemical procedures, animals were transcardially perfused with 
4% w/v paraformaldehyde before removal of the spinal cord. Perfused tissue 
was stored at 4°C in 30% sucrose, 10% Thiermesol in phosphate buffer until 
use.
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Implantation Method I: Intraventricular
2x105 CHO-EGFP cells were trypsinised, pelleted and washed in sterile 37°C 
PBS before being resuspended in 5pl sterile PBS. Cells were injected into the 
right lateral ventricle using standard coordinates (Paxinos and Watson, 1986) 
by stereotaxic injection. Animals were transcardially perfused with 4% w/v 
paraformaldehyde after three days.
Implantation Method II: Lesion Site
Sterile collagen gelfoam was soaked overnight in CHO growth medium at 
37°C. 2x105 trypsinised, washed and dispersed CHO-EGFP cells were then 
seeded onto the gelfoam and left to settle for 24hrs. Animals underwent a 
normal spinal cord injury at C6 with the exception that the dura was not 
sutured back together. A small (2mm x 3mm) segment of collagen gelfoam 
was then inverted onto the injury and sutured into place, such that the cells 
were as close as possible to the spinal cord (Figure 3.M12A). Overlying 
muscle was then sutured over the gelfoam. Animals were transcardially 
perfused with 4% w/v paraformaldehyde after ten days.
Implantation Method III: Para-Lesion Site
Collagen gelfoams were prepared and spinal cord injury performed as 
directed above. The dura was once again left unclosed to permit good access 
of the ectodomains to the spinal cord injury, especially at early time points 
following injury. Gelfoam was then sutured inverted roughly 1 mm rostral to the 
lesion site (Figure 3.M12B). Animals were transcardially perfused with 4% w/v 
paraformaldehyde after ten days.
Immunohistochemistry
Fixed tissue was cut at 40pm thickness on a freezing microtome. Samples 
were permeabilised in TBST buffer (0.1M Tris Buffered Saline with 0.5% 
Triton-X100, Sigma) for one hour prior to incubation for one hour at room 
temperature in goat blocking solution (0.1 M TBS, 1% BSA, 0.1% Triton X- 
100, 10% normal goat serum). Sections were incubated in monoclonal mouse 
anti-GFAP (1:1000 in goat blocking solution) overnight at 4°C and washed 
three times in TBST before a two hour incubation in goat blocking medium
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containing steptavidin-Alexa 568 (1:1000) and goat anti-mouse FITC (1:400, 
Sigma) at room temperature. Sections were then washed three times in TBST 
before being mounted on gelatinised slides, coverslipped in DABCO and 
sealed with nail varnish.
Digital image capture and analysis
Fluorescence images were acquired on a Zeiss 510 confocal microscope 
using conventional filter based fluorescence optics. Excitation and emission 
wavelengths were, respectively: FITC, Alexa 488 and EGFP = 488nm, 505 - 
550nm; Alexa 568 and Alexa 594 = 543nm, >560nm. Imaging of slides 
labelled with multiple dyes was always sequential such that the preparation 
was only illuminated with light of one wavelength at any one time. Transmitted 
light images were acquired on the same microscope using bright field 
illumination.
RESULTS
Selection of ephrin family members
To inhibit ephrin signalling in the injured spinal cord using monomeric 
ephrin/Eph ectodomains that would be capable of binding endogenous ligand 
and receptors, the choice of sub-family members was critical. A literature 
search was performed to identify those members of the Eph/ephrin family 
thought to play a role in axon guidance, neurite outgrowth or spinal cord 
injury, or those shown to be expressed in the adult or developing spinal 
cord229, 323 One member of each family of ligand and receptor were then 
selected for their ability to bind with high affinity to all of the corresponding 
Eph/ephrins identified. The promiscuity of ligand-receptor binding in the ephrin 
family facilitates this approach424 (Figure 3.1 A). EphrinBI, EphB3, EphA7 and 
ephrinA5 were selected and show high affinity binding to many Eph/ephrins 
identified as potentially important in the damaged spinal cord (Figure 3.1B).
Cloning
The receptor/ligand binding domains of ephrinBI, EphB3, ephrinA5 and 
EphA7 were successfully cloned from rat brain cDNA and inserted into the 
Mlul restriction site of pEF-BOS as determined by DNA sequencing (Figures
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3.M1-4). These IL-6 secretion signal- and c-myc-tagged fusion protein coding 
regions were subcloned into the Xba\ restriction site of pCS2+ in the correct 
orientation, also shown by sequencing (Figures 3.M5-8).
Predicted Ectodomain Structures
Based on the crystal structure of the EphB2 receptor extracellular domain425 
and the ephrinB2-EphB2 tetramer crystal structure247, it is possible to produce 
a predicted protein structure for each of the ectodomains using the SWISS- 
PROT program. Due to the primary sequence and structural homology 
between the subfamily ligands and receptors, sequence-based structure 
matching should be sufficiently accurate to assess the location of critical 
binding domains.
For effective signalling blockade, the structure of the secreted globular 
domains must be effectively identical to the structure that exists in the native 
protein. Accurate folding of the second order structures is essential in the 
ectodomains to ensure correct internal packing of each domain, and hence its 
overall structure. Rasmol rendering of the SWISS-PROT data indicated that 
the a-helical and (3-sheet structures within each globular domain would be 
preserved as would the overall domain structure of each ectodomain. 
Domains required for both the primary and secondary ephrin-Eph interactions 
are built from flexible loops and a-helices from various non-sequential regions 
of the primary structure247, 425_427. Based on the tertiary structure at the 
interface of ligand and receptor and the sequence conservation between 
family members, it is possible to predict those sequences required for the 
formation of ephrin-Eph dimers and ephrin-Eph-ephrin-Eph 
stereotetramers247. As shown in Figure 3.2, the residues that play essential 
roles in Eph-ephrin interactions are clearly positionally conserved in the 
predicted structure of the secreted ectodomains. The structural preservation 
of these binding interface components implies that specificity (or promiscuity 
in this case) of binding will be preserved. Obviously SWISS-PROT modelling 
is only an approximation of the real protein folding, but the general 
preservation of structure and the formation of the correct amino acid 
conformation at the binding sites suggests that cognate ligand/receptor
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interactions with soluble ectodomains will be of high (nanomolar) affinity and 
hence be able to block signalling effectively.
Immunoprecipitation and SDS-PAGE of Secreted Ectodomains
The ephrinA5 and EphA7 ectodomain pCS2+ vectors were used to transiently 
transfect HEK and CHO cells via the calcium phosphate precipitation method. 
10-20pg of DNA in an 80% confluent 10cm diameter culture dish (approx. 
3x106 cells) produced sufficient ectodomain to produce a 5nM solution. Spin 
filtration through a 10kDa size-exclusion filter therefore typically resulted in 
1 ml of 50nM ectodomain product. Detection was performed using the c-myc 
tag capture assay followed by exposure to ephrinA2-AP or EphA2-AP, 
alkaline phosphatase fusion proteins permitting chromogenic quantification of 
expression levels. This method indicated that binding was successful at both 
the immunorecognition tag and also the globular domain. The ability of the 
ectodomain to bind with high affinity to another soluble receptor/ligand 
globular domain in vitro was especially encouraging as the binding conditions 
in this scenario are much more stringent than those that will be encountered 
by the ectodomains in vivo.
Coomassie staining of SDS-PAGE gels of ephrinA5 and EphA7 ectodomains 
immunoprecipitated with anti-c-myc antibodies revealed strong, clear 
expression bands (Figure 3.3A). Immunoprecipitated ectodomains were also 
detected with anti-c-myc antibodies in a Western blot (Figure 3.3B). In all 
cases, ectodomains ran at the expected molecular weights, approximately 
30kDa. Successful immunoprecipitation to pull down the ectodomains prior to 
electrophoresis and the Western blotting procedure also indicate good binding 
to the c-myc tag. Furthermore, the bands seen in the blots are sharp and 
distinct with no significant secondary bands nearby. This indicates reliable 
translation and glycosylation of the complete ectodomain product with minimal 
degradation.
Stable Cell Line Production for EphrinA5-cmyc and EphA7-cmyc 
Stable cell lines selected for use in the implantation studies demonstrated 
normal growth rates and morphology. Secretion rates were estimated at
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100pmol protein secretion per 3x106 cells over a 24hr period. 
Immunoprecipitation and SDS-PAGE of the growth medium revealed bands of 
the appropriate size following Coomassie staining (as per Figure 3.3A). 
Combined with the successful c-myc capture assay with ephrin/Eph-AP 
detection this confirms that the cell lines are secreting the required 
ectodomain at good levels.
As well as the ectodomain-secreting lines developed, a number of cell lines 
were obtained from other researchers. CHO cell lines stably secreting 
ephrinA5-Fc, ephrinA2-Fc and ephrinA5-AP were a generous gift from 
Caroline Brennan (Queen Mary, University of London) and ephrinA5-FLAG 
from was a generous gift from Andrew Boyd (Queensland Institute of Medical 
Research, Canada).
Assaying Blocking Ectodomains in vitro
Before in vivo experiments commenced, an assessment of the capacity of 
each ectodomain to block ephrin signalling in vitro was performed.
Coverslip-based Stripe Assays
Stripe assay studies using glass coverslips coated in laminin and stripes of 
Fc-tagged ephrinAS produced good outgrowth and lane selectivity. Staining of 
cultures with phalloidin-Alexa 488 revealed long straight axons (often 
fasciculated) growing up to 1mm in 48hrs (Figure 3.4A). However, co-staining 
of cultures with an anti-Fc primary antibody and detection with an Alexa 594- 
coupled secondary antibody (Figures 3.4B and 3.4C) revealed that, instead of 
avoiding the ephrinA5, axons were preferentially growing on stripes containing 
ephrinA5-Fc. Control assays using human IgG Fc on stripes produced an 
identical selection phenotype (Figure 3.5A). Subsequent experiments with 
stripes produced following injections of sterile PBS only also produced this 
outgrowth phenotype. A final round of experiments were performed to identify 
the cause of the complications. It appears that, on removing the matrix from 
the coverslip, the poly-L-lysine remains attached to the matrix rather than to 
the coverslip. This results in pronounced lanes of poly-L-lysine separated by 
glass. This is readily visible by washing the coverslips and then incubating
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them with Albumin-Alexa 594 (see Figure 5.5B). Subsequent incubations 
therefore only deposit material on the ‘channel’ stripes hence, despite these 
stripes containing ephrinA5-Fc, they are the only substrate that will support 
growth as axons are unable to grow on glass. As the chemorepulsive action of 
ephrinA5 is only effective over long time periods when there are alternative 
growth substrates, the neurites eventually grow on the ephrinA5 lanes. 
Conversations with a number of groups who have worked with this form of 
stripe assay indicated that this is a commonly found, but little reported, 
problem with this assay. Hence, alternative assays were pursued to 
investigate the efficacy of ectodomain signalling block.
Filter-based Stripe Assays
CHO cell membrane fragments or ~300kDa Poly-D-Lysine appeared to 
successfully bind to the filter surface and remain in place for the period of 
incubation, as indicated by the preservation of Alexa594-BSA staining (see 
Figure 3.M11B). Axons were successfully visualised using a phalloidin-Alexa 
488 conjugate but outgrowth was frequently poor, especially on HEK293 
membranes (Figure 3.5C), and did not show any evidence of responding to 
the substrate stripes.
Neurite Outgrowth Assay
As the stripe assay did not provide a useful framework to draw convincing 
conclusions about ectodomain efficacy, the outgrowth assay was used421. 
This is based on in vitro assays used to assess the effects of astrocytes on 
dendrite or axon outgrowth from neuronal explants422. Temporal E6 chick 
retinal ganglion cells were dispersed on near-confluent layers of HEK293 cells 
or HEK cells transiently transfected with full-length ephrinA5a. Following 
fixation and staining with an anti-neurofilament antibody, the effect of 
including the EphA7 or ephrinA5 ectodomains in the co-culture stage could be 
assessed (Figure 3.6A). The average axonal lengths for neurons cultured in 
each condition were assessed under a fluorescence microscope under 
blinded conditions. However, as shown in Figure 3.6B, growth on the HEK- 
ephrinA5 cells appears to be more robust. The time course of the growth 
cone-collapsing response induced by ephrins is short, with axons generally
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recovering after 30min405. This means that the axon avoidance response will 
only be functional when there are alternative substrates available. Hence, in 
this culture, once axons have adapted to growing on the ephrinA5, there is no 
impediment to growth. The increased outgrowth may, in fact, be attributable to 
the ephrinA5a itself as this could provide a further substrate for attachment.
Collapse Assays
Because of these complications, it became necessary to use another 
technique to assess the efficacy of my ectodomain blockers. The collapse 
assay is a simple technique utilizing retinal ganglion cell growth cone 
collapse. EphrinA5-Fc (when homodimerised) induces growth cone collapse 
of EphA3-positive E6 chick temporal RGC axons. Co-application of a blocking 
ectodomain together with the ephrinA5-Fc to cultures should protect growth 
cones from collapse, permitting assessment of ectodomain efficacy. Explants 
of ~1 mm square RGC tissue put out long, occasionally fasciculated axons (up 
to 300pm) in 24hrs. Uncollapsed growth cones were obvious due to their 
spread out phenotype with multiple extended filopodia and lamellipodia 
(Figure 3.7A). Collapsed growth cones were also readily identified by their 
compressed and highly actin-dense heads which often retained a single 
characteristic filopodium (Figure 3.7B).
Baseline collapse present following addition of pre-warmed sterile PBS was 
28% in agreement with published data341. The positive collapse control, NOC- 
7, induced a large-scale collapse (80 ±12%) also equivalent to that reported in 
the literature423 suggesting the system is responsive to collapse and this 
change is accurately picked up by the staining, imaging and quantification. 
Two monomeric blockers were assayed in this culture; the EphA7-c-myc 
ectodomain and the ephrinA5-Fc monomer. Both showed robust and reliable 
abrogation of the collapse action and, on their own, demonstrated no 
collapsing ability (Figure 3.8). Growth cones treated with sterile PBS alone 
showed a 28 ± 9% (± 95% confidence interval) collapse rate, similar to the 31 
± 12% collapse rate of growth cones treated with the EphA7-cy/77c ectodomain 
and the 19 ± 10% collapse rate of growth cones treated with the ephrinA5 
ectodomain. The 68 ±6% collapse rate of growth cones exposed to 20nM
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dimeric ephrinA5 was significantly different to all three control assays (p < 
0.001 Fisher's Exact Two-Tailed Test). Co-application of 80nM monomeric 
ephrinA5 ectodomain or pre-incubation of the dimeric ephrinA5 with 80nM 
monomeric EphA7 induced a collapse rate of 34 ±5% and 31 ±9%, 
respectively. These values are significantly different from the collapse rate 
seen for dimeric ephrinA5 alone (p < 0.001 Fisher's Exact Two-Tailed Test).
Control Cell Implantation Studies
Cell implantation studies are established for some cell lines428"430, notably 
some of the original work by Martin Schwab and co-workers used IN-1 
secreting hybridomas implanted into the ventricular system114. However, there 
are no reports in the literature that describe the implantation of non-rat 
mammalian cell lines into rat nervous system. Hence, preliminary work 
focussed on minimising side-effects due to implantation and stabilising the cell 
mass within the animal. To identify and locate implanted cells, a normal CHO 
cell line was transduced with a lentivirus encoding soluble EGFP. The 
expression ratio for this virus was remarkably high (—99%) at a MOI of 
approximately 5 permitting the localisation of nearly all cells implanted in the 
animals (Figure 3.9A). Later studies using clonal cell lines secreting 
ectodomains incorporated a 5% cell population from this EGFP-expressing 
line to permit visualisation of the cell mass in vivo.
Injection of EGFP-expressing CHO cells into rat lateral ventricles using 
stereotaxic coordinates was successful and cells appeared to have integrated 
into the ventricular walls within 3 days. 40pm coronal sections through the 
injection site revealed numerous EGFP-positive cells (Figure 3.9B) with a 
typical CHO cell morphology suggesting that at this time point no immune 
rejection had occurred. However, staining for OX-42 revealed a strong 
macrophage and microglia response (Figures 3.9B and 3.9C) around the 
lesion with activated immune cells closely associated with implanted CHO 
cells. Hence, despite prior immunosuppression of animals with FK506, 
immune rejection of the implant occurred and OX-42-positive macrophages 
and microglia would be expected to clear EGFP-CHO cells within the following 
days.
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An alternative approach was then employed; to enhance access of the soluble 
blocking proteins to the lesion site and to improve the immunosuppressant 
exposure, cells were implanted near the lesion site (Figure 3.M12A). Collagen 
gelfoams were seeded with EGFP-CHO cells and this material was sutured 
onto the dura at the lesion site. Preliminary studies indicated that these cells 
became highly metastatic following exposure to the injured spinal cord 
environment and invaded the lesion site in a similar manner to endogenous 
meningeal fibroblasts. As can be seen in Figure 3.10A, EGFP-positive CHO 
cells can be seen penetrating the original margin of the spinal cord and 
invading the lesion cavity, past surviving GFAP-positive astrocytes. 
Endogenous meningeal fibroblasts in the lesion site are a source of growth 
inhibitors and interact with reactive astrocytes to induce the formation of the 
glial scar. Hence, the presence of exogenous fibroblasts in the lesion site is 
unlikely to be conducive to successful regeneration. However, minimal 
immune rejection had occurred suggesting that this method of blocker delivery 
warranted further investigation. To avoid this complication, seeded collagen 
gelfoams were then implanted 1-2mm rostral to a lesion site (Figure 3.M12B). 
Ten days following dorsal column lesion, minimal invasion by endogenous 
macrophages or microglia was seen and the implanted cells demonstrated 
their typical spread-out morphology. No obvious invasion of tissue was 
apparent suggesting this technique would provide a reliable platform for 
ectodomain delivery.
The data presented in Chapter II and in the published scientific literature 
suggests that ephrinB ligand interactions with EphA4 are likely to be a major 
determinant of functional recovery following spinal cord injury. The ephrinA5 
ectodomain was therefore selected as the primary blocker for investigation. 
Control CHO cells or secreting cells (CHO-ephrinA5) were seeded onto 
collagen gelfoams and maintained in culture for two days before being sown 
onto the dura over a region of undamaged spinal cord. Animals were 
investigated over a two week period, receiving FK-506 injections prior to, and 
throughout, the investigation. Corticospinal tract regeneration following 
implantation of the cell lines was traced using BDA injection to the motor
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cortex at the time of injury. Two weeks following injury the animals were 
perfused with 4% paraformaldehyde and their spinal cords removed.
Ectodomain Effects on Spinal Regeneration
The main gross anatomical observation of the excised tissue was the 
presence, in all animals, of a large tumourific cell mass centred on the 
collagen gelfoam. Horizontal freezing microtome sections of the spinal cords 
revealed that the invasion of the gelfoam by meningeal fibroblasts (and also 
probably the proliferation of implanted fibroblasts) had placed pressure on the 
uninjured cord within the constraints of the dura, causing some deformation 
(Figure 3.1 OB). While there was no obvious locomotor deficiency in the 
animals other than that expected in the 48-72hrs following surgery, some 
disruption of ascending and descending pathways must have occurred. The 
BDA-labelled CST was seen to have been displaced by the cell mass to a 
level more deep than usual although both rostral and caudal to the implant it 
appeared anatomically normal. At the lesion site, caudal to the implant, BDA- 
labelled CST axons were seen to extend to the lesion site with typical dorsal 
CST morphology in all animals (Figure 3.11).
As the sample number for this study was small (n = 2 for control and 
experimental) no statistical conclusions can be drawn. Furthermore, the extent 
of the ‘tumour’ produced by the implant was such that it would not be humane 
to perform further experiments of this nature to draw more firm conclusions. 
However, observations of the injury site do permit some useful information to 
be gained from the investigation. In animals receiving CHO-ephrinA5 
implants, the degree of CST retraction was visibly smaller than that found in 
the CHO animals (Figure 3.11B compared to 3.11 A). Individual termination 
bulbs in the ephrinAS-treated animals were seen to be putting out sprouts 
towards the lesion site (Figure 3.12A) many of which reached the lesion 
margin, as defined by GFAP staining (Figure 3.12B). However, the extent of 
glial scarring and cyst formation did not seem to be affected by the presence 
of the ephrinA5 ectodomain. Similarly there was no change in the 
upregulation of GFAP by reactive astrocytes (Figure 3.12C).
131
DISCUSSION 
Ectodomain Expression
Predictive modelling of each ectodomain using SWISS-PROT based on 
existing X-ray crystal structures suggested that the extracellular regions 
selected will correctly fold and will bind with good affinity to endogenous full- 
length Ephs and ephrins. Regions of the proteins known to be important in the 
formation of receptor-ligand complexes are retained and predictive folding 
suggests they will be correctly positioned for high affinity binding. 
Furthermore, sufficient secondary and tertiary structure appears to be 
preserved within the globular domains to retain correct folding and stability in 
solution. This is supported by the data from the c-myc capture assay that 
indicates not only binding at the c-myc immunorecognition tag to capture the 
ectodomain, but also high affinity binding at the binding domains to permit 
effective chromogenic detection of the ectodomains using the AP-tagged 
constructs. The SDS-PAGE data also shows the ectodomains migrate at the 
expected molecular weight and are immunodetectable under Western blotting 
conditions.
The release rate of the ectodomains from the stable cell lines was also 
encouraging. Assuming a 40pl_ volume of CSF within the spinal cord (the 
likely volume of dilution for secreted ectodomain), Figure 3.13 shows the likely 
concentration profile following implantation. Assuming a 50nM concentration 
is required (based on the in vitro findings of Murai et al.389 and a 4:1 molar 
ratio for effective blockade) 22hrs will be required before a ‘therapeutic’ 
concentration has been reached. This is a reasonable time window for 
beneficial function. The use of a cell line as the means of production of the 
ectodomains means that the products should always be properly glycosylated 
and folded, a requirement for effective binding and signalling blockade.
Collapse Assays
The collapse assay offers the benefits of being highly responsive and readily 
quantifiable. The monomeric blockers produced by the stable cell lines CHO- 
ephrinA5 and CHO-EphA7 were assayed in this culture; the EphA7-cmyc and 
ephrinAS-cmyc ectodomains. The 70% collapse of the growth cone population
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induced by dimeric ephrinA5 was almost completely attenuated by monomeric 
ephrinA5 or EphA7 in a 4:1 molar ratio. Hence, in the context of EphA3-based 
collapse of E6 chick RGC growth cones, the EphA7 and ephrinA5 
ectodomains are both capable of interrupting Eph-ephrin interactions in vitro. 
The lack of toxic or other side-effects and the high affinity and very efficacious 
blockade of A-class ephrin signalling suggests the blockers will work 
effectively in the injured spinal cord environment.
Imaging data suggested that both NOC-7 and ephrinA5 induce lamellipodial 
withdrawal and growth cone collapse, but filopodia appear to remain attached 
and extended. This is unsurprising as it is known that following the initial 
collapse response to ephrinA family proteins, axons recover and continue to 
grow as long as the ephrin concentration remains constant, suggesting that 
the collapse response is rapidly reversible and does not involve large-scale 
actin depolymerisation.
Cell Implantation Studies
Considering the work of Professor Schwab’s laboratory114 using IN-1 secreting 
hybridomas implanted in the ventricular system, it was surprising to find such 
rapid and efficacious immune rejection of the ventricularly implanted CHO- 
EGFP cells following three days of FK-506 administration. However, 
communication with authors from this publication suggested that during these 
studies the balance of immunosuppression and cell implantation was a very 
delicate one that required many repetitions. Too great a dose of 
immunosuppressant and the cell line became malignant and proliferative and 
form a tumour mass, too small a dose of immunosupression and the implant 
was rapidly removed by invading macrophages and microglia. Our dosing of 
the FK-506 was identical to that used throughout all the other implants and 
the drug is known to pass the blood-brain barrier. Furthermore the size of the 
implant was small. However, perhaps the formation of a hole into the brain by 
the stereotaxic injection might have permitted an influx of meningeal cells that 
may have enhanced the immune response.
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The opposite reaction, i.e. an aggressive implanted cell response, was seen 
in the second implant study (Figure 3.M12A). The implanted cells were 
obviously not held in check by the usual anti-proliferative mechanisms and 
were able to aggressively invade the lesion cavity. The proliferation of the 
implanted cell line, and the likely invasion of the collagen gelfoam by 
endogenous meningeal fibroblasts, were unexpected and unfortunate as this 
‘on lesion’ implant offers the best delivery of ectodomain.
The final implantation method used (Figure 3.M12B), highlighted the main 
complication of the procedure -  the difficulty in balancing the 
immunosuppression with the implantation volume. In the initial CHO-EGFP 
pilot animal, the cell implant remained quiescent and showed no proliferation 
or invasive tendency. However, an identical FK-506 dosing regime and cell 
implantation number with the CHO or CHO-ephrinA5 implant, produced 
massive proliferation/invasion and the formation of a tumour mass. Slight 
differences in the proliferative capacity of the three cell lines could perhaps 
have tipped the proliferation/engulfment balance towards growth.
Perhaps a method of encapsulating the cell implant, as has been used 
previously with PC 12 cells431, would prevent these unwanted side effects but 
still permit effective ectodomain delivery. Such a development would be costly 
and time-consuming and the para-lesion implant offers almost as effective 
delivery. The collagen gelfoam, while an excellent substrate for the growth of 
the fibroblastic CHO cells used in the study, is obviously also likely to provide 
an attractive target for meningeal fibroblasts. Perhaps a substrate that can 
support cells under media-rich in vitro culture conditions but does not provide 
a favourable platform for proliferation would be a more suitable choice.
Despite the low replication numbers (n of 2 for control and experimental), a 
number of interesting observations can be made. CHO-ephrinA5 animals 
show a clear reduction in the retraction of the bulk of the termination bulbs 
from the lesion margin (as defined by GFAP staining) compared to control 
animals (Figure 3.12). This supports the concept outlined in Chapter II that 
EphA4 in the CST axons mediates this retraction from the lesion site in the
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first few days following injury. Furthermore, CHO-ephrinA5 animals show 
improvements in regenerative sprouting of processes towards the lesion site 
with many of these growing as far as the astrocyte margin (Figures 3.13A-B).
In the work of Goldshmit et al.12, knocking out the EphA4 gene is shown to 
reduce astrocytic gliosis and reactivity following spinal cord injury and to 
diminish the wound-healing response in vitro. Furthermore, the lesion site 
produced 6 weeks after a lateral white matter injury in EphA4 knock-out mice 
was described as minimal and often hard to distinguish, with numerous 
spouting/regenerating axons traversing its length. However, in the CHO- 
ephrinA5 animals, the extent of glial scarring and cavity formation following 
central white matter injury did not seem to be affected by the presence of the 
ephrinA5-c-myc ectodomain (Figure 3.12C). Similarly there was no apparent 
change in the upregulation of GFAP by reactive astrocytes, when compared 
to spinal cord injuries in the CHO animals. Assuming that effective blockade is 
occurring at the EphA4 receptor, which is certainly indicated by the 
observations of increased sprouting, this suggests that blocking the EphA4 
receptor encourages CST regenerative sprouting but does not prevent 
astrocytic gliosis. Two possibilities would account for this:
• EphA4 in astrocytes is transactivated by cytokines released after injury 
and the ligand binding domain of the receptor is not required for the 
role of the receptor in astrocytic gliosis.
• EphA4 on the CST is a major mediator of the inability of injured CST 
axons to regenerate (as outlined in Chapter II).
The concept of EphA4 being transactivated during astrocytosis is proposed in 
the work by Goldshmit et a l}2. In this model activation of EphA4-mediated 
signalling is required for the cytokine-mediated signals that induce astrocyte 
reactivity. Which component of EphA4 signalling (i.e. PDZ-, SH-2- or kinase- 
mediated) is not known, but it is likely to be independent of ligand binding to 
the receptor, unless cis-interactions with co-expressed ephrinB2 were 
sufficient. This hypothesis would agree well with the data presented here. 
Hence, while inhibitory post-injury responses due to EphA4 on the CST are 
minimised, those due to EphA4 on astrocytes are unaffected.
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The second possibility would account for the improvements seen in 
regenerative sprouting despite the lack of effect on the lesion site and 
astrocytic gliosis. Inhibiting EphA4 will minimise the repulsive interactions 
induced by ephrinB2 in reactive astrocytes and ephrinB3 expressed in 
damaged myelin. The ability of the CST termination bulbs to sprout and put 
forward regenerative processes towards the lesion site in animals receiving 
the ectodomain implant suggests that EphA4 is a major, if not the only, 
negative mediator preventing the CST from undergoing a normal regenerative 
response to injury. Furthermore, by reducing the extent of the CST die back, 
the platform for regeneration is significantly improved and presents a scenario 
for regeneration that will likely synergise with other treatments.
One other possibility is that other EphA receptors may be expressed in the 
lesion site. Data presented here (Figure 3.6A) and in published form318 
suggest that this is the case but as yet no localisation of these receptors has 
been performed. While it is possible that another EphA receptor may be 
partially responsible for the improvements in CST regeneration seen, this is 
unlikely as no study to date has identified any such receptor in the cortex 
during adulthood. Furthermore EphA4 alone is responsible for CST targeting 
during development234,319. Also, Chapter IV demonstrates that the increased 
regeneration seen here can be entirely attributed to blockade of EphA4 alone.
CONCLUSION
While the observations detailed suggest that further experimentation with this 
implantation technique could yield exciting and interesting data, the invasion 
of non-pathological tissue by the implants suggests that this method of 
blocker delivery may cause discomfort to the animals and is hence not 
suitable for longer term investigation. The data highlights inhibition of EphA4 
as a promising candidate for improving spinal cord regeneration following 
injury and this has been pursued pharmacologically in Chapter IV.
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Figure 3.M1
EphrinBI Ectodomain cloned into pEF-BOS
B1-Forw: Sequence derived from 5’ cloning primer.
B1-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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1 10 20 30 40 50 60 70 80 90 100 110 120 130I------- +--------     +--------       ♦-------- ♦-------- 1-------- ♦-------- 1---------1
B l-F o ru
B l-R /C  NNTGGGGGNCNAAGGGNTGGCCCCGNTNGGNCNCCRRTTTGTNTRGGNGGRARARRTGGCCGTTTTCCGGCCCTTGTTGCRNGGGAGNNTNAARRTTGAGGAACCCNGCCCNTCNGGRflARGCGGGCGGG
Expected
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
B l-F o ru  
B l-R /C  
Expected
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
261 270 280 290 300 310 320 330 340 350 360 370 380 390I------- ♦-------- +------- -+-------- ♦-------- 4-------- ♦-------- ♦--------   ♦------- -+-------- *-------- ♦-------- 1
B l-F o ru
B l-R /C  TAGGTTGGGGGGRGGGGTTTTRTGCGRTGGRGTTTCCCCRCRCT6RGTGGGTGGRGRCTGRRGTTRGGCCRGCTTGGCRCTTGRTGTRRTTCTCCTTGGARTTTGCCCTTTTTGRGTTTGGRTCTTGGTT 
Expected
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
391 400 410 420 430 440 450 460 470 480 490 500 510 520I------- 4-------- +---------►-------- 4-------- <-------- +--------          +------- -4---------I
B l-F o ru
B l-R /C  CRTTCTCRRGCCTCRGRCRGTGGTTCRRflGTTTTTTTCTTCCRTTTCRGGTGTCGTGRGGRRTTCTCTRGRCTRGTGCTflGCR :RRTGGT rCTTGCCRGCTCTRCCflCCRGCRTCCflCRCCflTGCTGCTC 
Expected GCTRGCR :RRTGGTrCTTGCCRGCTCTflCCflCCRGCRTCCflCRCCflTGCTGCTC
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . gctagca :aa tg g t ,c ttg cca g c tc ta cca cca g ca tcca ca cca tg c tg c tc
521 530 540 550 560 570 580 590 600 610 620 630 640 650
I ---------------------- 4----------------------- 4------------------------ 1----------------------- 4----------------------- 4------------------------ 1----------------------- 4-----------------------4------------------------- 1----------------------- ►----------------------- 4----------------------- 4---------------------- 1
B l-F o ru   GGRNCGTGTCCGGACTCT
B l-R /C  CTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRRGCTTCRATCTCGGCGCGCCR GRGCRGRRGCTTRTCTCGGRGGRGGflCCTG CGCGTRCGCCGTTGGCCRRGRRCCTGGRGCCCGTGTCCCGGRGCT 
Expected CTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRRGCTTCRRTCTCGGCGCGCCR GRGCRGRRGCTTflTCTCGGRGGRGGRCCTG CGCGTRCGCCGTTGGCCRRGRRCCTGGRGCCCGTGTCCTGGRGCT
gagcagaagctta tc tcggaggaggacctgConsensus c tg c tc c tg a tg c tc ttc c a c c tg g g a c tc c a a g c ttc a a tc tc g g c g c g c c < :gcgtacgccgttggccaagaacctggaGccCGTGTCC.GgagCT
651 660 670 680 690 700 710 720 730 740 750 760 770 780
I --------------------4--------------------- - 4 ------------------------1— ------------------ 1------------------------ 1----------------------- » -----------------------4------------------------  4------------------------     1------------------------ I
B l-F o ru  CTT RCCCTRRGTTCCTRRGTGGGRRGGGCTTGGTGRTCHRCNCGRRGflTTGGRGflTRRGCTGGRCRTCRTCTGCCCCCGRGCRGRRGCRGGRCGGCCCTRCGRGTRCTRCRRGCTGTRCCTGGTGCG
Bl-R /C  CTCTTRRCCCTRRGTTCCTRRGTGGGRRGGGCTTGGTGRTCTRCCCGRRGflTTGGRGflTRRGCTGGRCRTCRTCTGCCCCCGRGCRGflRGCAGGRCGGCCCTACGRGTRCTRCflflGCTGTRCCTGGTGCG 
Expected CTCTTRRCCCTRRGTTCCTRRGTGGGRRGGGCTTGGTGRTCTRCCCGRflGRTTGGHGRTRRGCTGGRCRTCRTCTGCCCCCGRGCRGRRGCRGGRCGGCCCTRCGRGTflCTRCRRGCTGTRCCTGGTGCG 
Consensus CTcttaflCCCTRRGTTCCTRRGTGGGflRGGGCTTGGTGRTCtRCcCGRRGHTTGGRGflTRRGCTGGRCRTCRTCTGCCCCCGflGCRGRRGCRGGRCGGCCCTRCGRGTRCTRCRRGCTGTRCCTGGTGCG
781 790 800 810 820 830 840 850 860 870 880 890 900 910
I ---------------------------------------------- 4 -------------   1-------------------------- 1--- ------------------ 1---------------- 4-----  4------------------------- 4------------------------ 1------------------------ 1------------------------ 1------------------------ 1----------------------1
B l-F o ru  GCCGGRGCRGGCRGCTGCTTGCRGCRCTGTGCTTGRTCCCRRTGTRCTGGTCACTTGCRRCRRGCCRCRGCRGGRRRTCCGCTTTRCCRTCRAGTTCCRGGRGTTCRGCCCCRflCTRCRTRGGCCTGGRR 
B l-R /C  GCCGGAGCRGGCRGCTGCTTGCRGCRCTGTGCTTGRTCCCRRTGTflCTGGTCRCTTGCRRCRRGCCRCRGCRGGRRRTCCGCTTTRCCRTCRRGTTCCRGGRGTTCRGCCCCRRCTRCRTRGGCCTGGRR 
Expected GCCGGRGCRGGCRGCTGCTTGCRGCRCTGTGCTTGRTCCCflRTGTRCTGGTCRCTTGCRRCRRGCCRCRGCRGGRRRTCCGCTTTRCCRTCRRGTTCCRGGRGTTCRGCCCCRRCTRCRT6GGCCTGGRR 
Consensus GCCGGRGCRGGCRGCTGCTTGCRGCRCTGTGCTTGflTCCCRRTGTRCTGGTCRCTTGCRRCRRGCCRCRGCRGGRRRTCCGCTTTRCCflTCRflGTTCCRGGRGTTCRGCCCCRflCTRCRTaGGCCTGGRfl
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
I --------------------   -4 ----------------  ♦ -----------------------   1----------------------- * -----------------------4------------------------  » ----------------------- 1------------------------  I------------------------I
B l-F o ru  TTCRRRRAGTRCCRTGRTTRCTRCRTTRCATCRRCRTCCRRTGGGRGCTTGGRRGGGCTGGRGAACCGRGAGGGRGGTGTGTGCCGTRCACGCACTRTGRRGRTTGTTATGARGGTTGGGCRAGRTCCAR 
B l-R /C  TTCRRRRRGTRCCRTGRTTRCTRCRTTRCRTCRRCRTCCRRTGGGRGCTTGGRRGGGCTGGRGRflCCGRGRGGGRGGTGTGTGCCGTRCRCGCRCTRTGRRGRTTGTTRTGRRGGTTGGGCRRGRTCCRR 
Expected TTCRflflflRGTflCCflTGflTTRCTRCRTTflCRTCRflCRTCCflRTGGGRGCTTGGflBGGGCTGGRGRflCCGRGRGGGRGGTGTGTGCCGTRCflCGCflCTRTGflflGRTTGTTRTGflftGGTTGGGCRflGRTCCflR 
Consensus TTCRRRRAGTACCRTGRTTRCTRCflTTACATCRRCRTCCflRTGGGRGCTTGGRflGGGCTGGflGRflCCGAGRGGGAGGTGTGTGCCGTRCRCGCACTRTGRRGRTTGTTRTGARGGTTGGGCRRGRTCCRR
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170
I ---------------------1---------------------- ♦ ---------------  1------------------------ 4-----------------------4------------- -------     + ----------------------- 1------------------------   4----------------------- 4------------------------ 1
B l-F o ru  RTGCCGTRnCGCCTGRGCRGTTGflCTRCCRGCCGGCCRRGCRRflGRGTCRGRCRRCRCTGTCRflGRCRGCCRCRCRGGCTCCTGGTCGGGGGTCCCRGGGGGRCTCTGRTGGCRRGCflTGRGRCTGTGRfl 
B l-R /C  RTGCCGTRRCGCCTGflGCRGTTGRCTRCCRGCCGGCCRRGCRRflGRGTCRGRCRflCRCTGTCRRGRCRGCCRCRCRGGCTCCTGGTCGGGGGTCCCRGGGGGflCTCTGRTGGNRRGCRTGRGRCTGTGRR 
Expected RTGCCGTRRCGCCTGRGCRGTTGRCTRCCRGCCGGCCRRGCRRflGRGTCRGRCRRCRCTGTCRflGRCRGCCRCRCRGGCTCCTGGTCGGGGGTCCCRGGGGGRCTCTGflTGGCRRGCRTGRGRCTGTGRR 
Consensus RTGCCGTRRCGCCTGRGCRGTTGRCTRCCflGCCGGCCRRGCRflflGRGTCRGRCRRCRCTGTCRflGRCRGCCRCRCRGGCTCCTGGTCGGGGGTCCCRGGGGGRCTCTGRTGGcflflGCflTGRGRCTGTGRR
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
B l-F o ru  CCRGCRRGRGRRGRGTGGCCCAGGTGCAGGTGGTAGTGGCAGCG6GGRCACCGRCRGCTTCTTTRRC 
B l-R /C  CCRGCRRGRGRRGRGT GGCCCRGTGCRGGG6
Expected CCAGCRHGRGRRGAGTGGCCCflGGTGCRGGTGGTflGTGGCflGCGGGGBCACCGACAGCTTCTTTRBC 
Consensus CCRGCRRGRGRRGRGTGGCCCRGgtgcaGGtggtagtggcagcggggacaccgacagcttctttaac
CCTRRHCii TGIGCIHGLRCTRGTCTRGRGTGflGGGTCCCCRCCTGGGRCCCTTGRGRGTRTC 
MNNNNNCT----------------------------------------------------------------------------------
CCTRRRCG :GTGCTRGC- 
c c t a a f ic l i  : g t g c t a g c .
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430
I --------------------    1----------------------- 4------------------------ 1----------------------- 4 -----------------------4------------------------ ►-----------------------4.----------------------- 4---------------------- + -----------------------4----- ------------------ 1
B l-F o ru  RGGTCTCCCRCGTGGGRGRCRAGflRflTCCCTGTTTRRTRTTTRRRCRGCRGTGTTCCCCRTCTGGGTCCTTGCRCCCCTCRCTCTGGCCTCRGCCGRCTGCRCRGCGGCCCCTGCRTCCCCTTGGCTGTG 
B l-R /C  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected
Consensus
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
I ------------------------ ♦ --------------------4 ----------------------- ►---------------------- 4 ------------------------4-----------------------4 -----------------------4 ---------------------- 4 -----------------------4 --------------------- 4 -----------------------4 ----------------------- 4---------------------- 1
B l-F o ru  AGGCCCCTGGACRAGCAGRGGTGGCCAGRGCTGGGRGGCRTGGCCCTGGGGTCCCRCGARTTTGCTGGGGRflTCTCGTTTTTCTTCTTAAGACTTTTGGGRCRTGGTTTGRCTCCCGAflCRTCRCCGRCG 
B l - R / C ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------
Expected
Consensus
1561 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690
I -------------------- ►-----------------------4 ------------------------4-----------------------4 -----------------------4 - --------------------4 ---------------------- 4 -----------------------4 -----------------------4 ----------------------- 4-----------------------4 -----------------------4------------------------ 1
B l-F o ru  TGTCTCCTGTTTTTCTGGGTGGCCTCGGGRCRCCTGCCCTGCCCCCACGRGGGTCAGGACTGTGRCTCTTTTTRGGGCCRGGCRGGTGCCTGGRCRTTTNCCCTTGCTGGACGGGHflCTGGGGflTGTGGG 
B l-R /C  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected
Consensus
B l-F o ru
B l-R /C
Expected
Consensus
1691 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820
I ------------------------4 --------------------4 ----------------------- 4------------------------4 ----------------------- 4----------------------- 4---------------------- 4 ----------------------- 4---------------------- 4 -----------------------4-----------------------4 ----------------------- 4-----------------------1
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Figure 3. M2
EphrinBI Ectodomain cloned into pCS2+
B1-Forw: Sequence derived from 5’ cloning primer.
B1-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
139
1--------1-------- ►---------1-------- ►---------+-------- ♦-------- +-------- +-------- 4-------- H-------- 4-------- ►--------1
B l-F o ru  HTG---------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
B l-R /C  NGTTTTMCflCGCCCCCCTNTTTGflCGTTNflNTGflNMGTNRHRTGGCCCCCNTTGGCCflGTfiHNTTCRAHNTTTHTTNRTRGTNRCNTNGGCNfl6TfiCHTTRCTNTTNGRRGTACGCCAGGGTNNCMTTGG
Expected CG -----   — ------------------------------------■■■------------------------------------------------------  — -— - — ------------------
Consensus ng......................... ...................................................................................................................................................................... ...................................................... ................................
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I ------------------ H ----------------------  1----------------------1----------------------1---------------------     1--------------------- 1----------------------1----------------  1--------------------- >--------------------- 1
B l-F o ru  -------------------------------------- ----------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -
B l-R /C  CflGTRCTTCCCCRTTGRCGTCRRTGGCGGTNRRTGGNCCCGCGRTGGCTGCCRRGTRCRTHCCCCRTTGRCGTTCRRTGGGGRGGGGGCRRTGRCGCRRRTGGGCGTTNCCRTTGRCGTRRRTGGGCGGT
Expected — -----------------— -------  — ------ — —  ■ ■ — — — ----------------------------------------------------------------- ------ ------------ --------------
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
261 270 280 290 300 310 320 330 340 350 3G0 370 380 390
| ------------------4----------------------      4---------------------+ --------------------+ ---------------------1----------------------1----------------------1---------------------    1
B l-F o ru  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B l-R /C  AGGCGTGCNTRRTGGGRGGTCTATATRBGCRRTGCTCGTTTRGGGRRCCCGCCATTCTGCCTGGGGACGTCGGAGCARGCTTGRTTTAGGTGACACTflTAGRATRCAAGCTACTTGTTCTTTTTGCAGGA
Expected --------------------------------------------------------------------------------------------- CCflTTCTGCCTGGGGRCGTCGGRGCflflGCTTGflTTTflGGTGRCRCTHTRGflflTRCRRGCTRCTTGTTCTTTTTGCflGGfl
Consensus . ..c c a ttc tg c c tg g g g a c g tc g g a g c a a g c ttg a tt ta g g tg a c a c ta ta g a a ta c a a g c ta c ttg ttc t tt t tg c a g g a
391 400 410 420 430 440 450 4G0 470 480 490 500 510 520
B l-F o ru
B l-R /C  TCCCRTCGflTTCGflRTTCRflGGCCTCTCGflGCCTCTAGRCTRGTGCTRGCRCRRTGGTTCTTGCCflGCTCTflCCflCCflGCRTCCHCR XRTGCT iCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCH
Expected TCCCRTCGHTTCGflflTTCRRGGCCTCTCGflGCCTCTAGH GCTRGCHCRHTGGTTCTTGCCRGCTCTRCCRCCHGCHTCCRCfl XRTGCT iCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCfl
Consensus tc c c a tc g a ttc g a a ttc a a g g c c tc tc g a g c c tc ta g a .....g c ta g c a c a a tg g ttc ttg c c a g c tc ta c c a c c a g c a tc c a c a  x a tg c t  > c tcc tg c tc c tg a tg c tc ttc c a c c tg g g a c tc c a
B l-F o ru
521 530 540 550 560 570 580 590 600 610 620 630 640 650I------ --------- ►--------1------- ►--------+------- ►--------+------- ►------- <--------1------- «------- ►------- 1
---------- GflCCGTGTC-TGllRGCTCTCTTR-CCCTRRGTTCCTRBGTGGGRflGGGC
Bl-R /C  RGCTTCRRTCTCGGCGCGCCflfGRGCAGARGCTTRTCTCGGAGGAGGRCCTGfi :GCGTACGCCGTTGGCCBAGAACCTGGAGCCCGTGTCCTGGRGCTCTCTTRACCCTRRGTTCCTfiRGTGGGRRGGGC 
Expected AGCTTCAATCTCGGCGCGCCAl GAGCAGAAGCTTATCTCGGAGGAGGACCTGA :GCGTACGCCGTTGGCCAAGAACCTGGAGCCCGTGTCCTGGAGCTCTCTTAACCCTAAGTTCCTAAGTGGGAAGGGC 
Consensus a gc ttca a tc tcggcgcg cca f gagcagaagcttatctcggaggaggacctga jgcgtacgccgttggccaagaacctggaGcCCGTGTCcTGgRGCTCTCTTRaCCCTBRGTTCCTRRGTGGGRRGGGC
651 660 670 680 690 700 710 720 730 740 750 760 770 780I-------1--------♦--------►--------1--------►------- +------- ♦------- +------- *--------1--------  1--------1
B l-F o ru  TTGGTGflTCTflCHCGHflGflTTGGflGflTRBGCTGGHCRTCRTCTGCCCCCGRGCRGflHGCHGGRCGGCCCTBCGflGTRCTBCRflGCTGTRCCTGGTGCGGCCGGflGCflGGCflGCTGCTTGCAGCRCTGTGC 
B l-R /C  TTGGTGATCTRCCCGAflGRTTGGAGATRAGCTGGACATCATCTGCCCCCGAGCRGRAKRGGRCGGCCCTACGAGTRCTACAAGCTGTRCCTGGTGCGGCCGGAGCRGGCAGCTGCTTGCRGCRCTGTGC 
Expected TTGGTGATCTBCCCGAAGATTGGAGATAAGCTGGACATCATCTGCCCCCGAGCHGAAGCAGGACGGCCCTACGAGTACTACAAGCTGTACCTGGTGCGGCCGGAGCAGGCAGCTGCTTGCRGCRCTGTGC 
Consensus TTGGTGATCTACcCGAAGATTGGAGATAAGCTGGRCATCATCTGCCCCCGAGCAGAAGCAGGACGGCCCTACGAGTACTACHAGCTGTACCTGGTGCGGCCGGAGCAGGCAGCTGCTTGCAGCRCTGTGC
781 790 800 810 820 830 840 850 860 870 880 890 900 910I------ 4--------  ►--------►--------►------- ♦------- *------- +------- H--------<--------<------- +--------I
B l-F o ru  TTGATCCCRflTGTACTGGTCACTTGCRACRRGCCACBGCAGGRAATCCGCTTTACCATCAAGTTCCAGGAGTTCBGCCCCAACTACATGGGCCTGGflATTCRAAARGTRCCATGATTACTACATTRCATC 
B l-R /C  TTGATCCCAATGTACTGGTCACTTGCAACAAGCCACAGCAGGBAATCCGCTTTACCATCAAGTTCCAGGAGTTCAGCCCCARCTACATGGGCCTGGAATTCRRAAAGTRCCATGATTACTACATTACATC 
Expected TTGRTCCCAATGTACTGGTCBCTTGCBACBAGCCACAGCAGGBAATCCGCTTTBCCATCABGTTCCAGGAGTTCAGCCCCBACTACATGGGCCTGGBATTCAAARAGTACCATGATTACTACATTRCRTC 
Consensus TTGATCCCAATGTACTGGTCACTTGCAACAAGCCACAGCAGGAAATCCGCTTTACCATCAAGTTCCAGGAGTTCAGCCCCAACTACATGGGCCTGGBATTCAAAAAGTACCATGATTBCTACATTACATC
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040|------- 4--------     ►-------- ♦-------- —------- *-------- ♦-------- H---------<--------   ►-------- 1
B l-F o ru  BACATCCAATGGGAGCTTGGAAGGGCTGGAGAACCGAGAGGGAGGTGTGTGCCGTACACGCACTATGABGATTGTTATGABGGTTGGGCBAGATCCABATGCCGTRACGCCTGAGCAGTTGACTRCCAGC 
B l-R /C  ARCATCCARTGGGAGCTTGGAHGGGCTGGAGflACCGAGBGGGAGGTGTGTGCCGTACACGCRCTRTGAAGATTGTTATGAAGGTTGGGCAAGRTCCARATGCCGTAACGCCTGAGCAGTTGACTRCCAGC 
Expected AACATCCARTGGGAGCTTGGAHGGGCTGGAGARCCGAGAGGGAGGTGTGTGCCGTACACGCACTRTGRAGATTGTTATGARGGTTGGGCAAGATCCAAATGCCGTAACGCCTGAGCAGTTGACTACCAGC 
Consensus BACATCCAATGGGAGCTTGGAAGGGCTGGRGARCCGAGAGGGflGGTGTGTGCCGTACACGCflCTATGRflGRTTGTTRTGAflGGTTGGGCRflGATCCRflATGCCGTAflCGCCTGAGCAGTTGACTACCAGC
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170|------- 4-------- ♦-------- ►-------- ►-------- ♦-------- ♦-------- +-------- ♦-------- H-------- 4-------- ----------►-------- 1
B l-F o ru  CGGCCARGCflABGflGTCAGRCAACBCTGTCRAGACAGCCACACAGGCTCCTGGTCGGGGGTCCCAGGGGGflCTCTGRTGGCRAGCATGAGflCTGTGAflCCAGCAAGAGAflGBGTGGCCCAGGTGCAGGTG 
B l-R /C  CGGCCAAGCBARGflGTCAGBCAACHCTGTCAAGRCAGCCBCACRGGCTCCTGGTCGGGGGTCCCAGGGGGflCTCTGATGGCRAGCATGAGflCTGTGRflCCAGCBAGAGAAGAGTGGCCCAGGTGCAGGTG 
Expected CGGCCHAGCBAAGRGTCAGRCflACACTGTCAAGACAGCCACACAGGCTCCTGGTCGGGGGTCCCflGGGGGACTCTGRTGGCAAGCATGAGACTGTGAflCCBGCAAGAGAAGAGTGGCCCAGGTGCBGGTG 
Consensus CGGCCAAGCfiflAGAGTCAGACARCflCTGTCRAGACAGCCRCACRGGCTCCTGGTCGGGGGTCCCflGGGGGACTCTGATGGCRAGCATGAGflCTGTGRflCCflGCRRGAGflflGAGTGGCCCRGGTGCAGGTG
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
B l-F o ru  GTAGTGGCAGCGGGGRCACCGRCAGCTTCTTTAACTCCTAARCGCGTGCTAGCflCTRGTCTBGARCTATAGTGAGTCGTATTACGTRGATCCAGACJfGATAAGAflCATTGATGAGTTTGGBCABACCA 
B l-R /C  G IHGGGCRNC-
Expected GTRGTGGCAGCGGGGRCACCGACAGCTTCTTTRACTCCTRRRCGCGTGCTAGC-------- TCTAGAACTATAGTGAGTCGTATTACGTAGATCCAGRCfrGATRAGAlRCRTTGATGAGTTTGGACARACCA
Consensus G TRG tG gcagcggggacaccgacagcttctttaactcctaaacgcgtgctagc......... tc ta g a a c ta ta g tg a g tc g ta tta c g ta g a tc c a g a c i Lgataagat aca ttga tgag tttggacaaacca
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430,------ 4--------      <--------+------- *------- ♦--------1--------<--  H-------->--------1
B l-F o ru  CAACTAGAATGCRGTGAAARAAATGCTTTATTTGTGAflHTTTGTGflTGCTATTGCTTTATTTGTBflCCflTTflTAHGCTGCHRTAflRCRRGTTAflCRRCBACARTTGCHTTCRTTTTBTGTTTCBGGTTCfl
B l - R / C ----------------------------------------------------------------GN--------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected CAACTAGAATGCBGTGflBHRAAATGCTTTATTTGTGR-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Consensus c a a c t a g a a t g c a g t g a a a a a a a t g ( H ; t t a t t t g t G a . . . . . . . . .
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560I------ +------- +--------►------- ♦------- ♦-------   ♦------- +------- *--------+------- +--------►------- 1
B l-F o ru  GGGGGflGGTGTGGGAGGTTTTTTflATTCGCGGCCGCGGCGCCflATGCATTGGGCCCGGTACCCAGCTTTTGTTCCCTTTRGTGflGGGTTARTTGCGCGCTTGGCGTflATCflTGGTCRTRGCTGTTTTCCT
B l-R /C  -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
Expected — — — — ---------— -------    — -------------- — - — ----------------------       -—
Consensus .......................................................................... ............................................................... ....................................................................................... ..........................................................
1561 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690
| ------------------------ 4--------------------4------------------------►---------------------- + ---------------------- + ---------------------- ♦ ----------------------- *------------------------ ►------------------------1----------------------- * ----------------------- H-----------------------*•----------------------1
B l-F o ru  GTGTGAARATTGTTATCCGCTCRCflRHTTCCRCACRACATACGRHCCCGGGflGCATflflflGTGTRRHGCCTGGGGGTGCCTARTGflGTGAGCTTRflCTCACRTTTflATTGCGTTGCGGCTCMCTGCCCGCT
B l-R /C  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected —  ------  — -----   — ------------------  — ------------------------   —
Consensus .............................................................. .................................................................................................. ..................... .......................................................................... .........................
1E31 1700 1710 1720 1730 1740 1750 1760 1770 1778
I ------------------- 4 - --------------------   ►-----------------------►---------------------- + ---------------------- ♦ ---------------------- ♦ ---------------------- ♦ ------------------ 1
B l-F o ru  TTCCRNGTCMGGMRRCCTGTTCGTGMCCRMCTHCAMTTARTGRRMCCGCCARNCCCCGGGGGRARGGGHGGHTTTHCHHNTTNGGCNC
B l - R / C ------------------    CC
Expected ----------------------------------------      AR
Consensus ......................       c
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Figure 3.M3
EphB3 Ectodomain cloned into pEF-BOS
B3-Forw: Sequence derived from 5’ cloning primer.
B3-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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1 10 20 30 40 50 60 70 80 90 100 110 120 130
I-------♦--------H-------- ►-------- «-------- 1--------       1-------------  1---   1
B3-Foru HR----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B3-R/C NRNTNCGRCNGGGGNRRNTTTCNRGNTGGCCGGCCTNTTTTTGNTGNCTGGCCTCGGGCCNCCCGTTRTTCCCCCCCCCCTGGGNGNCNRNGNTTGGCCCCGNTTGGCCCCRGTTGCGTGRGCGGRRRGR
Expected G--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------
Consensus . a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I------------+----------------------   — -- -i-------------- 1--------------1-------------- 1-------------- 1-------------- ►--------------    - I-------------- 1
B3-Foru --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B3-R/C TGGCCGNTTTCCHGGCCNTGCTGCRGGGRRGCTCNRRRRTNGRNGRRCGCGGCCCTCGGNRGRNCNGGCNGGTGRNTCRCCCRCRCRRRGGRRRRRGGGCCTTTCCGTCNTCRGCCGTCGCTTCRTGTGR
Expected -----        — ------------  — --------------------- ----- -----_ _ _ _ _ ---------------------------- ----------------
Consensus  ........................................................................................................................................................................................................................................................................................
261 270 280 290 300 310 320 330 340 350 3G0 370 380 390I----+---- H-----♦---- ♦---- -I-----  +-----►---- ♦---- H-----►---- *-----1
B 3 - F o r u --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
B3-R/C CTCCflCGGRGTflCCGGGCGCCGTCCflGGCRCCTCGflTTflGTTCTCGRGCTTTTTGGflGTRCGTCGTCTTTRGGTTGGGGGGRGGGGTTTTRTGCGflTGGRGTTTCCCCflCRCTGflGTGGGTGGflGRCTGR
Expected „ ■■■------------------------------— -----—— —, - - --— -------------------— ..... ......— . . .—— — — —-------- —----- -----
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
391 400 410 420 430 440 450 4G0 470 480 490 500 510 520
I-------♦--------  1------- -I-------- 1----   1--- 1-------- ►--------  1--------     1
B3-Forw --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B3-R/C RGTTflGGCCfiGCTTGGCflCTTGflTGTflflTTCTCCTTGGflflTTTGCCCTTTTTGBGTTTGGflTCTTGGTTCflTTCTCRRGCCTCflGRCflGTGGTTCRRRGTTTTTTTCTTCCflTTTCflGGTGTCGTGflGGfl
E x p e c te d --------------_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ -----------------------------  — ---------------------------------------------------------------      — ------------
Consensus ........... ............................................................................................................... ..............................................................................................................................................................................................
521 530 540 550 560 570 580 590 600 610 620 630 640
B3—Fotm
B3-R/C RTTCTCTRGRCTRGTGCTRGCf :RHTGG1 FCTTGCCflGCTCTRCCfiCCRGCRTCCRCflCCRTGCTGCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRflGCTTCRflTCTCGGCGCGCCfl IGRGCRGR
E x p e c te d -----------------------------CTHGCf :RRTGG1 rCTTGCCflGCTCTflCCRCCRGCRTCCRCflCCRTGCTGCTCCTGCTCCTGflTGCTCTTCCRCCTGGGRCTCCRflGCTTCRflTCTCGGCGCGCCfl IGRGCRGR
Consensus . . . . . . . . . . . . . . . . c ta g c i :aatggt :.c ttgcca g c tc ta cca cca g ca tcca ca cca tg c tg c tcc tg c tcc tg a tg c tc ttcca cc tg g g a c tcca a g c ttca a tc tcg g cg cg cca  'gagcaga
B3-Foru
B3-R/C
Expected
Consensus
651 660 670 680 690 700 710 720 730 740 750 760 770 780I ►  -I-------- +-------- ♦---------1-------- +-------- +-------- ►-------- 1-------- A--------   +-------- 1
-TCTRTGGRHCGRflflTGGGTGRCGTCCGRGCTGGCRTGGRCRTCTCRTCCRGGGRGTGGCCNGTTTRRGRRGTGRGCGGC
RGCTTRTCTCGGRGGRGGRCCTGICGCGTTGCTGGGCGCTGGRRGRGRCTCTCRTGGRCRCGRRRTGGGTGRCGTCCGRGCTGGCRTGGRCHTCTCRTCCHGGGRGTGGGTGGG— RRGRRGTGRGCGGC 
RGCTTRTCTCGGRGGRGGRCCTG ICGCGTTGCTGGGCGCTGGRRGRGRCTCTCRT6GRCRCGRRRTGGGTGRCGTCTGRGCTGGCRTGGRCRTCTCRTCCRGRGRGTGGGTGGG— RRGRRGTRRGCGGC 
agctta tc tcggaggaggacc tg  icgcgttgctgggcgctggaagagactcTCatgGacaCGRRRTGGGTGRCGTCcGRGCTGGCRTGGRCRTCTCRTCCRGgGRGTGGgtgGg..RRGRRGTgRGCGGC
781 790 800 810 820 830 840 850 860 870 880 890 900 910I----+----   +---- A-----  +---- ♦-----►---- +---- A-----►---- A-----1
B3-Foru TRCGHTGRRGCCHTGRflTCCTRTCCNNflCGRTRTCRGGTGTGTHRCGTGCGCGflGTCCRGCCRGflflCRflCTGGCTGCGGRCCGGTTTCfiTCTGGCGGCGGGflflGTCCflGCGCGTCTRCGTGGRGCTGRflG 
B3-R/C TRCGRTGRRGCCflTGRRTCCTRTCCGCRCG-TRTCRGGTGTGTRRCGT6CGCGRGTCCRGCCRGflflCRRCTGGCTGCGGRCCGGTTTCRTCTGGCGGCGGGRRGTCCflGCGCGTCTRCGTGGRGCTGRRG 
Expected TRTGRTGRRGCCRTGRflTCCTRTCCGCRCG-TRTCRGGTGTGTRflTGTGCGTGRGTCGflGCCRSiRCRRCTSiCTGCGGRCGGGTTTCRTCTGGCGGCGGGRRGTCCRGCGCGTCTRCGTGGRGCTGRRG 
Consensus TRcGRTGRRGCCRTGRRTCCTRTCCgcRCG.TRTCRGGTGTGTRRcGTGCGcGRGTCcRGCCRGRRCRRCTGGCTGCGGRCcGGTTTCRTCTGGCGGCGGGRRGTCCRGCGCGTCTRCGTGGRGCTGRRG
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
|------------ »-------------                   <-------------- 1-------------a-------------- 1
B3—Foru TTTRCCGTGRGflGATTGCRRCRGCRTCCCCRflCRTCCCTGGCTCCTGCRRGGHRRCCTTCRRCCTTTTTTRCTRCGflGGCTGflTRGCGRTGTGGCGTCRGCCTCCTCTCCCTTCTGGRTGGRGRRCCCCT 
B3-R/C TTTRCCGTGflGRGflTTGCRRCRGCRTCCCCRRCRTCCCTGGCTCCTGCRRGGRRflCCTTCRRCCTTTTTTRCTRCGflGGCTGRTRGCGRTGTGGCGTCflGCCTCCTCTCCCTTCTGGRTGGRGRRCCCCT 
Expected TTCRCCGTRRGRGRCTGTRRCRGCRTTCCCRRCRTCCCTGGCTCCTGCRRGGRRRCCTTCRRCCTTTTCTRCTRCGRGGCTGflTRGCGRTGTGGCCTCRGCCTCCTCTCCCTTCTGGRTGGRGRRCCCCT 
Consensus TTtflCCGTgflGflGfltTGcflflCflGCRTcCCCRRCflTCCCTGGCTCCTGCflflGGflflflCCTTCflRCCTTTTtTRCTRCGflGGCTGfiTflGCGflTGTGGCgTCfl6CCTCCTCTCCCTTCTGGRTGGflGflflCCCCT
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170|----»---- ♦----      1         a.....1
B3-Foru RCGTGRRRGTGGRCflCCRTTGCGCCRGRTGRGRGCTTCTCGCGGCTRGRCGCTGGGCGCGTTRRCRCCRRRGTGCGCRGCTTCGGGCCGCTTTCCRRRGCCGGCTTCTRCTTGGCCTTCCRGGRCCRGGG 
B3-R/C flCGTGflfiRGTGGflCRCCRTTGCGCCRGRTGflGRGCTTCTCGCGGCTRGflCGCTGGGCGCGTTRRCflCCRflRGTGCGCRGCTTCGGGCCGCTTTCCBflBGCCGGHTTCTflCTTGGCCTTCCflGGflCCflGGG 
Expected RCGTGRRRGTGGRCRCCRTTGCGCCRGRTGRGRGCTTCTCGCGGCTCGRTGCCGGGCGTGTCRRCRCCRRGGTGCGCRGCTTCGGGCCGCTTTCCRRGGCTGGCTTCTRCTTGGCCTTCCRGGRCCRflGG 
Consensus RCGTGRRRGTGGRCRCCflTTGCGCCRGRTGRGRGCTTCTCGCGGCTaGRcGCtGGGCGcGTtRRCRCCRRaGTGCGCRGCTTCGGGCCGCTTTCCRRaGCcGGcTTCTRCTTGGCCTTCCRGGRCCflgGG
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
B3-Forw TGCCTGCRTGTCRCTCRTCTCTGTGCGCGCCTTCTRCRRGRRGTGTGCRTCCRCC ICTTRRRCt :GTGCTRGCRCTRGTCTRGRGTGRGGGTCCCCRCCTGGGRCCCTTGRGRGTflTCflGGTCTCCCRCG
B3-R/C TGCCTGCRT-TCRCTCRTCTCTTMTRT-
Expected TGCCTGCRTGTCRCTCRTCTCTGTGCGTGCCTTCTRCRRGRRGTGTGCRTCCRCC 1CTTRRHCICGTGCTRGC 
Consensus TGCCTGCRTgTCRCTCRTCTCTgtgcg.gccttctacaagaagtgtgcatccacc » c tta a a c |cgtgCtflgC
-CRRHC--------
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430
I ---------------  A---------------- ♦ - -------------- ♦-----------------1----------------   ♦-----------------►-----------------►----------------H---------------- +----------------+---------------- 1
B3-Foru TGGGflGRCRRGRflRTCCCTGTTTRRTRTTTRflRCRGCRGTGTTCCCCRTCTGGGTCCTTGCRCCCCTCRCTCTGGCCTCRGCCGRCTGCRCRGCGGCCCCTGCRTCCCCTTGGCTGTGRGGCCCCTGGRC
B3-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected -----— ---------------— — — — — — —  , — _ _ _ _ _ _ ---------— -------------------------- ----------— ---------— _ _ _ _ _ _ _ _ _ _ _ _
Consensus ................................................................................................................................ ............................................. ........................................................................................... ..............
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
I --------------♦---------------- A-----------------  ♦--------------         +----------------H---------------- +----------------♦---------------- 1
B3-Foru RRGCRGRGGTGGCCRGflGCTGGGRGGCRTGGCCCTGGGGTCCCRCGRRTTTGCTGGGGflRTCTCGTTTTTCTTCTTRRGRCTTTTGGGRCRTGGTTTGRCTCCCGRflCRTCRCCGflCGTGTCTCCTGTTT
B3-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected --------------------------------------------------------------      — ---------------- -—  -     — -— -  — ----------
Consensus .................................................................. .................................. ........................................................................................................................................................................... ..
1561 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690
I -------------- ►---------------- * — ------------ ♦----------------       ♦-----------------►---------------- ♦----------------♦----------------+----------------♦---------------- 1
B3-Foru TTCTGGGTGGCCTCGGGRCRCCTGCCCTGNCCCCCflCGRG66TCRGGRCTGTGRCTCTTTTTRGGGCCRGGCRGGTGCCTGGRCHTTTGCCTTGCTGGRCGGGGflCTGGGGGHTGTGGGRGGGRNCAflflC
B 3 - R /C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------
E x p e c te d ------------------------------------------------------------------------       - ------ ------------ ----------------- -------------------------------_ _ _ _ _ _ _ ........ ...... ........  .. ..........
Consensus  ............................................................................................................................................................. ......................................................
1691 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820
I --------------1-----------------    1----------------- 1---------------- +----------------+---------------- ►---------------- ♦----------------A----------------- 1---------------- ♦---------------- 1
B3-Fom  RGGRGGflflTCRTGTCRGGCCTGTGTGTGRRRGGRRNCTCCRCTGTCRCCCTNCRCCTTHTTNRCCCCCRRTTCRCCRNGNNTCCCCTCRCTGTCRNRTNGTflRCTGRRCTTCRGGflTRTRRRGGGNTTNN
B3-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected -------------------- ■ ------------     —  , — — — — — — — — — ------- —----- _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Consensus  .......... ............................ ................................ ...................................... ........................................................................................................................... ..
1821 1830 1840 1850 1860 1870 1880 1887
| ------------------A---------------<-----------------A-----------------A----------------- 1----------------♦---------1
B3-Foru 
B3-R/C 
Expected 
Consensus
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Figure 3.M4
EphB3 Ectodomain cloned into pCS2+
B3-Forw: Sequence derived from 5’ cloning primer.
B3-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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B3-Foru
B3-R/C
Expected
Consensus
10 20 40 50 BO 110 120 130 --1
CCTGGGNTHRRTGCCCCRTTTGRCGNTCflRTRNGGNCCNCCCCCCCNNTTGRCCMTCRflTGGGflTNGNNTCflTTGCCCCNTTNRRTTCCGNTTTTCfiCCGCCCCCCTflTTGRCGTTCRflTGRCGGTflRflT 
C------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
B3-For«
B3-R/C
Expected
Consensus
131 140
I------------ k- 150 160 170 180 190 200 210 220 230 240 250 260 --1
GGCCCRCTTGGCRGTRCHTCflHTRTCTRTTflflTRGTRRCTTGGCHflGTHCRTTRCTHTTGMHRGTRCGCCRGGGTRCRTTGGCRGTRCTCCCflTTGflCGTCRflTBGCGGTHRHTGGCCCGCGRTGGCTGC
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Focu
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
B3-For«
B3-R/C
Expected
Consensus
B3-Foru
B3-R/C
Expected
Consensus
261 I-- 270 280 290 310 320 330 340 350 360 370 390 --1
CRRGTRCRTCCCCRTT6RCGTCRRTGGGGRGGGGCRflTGflCGCRRRTGGGCGTTCCRTTGRCGTRRRTGGGC6GTRGGCGT6CCTRRTGGGRG6TCTRTflTRflGCRRTGCTCGTTTRGGGRRCCGCCBTT
----------------------------------------------------------------------------------------------------  GCCRTT
.g c c a tt
391 I-- 400 410 420 430 440 450 480 490 500 510 520 --1
CTGCCT6GGGRCGTCGGAGCRRGCTTGRTTTRGGTGRCRCTATRGRRTRCRRGCTRCTTGTTCTTTTTGCRGGATCCCRTCGRTTCGRRTTCRRGGCCTCTCGRGCCTCTRGRCTRGTGCTRGCf CRRTG
CTGCCTGGGGflCGTCGGRGCRflGCTTGflTTTflGGTGflCRCTflTflGRRTflCRflGCTRCTTGTTCTTTTTGCRGGflTCCCRTCGflTTCGRflTTCflRGGCCTCrCGRGCCTCTRGfl GCTRGCf CRRTG
c tg cc tg g g g a cg tcg g a g ca a g c ttg a ttta g g tg a c a c ta ta g a a ta c a a g c ta c ttg ttc tttt tg c a g g a tc c c a tc g a ttc g a a ttc a a g g c c tc tc g a g c c tc ta g a . .  . . .g e t  age; caatg
521 I— 530 540 550 560 570 580 590 600 610 620 630 640 650 --1
GTTCTT6CCRGCTCTRCCRCCRGCRTCCRCRCCRTGCTGCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRRGCTTCRRTCTCGGCGCGCCR IGAGCAGARGCTTRTCTCGGRGGAGGRCCTGf CGC 
GTTCTTGCCRGCTCTRCCRCCflGCRTCCflCHCCflTGCTGCTCCTGCTCCTGflTGCTCTTCCRCCTGGGRCTCCflRGCTTCflflTCTCGGCGCGCCR iGRGCRGRRGCTTRTCTCGGRGGflGGRCCTGf CGC 
g ttc ttg c c a g c tc ta c c a c c a g c a tc c a c a c c a tg c tg c tc c tg c tc c tg a tg c tc ttc c a c c tg g g a c tc c a a g c ttc a a tc tc g g c g c g c c a  ’gagcagaagcttatctcggaggaggacctg i cgc
651 I-- 660 670 680 690 700 710 720 730 740 750 760 770 780 --1
------------------------------------ HRRNNf TANUGANMilDiflTGGGTGRCGTCCGAGCTGGCRTGGRCRTCTCRTCCRGGGAGTGGNTGNGAAGARGTGflGCGGCTACGATGRAGCCATGRflTCCTRTCCGCRC
GTTGCTGGGCGCTGGRRGnGRCTCTCRTGGflCflCGRRRTGGGTGRCGTCCGRGCTGGCflTGGRCRTCTCRTCCRGGGRGTGGGTGGGRRGRRGTGRGCGGCTRCGRTGRRGCCRTGRRTCCTRTCCGCflC
GTTGCTGGGCGCTGGflflGflGRCTCTCRTGGflCflCGRRRTGGGTGRCGTCTGRGCTGGCRTGGflCRTCTCRTCCRGRGRGTGGGTGGGRRGRflGTRRGCGGCTRTGRTGRRGCCRTGRflTCCTRTCCGCRC
gttgctgggcgctggaagagflctctCatgGacaCGRRflTGGGTGRCGTCcGRGCTGGCflTGGRCRTCTCflTCCRGgGRGTGGgTGgGRHGflRGTgflGCGGCTRcGflTGRRGCCflTGflflTCCTflTCCGCRC
781I- 790 800 810 820 830 840 850 860 870 880 890 900
910 
—  I
GTRTCRGGTGTGTRRCGTGCGCGRGTCCRGCCRGflflCRRCTGGCTGCGGRCCGGTTTCRTCTGGCGGCGGGRRGTCCRGCGCGTCTRCGTGGRGCTGRRGTTTRCCGTGRGRGflTTGCRRCflGCRTCCCC
GTRTCRGGTGTGTRRCGTGCGCGRGTCCRGCCAGRRCRRCTGGCTGCGGACCGGTTTCRTCTGGCGGCGGGRRGTCCRGCGCGTCTACGTGGRGCTGRRGTTTRCCGTGRGRGRTTGCARCRGCRTCCCC
GTRTCRGGTGTGTRRTGTGCGTGflGTCGflGCCflGRRCRRCTGGCTGCGGflCGGGTTTCRTCTGGCGGCGGGflRGTCCRGCGCGTCTRCGTGGflGCTGRRGTTCRCCGTRflGRGflCTGTflflCRGCflTTCCC
GTRTCRGGTGTGTRflcGTGCGcGRGTCcflGCCRGRRCRflCTGGCTGCGGflCcGGTTTCRTCTGGCGGCGGGflRGTCCRGCGCGTCTRCGTGGflGCTGflflGTTtRCCGTgflGRGfltTGcflflCRGCRTcCCC
920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 -I911 I--
RRCflTCCCTGGCTCCTGCflflGGRRRCCTTCflflCCTTTTTTRCTRCGflGGCTGflTRGCGflTGTGGCGTCflGCCTCCTCTCCCTTCTGGRTGGRGflflCCCCTBCGTGRRflGTGGRCHCCRTTGCGCCflGflTG 
RRCRTCCCTGGCTCCTGCHflGGRflflCCTTCflflCCTTTTTTRCTRCGRGGCTGflTRGCGRTGTGGCGTCAGCCTCCTCTCCCTTCTGGRTGGRGHflCCCCTRCGTGflflRGTGGRCflCCflTTGCGCCflGflTG 
HHI'RTCCCTGGCTCC IGCHHGGHHHCCr 1CHRCC1T1 rCTRCIHCGRGGCTGflTRGCGHTGTGGCClCflGCCTCCTCTCCCTTCTGGfllGGRGRRCCCCTRCGTGRflRGTGGRCRCCRTTGCGCCflGRTG 
RfiCRTCCCTGGCTCCTGCflflGGRHRCCTTCflflCCTTTTtTRCTRCGRGGCTGflTflGCGRTGTGGCgTCRGCCTCCTCTCCCTTCTGGRTGGflGflflCCCCTflCGTGAflflGTGGflCflCCflTTGCGCCflGflTG
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170 -I
RGRGCTTCTCGCGGCTBGRCGCTGGGCGCGTTflRCRCCRRRGTGCGCRGCTTCGGGCCGCTTTCCRRflGCCGGCTTCTRCTTGGCCTTCCflGGRCCflGGGTGCCTGCRTGTCRCTCflTCTCTGTGCGCGC
RGRGCTTCTCGCGGCTRGflCGCTGGGCGCGTTflflCRCCflRflGTGCGCflGCTTCGGGCCGCTTTCCRRflGCRGGGTTCTRCTTGGCCTTCCflGGRCCRGGGTGCCTGCflTGTCflCTCflTIITMT--------------
RGRGCTTCTCGCGGCTCGRTGCCGGGCGTGTCRRCRCCRRGGTGCGCRGCTTCGGGCCGCTTTCCRRGGCTGGCTTCTRCTTGGCCTTCCRGGRCCHRGGTGCCTGCRTGTCRCTCRTCTCTGTGCGTGC
RGAGCTTCTCGCGGCTaGRcGCtGGGCGcGTtHRCRCCRflaGTGCGCRGCTTCGGGCCGCTTTCCRRaGC.GGcTTCTACTTGGCCTTCCRGGflCCHgGGTGCCTGCRTGTCRCTCRTcTcTgtgcg.gc
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
CTTCTRCflflGflRGTGTGCRTCCflCCRCTTRflflCGCGTGCTRGCflCTRGTCTRGflflCTRTRGTGRGTCGTRTTRCGTRGRTCCRGflCRT iflTRRGHTR :rttgrtgrgtttggrcrrrccrcrrctrgrrt
CTTCTRCRRGARGTGTGCRTCCRCCRCTTRRRCGCGTGCTRGC—  
c ttc ta ca a g a a g tg tg ca tcca cca c tta a a cg cg tg c ta g c .. .
— TCTRGRRCTRTRGTGRGTCGTRTTRCGTRGRTCCRGRCRT 
. . . tc ta g a a c ta ta g tg a g tc g ta tta c g ta g a tc c a g a c a t
iHTHRGRTR
'a t a a g a ta
:rttgrtgrgtttggrcrrrccrcrrctrgrrt
:a ttga tgag tttggacaaaccacaactagaa t
1380 1390 1400 1410 1420 1430 -I1301 1310 1320 1330 1340 1350 1360 1370I------------ ,-------------- ,--------------  ►------------- ♦------------- *-------------- ►-
GCRGTGRRRRRRRTGCTTIRIT16fGflflflTTTGTGflTGCTHTTGCTTTRTTTGTRflCCHTTRTflBGCTGCRflTHflflCRRGTTRRCHRCRRCRflTTGCHTTCRTTTTRTGTTTCRG6TTCflGGGGGRGGTG
---------------------------------TNTRTCR----------------------------------------------------------------------------------
GCRGTGRRRRRRRTGCTTTRT T T GT---------------------------------------------------------------------------------
gcag tgaa aaaaa tgc ttF a l t T g t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 15501431 1440
I------------ ►-
TGGGflGGTTTTTTflflTTCGCGGCCGCGGCGCCflRTGCHTTGGGCCCGGTflCCCHGCTTTTGTTCCCTTTRGTGflGGGTTRflTTGCGCGCTTGGCGTflflTCRTGGTCflTRGCTGTTTCCTGTGTGflRflTTG
1560 -I
1561 1570 1620 1630 1640 1650 1660 1670 1690 -I
TTRTCCGCTCfiCRHTTCCRCRCRflCHTflCGRGCCGGGRGCRTRRRGTGTflflRGCCTGGGGGTGCCTRflTGRGTGRGCTflRCTCflCflTTRATTGCGTTGCGCTCflCTGCCCGCTTTCCflGTCGGGflflflCCT
1691 1700 I- 1710
1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820 -I
GTCGTGCCRGCTGCRTTRRTGflRTCGGCCRRCGCGCGGGGGflflRGGCGGTTTGCGTRTTGGGGGGCTNTTHCGIITTTCCTCGCTTCRMTMRNTNMGCTGCCCTTMMGGHCGTTTGGGTTGMCGGHflRMCG
83-Foru
B3-R/C
Expected
Consensus
1821 1830
I ------------- _
1838 ---1
GTTTNRGCNTCNCTNRRR 
------------------------- RNNC
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Figure 3.M5
EphrinA5 Ectodomain cloned into pEF-BOS
A5-Forw: Sequence derived from 5’ cloning primer.
A5-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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1 10 20 30 40 50 60 70 80 90 100 110 120 130
I---------,---------- i---- ----- .---------- ►----------   .----------♦--------- ♦---------         1
85-Fotm GCT---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
85-R/C NGGGGGGGGCCTTGNNAGGGGGNCCCCCCGAAANTNGHNGNGGGGGTRGTTTTCRHGNTGGNCCGNCCTTTTTTTGGTGCCTGGNCCTNGGGCCCNCCNGTGTRTCGCCCCNCCCTGGGGNGNCARGGCT 
Expected G -■ ■ ■----------- ------- --------------------------■■■■■ — --------------   — --------- — ----------------------------------------------
Consensus  ................................................................................................ ............................................................. ...........................................................................................................................
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I---------■---------- •--- ------ <---------- +---------- 1----------♦--------- 4----------   ♦--------- ►---      1
85-Forw ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A5-R/C GGCCCGGTCGGCACCAGTTGCGTGAGCGGRARATGGCCGCTTCCCGGCCCTGCTGCRGGGRGCTCARAATGGAGGACGCGGCGCTCGGGAGAGCNGGCCGGTGAGTCACCCACACAAAGGRARAGGGCCT
E x p e c te d ------------     —    ■ ■ ..    —---------------  — -----
Concensus ...........................................................................................................................................................
261 270 280 290 300 310 320 330 340 350 360 370 380 390
I---------  1---- -----   4---------- 4---------- ♦--------- +--------- ♦---------       »--------- 1
R5-Foru --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R5-R/C TTCCGTCMTCflGCCGTCGCTTCRTGTGRCTCCflCGGnGTRCCGGGCGCCGTCCRGGCRCCTCGRTTRGTTCTCGRGCTTTTGGflGTRCGTCGTCTTTflGGTTGGGGGGflGGGGTTTTHTGCGflTGGflGTT 
Expected — — _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ -----— — --------_ _ _ _ _ _ _ ---------------------- — — — — —— — _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
391 400 410 420 430 440 450 460 470 480 490 500 510 520
I--------- 1---------- 1-------- *---------- +---------- 4--------- ♦--------- +---------- +--------- ♦--------- +--------- +----------►--------- I
R5-For« ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------
R5-R/C TCCCCflCACTGAGTGGGTGGRGACTGRHGTTRGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGARTTTGCCCTTTTTGflGTTTGGATCTTGGTTCRTTCTCflAGCCTCRGACRGTGGTTCAARGTTTT
Expected        ■■■■- ■ — --------------------------   — ------------------------ — — -----
Consensus  ........................................................................ ..
521 530 540 550 560 570 580 590 600 610 620 630
R5-Foru
R5-R/C TTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTRGACTRGTGCTRGCfl 'HflTGGT rCTTGCCAGCTCTHCCRCCAGCRTCCACRCCRTGCTGCTCCTGCTCCTGATGCTCTTCCRCCTGGGRCTCCflflG
E x p e c te d  CTRGCR :RRTGGT rCTTGCCRGCTCTRCCRCCRGCflTCCRCRCCRTGCTGCTCCTGCTCCTGflTGCTCTTCCflCCTGGGflCTCCflflG
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .c ta g ca  :a a tg g t .c ttg c c a g c tc ta cca cca g ca tcca ca cca tg c tg c tcc tg c tcc tg a tg c tc ttcca cc tg g g a c tcca a g
651 660 670 680 690 700 710 720 730 740 750 760 770 780
R5-Foru -CGCGTCTCTGGRCRGCAGCRRCCCCRGATTCCRGRGGGGTGRCTACCRCflT
R5-R/C CTTCRRTCTCGGCGCGCCR iGRGCRGRRGCTTRTCTCGGRGGRGGflCCTGHCGCGTRRRGTCGTCGCCGRCCGCTRCGCCGTCTRCTGGflRCRGCRGCRRCCCCRGflTTCCRGRGGGGTGRCTRCCRCRT 
Expected CTTCRRTCTCGGCGCGCCR iGAGCAGRAGCTTATCTCGGflGGAGGACCTGHCGCGTfiRflGTCGTCGCCGACCGCTACGCCGTCTRCTGGARCHGr.RGCAfir.CCr.flGnTTCCFIGflGGGGTGnCTflCCflCnT  
Consensus c ttca a tc tcg g cg cg cca  'gagcagaagcttabctcggaggaggacctgacgcgtaaagtcgtcgccgaccgctacgcCGtcTactgGaACAGCAGCARCCCCRGRTTCCRGRGGGGTGRCTRCCRCRT
781 790 800 810 820 830 840 850 860 870 880 890 900 910I------- ,---------,--------       ♦-------- *--------   ►-------- ♦-------- +-------- ►-------- 1
R5—Foru CGRTGTCT6TRTCRRTGflCTRCCTGGflTGTTTTCTGCCCTCRCTRTGRGGRCTCTGTflCCflGRGGRTRRGflCTGRGCGCTflTGTCCTGTRCRTGGTGRRTTTTGflTGGCTRCflGTGCCTGCGRCCflCRCfl 
R5-R/C CGRTGTCTGTRTCRATGRCTACCTGGATGTTTTCTGCCCTCACTATGRGGACTCTGTACCAGRGGATARGRCTGRGCGCTAT6TCCTGTACRTGGTGAATTTTGRTGGCTRCAGTGCCTGCGRCCACACR 
Expected CGRTGTCTGTRTCRflTGRCTRCCTGGflTGTTTTCTGCCCTCRCTRTGRGGflCTCTGTRCCRGRGGRTRRGRCTGflGCGCTRTGTCCTGTRCRTGGTGRRTTTTGflTGGCTRCRGTGCCTGCGRCCRCRCR 
Consensus CGRTGTCTGTflTCRRTGRCTRCCTGGATGTTTTCTGCCCTCflCTRTGflGGRCTCTGTRCCflGflGGRTRRGRCTGflGCGCTRTGTCCTGTRCRTGGTGRRTTTTGflTGGCTRCRGTGCCTGCGRCCRCRCfl
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040I------- 1---------1-------- 4-------- +-------- ♦-------- ♦-------- ♦-------- ♦--------   *--------+-------- ►-------- I
R5—Focu TCCRRRGGGTTCRRGRGRTGGGRRTGTRRCCGGCCTCRCTCTCCRRRCGGRCCGCTGRRGTTCTCGGRGRflRTTCCRGCTCTTCRCTCCCTTTTCTTTRGGRTTTGflflTTCRGGCCRGGCCGRGRGTRTT 
R5-R/C TCCRflflGGGTTCRRGRGRTGGGflflTGTflRCCGGCCTCflCTCTCCRRflCGGflCCGCTGRHGTTCTCGGRGRRflTTCCRGCTCTTCRCTCCCTTTTCTTTRGGRTTTGflflTTCRGGCCRGGCCGRGflGTRTT 
Expected TCCRflRGGGTTCflRGRGflTGGGRRTGTflRCCGGCCTCRCTCTCCRRflCGGflCCGCTGRRGTTCTCGGRGflRflTTCCRGCTCTTCRCTCCCTTTTCTTTRGGRTTTGflflTTCRGGCCRGGCCGRGflGTflTT 
Consensus TCCAAAGGGTTCARGAGATGGGAATGTAACCGGCCTCACTCTCCAAACGGACCGCTGAAGTTCTCGGAGRAATTCCAGCTCTTCACTCCCTTTTCTTTAGGATTTGAATTCRGGCCAGGCCGAGAGTATT
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170I-------     1--------♦-------      +------- «--------    1
R5-For« TCTflCRTCTCCTCTGCRflTCCCRGRCflflTGGRRGRRGflTCCTGCCTRRflGCTCRRRGTCTTTGTGflGGCCRflCflflflCflGCTGTRTGflflRRCTRTRGGTGTTCflTGRTCGTGTTTTCGRTGTTRRCGRCRfl 
R5-R/C TCTRCRTCTCCTCTGCRflTCCCRGflCRflTGGflRGRRGflTCCTGCCTRflflGCTCflflRGTCTTTGTGRGGCCRRCRRRCRGCTGTRTGflflRflCTflTRGGTGTMMflTGRTCGTGTTTTCGRTGTTRRCGflCRR 
Expected TCTflCRTCTCCTCTGCRflTCCCRGRCRflTGGflRGflflGRTCCTGCCTRRflGCTCflflflGTCTTTGTGRGGCCRflCRRflCRGCTGTflTGflRRRCTRTRGGTGTTCGTGflTCGTGTTTTCGflTGTTRRCGflCRfl 
Consensus TCTRCRTCTCCTCTGCRRTCCCRGRCRRTGGflRGRRGRTCCTGCCTfiRflGCTCRflRGTCTTTGTGRGGCCflflCflflflCflGCTGTRTGRRRflCTflTRGGTGTtcaTGflTCGTGTTTTCGflTGTTRRCGRCRfl
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300-I
Expected IIGIIIGflllllH I TCRTTRGRRCCRGCRGRTGRCRCCGTRCRTGRGTCRGCCGRGC :RTRRRCGC .TGCTRGC 
Consensus RGTRGRRRRTtCattagaaccagcagatgacaccgtacatgagtcagccgagcfcataaacgcfcttg c ta g c
R5-Foru RGTRGRRARTTCRTTRGAACCRGCAGATGACACCGTACRTGAGTCAGCCGflGCfcATAARCGCJjTGCTRGCACTflGTCTRGAGT6flGGGTCCCCACCTGGGACCCTTGRGAGTATCAGGTCTCCCRC6TGG 
R5-R/C RGTRGAAAATMC-
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430I-------    <--------►------- ♦------- +------- «--------♦------- ♦------- ♦------- ►------- 1
R5-Forw GRGRCRflGHRRTCCCTGTTTRflTflTTTRflRCRGCRGTGTTCCCCRTCTGGGTCCTTGCRCCCCTCRCTCTGGCCTCflGCCGflCTGCRCflGCGGCCCCTGCRTCCCCTTGGCTGTGRGGCCCCTGGRCRRG
R5-R/C ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected — — — — — — — — — — — — —  -------   - ,, , ...... .
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
I------------   1--------------4--------------♦--------------♦------------- +------------- +------------- ♦------------- +-------------     ►--------------1
A5-Foru CRGflGGTGGCCRGRGCT6GGRGGCRTGGCCCTGGGGTCCCRCGRRTTTGCTGGGGRRTCTCGTTTTTCTTCTTflHGRCTTTTGGGRCRTGGTTTGHCTCCCGflRCRTCflCCGRCGTGTCTCCTGTTTTTC
R5-R/C ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
E x p e c te d -------------------     — -----------    — --------------------------------- ----------
Consensus  ........................................................................................................................................................................................................................................................................................
1561 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690
|---------1----------   4---------- 4---------- ►--------- ♦--------- ♦--------- ♦--------- ♦--------- ♦--------- +----------►----------I
R5-Foru TGGGTGGCCTCGGGfiCRCCTGGCCCTGCCCCCCflCGRGGGTCRGGRCTGTGRCTCTTTTTTRGGGCCflGGCflGGTGCCTGGflCRTTTGCCTTGCTGGflCGGGGflCTGGGGGRTGTGGGflHGGRGCRGflCR
R5-R/C ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected -------— —  ----------------------- — --------------------------------------     _ _ _ _ _ _ _ _ _ _ _ _ _ ---------------- -------------------------------------------------------
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1691 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820I-------    +------- +------- ♦------- ♦------- ♦------- +------- ♦------- +------- +------- ►--------1
R5~Foru GGRGGRATCflTGTCAGGNCTGTGTGTGflflflGGflRGCTCCHCTGTCflCCCTCCflCCTCTTCACCCCCRCTCRCCAGTGTCCCCTCCRCTGTCRCRTMGTRRCTGAflCTTCNGGRTHRTTAflGGNGTTGCCT
R5-R/C ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected — --------      — ----------------------------------------   _ _ _ _ _ ------— — ----
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1821 1830 1840 1850 1860 1870 1880 1890 1900I-------1--------      1------- ♦------- *--------1
R5-Foru CCCNMNAAANNNNNNNNNNMNAANNNNAAHANAAAARHflAAHAARACCNNATTTNTGGNNNMTTTTTRRANAAAACCNNN
A5-R/C --------------------------------------------------------------------------------------------------------------------------------------------------
Expected — — — ------ — — — — — — — — — —
Consensus ................................................................... ...........................................................................................................
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Figure 3.M6
EphrinA5 Ectodomain cloned into pCS2+
A5-Forw: Sequence derived from 5’ cloning primer.
A5-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
147
1 10 20 30 40 50 GO 70 80 90 100 110 120 130I----- I--------    1--------  ♦--------  ♦-------   *------- ►------- ►------- ►--------I
Rb-forw T------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A5-R/C GTTCAATHGCCCCRTTGRMNGTCRANTRNGGACCNCCCCCCCCATTGGACGTTCARTGGGATGGCTCCRTTGCCCCATTCATTTCCGNTCTCCRCGCCCCCCTNTTGRCGTCflARTGRCNGTRATGGCCC
E x p e c te d ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
Consensus ..........................................................................................................................................................................................................................................................................................
131 140 150 160 170 180 190 200 210 220 230 240 250 2G0
R 5 - F o r u ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
R5-R/C RCTTGGCRGTRCRTCNRTRTNTRTTRRTRGTRRCTTTGGCRnGTRCRTTRCTRTTGGRRGTRCGCCRGGGTRCHTTGGCRGTRCTCCCRTTGRCGTCRRTGGCGGTRRRRTGGCCCCGCGflTGGCTGCCH
E x p e c te d ------------------------------------------------------------------------------------------------------   _ _ _ _ _ _ _ _ ------------------------------------------ — — ------
Consensus ..........................................................................................................................................................................................................................................................................................
2G1 270 280 290 300 310 320 330 340 350 360 370 380 390I-------  -•--------      ♦------- ♦------- ♦------- +------- ►--------    1
R 5 - F o r v --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R5-R/C RGTRCRTCCCCRTTGRCGTCflRTGGGGRGGGGCRRTGRCGCRflRTGGGCGTTCCflTTGflCGTRflRTGGGCGGTRGGCGTGCCTRRTGGGRGGTCTRTRTRRGCRRTGCTCGTTTRGGGRRCCGCCRTTCT
E x p e c te d -----------------------   CGCCRTTCT
Consensus ...........      c g c c a ttc t
391 400 410 420 430 440 450 460 470 480 490 500 510 520
R5-Foru
B5-R/C GCCTGGGGRCGTCGGflGCRRGCTTGRTTTflGGTGRCflCTRTRGflflTflCflRGCTRCTTGTTCTTTTTGCRGGRTCCCRTCGRTTCGRflTTCflRGGCCTCTCGRGCCTCTRGRCTflGTGCTRGCf :flflTGGT
Expected GCCTGGGGRCGTCGGRGCRRGCTTGRTTTRGGTGRCRCTflTRGRRTRCRRGCTRCTTGTTCTTTTTGCRGGRTCCCRTCGRTTCGRflTTCRflGGCCTCTCGRGCCTCTflGR GCTRGCf :RATGG1
Consensus g cc tg g g g a cg tcg g a g ca a g c ttg a ttta g g tg a c a c ta ta g a a ta c a a g c ta c ttg ttc tttttg c a g g a tc c c a tc g a ttc g a a ttc a a g g c c tc tc g a g c c tc ta g a .. . . .  gctagce :aatggt
521 530 540 550 560 570 580 590 GOO 610 G20 630 G40 650
I ----------  I----------------- 1-----------------4-----------------* -----------------1--------------- -H-----------------♦----------------     ♦----------------♦----------------   I
R5-Forw
R5-R/C TCTTGCCflGCTCTRCCRCCRGCflTCCRCflCCflTGCTGCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRRGCTTCRRTCTCGGCGCGCCR iGRGCRGRRGCTTRTCTCGGRGGRGGRCCTGf CGCGT 
Expected TCTTGCCflGCTCTRCCRCCRGCflTCCRCflCCRTGCTGCTCCTGCTCCTGRTGCTCTTCCRCCTGGGRCTCCRRGCTTCRRTCTCGGCGCGCCfl iGRGCRGRRGCTTRTCTCGGRGGRGGRCCTGf CGCGT 
Consensus tc ttg c c a g c tc ta c c a c c a g c a tc c a ca cca tg c tg c tcc tg c tcc tg a tg c tc ttcca cc tg g g a c tcca a g c ttca a tc tcg g cg cg cca  tgagcagaagcttatctcggaggaggacctgi cgcgt
651 660 670 680 690 700 710 720 730 740 750 760 770 780|--------- ,-----------1----------- ,-----------1---------- ♦---------- 1-----------  <-----------    H--------- 1-----------1-----------1
R5—Foru ------------------------------------------------------------AGGACNCHG6GNCCCAGATTCCAGA6GGGTGACTACCACRTCGATGTCCCTTTHAANGACTACCTGGRTGTTTTCTGCCCTCRCTATGACNANTCTG
R5-R/C RflRGTCGTCGCCGRCCGCTRCGCCGTCTRCTGGRRCRGCflGCflflCCCCRGRTTCCRGflGGGGTGflCTRCCRCRTCGRTGTCTGTflTCRRTGRCTflCCTGGRTGTTTTCTGCCCTCRCTflTGRGGRCTCTG 
Expected RRRGTCGTCGCCGRCCGCTRCGCCGTCTflCTGGflRCRGCflGCflflCCCCflGflTTCCRGflGGGGTGflCTflCCRCRTCGRTGTCTGTflTCflRTGRCTflCCTGGflTGTTTTCTGCCCTCflCTRTGRGGflCTCTG 
Consensus aaagtcgtcgccgaccgctacgccgtctactggRacRgcagcaacCCCRGRTTCCRGRGGGGTGRCTRCCRCRTCGRTGTCtgTaTcRfltGRCTRCCTGGRTGTTTTCTGCCCTCRCTRTGflggflcTCTG
781 790 800 810 820 830 840 850 860 870 880 890 900 910
I --------------       ♦---------------- ♦---------------- ♦---------------- ♦----------------♦---------------- ♦----------------♦----------------+----------------+-------------- 1
R5-Foru TRCCRGRGGRTRRGGCTGRGCGCTRTGTCCTGTRCRTGGTGRRTTTTGRTGGCTRCRGTGCCTGCGRCCRCRCflTCCRRRGGGTTCRRGRGHTGGGRRTGTRRCCGGCCTCRCTCTCCRflRCGGRCCGCT 
R5-R/C TRCCflGflGGRTflRGGCTGRGCGCTRTGTCCTGTRCRTGGTGRRTTTTGflTGGCTRCRGTGCCTGCGflCCRCflCflTCCfiRRGGGTTCflRGfiGRTGGGflflTGTflflCCGGCCTCRCTCTCCRRRCGGRCCGCT 
Expected TRCCflGflGGRTflRGRCTGRGCGCTHTGTCCTGTRCRTGGTGRHTTTTGHTGGCTRCRGTGCCTGCGRCCRCRCflTCCRfifiGGGTTCARGRGHTGGGflflTGTRflCCGGCCTCRCTCTCCRflflCGGRCCGCT 
Consensus TACCRGA6GATARGgCTGAGCGCTRTGTCCTGTBCATGGTGAATTTTGATGGCTRCAGTGCCTGCGACCRCACATCCARAGGGTTCAAGAGATGGGRRTGTRACCGGCCTCRCTCTCCAAACGGACCGCT
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
I --------------      ►----------------+----------------     ♦---------------- 4----------------   1-----------------►---------------- 1
R5-Foru GRRGTTCTCGGRGflflflTTCCRGCTCTTCflCTCCCTTTTCTTTRGGflTTTGRflTTCHGGCCRGGCCGBGflGTflTTTCTRCRTCTCCTCTGCRRTCCCflGflCflflTGGflRGHflGflTCCTGCCTARflGCTCRRH 
R5-R/C GRHGTTCTCGGHGRRATTCCHGCTCTTCflCTCCCTTTTCTTTHGGRTTTGRHTTCRGGCCRGGCCGRGHGTflTTTCTRCflTCTCCTCTGCRHTCCCRGRCflflTGGAflGflRGHTCCTGCCTRRflGCTCRRfl 
Expected GRRGTTCTCGGRGRRflTTCCRGCTCTTCflCTCCCTTTTCTTTRGGRTTTGRRTTCRGGCCflGGCCGRGRGTRTTTCTRCRTCTCCTCTGCRflTCCCflGRCRRTGGRRGRRGflTCCTGCCTRflflGCTCRRfl 
Consensus GRflGrTCTCGGflGflRRTTCCflGCTCTTCflCTCCCTTTTCTTTRGGRTTTGRflTTCRGGCCflGGCCGflGRGTflTTTCTRCflTCTCCTCTGCflflTCCCRGflCRRTGGRflGflRGRTCCTGCCTflRRGCTCflRfl
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170
85-Foru GTCTTTGTGflGGCCRRCflRRCRGCTGTRTGRflflflCTflTflGGTGTTCflTGRTCGTGTTTTCGHTGTTRRCGflCHRRGTflGRRflflTTCflrTRGHRCCRGCRGRTGHCRCCGTRCRTGRGTCRGCCGflGCf IT
R5-R/C GRHNTTGTGAGGCCHACAARCAGCTGTRTGARflflCTRIHGNNAflGGMTGATCGTGTTTTCGATGTTAACGACAAHGTRGRHflNCCCCTAGARMN----------------------------------------------------------------
Expected GTCTTTGTGAGGCCHRCRABCAGCTGTATGAAAACTRTflGGTGTTCGTGflTCGTGTTTTCGATGTTAACGACARAGTRGARAATTCATTAGRACCRGCAGATGACACCGTACATGAGTCAGCCGAGC( IT 
Consensus GtctTTGTGAGGCCAACAARCAGCTGTRTGAAAACTRTAGgtgttc.TGATCGTGTTTTCGATGTTRACGACAAAGTAGRAAattCaTtagRaccagcagatgacaccgtacatgagtcagccgagcc at
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300I
A5-Forw RAR GCGTGCTAGCACTAGTCTAGAACTATBGTGAGTCGTATTACGTAGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCflCflRCTBGAATGCRGTGAAAflARflTGCTTTATTTGTGAAA
R5-R/C - f l
Expected RAR GCGTGCTAGC TCTAGAACTATAGTGAGTCGTRTTACGTAGATCCBGACATGATAAGATACATTGATGAGTTTGGRCAAACCACARCTRGAATGCRGTGAARARAATGCTTTATTTGTGARfl
Consensus aaa gcg tgc tagc . . . .  . tc ta g a a c ta ta g tg a g tcg ta tta cg ta g a tcca g a ca tg a ta a g a ta ca ttg a tg a g tttg g a ca a a cca ca a c ta g a a tg ca g tg a a a a a a a tg c ttta tttg tg a a A
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430
I ------------------ ,--------------- ,-----------------4----------------+----------------♦-----------------+----------------♦----------------+----------------+----------------♦----------------+--------------- ►----------------1
R5-Foru TTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCRRTAAACAA6TTAACAACAACRATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAATTCGCGGCCGCGGC
A5-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected  -------------------------— --------------------------------------------— —  ----------------------- -------------------------------------------------------------------- — — - — -------------- — -----------------
Consensus  ........................................................................... ................................................................... .................................. ........................... ..........................................
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
I ------------------------------------1---------------H----------------♦----------------♦-----------------♦----------------♦----------------+----------------♦----------------+---------------- * --------------- ►----------------1
A5-Foru GCCAATGCATTGGGCCCGGTRCCCAGCTTTTGTTCCCTTTRGTGBGGGTTARTTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGNBARTTGTTATCCGCTCACAATTCCRCACAACRTA
R5-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
E x p e c te d   --------  -           — ---------------------------------------------
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1561 1570 1580 1590 1600 1610 1620 1630 1640 1G50 1660 1670 1680 1690
I -------------- f - ---------------1-----------------+— -----------♦---------------- ♦----------------♦----------------♦---------------- ♦----------------♦----------------♦----------------+---------------- 1----------------- 1
A5-Foru CGAGCCGGGBGCATAABGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGARAACCTGGTCGTGCCAGCTGCATTAATGAATCG
R5-R/C --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected ---------- _ _ _ _ _ ----------------------_ _ _ _ _ _ _ _ _ -------------- _ _ _ _ _ _ _ _ _ _ ---------_ _ _ _ _ _ _ _ _ _ _ _ _ _ -------_ _ _ _ _ — _ _ _ _ _ _ _ _ _ _ _ ____ _____ ______ ______ _
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1691 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820
I ---------------1----------------- 1-----------------H-----------------♦---------------- * -----  ♦----------------♦----------------* ----------------* ----------------   +----------------   I
A5-Foru GGCCAACGCGCGGGGAGAGGCGGGTTTGCGTRTTGGGGNGCTCTTCCGCTTCCTCGCTTCAMTGRNCTCGCTGCNCTCGGTCGTTTCGGGNTGCGGCCRAGCGGNTATCAGCTCNCCTCAAAGGGCGGTH
R5-R/C ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected ------- 1  __________--------- — — -----------— — ----------------- —------- -------— — .......    — ■-— -----   — --------------------- -----
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1821 1830 1840 1850 1859
| -------------- 1-----------------  H--------------- 1
A5-Foru ARTACCGGTTHTNCCNCAGAAATCGGGGGGAflHANCGCA
A5-R/C -----------------------------------------------------------------------
Expected ... -------------------------------- —  —
Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Figure 3.M7
EphA7 Ectodomain cloned into pEF-BOS
A7-Forw: Sequence derived from 5’ cloning primer.
A7-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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1 10 20 30 40 50 GO 70 80 90 100 110 120 130
I------ +— ---   1--------    ♦------- 4--------    1--------►— ------1--------1
R7-Foru CCN8GGRGG-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R7-R/C TTCGGNGNGGGGGNAGTTTCCAAGTTTGGCCNGGCCCTNTNTTTGGNTNCCTNGCCCCC6GCCCCCCCCNGNTNTTCCCCCCCCCCCTTGGGCGNCAAGGCTTGCCCCGGTCGGCNCCCRGTTTGCGTGA
Expected — — —  —------- -------— - — ---------------------------— — — -■ ■    — ——— — — — -----  — ----- — — —
Consensus  ........................................ ......................................................................................................................................................................... ..............................................................
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I *--------  — I--------   1--------        +-------    ♦------- ♦--------1
R7-For» ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R7-R/C GNGGAARGATGGCCGCTTNCCNGNCCMTGCTGCAGGGAGCTCARARTGGAGGACCCGGCCCTCGGGRGRNCCGGCCGGGTGAGTCRCCCACCCCAANGGRRRAGGGCCTTTCCGTCCTTCAGCCGTCGCT
Expected — ■- ■ — — —  -----------------------------------------------------------------  ■ — ----- — —
Consensus  .........................................................................................................................................................................................................................................................................................
2E1 270 280 290 300 310 320 330 340 350 360 370 380 390
I------   1--- 1-------- ►----  1---  1--------<--------H--------       ►--------,--------1
R 7 - F o r * i----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R7-R/C TCfiTGTGRCTCCHCGGRGTRCCCGGGCGCCGTCCflGGCRCCTCGflTTRGTTCTCGRGCTTTTTGGRGTRCGTCGTCTTTflGGTTGGGGGGfiGGGGTTTTflTGCGRTGGflGTTTCCCCflCRCTGflGTGGGT
Expected ■ . — —.   ■■ — .................................. ------------------- _ _ _ _____ -------- — — — — — — — — —
Consensus ............ ...................................................................................................................................... ................................................................................................................................................
391 400 410 420 430 440 450 460 470 480 490 500 510 520
I-------     «---------+--------- 1--------- ♦--------- +---------+--------- 1----------+---------+---------H--------- 1
R7-Foru ----- — ------ — ------- — --------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
R7-R/C GGRGRCTGARGTTRGGCCRGCTTGGCRCTTGRTGTRRTTCTCCTTGGflflTTTGCCCTTTTTGRGTTTGGATCTTGGTTCRTTCTCRRGCCTCAGACAGTGGTTCARRGTTTTTTTCTTCCRTTTCRGGTG
Expected ------------ _________________— _____----- ----- -------------------------------- ------- ----- __________— _____------- __________------- _________________________________
Consensus ....................................................................................................................................................................................................................................................................................................
521 530 540 550 560 570 580 590 600 610 620 630 640 650
|  ,       <      . .       1
R7-Foru ----------------------------------------------------
R7-R/C TCGTGHGGAATTCTCTRGACTAGTGC1RGCF :RRTGG1 TCTTGCCRGCTCTfiCCfiCCHGCRTCCflCRCCflTGCTGCTCCTGCTCCTGRTGCTCTTCCACCTGGGRCTCCRflGCTTCHRTCTCGGCGCGCC
E x p e c te d --------------------------------------------- GCTRGCF :RHTGG1 ICTTGCCflGCTCTRCCflCCRGCflTCCRCRCCflTGCTGCTCCTGCTCCTGRTGCTCTTCCflCCTGGGflCTCCflflGCTTCRRTCTCGGCGCGCC
Consensus.... .......................................................   . gctagca :aa t ggt tc ttg c c a g c tc ta c c a c c a g c a tc c a c a c c a tg c tg c t c c tg c  t c c tg a tg c t  c ttc ca c c tg g g a c tc c a a g c t tcaa tc tcggcg cgcc
651 660 670 680 690 700 710 720 730 740 750 760 770 780
I --------------   ♦-----------------    1------------------1----------------- +---------------- +-----------------♦ ---------------- +----------------     I
R7-Foru --------    CTGTRTCTGGRCTCGRR-GCRCRRCRflRCRGRRTTGGRRTGGRTTTCCTCTCCRCCCRGCTGGGTGGG
R7-R/C R( GAGCAGAAGCTTATCTCGGAGGAGGRCCTGICGCGTGAGGCGCRGGCTGCGRAGGRRGTACTGTTACTGGRCTCGAAAGCACFIRCRRACRGRATTGGRATG6RTTTCCTCTCCRCCCRG-TGGGTGGG
Expected R( GAGCAGHAGCTTATCTCGGAGGAGGACCTGiCGCGTGAGGCGCRGGCTGCGRRGGRAGTACTGTTRCTGGRCTCGARRGCACRACAAACRGRATTGGRATGGHTTTCCTCTCCACCCAG-TGGGTGGG
Consensus af gagcagaagcttatctcggaggaggacctglcgcgtgaggcgcaggctgcgaaggaagtaCTGTtaCTGGACTCGAAaGCflCARCAAACAGARTTGGAATGGATTTCCTCTCCRCCCAG.TGGGTGGG
781 790 800 810 820 830 840 850 860 870 880 890 900 910
I -------------- »---------  *-----------------     1----------------- +------------- — -------------------  1-----------------     ♦-----------------1
R7-Forw RRGflflflTTflGTGGTTTGGRTGRGRRCTRCRCACCAflTRRGRflCHTRCCHGGTGTGCCRGGTCflTG6fl6CCCHRCCRGRRCRflCTGGCTTCGGRCTRflCTGGRTTTCTflRRGGCRRCGCflCflflflGGflTTTT 
R7-R/C RRGRRRTTRGTGGTTTGGRTGRGRRCTRCRCRCCRRTRRGRRCRTRCCRGGTGTGCCRGGTCRTGGRGCCCRRCCRGRRCRRCTGGCTTCGGRCTRRCTGGRTTTCTRRRGGCRRCGCRCRRRGGRTTTT 
Expected RflGRRflTTRGTGGTTTGGRTGflGRflCTRCflCRCCflflTfiRGRflCRTRCCflGGTGTGCCflGGTCflTGGflGCCCRRCCflGfiflCflflCTGGCTTCGGflCTRflCTGGHTTTCTflRflGGCRRCGCflCRflRGGflTTTT 
Consensus RRGRAflTTRGTGGTTTGGRTGRGRACTRCRCflCCRRTRRGRRCRTRCCflGGTGTGCCRGGTCRTGGRGCCCRRCCRGARCRRCTGGCTTCGGRCTRRCTGGflTTTCTRflRGGCRRCGCRCAflflGGATTTT
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
| -------------------- >- --------------------- i ------------------------ >......... t ------------------------«-------------------------1—----------------- — ►----------------------   1-------------------------1--------  + ----------------------- 1------------------------1
R7-Forw TGTRGflATTGRflflTTCACCTTGHGGGRTTGTfiflTRGTCTTCCCGGRGTCCTGGGRRCTTGCAflGGflAflCCTTTAflTTTGTRCTflTTHTGRflflCBGACTACGACACCGGCAGGflHTflTACGAGflflflflCCTT 
A7-R/C TGTAGAHTTGAARTTCACCTTGAGGGATTGTAATAGTCTTCCCGGAGTCCTGGGAACTTGCAAGGRAACCTTTAATTTGTACTATTATGAAACflGACTACGACflCCGGCAGGAATATACGAGAAAACCTT 
Expected TGTAGARTTGAflflTTCRCCTTGflGGGflTTGTRRTRGTCTTCCCGGflGTCCTGGGARCTTGCAflGGRARCCTTTARTTTGTRCTATTRTGRARCRGACTACGRCRCCGGCRGGRATATRCGRGRRflflCCTT 
Consensus TGTRGAflTTGflflflTTCRCCTTGRGGGflTTGTARTflGTCTTCCCGGRGTCCTGGGRACTTGCAAGGRflflCCTTTAATTTGTACTATTATGAAACRGRCTACGACACCGGCAGGAATATACGAGAAflACCTT
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170
I -------------    «-----------------       +-----------------♦ -----------------♦----------------- 1----------------- ►-------------- ~ f -----------------1
87-Foru TACGTTRARATRGflCACTRTTGCTGCRGATGARRGTTTTACRCAAGGTGACCTTGGTGAAAGARRGATGRRGCTGRACRCTGAGGTGAGAGRGATTGGRCCTTTGTCCAflAAAGGGRTTCTATCTTGCCT 
R7-R/C TRCGTTRflflflTRGRCRCTRTTGCTGCRGflTGRflRGTTTTflCRCflAGGTGflCCTTGGTGflARGRRflGRTGAAGCTGRRCflCTGRGGTGRGRGAGATTGGflCCTTTGTCCflflflRAGGGATTCTRTCTTGCCT 
Expected TACGTTRRflflTRGflCACCATTGCTGCRGflTGAflAGTTTTRCflCRflGGTGRCCTTGGTGAAAGAflRGATGAAGCTGAACACTGAGGTGRGAGRGATTGGRCCTTTGTCCAAARAGGGRTTCTRTCTTGCCT 
Consensus TACGTTRAAATRGnCACtRTTGCTGCRGRTGARAGTTTTRCRCRRGGTGRCCTTGGTGRAflGAflflGATGAAGCTGflACRCTGflGGTGRGAGRGRTTGGRCCTTTGTCCRflRRAGGGflTTCTRTCTTGCCT
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
R7-Foru 
q7_dy r
TTCAGGRTGTRGGGGCTTGCATRGCflTTGGTTTCTGTCRAflGTRTRCTACflflGAAGTGCTGG CCTRRACGlbGTGCTAG(RCTRGTCTRGRGTGRGGGTCCCCRCCTGGGRCCCTTGRGRGTRTCRGGTC
i itn u  
TTrtMl . ■ I ! , : ,  1 l : 1 I C 1 I 1' I I' I 1 i IU 011 1 O T O ( ’ T O C OIJ11C1IJ11 1 111' T 111' rrTB aprr.
. — ___ _____ _______________
Expected
Consensus
i i tnuun i u i nuuuut i i i run i nuun i i uu i i iu iu i  u iniiiu i vi i nu 1 iu iii iui ii iu i uu ■ uu
T TCRGGRTGTAGGGGCTTGCATAGCRttGgTttctgtcaaagtatactacaagaagtgctgg
uu innncu 
c ctaa ac g p g tg c ta g C .. .
1301 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430
H7-Foru 
Q 7.D /r
TCCCRCGTGGGRGRCBRGflflflTCCCTGTTTRflTflTTTRflflCRGCRGTGTTCCCCRTCTGGGTCCTTGCRCCCCTCRCTCTGGCCTCRGCCGRCTGCRCRGCGGCCCCTGCflTCCCCTTGGCTGTGRGGCC
Lxpected
Consensus
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560
R7—Focu
Q7.D/P
CCTGGRCRAGCAGRGGTGGCCAGRGCTGGGRGGCRTGGCCCTGGGGTCCCACGRATTTGCTGGGGRATCTCGTTTTTCTTCTTRRGflCTTTTGGGACRTGGTTTGRCTCCCGRflCATCflCCGflCGTGTCT
Expected
Consensus
15611
1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690
R7-ForuQ7_n / r CCTGTTTTTCTGGGTGGCCTCGGGRCRCCTGCCCTGCCCCCCRCGRGGGTCRGGRCTGTGACTCTTTTTRGGGCCRGGCRGGTGCCTGGRCRTTTGCCTTGCT6GRCGGGGRCTGGGGGATGTGGGRGGG
funar'F _ Jt  xpected 
Consensus
1691 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820
R7-Foru AGCAAACAGGGAGGflATCATGTCAGGCCTGTGTGTGAAAGGAAGCTCCRCTGTTCRCCCTTCCRCCTNTTCRCCCCCCNRHTTCRCCAGGGTCCCCCTCCCCCTGNTCNCHNTHNTRACCTGAflflCTTTC
R7-R/C ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Expected-----------------------------------------------------------  ,—  ........  .------     _______------------- _________________------ ---------------------
Consensus ........................................................................................................................................................................... ................................................................... ....................................................
1871 1830 1840 1850 1860 1870 1880 18901894I------->----  +--------♦--------+--------  ♦--------  1
A7-Foru CGGGATAANARARGGGGNTTHGCCCCCCCAHHMNHANANNNNNNNHNHMNHNNAHANMNNNAAMAAAANAAAAN
R7-R/C -------------------------------------------------------------------------------------------------------------------------------------------
Expected — — — — — — --------______________—  ------------   — - —— ----- — — — — — ------
Consensus ................................... ................................................................................................... ...............................
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Figure 3.M8
EphA7 Ectodomain cloned into pCS2+
A7-Forw: Sequence derived from 5’ cloning primer.
A7-R/C: Reverse complement of sequence derived from 3’ cloning primer.
Expected: Anticipated sequence of clone.
Red boxes highlight the ATG translation start site, the
GAGCAGAAGCTTATCCTCGGAGGAGGACCTG sequence encoding the c-myc tag 
and the TAA translation stop site.
Images produced using multiple sequence alignment with hierarchical clustering432 
with red text indicating perfect agreement between both sequences and the expected 
sequence and blue text highlighting regions where only one sequence agrees with 
the expected result.
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261 278 280 290 300 310 320 330 340 350  360 370 380 390
CGCCfiTTCTGCCTraJGGflCGTCGGRGCRflGCTTGRTTTflGGTGflCflCTflTfiGflRTRCRflGCTfiCTTGTTCTTTTTG 
GGCGGTflGGCGTGCCTRflTGGGflGGTCTflTflTRflGCfiRTGCTCGTTTflGGGflfiCCGCCRTTCTGCCTGGGGflCGTCGGflGCRRGCTTGRTTTRGGTGflCRCTflTRGRRTRCflflGCTflCTTGTTCTTTTTG 
...................................................................................................................................... c g c c a t t c tg c c tg g g g a c g tc g g a g c a a g c t tg a t t t a g g tg a c a c ta ta g a a ta c a a g c ta c t tg t tc t t t t tg
391 400 410 420 430 440 450 460 470 488 490 500 510 520
CRGGRTCCCRTCGflTTCGRflTTCRRGGCCTCTCGflGCCTCTRGRCTflGTGCTflGCR IRRTGGT rCTTGCCRGCTCTRCCRCCflGCflTCCfiCACCRTGCTGCTCCTGCTCCTGflTGCTCTTCCfiCCTGGGA 
CRGGRTCCCRTCGfiTTCGfiflTTCflflCGCCTCTCGfiGCCTCTRGfiCTflGTGCTflGCfi :RRTGGT rCTTGCCRGCTCTACCflCCflGCRTCCACflCCRTGCTCCTCCTGCTCCTGflTGCTCTTCCRCCTGGGfi 
caggatcccatcgattcgaattcaaggcctctcgagcctctagactagtgctagca :aatggt tcttgccagctctaccaccagcatccacaccatgctgctcctgctcctgatgctcttccacctggga
521 530 540 550 560 570 580 590 600 610 620 630 640 650
|--------- +---------- 1---------- 1---------- -I---------- 1---------- -l----------+----------►-----------•---------- i---------- H---------- ¥--------- 1
TRTCTGGRCTCGflfi-GCRCflflCfiRflCRGflflTTGGflflTGGR
CTCCRRGCTTCRRTCTCGGCGCGCCRI GRGCRGRRGCTTRTCTCGGRCGflGGRCCTGI CGCGTGRGGCGCflGGCTGCGflfiGGflRGTRCTGTTRCTGGflCTCGflfiflGCRCRRCflRRCRGRflTTGGRRTGGR 
CTCCRRGCTTCfiflTCTCGGCGCGCCRf GRGCRGflflGCTTRTCTCGGRGGRGGflCCTGI CGCGTGflGGCGCRGGCTGCGflflGGRRGTRCTGTTRCTGGRCTCGRRflGCRCRRCRRRCRGRflTTGGRRTGGR 
c tc c a a g c ttc a a tc tc g g c g c g c c a <  g a g c a g a a g c tta tc tc g g a g g a g g a c c tg .  cgcgtgaggcgcaggctgcgaaggaagtactgTtaCTGGfiCTCGHRaGCRCflflCflflRCRGRflTTGGflRTGGfl
651 660 670 680 690 700 710 720 730 740 750 760 770 780
TTTCCTCTCCRCCCNGNTGGGTGGGfiflGflflflTTRGTGGTTTGGftTGfiGflflCTflCflCflCCflflTflfiGflflCRTflCCRGGTGTGCCfiGGTCflTGCRGCCCRflCCfiGflflCflflCTGGCTTCGGRCTflRCTGGflTTT
TTTCCTCTCCACCCRGT-GGGTGGGARCAHflTTflGTCGTTTGGflTGfiGAflCTflCflCflCCRflTflflGflflCflTACCAGGTGTGCCRGGTCflTGCRGCCCflflCCflCflRCflRCTGGCTTCGGflCTflfiCTCGflTTT
TTTCCTCTCCflCCCfiGT-GGGTGGGflfiGflflflTTRGTGGTTTGGRTGflGfiflCTflCftCflCCflflTRflGflflCflTfiCCRGGTGTGCCflGCTCRTGCfiGCCCflfiCCflGflfiCflfiCTGGCTTCGGflCTflRCTGGflTTT
TTTCCTCTCCflCCCaGt.GGGTGGGflRGRflflTTflGTGGTTTGGflTGflGRflCTRCRCRCCflflTflflGflflCflTRCCRGGTGTGCCflGGTCflTGGRGCCCflflCCRGRflCRflCTGGCTTCGGRCTflRCTCGflTTT
781 790 800 810 820 830 840 850 860 870 880 890 900 910
CTAflflGGCRACGCRCARflGGflTTTTTGTRGflflTTGflflflTTCflCCTTCRGGGflTTGTfiflTfiGTCTTCCCGGAGTCCTGCGflRCTTGCRflGGfiflflCCTTTRflTTTGTRCTflTTRTGHflflCfiGflCTflCGflCRC
CTflfiflGGCRflCGCRCflflRGGflTTTTTGTflGflfiTTGRflflTTCflCCTTGflGGGRTTGTflflTflGTCTTCCCGGRGTCCTGGGfiflCTTGCRRGGflflflCCTTTRRTTTGTRCTfiTTRTGfiflRCflGflCTflCGflCRC
CTflflflGGCRflCGCflCflflflGGflTTTTTGTflGflflTTGRRflTTCflCCTTCflGGGRTTGTRflTRGTCTTCCCGGRGTCCTCGGRflCTTGCRRGGfiRflCCTTTRflTTTGTflCTflTTRTGRflflCflGflCTflCGflCRC
CTRRflGGCRflCGCflCflRflGGflTTTTTGTRGRflTTGRRflTTCflCCTTGflGGGflTTGTfiflTAGTCTTCCCGGRGTCCTGGGflflCTTGCRRGGRflRCCTTTRflTTTGTfiCTfiTTRTGflflfiCflGRCTfiCGflCRC
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
CGGCflCGfiATATfiCGflGflRRRCCTTTACGTTfiAfiATAGflCACCATTGCTGCfiGRTGflAAGTTTTRCflCfiAGGTGflCCTTGGTGRRRGRflfiGflTGflAGCTGRflCfiCTGAGGTGflGflGRGflTTGGRCCTTTG
CGGCflGGflflTflTRCGflGfiflflflCCTTTACGTTfiRflflTfiGflCRCCflTTGCTGCRGflTGflflflGTTTTRCACflRGGTGACCTTGGTGRRRGRARGATGflRGCTGflfiCfiCTGflGGTGflGflGflGflTTGGflCCTTTG
CGGCflGGRflTRTRCGflGRflflflCCTTTfiCGTTflRflflTRGflCRCCfiTTGCTGCflGflTGflflRGTTTTRCRCflRGGTGRCCTTGGTGfiRRGRRRGRHGNRGCTGRRCRCTGRGGTGflGRGflGflTTGGflCCTTNG
CGCCRGGAflTRTflCGflGAflflflCCTTTACGTTflAAflTAGflCfiCCHTTGCTGCRGflTGflfifiGTTTTflCfiCRRGGTGRCCTTGCTGfififiCRflfiGfltGaRGCTGflflCACTGAGGTGRGRGflGflTTGGflCCTTtG
1041 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170I-
TCCflRRR-flGGGflTTCTRTCTTGCCTTTCflGGRTGTRGGGGCTTGCRTRGCRTTGGTTTCTGTCflflRGTRTRCTRCRRGRflGTGCTGG' CCTRRRCG IGTGCTRGCRCTRGTCTRGflflCTRTRGTGRGTC 
TCCARfiR-fiGGGfiTTCTfiTCTTGCCTTTCflGGflTGTRGGGGCTTGCflTRGCRTTGGTTTCTGTCflflflGTflTRCTACRRGRRGTGCTGG CCTRRRCG :GTGCTRGCRCTRGTCTRGflflCTflTflGTGRGTC 
TCNRRHCCRGCGflTTCTflTCTTGCCTTTCRGGflTGTRGGGGCT-CCRTRGCNTHGTTNNTC
TCcRflaa.fiGGGRTTCTRTCTTGCCTTTCRGGflTGTflGGGGCTtGCRTflGCaTtGgTttctgtcaaagtatactacaagaagtgctgg :cctaaacg :gtgctagcactagtctagaactatagtgagtc
1171 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
GTflTTflCGTACHTCCRGRCflTGATfifiGflTRCflTTGRTGflGTTTCGflCAflflCCflCflRCTAGflRTGCflGTGAARAARflTGCTTTflTTTGTGRflfiTTTGTGRTGCTATTGCTTTRTTTGTRRCCflTTRTfiflGC
GTfiTTflCGTRGflTCCflGftCRTGATAfiGflTACRTTGflTGRGTTTGGflCAAflCCflCflflCTRGRflTGCRGTGRAflRRRflTGCTTTRTTTGTGRflRTTTGTGRTGCTRTTGCTTTflTTTGTflRCCflTTflTflRGC
g ta t t a c g t a g a t c c a g a c a tg a ta a g a ta c a t tg a tg a g t t t g g a c a a a c c a c a a c ta g a a tg c a g tg a a a a a a a tg c t t t a t t t g tg a a a t t t g tg a tg c ta t tg c t t t a t t t g ta a c c a t ta ta a g c
1301 1310 1320 1330 1348 1350 1360 1370 1388 1390 1400 1410 1420 1430
TGCRRTRflflCflfiGTTRflCRflCRRCAATTCCHTTCHTTTTRTGTTTCfiGGTTCRGGCGGRGGTGTGGGNfiCGTTTTTTRflTTCGCGGCCGCGGCGCCRflTGCflTTGGGCCCCGTRCCCRGCTTTTGTTCCC
TGCflflTRflflCflflGTTflflCRflCRRCflRTTGCflTTCflTTTTRTGTTTCRGGTTCflGGGGGRGGTGTGGGfi-GGTTTTTTRflTTCGCGGCCGCGGCGCCRflTGCflTTGGGCCCGGTflCCCRGCTTTTGTTCCC
t g c a a ta a a c a a g t ta a c a a c a a c a a t tg c a t tc a t t t ta tg t t t c a g g t tc a g g g g g a g g tg tg g g .  . g g t t t t t t a a t t c g c g g c c g c g g c g c c a a tg c a t tg g g c c c g g ta c c c a g c t t t tg t t c c c
1431 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1558 1560
| -------------- +-----------------   4----------------------------------- ------------------4----------------- ♦----------------- ►----------------- ♦------------------ ------------------+-----------------t----------------1
TTTRGTGRCGGGTTAflTTGCGCGCTTGGCGTRfiTCflTGGTCATRGCTGTTTCCTCTGTGflRRTTGTTfiTCCGCTCRCRRTTCCNCACRflCflTflCCGAGCCCGGGGRGCflTAflflGTGTAflflGCCTGGGGGT 
TTTRGTGftGGG-TTRflTTGCGCGCTTGGCGTflflTCflTGGTCflTRGCTGTTTCCTGTGTGRRRTTGTTRTCCGCTCRCRflTTCCflCRCflRCfiTflC GflGCCGGRRGCRTRRflGTGTRRRGCCTGGGG-T
t t ta g tg a g g g .  t t a a t t g c g c g c t t g g c g ta a tc a t g g t c a t a g c t g t t t c c t g tg t g a a a t t g t t a t c c g c t c a c a a t t c c .  c a c a a c a ta c . . .  g . . c .  g g . a g c a ta a a g tg ta a a g c c tg g g g . t
1561 1570 1588 1590 1600 1610 1628 1630 1640 1650 1660 1670 1680 1690
GCCTRflTGRGTGRGCTRflCTC-CflTTRflTTGCGTTGCGCNCCCTGCCCGCTTTCCRGTCGGGNflRNCCTNTCNNGCCRCCTGCflNTNRRTGRRTCNGGCCflflCNCCCCGGGGGflflRRGNCGGTTTGCNHN 
GCCTRflTCAGTGHGCTflflCTCRCflTTAflTTGCGTTGCGCTCflCTGCCCGCTTTCCAGTCGGGRflfiCC-TGTCGTGCCAGCTGCRTTRA-TCflflTCGGCCflfl CGCGCGGGCRGRGGCGGTTTGCGTR
g c c ta a tg a g tg a g c ta a c tc .  c a t t a a t t g c g t t g c g c . c . c t g c c c g c t t t c c a g t c g g g . a a . c . t . t c . . g c c a . c tg c a .  t .  a . t g a a t c .  g . c .  a . . . .  c .  e g .g g g . a . a g . e g g t t t g e . . .
1691 1780 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1818 1820
I---------------     4-----------------+---------------- 1-----------------4-----------------1-----------------►----------------- .----------------- 4-----------------+-----------------►-----------------1
RTTCGGCCNCT
TTGGGCGCTCTTCCGCTTCCTCGCTCflCTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGRGCGCTRTCfiGCTCflCTCRRRGGCGGTfiflTRCGGTTflTCCflCfiGflfiTCAGGGGRTflfiCGCflGGflRRGflfl
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Figure 3.M9
pEF-BOS and pCS2+ vector diagrams
A. Simplified vector diagram of the pEF-BOS vector showing the EF1 a (elongation factor 
1a) promoter, the IL-3 secretion signal, the Mlul cloning site and the Xbal sites used 
for subsequent sub-cloning.
B. Simplified vector diagram of pCS2+ showing the CMV promoter and Xbal site used 
for cloning.
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Figure 3.M10
APtag-1 vector diagram and stripe assay production schematic
A. Figure showing important sites in the APtag-1 vector, including the MoLTR promoter, 
multiple cloning site and the SEAP domain 3’ to the inserted ectodomain.
B. Schematic of stripe assay production using glass coverslips. Blue arrows signify path 
and direction of flow of injected substrate.
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Figure 3.M11
Filter-based stripe production schematic and product
A-B. Schematic of stripe assay production using grilled filters with suction. A shows the
formation of the primary stripes as suction through the silicon grid matrix leads to 
deposition of the suspension at zones of low pressure (blue stripes). Replacing the 
solution with the secondary stripe suspension and applying suction through a 
completely porous nylon grid leads to the accumulation of secondary stripe material 
(red) between the primary lanes where the filter is not occluded. Image redrawn from 
Walter et a/.420.
C. 0.1pm pore Whatman polycarbonate filters with primary stripes of HEK293
membranes and secondary stripes of 1 pM BSA-Alexa-594 and 300kDa poly-D-lysine. 
Visualised after 48hrs in culture medium, 37°C, 5% C02. Scale bar 75pm.
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Figure 3.M12
Cell line implantation approaches
A. Implantation Method II. A dorsal column lesion was performed at C5 that completely 
transected the corticospinal tract. Collagen gel foam (orange) seeded with CHO cells 
was sutured over the top of this lesion site and the dura left open to permit 
ectodomain (green) access to the lesion. The CST was labelled by BDA injection to 
the hindlimb region of the motor cortex.
B. Implantation Method III. A dorsal column lesion was performed at C5 that completely 
transected the corticospinal tract. Collagen gel foam (orange) seeded with CHO cells 
was sutured 1mm rostral to the site of injury and the dura left open to permit 
ectodomain (green) access to the lesion. The CST was labelled by BDA injection to 
the hindlimb region of the motor cortex.
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Figure 3.1
Ephrin family member binding promiscuity and ectodomain interactions
A. Diagram highlighting the promiscuity of ephrin interactions. Interactions occur 
between most ligands and receptors within each receptor/ligand subfamily (not all 
family members shown). At present the only receptor known to interact with a ligand 
of the opposing subtype is the EphA4 receptor that binds ephrinB2 and ephrinB3.
B. Diagram illustrating that the four ephrin family members selected for use as blocking 
ectodomains show promiscuous binding to most ephrins and Eph receptors known to 
play a role in the spinal cord injury environment.
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Figure 3.2
Predicted structures of Eph and ephrin ectodomains
A. i, X-Ray crystal structure of the ephrinB2 receptor binding domain; ii, predicted 
structure of the secreted ephrinBI ectodomain; iii, predicted structure of the secreted 
ephrinA5 ectodomain. Showing residues predicted to be important in the dimerisation 
interface in red and the tetramerisation in green.
B. i, X-Ray crystal structure of the EphB2 receptor binding domain; ii, predicted structure 
of the secreted EphB3 ectodomain; iii, predicted structure of the secreted EphA7 
ectodomain. Showing residues predicted to be important in the dimerisation interface 
in red and the tetramerisation in green.
C. Predicted arrangement of the secreted ephrinBI ectodomain complexed with the 
EphB3 receptor. The primary (red) and secondary (yellow) interaction domains are 
clearly aligned.
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Figure 3.3
Ectodomain blotting
A. Coomassie stained SDS-PAGE of anti-c-myc immunoprecipitated EphA7 and
ephrinA5 ectodomains. Secreted ectodomain bands (*) migrate at the expected 
molecular weight and show a well defined band implying minimal degradation and 
complete translation.
B. Western blot of an SDS-PAGE of anti-c-myc immunoprecipitated EphA7 and
ephrinA5 ectodomains. Secreted ectodomains migrate as a well-defined band of the 
expected molecular weight. Some smearing at molecular weights below the
ectodomain suggests a small amount of degradation, however.
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Figure 3.4
Stripe assays showing growth on ephrinA5-Fc lanes
A-B. Retinal Ganglion cell axons stained with phalloidin-Alexa-488 (i, green) put out long,
highly fasciculated axons (direction of growth upwards) on glass coverslip stripe 
assays. Primary substrate lanes (P) containing ephrinA5-Fc stained with a primary 
antibody to human Fc (ii, red) show good resolution even after 72hrs in culture.
However, the expected avoidance response is not apparent (iii, merge) with RGC
axons growing on ephrinA5-Fc lanes and avoiding the ‘growth permissive’ secondary
lanes (S). Scale bars 200pm.
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Figure 3.5
Outgrowth on control coverslip stripe assays and filter stripe assays
A. Retinal Ganglion cell axons stained with phalloidin-Alexa 488 (i, green) develop long,
highly fasciculated axons (direction of growth upwards) on glass coverslip stripe 
assays produced using human IgG in the primary stripe (P). Substrate lanes 
containing ephrinA5-Fc stained with a primary antibody to human Fc (ii, red) show 
RGC processes growing preferentially on these IgG lanes and avoiding control
secondary lanes (S). IgG has no known axon guidance properties suggesting some
error in stripe generation. Scale bars 200pm.
B. This error is apparent when coverslips coated in poly-L-lysine are exposed to sterile 
PBS in the silicone mould and then incubated with albumin-Alexa 594. The presence 
of stripes at this stage of coverslip preparation indicates that the silicone mould 
removes the poly-L-lysine from the coverslip where it makes contact, resulting in 
secondary lanes that are bare glass and hence cannot support growth. Scale bar 
200pm.
C. Outgrowth of retinal ganglion cells on filter-based stripe assays. Phalloidin-Alexa 488 
staining successfully visualised processes (green) but these were frequently short (i) 
and showed no growth direction response to stripe substrates (ii). Scale bars 50pm.
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Figure 3.6
RGC and HEK293 co-culture outgrowth assay
A. Staining of outgrowth in co-culture assay. Immunohistochemistry for neurofilament 
(200kDa) revealed extensively sprouting retinal ganglion cell axons while only picking 
up minimal background staining from the co-cultured HEK293 cells. Sprouting was 
extensive in both control HEK (i) and ephrinA5-expressing HEK (ii) co-cultures. Scale 
bars 100pm.
B. Graph of outgrowth in co-culture assay. As shown, neurite length in co-cultures of 
retinal ganglion cells with ephrinA5-expressing HEK cells was greater than that found 
in control HEK cultures. Mean ± SEM plotted.
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Figure 3.7
RGC collapse assay growth cones
A. Retinal ganglion cell growth cones stained with phalloidin-Alexa 488 show clear 
morphological differences between the collapsed (B) and uncollapsed (A) states. 
Uncollapsed growth cones have a wide diameter, show extensive filopodia (arrows) 
and lamellipodia (triangles) and show raised actin expression compared to the 
axonal processes but no intense foci. Collapsed growth cones, by comparison, are 
small, highly actin dense and usually show one filopodial process (arrows) oriented in 
the direction of the associated axon. Scale bars 20pm.
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Figure 3.8
Quantification of RGC collapse assay
A-B. Percentage collapse of retinal ganglion cells growth cones increases following 
exposure to homodimeric ephrinA5-Fc and this is blocked by application of 
monomeric ephrinA5 (A) or EphA7 (B) ectodomains. Pre-administration of ephrinA5 
ectodomains or pre-incubation of EphA7 ectodomains with the ephrinA5-Fc reduces 
the growth cone collapse rate to levels very similar to control, sterile PBS exposure. 
Neither ectodomain induces growth cone collapse when administered alone. Bars 
show mean ±SEM for each set of cultures.
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Figure 3.9
Implantation of EGFP-CHO cell line into the lateral ventricle
A. CHO cells transduced with an EGFP-expressing lentivirus (CHO-EGFP) grow well in 
culture at normal growth rates, show normal cellular morphology and good EGFP 
expression without extensive protein aggregates. Scale bar 100pm.
B. Coronal 40pm section of the lateral ventricle of an adult rat three days following 
stereotaxic injection of suspended EGFP-CHO cells. Despite immunosuppression 
with FK506 for three days prior to injection, a strong immune response mediated by 
macrophages and microglia is identified in OX-42 stained slides (i). This accumulation 
of immune cells clearly envelops the tissue implant (ii). Scale bars 300pm.
C. Higher magnification images taken from the implant site show EGFP-CHO cells 
(green, i) surrounded by OX-42 positive macrophages and microglia (red, ii). Scale 
bars 50pm.
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Figure 3.10
Implantation methods II and III: cells invading the lesion site and spinal cord
A. Parasagittal 40pm section through the centre of a dorsal column lesion three days 
following injury and implantation of cells by method II. EGFP-CHO cells (green) 
cultured on collagen gelfoam (blue) were sutured over the site of the lesion. 
Immunohistochemistry for GFAP (red) outlines the surviving astrocytes (#) and the 
margin of the spinal cord (dotted line). As is evident, EGFP-CHO cells have migrated 
from the collagen gelfoam and invaded the lesion cavity (*). Scale bar 200pm.
B. Horizontal 40pm section through the dorsal column of a spinal cord that underwent 
cell implantation method III. The animal received a dorsal column transection 1mm 
caudal to the site of cell implantation (left in image). CHO-ephrinA5 (95% of cells) 
EGFP-CHO (5% of cells) cells were co-cultured on collagen gelfoam then sutured to 
the undamaged dura. Three days following surgery animals were transcardially 
perfused and stained for GFAP. GFAP-positive astrocytes (#) are present in the 
periphery of the tissue, but the implanted tissue (*, outlined with dotted line) has 
invaded and displaced the majority of the dorsal columns. Scale bar 500pm.
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Figure 3.11
Improved regeneration of the CST following CHO-ephrinA5 implantation
A-B. Horizontal 40pm section through the dorsal corticospinal tract ten days following 
transection, injection of BDA to the motor cortex and implantation of control CHO (A) 
or CHO-ephrinA5 cells (B) that secreted soluble ephrinA5 ectodomains. An 
improvement in the retraction of the corticospinal tract from the lesion margin (dotted 
line) was apparent in the ephrinA5 treated animals. Scale bar 200pm.
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Figure 3.12
CST sprouting and astrocyte GFAP expression following CHO-ephrinA5 implantation
A-B. The termination bulbs of lesioned corticospinal tract axons in animals exposed to the 
ephrinA5 ectodomain show an increased sprouting response ten days after injury. 
Numerous termination bulbs put forward regenerative sprouts (A, arrows) that grow in 
the direction of the lesion margin. These sprouts often grow significant distances (Bi) 
and regenerate as far as the astrocyte margin, as defined by GFAP staining (Bii). 
Scale bars 100pm (A) and 20pm (B).
C. Reactive astrocyte GFAP expression was unaffected by the exposure to the ephrinA5 
ectodomain, with similar astrocyte reactivity and lesion site morphology in control (i) 
and ephrinA5-treated (ii) animals. Scale bars 200pm.
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Figure 3.13
Theoretical accumulation of ectodomain within the CSF local to the injury site
The calculation is based on the approximate secretion rate of ectodomain in vitro, the 
number of cells implanted and a 40pl volume of dilution for local CSF. The likely 
therapeutic threshold of 50nM is based on the work of Murai et al.389 and this 
concentration should be surpassed within 22hrs of implantation, a feasible time 
window for beneficial effect.
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Chapter IV
Pharmacological Blockade of the EphA4 Receptor to 
Encourage Regeneration following Spinal Cord Injury
Abstract
Work presented in Chapter Ii indicates a likely role for EphA4 signalling in the 
injured corticospinal tract preventing regeneration and sprouting through an 
interaction with ephrinB2-positive reactive astrocytes at the lesion margin. 
Other published work12 suggests that EphA4 expressed in astrocytes may 
mediate their reactive response to a central injury. Chapter III demonstrated 
how interfering with EphA receptor signalling appears to improve regeneration 
suggesting a pharmacological approach to blocking ephrin signalling has 
merit. Hence, the effect of inhibiting EphA4 receptor signalling in the post­
injury spinal cord environment by infusing an EphA4-specific blocking peptide 
directly into the subdural space was studied. The study was performed on 
both Sprague-Dawley and Lewis rats and assessed regeneration at 14 and 28 
days following injury. This method of intervention was found to improve the 
sprouting and regenerative capacity of the injured CST and RST following 
dorsal and lateral lesions. Regenerating axons were seen to navigate 
significant distances towards the lesion cavity, often reaching the lesion 
margin. Astrocyte morphology was altered with increased invasion of the 
lesion cavity by astrocytic processes and axonal sprouts frequently grew 
along these astrocytic bridges into the lesion cavity. This is a marked 
improvement over the abortive regenerative response of these descending 
tracts seen in untreated rats. Functional recovery was also apparent following 
peptide administration with significant improvements attained in the paw 
reaching assay.
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METHODS
EphA4 Blocking Peptide
Murai et al,389 panned an M13 phage library of 12-mer peptides on 
immobilised EphA4 ectodomain to identify candidate binding peptides. One 
peptide sequence identified, termed KYL (full sequence KYLPYWPVLSSL), 
was selected for use in this study due to its high affinity (K d 0.5 ±0.06nM) and 
selectivity for EphA4 over other EphA receptors.
The peptide was synthesised (Alta Bioscience, University of Birmingham, UK) 
to greater than 95% purity and made up as a 3mM solution in artificial 
cerebrospinal fluid (ACSF). ACSF was prepared from a 1:1 ratio of sterile 
filtered Solution A (296mM NaCI, 6.5mM KCI, 2.8mM CaCI2.2H20 , 1.6mM 
MgCI2.6H20 ) and Solution B (1.6mM Na2HP0 4 .7 H20 , 0.39mM
NaH2P 04.H20).
Embryonic Rat Cortical Neuron Culture and Collapse Assay
10mm diameter coverslips (VWR) were washed in pure ethanol in a 24-well 
plate and then dried in a Class II laminar flow tissue culture hood. 100pL of 
Poly-L-Lysine (20pg/ml, Sigma) with natural mouse laminin (5pg/ml, 
Invitrogen) was applied to the coverslips for thirty minutes at 37°C followed by 
two washes in sterile distilled water and further drying in the hood. E17 
Sprague-Dawley rat embryos were dissected from the mother using sterile 
instruments and placed in oxygenated 4°C Hank’s Buffered Saline Solution 
(HBSS, Sigma). All subsequent dissection was performed in a clean 
dissection hood in oxygenated 4°C HBSS. Embryos were removed from the 
amniotic membranes and the skin and other tissue layers covering the brain 
removed with forceps. The cortical layer was dissected from the brain and 
placed in 37°C DCC medium (Neurobasal medium containing 2mM L- 
Glutamine, 2% B27, 2500units/ml Penicillin and 2500pg/ml Streptomycin, all 
from Invitrogen). DCC medium was replaced with Trypsin solution (0.05%, 
Sigma) for 15 minutes at 37°C and then replaced with Neurobasal medium 
containing 10% FBS (Sigma) to quench any remaining trypsin. Trypsinised 
cortices were triturated repeatedly through a standard 1ml blue pipettor tip 
and then a 100pl yellow pipettor tip until a fine cell suspension was attained.
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Cell density was then counted using a haemocytometer and the suspension 
diluted in DDC medium such that 2.8x104 cells were added to each well of the 
24-well plate together with 300pL of medium. Cultures were left overnight at 
37°C 5% CO2 when processes were apparent when observed under the light 
microscope.
Cultures received one of five treatments that were blinded subsequent to 
preparation. 100|jl of DCC medium was added at the start of the experiment 
containing either ACSF (control), or 80, 200 or 400nM blocking peptide in 
ACSF (peptide only control or blocking assays). 15 minutes later a further 
100pl of DCC medium was added to each well containing either ACSF 
(control) or 100nM homodimeric ephrinA5-Fc in ACSF (final concentration 
20nM, R&D Systems). 30 minutes later 1ml of 37°C 4% w/v 
paraformaldehyde in PBS was added to the cultures and left to fix for 20 
minutes.
Treatment Omin 15min
Control ACSF ACSF
100nM Peptide Control 400nM Peptide ACSF
EphrinA5-Fc ACSF 100nM EphrinA5-Fc
EphrinA5-Fc + 20nM Peptide 80nM Peptide 100nM EphrinA5-Fc
EphrinA5-Fc + 50nM Peptide 200nM Peptide 100nM EphrinA5-Fc
EphrinA5-Fc + 100nM Peptide 400nM Peptide 10OnM EphrinA5-Fc
Three washes with sterile PBS were followed by permeabilisation with 0.1% 
Triton in PBS for 5 minutes and three washes in PBS. Staining was performed 
using phalloidin-Alexa 488 (1:40 in PBS, Molecular Probes) for thirty minutes 
followed by three washes in PBS and mounting on glass slides under DABCO 
and sealing by nail varnish. Coverslips were analysed blind under the 
confocal microscope. Fifty growth cones were counted from each coverslip. 
To ensure that only axonal growth cones were counted, cells were rejected 
unless they bore a minimum of two growth cones. Only one growth cone was 
selected from each identifiable cell body and only those whose process was
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at least three times as long as all other processes from that cell body. Growth 
cones were selected from all areas of the coverslip to ensure no artefact 
developed due to the proximity of the cells to the initial DCC application point.
Mini-Pump and Cannula Preparation
Alzet osmotic mini-pumps (Charles River, UK) were used throughout this 
study. The 2002 model was used in the two week experiment and 
subsequently all other work used the 2004 model. Both pumps have the same 
capacity (approx. 210pl) but the 2002 model pumps at a rate of 0.5pl/hr for 
two weeks whereas the 2004 model pumps at a rate of 0.25pl/hr for four 
weeks. Both models required ‘priming’ to ensure that they were pumping at 
full speed when implanted. 2002 models were primed in 0.7% NaCI solution in 
sterile distilled water at 37°C for 8 hours before surgery, 2004 models 
required 48hrs of priming under identical conditions.
Pumps were filled with either ACSF or ACSF containing peptide using a 1 ml 
syringe and a supplied filling needle. The volume injected into each pump was 
carefully monitored to ensure no air bubbles were present as this would 
disrupt the osmotic mechanism and impair the pumping rate. At all times 
pumps were handled with gloves to maintain sterility and ensure the pumps 
did not come into contact with skin oils as these are known to disrupt the 
osmotic mechanism.
Cannulae were made from modified rat intrathecal cannulae (Charles River). 
Briefly, these cannulae consist of a very fine, flexible segment designed to be 
placed into the subarachnoid space connected to a larger gauge, more stiff 
section designed to prevent kinking under the skin. A 4cm section of the thick 
tubing was tied in a simple knot and superglued in that position. Subsequently 
a 2cm section of the fine tubing was superglued to one end and a 2cm stretch 
of even wider gauge, flexible tubing was attached to the other end, designed 
to be attached to the minipump (Figure 4.M1). This system provided many 
advantages:
• The thin tubing was readily inserted intrathecally unlike wider bore 
cannulae.
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• The medium gauge tubing was inflexible and hence did not kink. The 
knot in the tube provided a securement site to the animals’ overlying 
muscle layers to prevent movement of the intrathecal segment.
• The widest bore tubing was sufficiently flexible to fit over the mini-pump 
attachment.
For the delayed peptide investigation cannulae were trimmed such that, 
following final attachment of the primed mini-pump, they would contain 
approximately 20pl of ACSF. With a constant pumping rate of 0.5pl/hr from a 
2002 model mini-pump, a 40 hour delay in delivery of the peptide would 
ensue. In all other experiments the cannula contained the same solution as 
the mini-pump such that active agent was delivered from the time of 
implantation onward.
Surgical Techniques
All surgical procedures were approved by the UCL ethical committee and 
licensed by the Home Office. Adult female 200-220g Sprague-Dawley rats 
were anaesthetised with a mixture of halothane, nitrous oxide, and oxygen. 
For cannulation experiments, animals were operated on two days before the 
spinal cord injury was performed (day of injury defined as Day 0 throughout). 
Cannulae were filled with either ACSF or EphA4 blocking peptide in ACSF 
and the wide-bore end sealed with superglue to minimise uptake of blood 
once inserted and escape of peptide into the CSF before mini-pump 
attachment. A small hole was created with a fine-bore needle in the dura 
above cervical segment one of the spinal cord and widened with a scalpel, 
without damaging the underlying spinal cord tissue. The cannula was then 
inserted (with the fine end foremost) into this hole and fully inserted until the 
knot in the cannula sat submerged in the muscle layers overlying the C1-2 
spinal cord levels. The cannula was then sutured into place through this knot 
and the remaining cannula section placed under the skin.
Animals were checked on Day -1 of the surgery for normal locomotion, 
exploration, feeding and grooming to ensure that no spinal cord damage had
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been induced by the cannulation. Any animals showing behavioural changes 
or locomotor difficulties were removed from the experiment. On Day 0, 
animals were injected with tracing agents and spinal cord injuries were 
performed. Where anterograde labelling of the CST was required, 5pl of 10% 
biotinylated dextran amine (Molecular Probes, Oregon, USA) was injected into 
the motor cortex using standard coordinates (Paxinos and Watson, 1986). 
Labelling of the rubrospinal tract was carried out either by stereotaxic injection 
into the red nucleus of 3pl of replication-deficient HIV vector encoding EGFP 
(6.5 x 108 TU/ml) or injection of 5pl of 10% BDA. Spinal cord injuries were 
performed between C4 and C6 in all cases and were either a unilateral 
incision of the lateral column or, for anatomical and regeneration studies, an 
overinjury of one side of the dorsal column (Figures 4.M1B and C). For 
behavioural assays, a unilateral injury was performed designed to encompass 
the entire dorsal CST on one side while causing as little damage to the 
contralateral CST as possible (Figure 4.M1D).
At the end of each experiment animals were sacrificed by overdose with 
halothane and transcardially perfused with 4% w/v paraformaldehyde before 
removal of the spinal cord. Perfused tissue was stored at 4°C in 30% sucrose, 
10% Thiermesol in phosphate buffer until use.
The labelling efficiency of the BDA injections was estimated at 0.5% based on 
counting the number of labelled fibers in the medulla (Figure 4.M2A) 
compared to the accepted estimate of rat CST fibre number (approx. 
231.500433'434).
Immunohistochemistry
Fixed tissue was cut parasagittally (for dorsal column injuries) or horizontally 
(for lateral column injuries) at 40pm thickness on a freezing microtome. 
Samples were permeabilised in TBST buffer (0.1M Tris Buffered Saline with 
0.5% Triton-X100, Sigma) for one hour prior to incubation for one hour at 
room temperature in goat blocking solution (0.1 M TBS, 1% BSA, 0.1% Triton 
X-100, 10% normal goat serum, Sigma). Sections were incubated in 
monoclonal mouse anti-GFAP (1:1000 in goat blocking solution, Sigma)
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overnight at 4°C and washed three times in TBST before a two hour 
incubation in goat blocking medium containing streptavidin-Alexa 568 (1:1000, 
Molecular Probes) and either goat anti-mouse FITC (1:400, Sigma) or goat 
anti-mouse 633 (1:400, Sigma) at room temperature. Sections were then 
washed three times in TBST before being mounted on gelatinised slides, 
coverslipped in DABCO and sealed with nail varnish.
Digital image capture and analysis
Fluorescence images were acquired on a Zeiss 510 confocal microscope 
using conventional filter based fluorescence optics. Excitation and emission 
wavelengths were, respectively: FITC and EGFP = 488nm, 505 - 550nm; 
Alexa 568 = 543nm, >560nm; Alexa 633 = 633nm, >650nm. Imaging of slides 
labelled with multiple dyes was always sequential with illumination at only one 
wavelength at any one time.
Analysis of each image for regeneration was performed identically, using the 
Zeiss Image Analyser Software. The GFAP channel for each image was 
isolated and the midline of the lesion site was drawn in on the image, using 
the edge of the GFAP staining as a guide. The ‘red’ channel was then isolated 
such that only the BDA-labelled CST or RST and the drawn-in midline marker 
were visible. The distance of identifiable termination bulbs from the guideline 
was then established. If both the RST and CST had been labelled, the ‘green’ 
channel containing the RST tracing data was then isolated and similar 
distances calculated. Subsequently these distances were collated and 
analysed. An example of this analysis is demonstrated in Figure 4.M2B.
GFAP analysis was performed on the Image Analyser Software. Sections of 
lateral column injuries were only used in analysis if the background 
streptavidin-Alexa 568 staining (which is an excellent marker for tissue loss) 
indicated that the entire contents of the lesion cavity were present. The ‘cavity’ 
region of the lesion was isolated and the average GFAP staining intensity 
calculated based on pixel intensity within this region. A 150pm thick 
‘penumbra’ around each lesion was similarly analysed and a control region of 
contralateral, uninjured, lateral white matter was also analysed for GFAP
193
intensity (see Figure 4.M3A). The two values were normalised against this 
control intensity and combined with values from a range of horizontal sections 
through the spinal cord.
Behavioural Training and Assay
Two behavioural assays were used to assess improvements in functional 
recovery following peptide administration. The rearing assay and the paw 
reaching assay, developed by Professor Raisman’s laboratory225, were used 
to assess locomotor and fine movement respectively for a 28 day period 
following a dorsal column lesion. Training of animals for the rearing assay was 
not required as the animals’ natural curiosity was sufficient for exploration of 
their environment once they became comfortable in their surroundings. 
Animals were placed in a clear Perspex cylinder 40cm high with a diameter of 
24cm (Figure 4.M3B). Animals were pre-conditioned for three ten minute 
periods in the apparatus two weeks before the surgical process was begun to 
ensure anxiety did not influence the results. During the week before surgery 
animals were assessed three times to build up a base-line paw usage record 
to compare with the post-injury data. During result taking, animals were left in 
the apparatus until they began to groom, signalling that they were relaxed, 
before data was collected. Each animal was observed until it performed 
twenty rears, a successful rear defined as the animal facing the Perspex wall 
directly and showing a fully raised rear with clear weight bearing on the 
forepaws. The usage of each paw was noted and the proportion of rears using 
the injured forepaw calculated.
The paw reaching assay required extensive training of the animals. 140g male 
Sprague-Dawley rats were used in this study as the complete training usually 
required a month, resulting in animals bring ready for surgery around 240- 
280g, similar to that used in the anatomical studies. Male rats are also known 
to be easier to habituate and train and were therefore used. Animals were 
housed in pairs throughout the entire training and analysis period as often one 
rat would learn a particular phase of the training more rapidly and stimulate 
the other rat to follow its actions and learn the task. The apparatus used for 
this task was designed to slot into the animals’ cage and provide a clear
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Perspex wall with a 7cm wide and 1.5cm wide slot with a ledge on the 
external side on which to place food rewards (Figure 4.M4A). The apparatus 
incorporated an extended ‘roof of Perspex to completely isolate the animals 
in the cage to minimise external influences. For the first week animals were 
habituated to the apparatus for 20 minute periods every other day. During this 
time small amounts of food reward were freely available and animals rapidly 
accepted the new foodstuff into their diet. Phase two of the training (usually 7- 
10 days in duration) involved supplying the food reward through the slot in the 
Perspex with blunt forceps to teach the animals to accept the experimenter’s 
presence and also to accustom them to retrieving the reward from this area. 
Phase three (usually 10-14 days in duration) taught the animals to retrieve the 
reward from the ledge. At first the reward would be stabilised by blunt forceps 
as the animals’ grasp and retrieve failure rate was high and this permitted 
them to maintain interest in the training. At the beginning of phase three 
animals often showed no preference for either forepaw but rapidly a dominant 
(termed ‘on’) paw developed such that by the end of phase three when rapid 
and reliable retrieval of rewards was attained, the ‘off paw was rarely used.
Animals were only selected for surgery and inclusion in the study if, during the 
initial training period, they had shown frequent use of both forepaws. An initial 
pilot study indicated that animals that were strongly trained in only one 
forepaw rarely leamt to use their off-paw after the lesion and instead persisted 
in the use of the injured paw until an adapted method of reaching was learnt 
which involved a ‘scooping’ use of the forepaw -  probably mediated by the 
RST. The distinctive nature of this reaching action meant that it was readily 
identified and all animals were monitored closely in subsequent studies to 
ensure no RST-based recovery occurred. Another important consideration 
raised during this pilot study was the requirement for weight-bearing on the 
opposite paw for a successful reach. In the pilot study animals were assessed 
for recovery in the days immediately following an injury, before weight-bearing 
on the injured forepaw had been fully restored. Under these circumstances 
animals were unable to reach with their uninjured forepaw and often persisted 
with the uncoordinated, injured paw until the RST-mediated reaching 
technique was learnt. Hence, in the full study, animals were left and only
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assessed for rearing when moderate weight-bearing had returned. This was 
often a period of five days and initial improvements in the rearing assay were 
apparent around this time point also.
Each pair of animals was trained and analysed three times a week between 
9am and 10am as later times of day often yielded poor results due to the 
nocturnal nature of the rats. Analysis consisted of providing food rewards 
repeatedly until the animals showed no further interest. The success rate of 
each forepaw at navigating through the slot and, separately, successfully 
grasping and retrieving the reward was recorded. During the week before 
surgery the animals were assessed three times to develop a base-line record 
with which to compare post-injury data.
RESULTS
In Vitro Analysis of Peptide inhibition of EphA4 Signalling
E17 Sprague-Dawley rat neocortical neuron growth cones had a typical 
spread out morphology with multiple filopodial and lamellipodial protrusions 
(Figure 4.1 A). The collapsed growth cones were readily identifiable with a 
highly F-actin dense appearance and often a single filopodial process (Figure 
4.1B). Control cultures showed a low level of basal collapse (37 ± 5%, 95% 
confidence interval, Figure 4.1C) when exposed to DCC medium alone, 
comparable to that seen in the E7 chick RGC axon collapse assay (28%, 
Figure 4.9) and in the literature235 (32%). Addition of EphA4 blocking peptide 
alone at a final concentration of 100nM for 45 minutes resulted in no change 
in this collapse rate (38 ±5%) indicating that binding of the peptide to the 
EphA4 receptor results in no receptor activation or other side-effects. Addition 
of ephrinA5-Fc homodimer at a final concentration of 20nM for 30 minutes 
resulted in an increase in growth cone collapse to 67 ±6%, significantly higher 
than that seen for the control assays (p < 0.0001 Fisher's Exact Two-Tailed 
Test). This confirms that E17 Sprague-Dawley rat cortical neurons express an 
EphA receptor that induces repulsive or collapse responses on activation, 
most likely the EphA4 receptor.
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Three peptide concentrations were investigated to give an indication of the 
likely concentration required in vivo to abrogate most EphA4 signalling. As 
shown in Figure 4.1C, all three concentrations used (20nM, 50nM, 100nM) 
prevented EphA4-induced growth cone collapse when presented to 
neocortical neurons for 15 minutes prior to a 30 minute exposure to 
homodimeric ephrinA5-Fc (p < 0.0001, Fisher's Exact Two-Tailed Test for all 
three concentrations).
These data can be applied to the in vivo infusion protocol. Assuming a volume 
of CSF dilution of 400pL and a 50% CSF turnover rate per hour435, 3mM 
peptide delivered at a rate of 0.25pL/hr will rapidly accumulate in the CSF to a 
concentration expected to block EphA4 (Figure 4.2A). 1.5mM peptide 
delivered at 0.5pl/hr in the two week study will show a very similar 
accumulation. As Figure 4.2A shows, 100nM will be reached very rapidly, 
although in practise diffusion of the peptide and leakage through the region of 
dural damage are likely to reduce the effective concentration around the injury 
site. However, the high concentration theoretically attained provide a large 
margin of error such that even extensive CSF leakage acutely after injury 
should not prevent effective EphA4 blockade.
Two Week Investigation of CST Regeneration with Immediate and 
Delayed Peptide Treatment
As is the case for all therapeutic interventions, there is a time window of 
opportunity during which the treatment will be fully effective. Published work436 
indicates that successful recovery of the CST occurs when olfactory 
ensheathing cells are implanted as late as six months following injury. Hence, 
it is critical to determine whether EphA4 blocking peptide infusion is similarly 
flexible as this will define its use in the clinical scenario. Furthermore, the ideal 
model for analysis of functional improvements following injury when peptide is 
administered would be a well established and stable injury to ensure that 
spontaneous recovery through spared fibres cannot complicate the analysis. 
Defining the latest viable treatment time will determine whether animals in 
behavioural studies can be left before treatment to ensure the formation of an 
established and stable behavioural phenotype.
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An initial investigation assessed whether immediate or 48 hour delayed 
1.5mM peptide treatment encouraged CST regeneration following dorsal 
column injury over a short time-course of two weeks. Control spinal cords 
showed a clear indication of the well-documented ‘die back’ of the CST from 
the lesion site38,390 with the formation of large, well-established dystrophic end 
bulbs (Figure 4.4A). There was also a notable lack of regeneration and 
sprouting from these termination bulbs, typical of the CST following injury but 
atypical of most CNS tracts in this environment. Furthermore, in all control 
animals a large cavity had formed with strong indicators of secondary damage 
such as a ‘honeycomb’ effect seen in GFAP staining of astrocytes (Figures 
4.3A and 4.3C) not seen in uninjured white matter (Figure 4.3D). Animals 
receiving the delayed peptide treatment showed an identical phenotype to the 
control animals (Figure 4.4B).
Those animals receiving immediate peptide treatment showed significant 
improvements in the post-injury architecture of the lesion site. A clear 
reduction in cavitation and secondary injury were apparent with increased 
CST axon sprouting from termination bulbs and the formation of regenerative 
sprouts often oriented towards the lesion site (Figures 4.3B and 4.4C). 
Analysing termination bulb distances from the lesion epicentre using the Zeiss 
Image Analysis software for the confocal microscope revealed that immediate 
peptide delivery permitted a high level of recovery of the lesioned CST (Figure 
4.5A). Control termination bulbs were an average of 556 ± 36pm from the 
lesion centre. In animals receiving peptide however, the mean termination 
bulb distance was reduced to 204 ±19pm (p < 0.002 with an n of 3 for each 
treatment, paired t-test, Figure 4.5). However, values seen in animals given 
delayed peptide treatment were not different from controls (Figure 4.5).
Four Week Investigation of CST Regeneration with Immediate Peptide 
Treatment
While significant CST retraction had occurred in the control animals two 
weeks following dorsal column injury and the improvements induced by the 
blocking peptide are obvious, significant recovery is likely to take longer than
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two weeks. Hence, 3mM blocking peptide was delivered over a period of four 
weeks subsequent to a lesion of the dorsal CST. As can be seen in Figure 
4.9B, die-back does not appear to worsen over the additional two week period 
in the control animals. However, cavitation and secondary damage are 
significantly more extensive at four weeks (Figure 4.6A). Animals treated with 
blocking peptide, however, show similar improvements in CST regeneration to 
that seen two weeks after injury (Figure 4.9A-B). The CST in control animals 
terminated on average 594 ±30pm from the lesion centre. In contrast, in 
peptide treated animals this value was reduced to 170 ±25pm, significantly 
smaller (p < 0.002 with an n of 3 or more for each treatment, paired t-test).
Few termination bulbs put forward regenerative sprouts and no significant 
progress towards the lesion margin was apparent in control animals (Figure 
4.7A). However, in treated rats the lesion cavity, extensive in control rats, was 
often diminished to a narrow incision often filled with invading astrocytes 
(Figures 4.6B-D and 4.8B-D). Furthermore, numerous regenerating axons 
were seen to migrate along these astrocytic bridges to navigate the lesion 
site. Numerous termination bulbs were seen to put forward regenerative 
sprouts, often right up to the lesion margin (Figure 4.8A) and regenerative 
sprouting into uninjured ascending dorsal column white matter and ipsilateral 
grey matter was also visibly enhanced (Figure 4.7B- C).
Effects of Peptide Administration on GFAP expression and astrocyte 
behaviour and morphology following SCI
Lateral white matter injuries do not induce extensive cavitation or astrocyte 
retraction in control animals and hence are an ideal model on which to study 
changes in astrocyte behaviour and morphology following lesion (Figure 
4.13C). Animals receiving a C5 lateral white matter injury were analysed 28 
days post-injury having received either EphA4 blocking peptide or ACSF 
infusion. Injuries were performed such that they extended just dorsal to the 
level of the canal (see Figure 4.M1B).
Typical morphological changes were seen in control astrocytes with an 
upregulation in GFAP expression in a graded fashion with proximity to the
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lesion centre. Hypertrophy and reorganisation of astrocytic processes was 
also seen (Figure 4.10B-E) consistent with many descriptions in the 
literature26, 437. Astrocytes in spinal cord tissue taken from animals that had 
received EphA4 blocking peptide for the duration of their injury showed very 
similar responses -  with normal hypertrophy (Figure 4.1 OF) and 
reorganisation (Figure 4.10G) occurring. GFAP expression was analysed 
using the Zeiss Image Analyser software and the GFAP expression intensity 
seen by immunohistochemistry in a 150pm penumbra around the lesion 
cavity, when normalised to the intensity seen in contralateral uninjured white 
matter, was similar between the two tissue populations. Normalised control 
astrocyte GFAP expression was 1.52 ± 0.42 fold greater than control (mean ± 
SEM) while expression in animals receiving peptide was 2.18 ± 0.26.
However, while the reactivity of astrocytes was clearly unaffected by the 
presence of the blocking peptide, invasion of the lesion cavity by astrocytes 
was significantly different. Image analyser software was used to find the 
average GFAP intensity inside the lesion cavity and this value was normalised 
to the intensity seen in contralateral uninjured white matter. As Figure 4.11 
shows there is a clear and significant difference in the invasion of the lesion 
site by astrocytes. As noted above for dorsal column injuries, sections stained 
for GFAP from animals receiving a lateral white matter injury show 
significantly less cavitation and retraction of surviving astrocytes away from 
the lesion centre when blocking peptide was infused (Figure 4.12A-C). Also of 
note is the apparent reduction in secondary tissue damage at sites distant to 
the original primary lesions (Figure 4.12D-E).
Four Week Investigation of RST Regeneration with Immediate Peptide 
Treatment
Published behavioural data suggests that the rubrospinal tract in rats is 
important in forelimb support while rearing, normal gait and for skilled 
locomotion438. As discussed in Chapter II, the RST in rats does not express 
EphA4 and hence provides a system in which to further test the mechanism of 
the EphA4 blocking peptide. Furthermore, any useful clinical intervention will 
be required to improve regeneration of more than one axonal tract, hence this
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approach will further assess it’s clinical suitability. Labelling of the RST was 
performed using a single stereotaxic injection of BDA into the red nucleus on 
the side contralateral to the injury. While the spread of BDA in the brain does 
present the risk of labelling axons of passage close to the red nucleus, 
particularly the CST, minimal labelling of other tracts was observed -  as 
evidenced by the lack of dorsal CST labelling (Figure 4.13A) -  while good 
RST labelling was achieved (Figure 4.13B).
The BDA-labelled RST could be clearly traced along the extent of the 
undisturbed lateral white matter on the contralateral side to BDA injection. 
Where it approached the lesion site, RST axons terminated at a range of 
distances from the lesion site and showed large, swollen dystrophic end bulbs 
some distance from the lesion centre (Figures 4.13D and 4.14). The die-back 
typical of the CST following injury was not apparent. However, due to the 
smaller number of labelled RST fibres quantification is required to build a 
reliable picture of the response of the tract to injury.
As shown in Figure 4.15, the RST retracts further 28 days after lateral white 
matter injury than at the two week time point (395 ±41 pm compared to 302 
±11 pm). The RST is seen to retract less far than the CST at this time point 
after injury (Figure 4.15) however, confirming the concept introduced in 
Chapter III that the expression of EphA4 on the CST is at least partially 
responsible for its atypical die-back response following lesion. In animals 
receiving 3mM EphA4 blocking peptide for the duration of the post-injury 
period, the RST recovered significantly (Figure 4.14) when compared to 
control animals treated with ACSF. Control RST termination bulbs were on 
average located 395 ±40pm from the lesion centre while peptide treated end 
bulbs were closer, at 250 ±6pm (p < 0.05 with an n of 3 for each treatment, 
paired t-test). The improved recovery of the RST under pharmacological block 
of EphA4 points to an underlying improvement in the recovery of the CNS to 
injury additional to the removal of inhibitory EphA4 signalling on axonal growth 
cones, an effect which will be restricted to the CST. As detailed above, this is 
most likely due to an effect on astrocytes, possibly by providing structural and 
trophic support in the lesion site or improved access to the lesion cavity.
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As documented above, while there was no significant change in astrocytic 
GFAP expression or hypertrophy, extensive astrocytic invasion of the lesion 
site was apparent in peptide treated animals. Furthermore, these astrocytic 
processes often branched some distance into the cavity, providing a complete 
bridge across the astrocyte-free zone. There was no apparent reduction in the 
size of the astrocyte-free zone following peptide treatment, but that is 
unsurprising as extensive secondary damage and astrocyte retraction is 
uncommon following lateral white matter injury. RST axons following 
treatment showed extensive sprouting from termination bulbs and the sprouts 
often extended in a lesion-ward direction, often navigating the lesion margin 
scar to successfully migrate along astrocytic bridges (Figures 4.13E and 
4.13F). Just as in peptide-treated CST regeneration, no neuronal processes 
were seen without associated astrocytes suggesting that astrocytes have a 
trophic or supporting role.
Comparing the Effects of Peptide Treatment on the CST and RST Four 
Weeks Following Lateral White Matter Injury
To ensure that the improvements seen in regeneration in Sprague-Dawley 
rats following peptide administration were not a strain-specific phenomenon, 
spinal cord injury in Lewis rats was investigated. To further our comparison of 
the CST and RST behaviour subsequent to injury and peptide treatment, a 
dual tract labelling procedure was employed. Lewis rats were injected 
stereotaxically with BDA into the motor cortex and an EGFP-expressing virus 
into the red nucleus. Animals underwent C1 peptide or ACSF cannulation and 
a lateral white matter spinal cord injury.
Figure 4.17A demonstrates the typical response of the two tracts to injury with 
the RST extending close to the lesion margin and the CST more retracted. 
Under control conditions neither tract put forward significant regenerative 
sprouts (Figures 4.17C and 4.18A) and both terminated in well-defined 
dystrophic end bulbs. Peptide administration in the Lewis rats induced a very 
similar response to that seen in the Sprague-Dawley strain with invasion of 
the lesion cavity by regenerative sprouts from both tracts (Figures 4.17B and
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4.18B) and improvements in regenerative sprouting from termination bulbs 
(Figures 4.17D and 4.18D).
As clearly demonstrated in Figure 4.16A, the story of improvements in both 
CST and RST regeneration is confirmed statistically for the second rat strain. 
When compared to data from Sprague-Dawley rats, the fit is remarkably 
accurate considering the complexity of the study (Figure 4.16B). Lewis rats 
show an identical die-back of the CST in control conditions when compared to 
the RST which can be attributed to the difference in EphA4 expression. 
Furthermore, both the RST and CST respond well to the peptide 
administration showing a good regenerative response. Similarly to that found 
in the Sprague-Dawley study, the two tracts recover to very similar extents 
suggesting that the inhibitory response of EphA4 receptors present on the 
CST has been completely annulled in Lewis rats.
Average Distance ± SEM
Strain Tract Control Treated
Sprague-Dawley CST 594.40 ±30.51 170.40 ±25.83
Lewis CST 514.95 ±18.52 226.24 ±7.75
Sprague-Dawley RST 395.99 ±40.94 250.40 ±5.69
Lewis RST 380.07 ±11.55 182.45 ±7.70
Functional Recovery Following Peptide Treatment
While anatomical recovery is a good indicator of beneficial changes in CNS 
regeneration following injury, it does not necessarily translate into functional 
benefits to the animal. To assess whether application of EphA4 blocking 
peptide to the site of a dorsal column lesion improves functional recovery 
following injury we employed the paw reaching assay developed by Professor 
Raisman’s laboratory225 and the rearing assay.
Control and treated animals showed no functional deficit in either test 
following intrathecal cannulation indicating that no damage was caused by the 
procedure, or at least any damage caused did not have any functional
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consequences. Inspection of the spinal cord following dissection indicated that 
on occasion some slight deformation of the dorsal side of the cord occurred 
due to the presence of the cannula but this did not appear to induce any 
behavioural phenotype. All animals showed an immediate loss of use of the 
injured forepaw in both assays with a short (2-5 day) period of clawing in the 
injured paw and diminished weight bearing on the injured side. Both animal 
sets showed a similar time course of recovery of function in the rearing assay, 
typically recovering 60% or more use of the injured paw within 5-10 days 
(Figure 4.19A). In the paw reaching assay, control animals never regained 
use of their injured forepaw showing a consistent 100% use of the uninjured 
paw. The time course for the use of the uninjured, previously non-preferred, 
paw varied and was probably influenced by the time required for useful 
recovery of weight bearing ability on the injured paw. Furthermore, the extent 
of off-paw use during training and the time spent in the final phase of training 
when the on-paw was used dominantly would also influence the time required 
to rediscover the ability to reach with the off-paw. Animals receiving EphA4 
blocking peptide, however, showed a gradual recovery of function in the 
injured paw subsequent to preliminary use of the uninjured paw (Figure 
4.19B). The time course for this recovery varied with a mean of 10.7 ±1.7 
days. Recovery was always limited in these animals with a mean percentage 
use of the injured forepaw of 30 ±1.9% after Day 10. Figure 4.20A shows a 
control animal trained to reach with both forepaws 28d following right hand 
side dorsal column injury, persisting in the use of it’s left forepaw. Conversely, 
an identically trained and operated animal that received a peptide infusion had 
recovered use of it’s right forepaw after 28 days (Figure 4.20B). Recovery 
occurred in all four animals analysed and no recovery was seen in the control 
group (Figure 4.20). As shown in Figure 4.19B, the difference in injured 
forepaw use is clear and statistically significant at p < 0.05 (comparing 
successful vs. unsuccessful recovery with an n of 4 for each animal set, 
Fischer’s exact t-test).
At the end of the 28 day period of functional assessment a subset of animals 
received a BDA injection into the motor cortex contralateral to the spinal cord 
injury to ensure that no sparing had occurred, especially in those peptide
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animals showing good recovery. All animals investigated showed no sign of 
sparing and usually a small degree of injury of the contralateral dorsal CST. 
Another subset of animals received BDA injections into the ipsilateral motor 
cortex to assess whether sprouting or plasticity from the uninjured 
contralateral dorsal CST could explain the improvements in functional 
recovery seen. As shown in Figure 4.21, neither control nor peptide treated 
animals show any sprouting of uninjured CST axons past the lesion site into 
contralateral dorsal white matter.
DISCUSSION
In Vitro Analysis of Peptide Inhibition of EphA4 Signalling
The ability of the EphA4 blocking peptide to abrogate ephrinA5-Fc mediated 
growth cone collapse at a 1:1 molar ratio of antagonist and ligand is highly 
encouraging. The high binding affinity of the peptide (Kd = 0.5nM389), for the 
receptor permits this efficacious and rapid (15 minutes for full blockade of 
growth cone collapse activity) action. The high selectivity389 of the peptide for 
the EphA4 receptor over other EphA receptors that bear a strong 
conformational and sequence homology is remarkable and this indicates that 
it is EphA4 that is mediating the collapse action of ephrinA5-Fc. In the lesion 
site the selectivity of the peptide is such that it will not be expected to interfere 
with the interaction of astrocytic ephrinB2 and EphB2 on meningeal 
fibroblasts. This interaction is essential for the re-formation of the blood brain 
barrier and exclusion of invading meningeal fibroblasts from the lesion site21. 
The full abrogation of collapse activity by the peptide is also encouraging as 
this indicates the neurons lack other EphA receptors that might bind cognate 
ligands in vivo following CNS injury. Published expression studies indicate 
that adult cortical neurons do not express EphB receptors323, hence 
application of the EphA4 blocking peptide should be sufficient to prevent all 
ephrin-mediated signalling affecting the injured CST. The rapid theoretical 
accumulation of peptide within the CSF, even with generous estimates of CSF 
turnover and peptide metabolism and leakage, indicates that full block of 
endogenous EphA4 should be achieved with a short time period following 
injury.
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Two Week Investigation of CST Regeneration with Immediate and 
Delayed Peptide Treatment
Figure 4.4 clearly demonstrates the significant improvement in the 
regenerative response of the CST in animals receiving immediate peptide 
treatment. A detailed study of the response of this tract indicated that the 
improvements came from a number of sources:
• Increased termination bulb sprouting
• A clear reduction in the die back of the main CST retraction bulb.
•  Improvements in the wound healing response of astrocytes
Termination bulbs in control animals rarely put out sprouts (a visual estimate 
would range from 5-15%) and those that occurred were usually not of any 
great distance. However, in animals treated with peptide numerous 
termination bulbs (estimated at 30-70%) put out sprouts many of which grew 
long distances (often over 200pm) and frequently reached the astrocyte 
margin. The reduction in the die-back of the main bulk of the CST fibres 
normally seen after injury is likely to be due to the abrogation of 
inhibitory/collapsing interactions between strongly expressed astrocytic 
ephrinB2 at the lesion margin, myelin ephrinB3 and EphA4 receptor 
accumulated in the termination bulbs of this tract. However, the improved 
response of hypertrophic astrocytes to the lesion when exposed to peptide 
may also reduce die-back by providing trophic or structural support. The 
observed improvements in the wound response of hypertrophic astrocytes is 
similar to that reported by Goldshmit et a/.12 who saw closing of the wound to 
the extent that the lesion site was often hard to define. While the response of 
the lesion site is not so dramatic in this shorter duration study (two weeks 
compared to six) it is still very positive. This closing of the wound and 
preservation of astrocytic processes into the lesion site may provide trophic 
support for regenerating axonal processes. Crucially, however, it will provide a 
stable structural support on which axons can migrate and help close the 
wound preventing excessive withdrawal of the axonal stump from the lesion 
centre. Hence, it is likely that improvements in the wound healing process and 
associated reduction in cavitation and secondary injury, as well as the
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improvement in the regenerative response of the CST both contribute to the 
quantified improvements in regeneration seen in Figure 4.5.
While it is disappointing that the window of therapeutic opportunity appears to 
be so short, which will preclude a behavioural approach using an established 
long-term lesion as the treatment model, this does tell us about the likely 
mechanism of action of the peptide. Interactions between CST-based EphA4 
and ephrinB2 and ephrinB3 local to the injury will have occurred during the 40 
hour delay of peptide administration and the sequence of events leading to 
the withdrawal of the CST will have been set in motion. Delayed inhibition of 
the EphA4 receptor cannot prevent this rapid retraction and die-back of the 
CST once it has begun, while rapid intervention can (Figure 4.4). This implies 
that the interaction between CST-based EphA4 and its ligands may be the 
start of a signalling cascade resulting in CST retraction such that inhibition of 
EphA4 at a later stage is unable to reverse the mechanism.
Four Week Investigation of CST Regeneration with Immediate Peptide 
Treatment
As Figure 4.9 indicates, the recovery of the CST seen at two weeks following 
injury when EphA4 blocking peptide is administered is retained but not 
significantly improved upon after four weeks. On first inspection this could be 
attributed to the presence of other inhibitory agents in the vicinity of the spinal 
cord lesion site, of which there are many. However, while the statistical 
approach is a good indicator of the behaviour of the main bulk of the CST -  
the main bullet-shaped mass of retraction bulbs -  it does not reflect the 
behaviour of individual axons effectively.
The clearly improved and reduced lesion cavity containing many more 
astrocytic processes should provide a fertile ground for axonal regeneration 
as shown in Figure 4.6. This is borne out by the extensive regenerative 
sprouting that often extends through the typical lesion margin and into the 
cavity (Figures 4.7 and 4.8). This sprouting phenomenon, seen in the two 
week data, has clearly expanded and the additional two week time period has 
permitted more astrocytes to invade the lesion site as a bridging structure for
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the regenerating axons and for these axons to migrate along them. Hence, 
while the main bulk of the CST termination bulbs show improved sprouting 
over control rats, this sprouting phenomenon does not appear to have 
increased during the two-four week period of peptide treatment. However, 
these processes are increasingly long and show a frequently directional 
approach to regeneration towards and into the lesion cavity. While many 
regenerating axons do not appear to be able to migrate through the physical 
barrier produced by the interaction of reactive astrocytes and invading 
meningeal fibroblasts, a small proportion of those seen in the four week 
animals do so. These labelled sprouts, perhaps only representing 0.5% of the 
actual sprouts present, represent a significant regenerative response that 
could provide functional improvements following injury. This regenerative 
sprouting would not be picked up by the statistical approach but is clearly a 
significant increase in regenerative potential over that seen following two 
weeks of peptide treatment. Whether the administration of the blocking 
peptide might diminish the tightness of the astrocytic barrier to regeneration or 
reduce the barrier’s inhibitory nature is difficult to asses. However, Goldshmit 
et a/.12 saw reductions in the expression of CSPG in glial scars in EphA4 
knock-out mice and hence a reduction in the inhibitory nature of the scar is a 
feasible explanation.
Also of note is the interaction between regenerating axons within the lesion 
margin, as defined by GFAP staining of astrocytes, and astrocytic processes 
invading the cavity. As axons were never seen in this location without 
association with an astrocyte it is likely that the astrocytic processes are 
providing both a ‘pioneer1 role into the lesion cavity and also structural support 
for the axons, rather than vice versa. Interestingly these processes appear to 
have abandoned their typical orientation parallel to the lesion margin, as 
usually seen four weeks after injury26; and returned to a morphology more 
reminiscent of earlier time points in the injury process when the glial scar was 
more flexible and permeable during the interaction with invading meningeal 
cells. Hence, these atypical pioneer astrocytes may provide not only the 
structural support required by regenerating axons to infiltrate the cavity, but 
also the access points (i.e. a weak link in the new glial limitans) to the cavity.
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The debate regarding the role of astrocytes as either positive (trophic, 
supportive) or negative (CSPG expression, physical barrier to regeneration) is 
very active with no firm conclusion yet resolved. However, the data presented 
here suggests that, following pharmacological blockade of the EphA4 
receptor, the surface of some, or all, astrocytes becomes an acceptable 
medium for regeneration and the physical barrier to regeneration induced by 
the glial scar appears to be relaxed.
Effects of Peptide Administration on GFAP expression and astrocyte 
behaviour and morphology following SCI
Astrocytes exposed to EphA4 blocking peptide subsequent to a lateral white 
matter injury showed the normal hypertrophic and reactive response to CNS 
injury seen in control, ACSF treated animals. However, animals receiving 
blocking peptide had notably smaller lesions with less secondary tissue 
damage and much greater numbers of astrocytic processes invading the 
cavity. Whether this improvement in cavity size is due to the ability of 
astrocytes to survive the primary/secondary injury phase, a reduction in the 
astrocytic withdrawal response to CNS injury or improvements in the invasion 
of the lesion cavity is hard to determine. The reduction in secondary tissue 
damage seen might suggest either an improved survival of astrocytes in this 
phase of the injury or a reduction in the severity of secondary damage.
These improvements in astrocytic behaviour cannot be readily explained 
based on established signalling interactions in the lesion site. A number of 
possibilities exist however, that might explain the changes in the astrocytic 
response following EphA4 blockade:
• Prevention of c/s-interaction between astrocytic EphA4 and ephrinB2
• Stopping the transactivation of EphA4 on astrocytes subsequent to 
exposure to cytokines
• Interfering with exposed oligodendrocyte myelin ephrinB3 binding to 
astrocytic EphA4
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C/s-interactions have been shown to modulate the effects of both ligands and 
receptors278. EphrinB2 upregulation in astrocytes appears to coincide with 
meningeal fibroblast invasion following injury26 and would be expected to 
interact with co-expressed EphA4. If this interaction mediates part of the 
astrocytic response to injury then blocking EphA4 may therefore uncouple 
part, or all, of the activation of astrocytes induced by the invasion of 
meningeal fibroblasts. The fact that delayed treatment does not induce any 
improvements in CST regeneration/sprouting or astrocytic invasion of the 
lesion cavity suggests that the mechanism of action must be rapid and must 
be on an interaction that occurs rapidly after the initial insult. The time course 
of the meningeal cell invasion is much longer than this, often taking up to a 
week for full invasion26, suggesting that this possibility is unlikely.
Published data12 indicates that knocking out the EphA4 receptor makes 
cultured astrocytes unresponsive to cytokine application in vitro, hence 
preventing gliosis. The data contained therein indicates the most likely 
signalling mechanism at work is a transactivation of EphA4 downstream of a 
cytokine receptor(s). Hence, pharmacological blockade of the EphA4 receptor 
would not be expected to interfere with this signalling process. If a 
conformational change is required as part of the transactivation then the 
blocking peptide may inhibit part or all of this process. The lack of any change 
in the hypertrophy and gliosis of astrocytes as shown by swollen cell bodies 
and upregulated GFAP expression suggests any change induced by the 
peptide must be subtle, however.
A third possibility is that the sudden exposure of EphA4-positive astrocytes to 
myelin ephrinB3 following injury might mediate part of the astrogliosis 
reaction. Hence, in this context blocking the EphA4 receptor would be 
expected to modulate astrocyte responses to CNS injury. The exposure of the 
CST to ephrinB3 in the lesion site is likely to be rapid as it is present in 
uninjured oligodendrocyte myelin. Hence this theory fits well with the probable 
time course of the CST response to injury and the action of the peptide 
blocker. However, immunohistochemical visualisation of the ephrinB3 protein 
is technically difficult which impedes investigation of this interaction.
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Hence, while no firm conclusion can be drawn from this study, it is readily 
apparent that there is a significant change in the astrocytic response to injury. 
Importantly, a more compact lesion with greater structural support will improve 
axonal regeneration and functional recovery significantly.
Four Week Investigation of RST Regeneration with Immediate Peptide 
Treatment
The aim of this approach was to discover if the regenerative improvements 
seen in the CST due to peptide administration were due solely to inhibition of 
the EphA4 receptor on the termination bulbs and proximal axonal stumps or 
whether there was a secondary underlying phenomenon also encouraging 
regeneration. Labelling of the RST using BDA is significantly more 
complicated than that of the CST due to the necessity for stereotaxic surgery, 
and the possibility of labelling axons of close passage. Furthermore, there are 
relatively fewer numbers of RST axons in comparison to the CST. However, in 
most animals sufficient RST labelling was seen to permit acquisition of good 
quantitative data regarding regeneration, while no labelling of the dorsal CST 
(and hence, by inference also the lateral CST) occurred.
As shown in Figure 4.14, good quantitative improvements in RST 
regeneration are seen following peptide administration with the associated 
increases in sprouting from termination bulbs and formation of regenerative 
sprouts into the lesion. As the RST in rats does not express EphA4323 this 
improvement cannot be ascribed to any mechanism intrinsic to the RST. 
Instead, as discussed above, post-injury changes in astrocytic behaviour 
induced by block of EphA4 signalling are the most likely candidate. However, 
the increased invasion of the lesion cavity (Figures 4.11 and 4.12) by 
astrocytes to provide structural, and possibly trophic, support is unlikely to be 
sufficient to promote regeneration into the lesion cavity to the extent found in 
peptide treated animals. The expression of growth inhibitory mediators such 
as CSPGs on the lesion scar, and the physical barrier produced by tightly 
interlocked astrocytes, would be expected to prevent significant regeneration 
into the lesion site, regardless of improvements in the permissive nature of the
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cavity. However, the possibility discussed above, that inhibiting EphA4 might 
reduce certain components of the astrogliosis to make areas of the scar more 
permissive for growth through reduced CSPG expression (as seen in 
Goldshmit et a/.12) and interlocking, would account for this increased 
navigation of the lesion scar.
The improvements seen in this RST study indicate that peptide administration 
is able to improve regeneration of two crucial descending motor tracts 
important in locomotion. Furthermore the increases in sprouting apparent will 
facilitate plasticity-induced recovery through spared white matter and possibly, 
at longer time points, regeneration through the lesion site to permit 
reformation of the original neural connections.
Comparing the Effects of Peptide Treatment on the CST and RST Four 
Weeks Following Lateral White Matter Injury
As shown in Figure 4.16A, the application of EphA4 inhibitory peptide during 
the 28 days following a lateral white matter injury induces a robust 
regenerative response from both the RST and CST in this region. The fact 
that this response directly mirrors that found when both tracts were 
investigated in a separate strain of rat, is highly encouraging. Furthermore the 
CST data is very similar to that seen following a dorsal column injury (Figure 
4.16B) for both treated and control animals, suggesting similar responses to 
lesion and similar regeneration mechanisms. The fact that the lateral CST 
retracts to the same extent as the dorsal CST, despite the nature of the dorsal 
column injury being significantly less deleterious than the lateral white matter 
injury, is testimony to the inhibitory nature of the EphA4 expressed on the 
CST. Furthermore, the dorsal CST recovers to the same extent as the lateral 
CST suggesting that the peptide is capable of reversing all the negative 
effects of EphA4 signalling and promote significant recovery.
The astrocytic response to peptide administration is maintained in the Lewis 
rats as well, with good invasion of the lesion site by astrocytic processes and 
formation of CST and RST sprouts along these processes. Hence, modulation
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of the astrocyte response to injury appears to be a common mechanism in 
improving recovery following CNS injury in these two rat stains.
Functional Recovery Following Peptide Treatment
The establishment of a reliable assay for recovery of CST function was 
essential and the final approach appears to give a quantitative and sensitive 
account of improvements in reaching and rearing associated with dorsal 
column injury. Ideally, our experimental procedure would allow a period of no 
treatment to ensure the lesion was stable and that no spontaneous recovery 
ensued over a period of months. Subsequent to this period, introduction of the 
treatment or control intervention would permit an assessment of recovery with 
confidence that no spared fibers could account for this recovery. However, as 
shown by the initial study into the duration of the window of therapeutic 
opportunity, a delayed treatment regime is not possible here. The injury type 
used here is very similar to that used in the work of Raisman and 
colleagues225 who find the phenotypic change robust and not prone to 
spontaneous recovery. The robust change in forepaw usage seen in all 
control and treated animals for one-two weeks prior to any recovery of 
function in the injured paw suggests all animals received a complete lesion of 
the injured CST. Spontaneous recovery from this injury occurs with as little as 
one percent of spared CST fibers and is sufficient to induce a near-full 
recovery of reaching ability225. However, the time course for this recovery is 
very rapid and complete and would be identified as such in the analysis. 
Furthermore, the best recovery seen from any animal only resulted in an 
approximately 40% recovery of function in the injured paw 28 days after injury 
suggesting that sparing did not account for the recovery seen. Animals were 
also labelled with BDA into the motor cortex associated with the injured 
forepaw after completion of the reaching analysis (day 29-32), sacrificed ten 
days later and examined for axonal sparing; none was apparent.
This functional recovery study, while only a small-scale (n of 4 in each group) 
study to investigate potential physiological improvements following peptide 
administration, gave excellent results (Figure 4.19). While the clear conclusion
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is that the peptide induced significant recovery in the CST, a number of 
phenomena require closer examination.
The recovery of the use of the injured forepaw in the rearing assay was rapid 
and appeared to be independent of the treatment protocol applied. This 
suggests that the uninjured RST was rapidly able to take full control of the 
weight-bearing and basic locomotion in the injured forepaw. However, lateral 
white matter injuries of the RST induce a similar rapid recovery response to 
that seen here and long term, stable loss of use of a forepaw in the rearing 
assay requires a lateral-central overinjury. Hence, while the RST is obviously 
a major coordinator of the weight bearing and locomotion required for the 
rearing assay, it cannot be the only regulatory tract. A likely explanation is that 
the ascending dorsal column plays a feedback role438 in controlling the rearing 
assay locomotion such that, following injury, accommodation or adaptation by 
the animal is required before confident use of the forepaw is regained.
The animals receiving EphA4-blocking peptide in this study did not show a full 
recovery of function within the 28 day period, reaching only 30 ±1.9% 
recovery on average. However, grasp strength recovery in EphA4 knock-out 
mice following lateral column injury show only a ~40% recovery of function12 
28 days following injury. Full recovery took three months to develop. 
Furthermore, mice develop much smaller lesion cavities than mice and the 
Goldshmit et al,12 study used the less deleterious lateral column injury, 
compared to the dorsal column injury in this study. Hence extending this study 
(readily achieved by replacing the mini-pumps every 28 days) to three months 
would be expected to produce even better recovery of function.
The lack of plasticity or sprouting of the uninjured contralateral CST into the 
opposing dorsal white matter suggests that the functional recovery seen in 
peptide treated animals was due to increases in regenerative sprouting of the 
lesioned CST and the increased invasion of the lesion site by these 
regenerating processes. While few axons were seen to fully navigate the 
lesion site, the labelling efficiency for the CST in these experiments could be 
as low as 0.5%, hence 200-fold as many regenerating axons would be
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present in a typical animal. Only minimal regeneration beyond the lesion site 
would be required for potentially beneficial connections with motor pattern 
generators or plastic reorganisation of intemeurons to provide functional 
connections to distal motor groups. Furthermore, the extensive sprouting seen 
on the rostral side of the injury extended significantly into the spared grey 
matter and interneuronal connections could potentially develop from these 
plastic changes.
The precise mechanism by which EphA4 blocking peptide improves 
regeneration following injury is likely to be amenable to investigation due to its 
specific pharmacology. A number of possible mechanisms of action might be 
at work:
- A reduction in CSPG, or other growth-inhibitory mediator, expression. An 
interesting experiment would be to look at CSPG, Nogo, etc. expression in 
the glial scar following peptide treatment to assess whether there is any 
change. The apparently growth-permissive or -promoting role of pioneer 
astrocytes that invade the lesion cavity following peptide administration 
suggests that they might demonstrate a reduced expression of these 
highly inhibitory molecules.
- A change in the expression profile of neurotrophins or other secreted 
factors from astrocytes. A simple experiment to assess any expression 
changes may explain the growth improvements seen and suggest 
neurotrophic support regimes tailored for regeneration.
- A change in the reactive nature of responsive astrocytes. The increased 
invasion of the lesion site seen following peptide infusion suggests that the 
physical barrier developed by tightly interacting astrocytes may be relaxed. 
Immunohistochemistry to highlight connexion-based tight junctions would 
identify any change in this growth-inhibitory mechanism.
- Preventing the initial retraction of the CST by interfering with ephrinB2- 
EphA4 interactions or promoting regeneration of this tract subsequent to 
retraction. The fact that delayed peptide treatment does not rescue the 
CST following injury suggests that the peptide prevents retraction in the 
first place. However, a time course following injury would permit the
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formation of a precise post-injury profile of the CST and RST when 
exposed to peptide.
Defining the precise mechanism at work would be simplified if the peptide 
could be traced. During the development of the blocking peptide Murai et 
a/.389 attached the peptide sequence to a display library to pan for binding to 
the EphA4 receptor. This suggests that the binding affinity is not severely 
affected by attaching large structures. Hence, the development of a peptide 
tagged with a fluorescent marker, similar to tagged tetrodotoxin, would permit 
an accurate analysis of where the peptide bound most strongly and hence 
indicate the mechanism of action. This construct could also be used to 
perform high affinity and specificity expression analysis on other tissues.
Work by Weidner et al. suggests that spontaneous recovery of forepaw 
reaching ability following dorsal CST injury in rats may occur through plastic 
sprouting from the ventral CST439. In this study animals were effectively forced 
to use their injured forepaws and in this situation perhaps the drive for spared 
CST components to take over dorsal CST functions is very strong. This is 
perhaps similar to the recovery of function seen in animals in the pilot 
functional study where due to weight bearing limitations the injured paw was 
used for reaching. Perhaps in this study the ventral CST also contributed to 
the recovery of function. However, in the main functional study presented 
here, no untreated animals recovered paw reaching ability suggesting that 
ventral CST sprouting was not induced. Furthermore sections through the 
dorsal spinal cord revealed no CST labelling beyond the lesion site 
suggesting that ventral CST sprouts did not re-innervate this half of the spinal 
cord.
CONCLUSION
This study strongly supports the hypothesis that accumulating EphA4 receptor 
present on the termination bulbs of CST fibres subsequent to either dorsal or 
lateral column injury is responsible for the atypical die-back of the CST 
compared to other descending tracts. Furthermore, blocking EphA4 reverses 
this effect, permitting the CST to regenerate in a similar fashion to the EphA4- 
negative RST. However, administration of EphA4-blocking peptide also
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appears to improve the regeneration of the RST following lesion suggesting 
that blockade of EphA4 on another cell type in the lesion site is responsible 
for part of the recovery seen. Astrocytes are known to express EphA4 and this 
has been linked to cytokine-induced astrocytosis following injury. Astrocytes in 
lateral column injuries show no changes in their reactive nature when 
exposed to peptide, but do appear to invade the lesion cavity to a greater 
extent. The extensive interaction between regenerating axonal sprouts and 
these invading astrocytic processes suggests that they may provide structural 
or trophic support. Administration of EphA4-blocking peptide also clearly 
improves functional recovery of the animals’ ability to control voluntary fine 
locomotion, a hallmark of CST function, demonstrating that the anatomical 
regeneration is accompanied by physiological benefits.
Hence, pharmacological antagonism of the EphA4 receptor appears to induce 
significant recovery in animals undergoing spinal cord injury through multiple 
mechanisms. This effect has been confirmed in two strains of rat, Sprague- 
Dawley and Lewis, and following both dorsal and lateral column injuries to two 
descending motor tracts. Further pre-clinical investigation is required to 
extend this data and to further dissect its mechanism of action.
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Figure 4.M1
Cartoons depicting cannulation and spinal cord injury procedures
A. Cartoon of implanted cannula and mini-pump. Cannulae were inserted at the C1 
region into the subarachnoid space and sutured through the inflexible tubing loop to 
the uppermost muscle layers. Mini-pumps were glued to the flexible tubing end of the 
cannula.
Cannulae were constructed from:
Blue -  Wide bore, flexible tubing attached to the mini-pump.
Green -  Medium bore, inflexible tubing 
Red -  Fine bore, flexible tubing
B-D. Cartoons of spinal cord injuries performed. White matter represented by yellow, grey 
matter by grey and injured regions by overlying diagonal lines. Dorsal side of cartoon 
is uppermost. Lateral column injuries (A) were designed to completely transect the 
lateral CST and the RST, usually including a small amount of grey matter to ensure 
complete transection was performed. Normally the lesion did not extend as ventral as 
the canal. Dorsal column injuries (B) were performed to completely transect the 
dorsal CST on one side of the animal. Ipsilateral dorsal horn grey matter and 
contralateral dorsal column tissue was normally transected to ensure complete lesion. 
Unilateral CST injuries for the behavioural studies (C) were designed to completely 
lesion the dorsal CST on one side of the animal but cause as little damage as 
possible to the contralateral CST.
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Figure 4. M2
Tract labelling and regeneration analysis
A. Coronal 40|jm section through the caudal medulla of a rat 28 days following injection 
of BDA to the motor cortex. The pyramidal tract is clear (dorsal is down in this image) 
and shows good CST labelling. Scale bar 300pm.
B. An example of the end product of the RST and CST regeneration analysis of a lateral 
white matter lesion. GFAP immunohistochemistry (blue) identifies astrocytes and 
hence the midline of the lesion cavity can be drawn (white line). BDA-labelled CST 
(red) and EGFP-labelled RST (green) termination bulbs are readily visible and the 
distance between these termination bulbs and the mid-cavity line is measured. 
Averaging a complete series of sections for both axonal tracts though a spinal cord 
produces a reliable quantification of the regeneration gap. Horizontal 40pm section, 
scale bar 200pm.
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Figure 4. M3
GFAP expression analysis and the rearing assay
A. Example of GFAP analysis. Horizontal 40pm section through a lateral white matter
injury 28 days after lesion stained for GFAP. Each lesion was divided into two zones 
for analysis -  the lesion cavity as defined by the margin of GFAP expression, and the 
lesion penumbra, a 150pm wide zone around the cavity. Quantification of the GFAP 
expression was performed using Zeiss Image Analyser software and normalising 
values to the contralateral, uninjured white matter GFAP expression.
6. The rearing assay. Animals were placed in a clear plastic tube and given sufficient
time to adapt to their surroundings. Exploratory rearing was then recorded and the 
proportion of use of each forepaw noted. Rears accepted for analysis involved the 
animal directly facing the glass, with forepaws in front of the body, obvious raising of 
the body weight to the hind paws and weight bearing on the forepaws in contact with 
the tube.
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Figure 4. M4
The paw reaching assay
Animals were conditioned to being placed in the apparatus (i) which entirely enclosed 
two thirds of the cage. Animals were then trained to reach with both forepaws for food 
rewards placed the other side of a small slot in the front wall of the apparatus (ii). As 
shown in (ii), animals typically used one forepaw to lean against the plastic front wall 
of the apparatus and used the other paw to reach for the food reward. Animals were 
trained, housed and assessed in pairs to increase their learning stimulus.
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Figure 4.1
Neocortical cultures and quantification of growth cone collapse rates
A-B. E17 rat neocortical cultures. Control cultures typically have one long, axonal process
with a well-extended growth cone showing multiple lamellipodia and filopodia (A) 
while collapsed growth cones have a small, F-actin dense body with a single 
filopodial process (B). Scale bars 25pm.
C. Collapse rates of growth cones depending on culture conditions. Base collapse rate
in normal culture was 36% and control cultures containing only EphA4 blocking 
peptide showed a very similar collapse rate. Exposure to homodimeric ephrinA5-Fc 
induced a collapse rate of 64% that was reduced to 44% by pre-administration of 
20nM EphA4 blocking peptide for 10 minutes. Pre-administration of 50 or 100nM 
peptide prevented all ephrinA5-induced growth cone collapse. All bars mean collapse 
percentage ± 95% confidence interval, * p < 0.01, Fischer’s exact t-test.
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Figure 4.2
Theoretical accumulation of EphA4 blocking peptide in the CSF
The calculation is based on the infusion rate of peptide, a turn-over rate for CSF of 
50% per hour and a 400pl volume of dilution for local CSF. This theoretical profile 
suggests that 100nM blocking peptide should develop within the first hour of injury, 
providing pharmacologically useful levels of peptide to the very acute lesion site.
228
Estimated CSF Concentration of Peptide
■ immediate - - - - Delayed
250
200
O 150
b.■£
f * ’
0 20 40 60
Time after Injury (hours)
o
u_
(0O
100
50
229
Figure 4.3
Astrocyte morphology following control or treated spinal cord injury
A-B. Untreated spinal cord two weeks following dorsal column injury showing the extent of 
cavitation and secondary injury development in both parasagittal (Ai) and horizontal 
(Aii) sections. Conversely, spinal cords from animals that received EphA4 blocking 
peptide for the entire duration of the injury showed reduced cavitation and secondary 
injury both horizontally (Bi) and parasagittally (Bii). Scale bars 1mm.
C-D. Lateral white matter astrocytes following injury commonly developed a ‘honeycomb’ 
appearance short distances from the lesion site probably due to necrosis of 
intervening tissue and hypertrophy in response to the injury (C). In contrast, control 
astrocytes in the uninjured lateral white matter show a well-organised parallel pattern 
designed to support axonal processes (D). Scale bars 100pm.
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Figure 4.4
CST behaviour following control or treated spinal cord injury
A-C. Horizontal 40pm sections taken through the dorsal CST two weeks following lesion 
stained for GFAP and BDA labelling of the CST. In control animals the lesion site 
shows cavitation with highly GFAP-positive astrocytes in the developing glial scar (A). 
The corticospinal tract is clearly retracted form the lesion site and few termination 
bulbs are seen to have sprouted. Spinal cords from animals that received delayed 
peptide treatment show an identical phenotype (B). In those animals that received 
peptide for the entire duration of the post-injury period (C), the CST was significantly 
less retracted, astrocytic processes were seen to invade the lesion site and provide 
bridges along which CST processes had advanced. Numerous CST termination bulbs 
were seen near the lesion margin and some were seen to have invaded the lesion 
cavity. Scale bars 250|jm.
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Figure 4.5
CST retraction from the lesion centre following spinal cord injury
Quantification of the distance between CST termination bulbs and the lesion centre. 
The delayed peptide treatment has no effect on CST retraction while immediate 
peptide administration induces significant improvements in CST regeneration (p < 
0.01 Student’s t-test, mean of three animals ±SEM).
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Figure 4.6
Astrocyte morphology 28 days following spinal cord injury
A-B. Parasagittal 40pm sections through spinal cords 28 days following dorsal CST lesion 
showing staining for GFAP. Control spinal cords (A) show a very similar injury to 
cords two weeks following injury although secondary necrosis has spread beyond the 
immediate insult (triangle). Those animals receiving EphA4 blocking peptide for the 
entire 28 day period show a small lesion site similar to that seen in Figure 4.3B with 
the progressive formation of astrocytic bridges in the lesion cavity (B). Scale bars 
1mm.
C-D. Higher magnification images of the lesion site of animals treated with EphA4 blocking 
peptide show numerous bridge structures along the length of the cavity that could 
provide both structural and trophic support for regenerating axons and also act to 
promote wound closure. Scale bars 400pm (C) and 100pm (D).
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Figure 4.7
The CST in control and treated 28 day old spinal cord injuries
A-C. Parasagittal 40pm sections through the BDA-labelled dorsal corticospinal tract 28 
days following lesion. ACSF-treated animals show the typical CST retraction bulb with 
a distinct bullet-shaped morphology (A) and minimal regenerative sprouting. Animals 
that received an infusion of EphA4 blocking peptide for the entire post-injury period 
demonstrate less retraction and evidence of regenerative sprouting into spared lateral 
or dorsal white matter and grey matter (B and C). Scale bars 200pm (A and B), 
100pm (C).
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Figure 4.8
CST sprouts regenerating into the lesion margin and cavity following peptide treatment
A-D. Parasagittal 40|jm sections through the lesion cavity at the level of the dorsal 
corticospinal tract. Stained for GFAP (green) and the BDA-labelled CST (red). In 
animals receiving EphA4 blocking peptide for the 28 day period following a dorsal 
corticospinal tract injury, regenerative sprouts from the CST were commonly seen to 
advance through the reactive astrocyte lesion margin (A). Furthermore, astrocytic 
processes were seen to invade the lesion cavity and provide structural support for 
axonal processes (no axons were seen without associated astrocytes) regenerating 
into the lesion site (B-D). Scale bars 25pm.
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Figure 4.9
Peptide administration reduces CST retraction from the lesion margin
A. Quantification of the distance between CST termination bulbs and the lesion centre in 
animals 28 days following dorsal corticospinal tract transection. Peptide treated 
animals show significantly less retraction of the CST from the lesion margin (p < 0.01 
Student’s t-test, mean of three animals ±SEM).
B. Comparing CST regeneration two and four weeks following injury with and without 
peptide treatment. CST retraction does not appear to worsen significantly during 
weeks two to four following injury. At either time-point EphA4 blocking peptide 
induces very similar improvements in regeneration. Mean of three animals ±SEM.
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Figure 4.10
Astrocyte behaviour following spinal cord injury
A-F. GFAP expression in horizontal sections through a lesion site typically shows a 
gradient of expression, increasing with proximity to the lesion centre. Following injury 
grey (A) and white (B) matter astrocytes become highly reactive, upregulate GFAP 
expression and become hypertrophic (C, triangles). This results in a remarkable 
change in the appearance of both the grey (C) and white matter (D) with invasion of 
the lesion margin and penumbra by both migrating astrocytes and processes of less 
proximal astrocytes. Administration of EphA4 blocking peptide for the 28 day period 
following lesion has no apparent effect on the gross anatomy of the astrocyte 
population in either the grey (E) or white (F) matter. Scale bars 100pm.
244
245
Figure 4.11
Quantification of astrocyte invasion of the lesion cavity
Astrocyte GFAP expression within the lesion cavity was analysed 28 days following 
lateral white matter injury. Values were normalised against the contralateral uninjured 
white matter expression of GFAP. Animals receiving EphA4 blocking peptide for the 
entire duration of the post-injury period show a significantly increased invasion of the 
lesion site by astrocytic processes (* p < 0.05, Student’s t-test, mean ± SEM).
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Figure 4.12
Immunohistochemical data showing astrocyte invasion of the lesion cavity following
peptide delivery
A-C. Lateral white matter injuries typically show minimal secondary damage or spread of 
the injury away from the primary lesion site. However, astrocyte retraction and the 
absence of significant numbers of astrocytic processes in the lesion site is common 
(A). Invasion of the lesion cavity by reactive astrocytes is enhanced in animals 
receiving EphA4 blocking peptide following injury (B and C). Horizontal 40pm 
sections through a lateral white matter lesion. Scale bars 200pm.
D-E. Secondary damage following spinal cord injury typically leads to areas of necrotic cell 
death separate from the initial lesion (*, D). In treated animals this secondary damage 
was less prominent and only a moderate lesion cavity was typically present (E). 
Parasagittal 40pm sections through a dorsal corticospinal tract lesion, stained for 
GFAP. Scale bars 1mm.
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Figure 4.13
Tract labelling permits visualisation of sprouting responses to injury
A. Horizontal 40pm section through the dorsal corticospinal tract ten days following BDA 
injection into the red nucleus. This procedure did not induce any labelling of the 
dorsal corticospinal tract. Scale bar 100pm.
B. Horizontal 40pm section through the lateral white matter ten days following BDA 
injection into the red nucleus. This resulted in good labelling of the rubrospinal tract. 
Scale bar 300pm.
C. Horizontal 40pm section through the centre of a lateral white matter lesion stained for 
GFAP. These injuries induce only minimal secondary damage in rats and the extent 
of cavitation is typically small. Lesions that fully transect the lateral CST and the RST 
rarely induce damage to the central white matter, as shown. Scale bar 1mm.
D-F. Rubrospinal tract termination bulbs in animals treated with ACSF following lateral
white matter lesions show negligible sprouting typical of a post-injury motor tract. 
Large, swollen dystrophic endbulbs form at various distances from the lesion margin 
by 28 days after injury (*, D) and these show minimal evidence of regenerative 
potential. In animals receiving peptide for this period termination bulbs generally 
occur closer to the lesion margin and there is increased evidence of a regenerative 
attempt with fine regenerative sprouts approaching the lesion site (arrows, E and F). 
Scale bars 20pm (D), 25pm (E) and 100pm (F).
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Figure 4.14
Peptide treatment improves RST regeneration following lesion
Graph illustrating the distance between rubrospinal tract termination bulbs and the 
lesion centre in animals 28 days following lateral white matter injury that completely 
transected the RST on one side. Peptide treated animals show a moderate reduction 
in the retraction of the RST from the lesion margin (p < 0.01 Student’s t-test, mean of 
three animals ±SEM).
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Figure 4.15
In the untreated spinal cord the CST retracts further than the RST following injury
The rubrospinal tract retracts less far from the lesion centre than the corticospinal 
tract both 14 and 28 days following lesion, (p < 0.01 Student’s t-test, mean of three or 
more animals ±SEM).
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Figure 4.16
Immediate peptide treatment improves regeneration in two rat strains
A. Graph showing quantification of the termination bulb-lesion centre distances for the 
rubrospinal and lateral corticospinal tracts in Lewis rats following a lateral white 
matter injury that completely transects both tracts. Both tracts show a significant 
reduction in the retraction distance following EphA4 blocking peptide administration (p 
< 0.01, Student’s t-test, mean of three or more animals ± SEM).
B. The effect of the peptide on regeneration in both tracts is very comparable between 
the two species of rat studied. Bars represent the mean of three or more animals ± 
SEM.
256
A Effect of Immediate Peptide Treatment on CST and RST Regeneration 28d Following Injury in Sprague-Dawley Rats
Control Peptide Treated
B
Comparing Regeneration Distances in Sprague-Dawley and Lewis 
Rats 28d Following Injury
700
600
500
400
300
0  Sprague-Dawley ■ Lewis
£
C
0)O
co
'35o
£
£ 200 O
E
2 100 o m
Control CST Peptide Treated
CST
Control RST Peptide Treated 
RST
257
Figure 4.17
Peptide administration reduces die-back and improves sprouting
A-D. Horizontal 40pm sections through the lateral white matter 28 days following a lateral 
white matter lesion completely transecting the lateral corticospinal tract and the 
rubrospinal tract. The BDA-labelled CST is shown in red, the EGFP-labelled RST is 
shown in green and GFAP staining for astrocytes is shown in blue. Animals receiving 
ACSF for the 28 day period following injury show typical retraction of both tracts from 
the lesion margin (A) while those receiving EphA4 blocking peptide show minimal 
retraction and processes invading the lesion site (B). Higher magnification images of 
the termination bulbs illustrates the difference in retraction between the two tracts. 
ACSF treated CST (*) fibres retract significantly further than comparable RST fibres 
(C) while in peptide treated animals the CST and RST show a similar regenerative 
capacity (D). Scale bars 200pm (A and B), 50pm (C and D).
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Figure 4.18
Regenerative sprouting is enhanced in the presence of peptide
A-D. Horizontal 40pm sections through the lateral white matter 28 days following a lateral 
white matter lesion completely transecting the lateral corticospinal tract and the 
rubrospinal tract. The BDA-labelled CST is shown in red, the EGFP-labelled RST is 
shown in green and GFAP staining for astrocytes is shown in blue. The response of 
the RST to peptide administration is readily evident using EGFP-labelling. The 
increased labelling intensity and number of labelled fibres identifies many more 
regenerating axons. The minimal sprouting and moderately retracted nature of the 
control RST (A) is completely reversed following peptide administration (B) with 
extensively sprouting axons that grow to the GFAP-labelled lesion margin. These 
sprouts also appear to predominately regenerate in a lesionwards direction (C). 
Sprouting from termination bulbs of both the CST (*) and RST (triangles) is apparent 
in animals receiving peptide following injury. Scale bars 150pm (A and B), 100pm (C) 
and 25pm (D).
260
261
w
-
Figure 4.19
Peptide infusion induces recovery of paw reaching function following injury
A. Animals recovered rapid use of the injured forepaw in the rearing assay following 
unilateral dorsal CST injury regardless of the treatment type. Near-complete recovery 
of function was attained within the 28 day post-injury period of analysis. Graph shows 
the mean percentage use of the injured forepaw in four animals per treatment regime 
± SEM.
B. In the paw reaching assay no recovery of function was achieved by any control 
animal throughout the period of study. Peptide treated animals showed a progressive 
recovery of function up to a mean 30% usage by twenty-eight days after injury. Graph 
shows the mean percentage use of the injured forepaw in four animals per treatment 
regime ± SEM.
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Figure 4.20
Grasping with the injured forepaw recovers within ten days of injury when EphA4 
blocking peptide is infused
A-B. Example images of animals reaching for food pellets in the paw reaching assay. Both 
animals shown were trained to use both forepaws in the reaching assay and both 
underwent a right hand side dorsal corticospinal tract lesion. In A the animal received 
control ACSF only for the duration of the post-injury period. In B the animal received 
EphA4 blocking peptide. Twenty-eight days following injury the control animal still 
used its uninjured left forepaw to reach while the peptide treated animal had regained 
the ability to use its injured forepaw.
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Figure 4.21
Plasticity and sprouting from the uninjured contralateral dorsal CST does not appear to 
mediate recovery of function
A-D. Horizontal 40|jm sections through the dorsal CST 38 days after a unilateral dorsal 
column injury. BDA was used to label the uninjured CST and GFAP staining (green) 
to define the lesion site. Animals undergoing a unilateral dorsal corticospinal tract 
lesion show no regenerative sprouting or plasticity from the uninjured, contralateral 
tract in either control (A and C) or peptide treated (B and D) animals. White squares 
indicate the regions of higher magnification shown in images C and D. Images C and 
D highlight the region of the CST just caudal to the injury site and hence a likely site 
for sprouting. In all images caudal is to the right. Scale bars 400pm (A and B) and 
100pm (C and D).
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Concluding Remarks
The data presented in this thesis identifies a potential interaction between 
ephrinB2 expressed in reactive astrocytes near the lesion site and the EphA4 
receptor in corticospinal tract axons. Furthermore it demonstrates how two 
approaches to interfere with this interaction promote regeneration of 
descending motor tracts. The second of these, infusion of a blocking peptide 
specific for the EphA4 receptor, induces improvements in functional recovery 
following corticospinal tract lesion and hence may have clinical potential.
The finding that peptide-induced regeneration of neither the corticospinal nor 
rubrospinal tract increased during the additional two weeks after injury in the 
extended study is disappointing, if unsurprising. The presence of numerous 
other growth-inhibitory agents in the lesion site, unaffected by inhibition of 
EphA4 signalling, would present a significant growth-inhibitory zone through 
which complete regeneration would be improbable. Hence, blockade of the 
EphA4 receptor alone is not sufficient for complete regeneration, although it is 
likely to contribute to any successful combinatorial therapy. The similarities 
between the work presented here and the work of Goldshmit et al.12 in mice, 
with improvements in descending fibre regeneration, functional recovery and 
changes in astrocyte behaviour, suggest that similar ephrin functions are at 
work in the post-injury spinal cord environment of both rats and mice. This 
conservation of function indicates that inhibiting EphA4 signalling in human 
spinal cord injury may also prove pro-regenerative.
As our understanding of ephrin signalling in the post-injury spinal cord 
environment grows the complex and far-reaching nature of these interactions 
is becoming apparent. Currently published literature indicates ephrin roles in 
four of the major CNS injury-related phenomena: astrocyte reactivity12, 
meningeal fibroblast invasion and the deposition of the basal lamina26, growth 
cone retraction330 and inflammation315. The only published study to date 
looking at spinal cord injury following abrogation of an ephrin interaction12 has 
reported robust and functionally relevant regeneration. Hence, these studies,
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combined with the data presented here, suggest that further investigation of 
ephrin signalling in spinal cord injury is warranted and is very likely to be 
translated into clinical initiatives.
269
Bibliography
1. Wolman, L., The Disturbance of Circulation in Traumatic Paraplegia in Acute and 
Late Stages: A Pathological Study. Paraplegia, 1965. 59: p. 213-26.
2. Dusart, I. and M.E. Schwab, Secondary cell death and the inflammatory reaction after 
dorsal hemisection of the rat spinal cord. Eur J Neurosci, 1994. 6(5): p. 712-24.
3. Wagner, F.C., Jr. et al., Pathological changes from acute to chronic in experimental 
spinal cord trauma. J Neurosurg, 1978. 48(1): p. 92-8.
4. Tator, C.H. and D.W. Rowed, Current concepts in the immediate management of 
acute spinal cord injuries. Can Med Assoc J, 1979.121(11): p. 1453-64.
5. Kobrine, A.I. et al., Local spinal cord blood flow in experimental traumatic myelopathy. 
J Neurosurg, 1975. 42(2): p. 144-9.
6. Anderson, D.K. etal., Spinal cord energy metabolism following compression trauma 
to the feline spinal cord. J Neurosurg, 1980. 53(3): p. 375-80.
7. Sandler, AN. and C.H. Tator, Review of the effect of spinal cord trauma on the 
vessels and blood flow in the spinal cord. J Neurosurg, 1976. 45(6): p. 638-46.
8. Faden, A.I. et al., N-methyl-D-aspartate antagonist MK801 improves outcome 
following traumatic spinal cord injury in rats: behavioural, anatomic, and 
neurochemical studies. J Neurotrauma, 1988. 5(1): p. 33-45.
9. Panter, S. S. et al., Alteration in extracellular amino acids after traumatic spinal cord 
injury. Ann Neurol, 1990. 27(1): p. 96-9.
10. Liu, D. et al., Excitatory amino acids rise to toxic levels upon impact injury to the rat 
spinal cord. Brain Res, 1991. 547(2): p. 344-8.
11. Guha, A. and C. H. Tator, Acute cardiovascular effects of experimental spinal cord 
injury. J Trauma, 1988. 28(4): p. 481-90.
12. Goldshmit, Y. et al., Axonal Regeneration and Lack of Astrocytic Gliosis in EphA4- 
Deficient Mice. J. Neurosci., 2004. 24(45): p. 10064-10073.
13. Demediuk, P. et al., Changes in lipid metabolism in traumatized spinal cord. Prog 
Brain Res, 1985. 63: p. 211-26.
14. Balentine, J.D. and M. Spector, Calcification of axons in experimental spinal cord 
trauma. Ann Neurol, 1977. 2(6): p. 520-3.
15. Eidelberg, E. et al., Immediate consequences of spinal cord injury: possible role of 
potassium in axonal conduction block. Surg Neurol, 1975. 3(6): p. 317-21.
16. Schwab, M.E. and D. Bartholdi, Degeneration and regeneration of axons in the 
lesioned spinal cord. Physiological Reviews, 1996. 76(2): p. 319-70.
17. Popovich, P.G. et al., Concept of autoimmunity following spinal cord injury: possible 
roles for T  lymphocytes in the traumatized central nervous system. J Neurosci Res,
1996. 45(4): p. 349-63.
18. Lawson, L. J. et al., Quantification of the mononuclear phagocyte response to 
Wallerian degeneration of the optic nerve. J Neurocytol, 1994. 23(12): p. 729-44.
270
19. Mocchetti, I. and J. R. Wrathall, Neurotrophic factors in central nervous system 
trauma. J Neurotrauma, 1995. 12(5): p. 853-70.
20. Miyake, T. et al., Quantitative studies on proliferative changes of reactive astrocytes 
in mouse cerebral cortex. Brain Res, 1988. 451(1-2): p. 133-8.
21. Faulkner, J. R. et al., Reactive astrocytes protect tissue and preserve function after 
spinal cord injury. J Neurosci, 2004. 24(9): p. 2143-55.
22. Fawcett, J.W. and R.A. Asher, The glial scar and central nervous system repair. Brain 
Research Bulletin, 1999. 49(6): p. 377-91.
23. Krikorian, J. G. et al., Origin of the connective tissue scar in the transected rat spinal 
cord. Exp Neurol, 1981. 72(3): p. 698-707.
24. Maxwell, W.L. et al., The response of the cerebral hemisphere of the rat to injury. I. 
The mature rat. Philos Trans R Soc Lond B Biol Sci, 1990. 328(1250): p. 479-500.
25. Koshinaga, M. et al., Altered acidic and basic fibroblast growth factor expression 
following spinal cord injury. Exp Neurol, 1993.120(1): p. 32-48.
26. Bundesen, L.Q. ef al., Ephrin-B2 and EphB2 regulation of astrocyte-meningeal 
fibroblast interactions in response to spinal cord lesions in adult rats. J Neurosci, 
2003. 23(21): p. 7789-800.
27. Li, M. et al., Functional role and therapeutic implications of neuronal caspase-1 and - 
3 in a mouse model of traumatic spinal cord injury. Neuroscience, 2000. 99(2): p. 
333-42.
28. Shuman, S.L. et al., Apoptosis of microglia and oligodendrocytes after spinal cord 
contusion in rats. J Neurosci Res, 1997. 50(5): p. 798-808.
29. Abe, Y. et al., Apoptotic cells associated with Wallerian degeneration after 
experimental spinal cord injury: a possible mechanism of oligodendroglial death. J 
Neurotrauma, 1999. 16(10): p. 945-52.
30. Balentine, J.D., Pathology of experimental spinal cord trauma. I. The necrotic lesion 
as a function of vascular injury. Lab Invest, 1978. 39(3): p. 236-53.
31. Giehl, K.M., Trophic dependencies of rodent corticospinal neurons. Rev Neurosci,
2001. 12(1): p. 79-94.
32. Jacobs, A. J. ef al., Recovery of neurofilament expression selectively in regenerating 
reticulospinal neurons. J Neurosci, 1997.17(13): p. 5206-20.
33. McBride, R. L. et al., Retrograde transport of fluoro-gold in corticospinal and 
rubrospinal neurons 10 and 20 weeks after T-9 spinal cord transection. Exp Neurol,
1990. 108(1): p. 83-5.
34. Schnell, L. and M.E. Schwab, Sprouting and regeneration oflesioned corticospinal 
tract fibres in the adult rat spinal cord. Eur J Neurosci, 1993. 5(9): p. 1156-71.
35. Gilson, B.C. and L. J. Stensaas, Early axonal changes following lesions of the dorsal 
columns in rats. Cell Tissue Res, 1974. 149(1): p. 1-20.
271
36. Li, Y. and G. Raisman, Sprouts from cut corticospinal axons persist in the presence of 
astrocytic scarring in long-term lesions of the adult rat spinal cord. Exp Neurol, 1995. 
134(1): p. 102-11.
37. Ramon y Cajal, S., Degeneration and regeneration of the nervous system (translated 
by R. M. May). 1928, London: Oxford Univ. Press.
38. Pallini, R. et al., Retrograde degeneration of corticospinal axons following transection 
of the spinal cord in rats. A quantitative study with anterogradely transported 
horseradish peroxidase. J-Neurosurg, 1988. 68(1): p. 124-8.
39. Kao, C .C .e t al., Electron microscopic observations of the mechanisms of terminal 
club formatbn in transected spinal cord axons. J Neuropathol Exp Neurol, 1977.
36(1): p. 140-56.
40. Houle, J. D., Demonstration of the potential for chronically injured neurons to 
regenerate axons into intraspinal peripheral nerve grafts. Exp Neurol, 1991.113(1): p. 
1-9.
41. Guest, J. D. ef al., The ability o f human Schwann cell grafts to promote regeneration 
in the transected nude rat spinal cord. Exp Neurol, 1997.148(2): p. 502-22.
42. Muma, N. A. et al., Alterations in levels of mRNAs coding for neurofilament protein 
subunits during regeneration. Exp Neurol, 1990.107(3): p. 230-5.
43. Bisby, M.A. and W. Tetzlaff, Changes in cytoskeletal protein synthesis following axon 
injury and during axon regeneration. Mol Neurobiol, 1992. 6(2-3): p. 107-23.
44. Yin, H.S. and M.E. Selzer, Axonal regeneration in lamprey spinal cord. J Neurosci, 
1983. 3(6): p. 1135-44.
45. Hall, G.F. et al., Cytoskeletal changes correlated with the loss of neuronal polarity in 
axotomized lamprey central neurons. J Neurocytol, 1997. 26(11): p. 733-53.
46. Fawcett, J. W. et al., Regenerating sciatic nerve axons contain the adult rather than 
the embryonic pattern of microtubule associated proteins. Neuroscience, 1994. 61(4): 
p. 789-804.
47. Reh, T. and K. Kalil, Functional role of regrowing pyramidal tract fibers. J Comp 
Neurol, 1982. 211(3): p. 276-83.
48. Bates, C.A. and D.J. Stelzner, Extension and regeneration of corticospinal axons 
after early spinal injury and the maintenance of corticospinal topography. Exp Neurol,
1993. 123(1): p. 106-17.
49. Li, D. et al., Failure of axon regeneration in postnatal rat entorhinohippocampal slice 
coculture is due to maturation of the axon, not that of the pathway or target. Eur J 
Neurosci, 1995. 7(6): p. 1164-71.
50. Condic, M. L. et al., Embryonic neurons adapt to the inhibitory proteoglycan aggrecan 
by increasing integrin expression. J Neurosci, 1999.19(22): p. 10036-43.
51. Cai, D. et al., Neuronal cyclic AMP controls the developmental loss in ability of axons 
to regenerate. The Journal of Neuroscience, 2001. 21(13): p. 4731-9.
272
52. Chauvet, N. et al., Tanycytes present in the adult rat medbbasal hypothalamus 
support the regeneration of monoamlnergic axons. Exp Neurol, 1998.151(1): p. 1-13.
53. Morrison, E.E. and R.M. Costanzo, Regeneration of olfactory sensory neurons and 
reconnection in the aging hamster central nervous system. Neurosci Lett, 1995. 
198(3): p. 213-7.
54. Fouad, K. et at., Cervical sprouting o f corticospinal fibers after thoracic spinal cord 
injury accompanies shifts in evoked motor responses. Curr Biol, 2001.11(22): p. 
1766-70.
55. Hatten, M.E. et at., Astroglia in CNS injury. Glia, 1991. 4(2): p. 233^43.
56. David, S. and A. J. Aguayo, Axonal elongation into peripheral nervous system 
"bridges" after central nervous system injury in adult rats. Science, 1981. 214(4523): 
p. 931-3.
57. Richardson, P.M. et al., Axons from CNS neurons regenerate into PNS grafts.
Nature, 1980. 284(5753): p. 264-5.
58. Richardson, P.M. and V.M. Issa, Peripheral injury enhances central regeneration of 
primary sensory neurones. Nature, 1984. 309(5971): p. 791-3.
59. Broude, E. et al., c-Jun expression in adult rat dorsal root ganglion neurons: 
differential response after central or peripheral axotomy. Exp Neurol, 1997.148(1): p. 
367-77.
60. Neumann, S. and C. J. Woolf, Regeneration of dorsal column fibers into and beyond 
the lesion site following adult spinal cord injury. Neuron, 1999. 23(1): p. 83-91.
61. Leon, S. et al., Lens injury stimulates axon regeneration in the mature rat optic nerve. 
J Neurosci, 2000. 20(12): p. 4615-26.
62. Werner, A. et al., Impaired axonal regeneration in alpha7 integrin-deficient mice. J 
Neurosci, 2000. 20(5): p. 1822-30.
63. Holmes, F. E.e t a i ,  Targeted disruption of the galanin gene reduces the number of 
sensory neurons and their regenerative capacity. Proc Natl Acad Sci USA, 2000. 
97(21): p. 11563-8.
64. de Felipe, C. et al., The role o f immediate early genes in the regeneration of the 
central nervous system. Adv Neurol, 1993. 59: p. 263-71.
65. Fan, M. et al., Analysis of gene expression following sciatic nerve crush and spinal 
cord hemisection in the mouse by microarray expression profiling. Cell Mol Neurobiol,
2001. 21(5): p. 497-508.
66. Skene, J.H., Axonal growth-associated proteins. Annu Rev Neurosci, 1989.12: p. 
127-56.
67. Widmer, F. and P. Caroni, Identification, localization, and primary structure of CAP- 
23, a particle-bound cytosolic protein of early development. J. Cell Biol., 1990.111(6): 
p. 3035-3047.
68. Wehrle, R. et al., Role o f GAP-43 in mediating the responsiveness of cerebellar and 
precerebellar neurons to axotomy. Eur-J-Neurosci, 2001.13(5): p. 857-70.
273
69. Mason, M.R. J. et al., Transcriptional Upregulation of SCG10 and CAP-23 Is 
Correlated with Regeneration of the Axons of Peripheral and Central Neurons in Vivo. 
Molecular and Cellular Neuroscience, 2002. 20(4): p. 595-615.
70. Tetzlaff, W. et al., Response of rubrospinal and corticospinal neurons to injury and 
neurotrophins. Prog Brain Res, 1994. 103: p. 271-86.
71. Doster, S.K. et al., Expression o f the growth-associated protein GAP-43 in adult rat 
retinal ganglion cells following axon injury. Neuron, 1991. 6(4): p. 635-47.
72. Andersen, L.B. and D.J. Schreyer, Constitutive expression of GAP-43 correlates with 
rapid, but not slow regrowth of injured dorsal root axons in the adult rat. Exp Neurol, 
1999.155(2): p. 157-64.
73. Laux, T. et al., GAP43, MARCKS, and CAP23 modulate PI(4,5)P(2) at plasmalemmal 
rafts, and regulate cell cortex actin dynamics through a common mechanism. J Cell 
Biol, 2000. 149(7): p. 1455-72.
74. Mason, M.R. et al., Corticospinal neurons up-regulate a range of growth-associated 
genes following intracortical, but not spinal, axotomy. European Journal of 
Neuroscience, 2003.18(4): p. 789-802.
75. Fernandes, K. J. et al., Influence of the axotomy to cell body distance in rat 
rubrospinal and spinal motoneurons: differential regulation of GAP-43, tubulins, and 
neurofilament-M. J Comp Neurol, 1999. 414(4): p. 495-510.
76. Chaisuksunt, V. et al., Axonal regeneration from CNS neurons in the cerebellum and 
brainstem of adult rats: correlation with the patterns of expression and distribution of 
messenger RNAs for L I, CHL1, c-jun and growth-associated protein-43. 
Neuroscience, 2000.100(1): p. 87-108.
77. Mason, M.R. et al., Overexpression of GAP-43 in thalamic projection neurons of 
transgenic mice does not enable them to regenerate axons through peripheral nerve 
grafts. Exp Neurol, 2000. 165(1): p. 143-52.
78. Buffo, A. et al., Targeted overexpression of the neurite growth-associated protein B- 
50/GAP-43 in cerebellar Purkinje cells induces sprouting after axotomy but not axon 
regeneration into growth-permissive transplants. J Neurosci, 1997.17(22): p. 8778-
91.
79. Bomze, H.M. et al., Spinal axon regeneration evoked by replacing two growth cone 
proteins in adult neurons. Nature Neuroscience, 2001. 4(1): p. 38-43.
80. Becker, T. et al., Readiness ofzebrafish brain neurons to regenerate a spinal axon 
correlates with differential expression of specific cell recognition molecules. J 
Neurosci, 1998. 18(15): p. 5789-803.
81. Thoenen, H. et al., Trophic support of motoneurons: physiological, 
pathophysiological, and therapeutic implications. Exp Neurol, 1993.124(1): p. 47-55.
82. Mansour-Robaey, S. et al., Effects of ocular injury and administration of brain-derived 
neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells.
Proc Natl Acad Sci USA, 1994. 91(5): p. 1632-6.
274
83. Frisen, J. et al., Increased levels oftrkB mRNA and trkB protein-like immunoreactivity 
in the injured rat and cat spinal cord. Proc Natl Acad Sci USA, 1992. 89(23): p. 
11282-6.
84. Frisen, J. et al., trkC expression in the injured rat spinal cord. Neuroreport, 1993. 5(3): 
p. 349-52.
85. Follesa, P. et al., Increased basic fibroblast growth factor mRNA following contusive 
spinal cord injury. Brain Res Mol Brain Res, 1994. 22(1-4): p. 1-8.
86. Reynolds, M E. et al., Localization o f nerve growth factor receptor mRNA in contused 
rat spinal cord by in situ hybridization. Brain Res, 1991. 559(1): p. 149-53.
87. Meiri, K.F. et al., Neurite outgrowth stimulated by neural cell adhesion molecules 
requires growth-associated protein-43 (GAP-43) function and is associated with GAP- 
43 phosphorylation in growth cones. J Neurosci, 1998.18(24): p. 10429-37.
88. Giehl, K.M. et al., The survival-promoting effect of glial cell line-derived neurotrophic 
factor on axotomized corticospinal neurons in vivo is mediated by an endogenous 
brain-derived neurotrophic factor mechanism. J Neurosci, 1998.18(18): p. 7351-60.
89. Giehl, K.M. and W. Tetzlaff, BDNF and NT-3, but not NGF, prevent axotomy-induced 
death of rat corticospinal neurons in vivo. Eur J Neurosci, 1996. 8(6): p. 1167-75.
90. Schnell, L. et al., Neurotrophin-3 enhances sprouting of corticospinal tract during 
development and after adult spinal cord lesion. Nature, 1994. 367(6459): p. 170-3.
91. Reier, P. J. et al., Intraspinal transplantation of embryonic spinal cord tissue in 
neonatal and adult rats. J Comp Neurol, 1986. 247(3): p. 275-96.
92. Caroni, P. and M.E. Schwab, Two membrane protein fractions from rat central myelin 
with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol, 1988. 
106(4): p. 1281-8.
93. Schwab, M.E. and P. Caroni, Oligodendrocytes and CNS myelin are nonpermissive 
substrates for neurite growth and fibroblast spreading in vitro. J Neurosci, 1988. 8(7): 
p. 2381-93.
94. Caroni, P. et al., Central nervous system regeneration: oligodendrocytes and myelin 
as non-permissive substrates for neurite growth. Prog Brain Res, 1988. 78: p. 363-70.
95. Schwab, M. E., Myelin-associated inhibitors of neurite growth and regeneration in the 
CNS. Trends Neurosci, 1990.13(11): p. 452-6.
96. Pasterkamp, R. J .e t  al., Peripheral nerve injury fails to induce growth of lesioned 
ascending dorsal column axons into spinal cord scar tissue expressing the axon 
repellent Semaphorin3A. Eur J Neurosci, 2001.13(3): p. 457-71.
97. GrandPre, T. et al., Nogo-66 receptor antagonist peptide promotes axonal 
regeneration. Nature, 2002. 417(6888): p. 547-51.
98. Oertle, T. et al., Nogo-A inhibits neurite outgrowth and cell spreading with three 
discrete regions. J Neurosci, 2003. 23(13): p. 5393-406.
99. McKerracher, L. et al., Identification of myelin-associated glycoprotein as a major 
myelin-derived inhibitor of neurite growth. Neuron, 1994.13(4): p. 805-11.
275
100. Kottis, V. et al., Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite 
outgrowth. J Neurochem, 2002. 82(6): p. 1566-9.
101. Wang, K. C .e t  al., Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that 
inhibits neurite outgrowth. Nature, 2002. 417(6892): p. 941-4.
102. Huang, J.K. et al., Glial membranes at the node of Ranvier prevent neurite outgrowth. 
Science, 2005. 310(5755): p. 1813-7.
103. Yang, L. J .e t al., Gangliosides are neuronal ligands for myelin-associated 
glycoprotein. Proc Natl Acad Sci U S A, 1996. 93(2): p. 814-8.
104. Mukhopadhyay, G. et al., A novel role for myelin-associated glycoprotein as an 
inhibitor of axonal regeneration. Neuron, 1994.13(3): p. 757-67.
105. Bartsch, U. et al., Lack of evidence that myelin-associated glycoprotein is a major 
inhibitor of axonal regeneration in the CNS. Neuron, 1995.15(6): p. 1375-81.
106. Fournier, A. E. et al., Identification of a receptor mediating Nogo-66 inhibition of 
axonal regeneration. Nature, 2001. 409(6818): p. 341-6.
107. Venkatesh, K. et al., The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent 
receptor selective for myelin-associated glycoprotein. J Neurosci, 2005. 25(4): p. 808-
22.
108. Dimou, L. et al., Nogo-A-deficient mice reveal strain-dependent differences in axonal 
regeneration. J Neurosci, 2006. 26(21): p. 5591-603.
109. Simonen, M. et al., Systemic deletion of the myelin-associated outgrowth inhibitor 
Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron,
2003. 38: p. 201-211.
110. Zheng, B. et al., Lack of Enhanced Spinal Regeneration in Nogo-Deficient Mice. 
Neuron, 2003. 38(2): p. 213-224.
111. Kim, J.-E. et al., Axon Regeneration in Young Adult Mice Lacking Nogo-A/B. Neuron,
2003. 38: p. 187-199.
112. Caroni, P. and M.E. Schwab, Antibody against myelin-associated inhibitor of neurite 
growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron, 
1988.1(1): p. 85-96.
113. Rubin, B.P. et al., A monoclonal antibody (IN-1) which neutralizes neurite growth 
inhibitory proteins in the rat CNS recognizes antigens localized in CNS myelin. J 
Neurocytol, 1994. 23(4): p. 209-17.
114. Schnell, L. and M.E. Schwab, Axonal regeneration in the rat spinal cord produced by 
an antibody against myelin-associated neurite growth inhibitors. Nature, 1990. 
343(6255): p. 269-72.
115. Raineteau, O. et al., Sprouting and regeneration after pyramidotomy and blockade of 
the myelin-associated neurite growth inhibitors Nl 35/250 in adult rats. Eur J 
Neurosci, 1999. 11(4): p. 1486-90.
276
116. Brosamle, C. et al., Regeneration of Lesioned Corticospinal Tract Fibers in the Adult 
Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment J. Neurosci.,
2000. 20(21): p. 8061-8068.
117. Bregman, B. S .e t  al., Recovery from spinal cord injury mediated by antibodies to 
neurite growth inhibitors. Nature, 1995. 378(6556): p. 498-501.
118. Liebscher, T. et al., Nogo-A antibody improves regeneration and locomotion of spinal 
cord-injured rats. Ann Neurol, 2005. 58(5): p. 706-19.
119. von Meyenburg, J. et al., Regeneration and sprouting of chronically injured 
corticospinal tract fibers in adult rats promoted by NT-3 and the mAb IN-1, which 
neutralizes myelin-associated neurite growth inhibitors. Exp Neurol, 1998.154(2): p. 
583-94.
120. Tang, X. et al., Changes in distribution, cell associations, and protein expression 
levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenasdn-C during 
acute to chronic maturation o f spinal cord scar tissue. J Neurosci Res, 2003. 71(3): p. 
427-44.
121. Zhang, Y. et al., Tenascin-C expression and axonal sprouting following injury to the 
spinal dorsal columns in the adult rat. Journal of Neuroscience Research, 1997.
49(4): p. 433-50.
122. Bareyre, F.M. et al., Long-lasting sprouting and gene expression changes induced by 
the monodonal antibody IN-1 in the adult spinal cord. J Neurosci, 2002. 22(16): p. 
7097-110.
123. Kartje, G. L. et al., Corticostriatal plasticity is restricted by myelin-associated neurite 
growth inhibitors in the adult rat. Ann Neurol, 1999. 45(6): p. 778-86.
124. Z'Graggen, W.J. et al., Functional recovery and enhanced corticofugal plasticity after 
unilateral pyramidal tract lesion and blockade of myelin-associated neurite growth 
inhibitors in adult rats. J Neurosci, 1998.18(12): p. 4744-57.
125. Fouad, K. et al., Regenerating corticospinal fibers in the Marmoset (Callitrix jacchus) 
after spinal cord lesion and treatment with the anti-Nogo-A antibody IN-1. Eur J 
Neurosci, 2004. 20(9): p. 2479-82.
126. Huang, D.W. et al., A therapeutic vaccine approach to stimulate axon regeneration in 
the adult mammalian spinal cord. Neuron, 1999. 24(3): p. 639-47.
127. Sicotte, M. et al., Immunization with myelin or recombinant Nogo-66/MAG in alum 
promotes axon regeneration and sprouting after corticospinal tract lesions in the 
spinal cord. Mol Cell Neurosci, 2003. 23(2): p. 251-63.
128. Xu, G. et al., Recombinant DNA vaccine encoding multiple domains related to 
inhibition of neurite outgrowth: a potential strategy for axonal regeneration. J 
Neurochem, 2004. 91(4): p. 1018-23.
129. Kim, J.E. et al., Nogo-66 receptor prevents raphespinal and rubrospinal axon 
regeneration and limits functional recovery from spinal cord injury. Neuron, 2004. 
44(3): p. 439-51.
277
130. Zheng, B. et al., Genetic deletion of the Nogo receptor does not reduce neurite 
inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc Natl Acad 
Sci USA, 2005. 102(4): p. 1205-10.
131. Li, S. and S.M. Strittmatter, Delayed systemic Nogo-66 receptor antagonist promotes 
recovery from spinal cord injury. J Neurosci, 2003. 23(10): p. 4219-27.
132. Li, S. et al., Blockade o f Nogo-66, myelin-associated glycoprotein, and 
oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal 
sprouting and recovery after spinal injury. Journal of Neuroscience, 2004. 24(46): p. 
10511-10520.
133. Davies, S. J. et al., Robust regeneration of adult sensory axons in degenerating white 
matter of the adult rat spinal cord. J Neurosci, 1999.19(14): p. 5810-22.
134. Davies, S. J. et al., Regeneration o f adult axons in white matter tracts of the central 
nervous system. Nature, 1997. 390(6661): p. 680-3.
135. Hunt, D. et al., Nogo Receptor mRNA Expression in Intact and Regenerating CNS 
Neurons. Molecular and Cellular Neuroscience, 2002. 20(4): p. 537-552.
136. Josephson, A. et al., Nogo-receptor gene activity: Cellular localization and 
developmental regulation o f mRNA in mice and humans. Journal of Comparative 
Neurology, 2002. 453(3): p. 292-304.
137. Wright, D.E. and W.D. Snider, Neurotrophin receptor mRNA expression defines 
distinct populations of neurons in rat dorsal root ganglia. J Comp Neurol, 1995. 
351(3): p. 329-38.
138. Moreau-Fauvarque, C. eta!., The transmembrane semaphorin Sema4D/CD100, an 
inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after 
CNS lesion. J Neurosci, 2003. 23(27): p. 9229-39.
139. Terman, J.R. et al., MICALs, a family of conserved flavoprotein oxidoreductases, 
function in plexin-mediated axonal repulsion. Cell, 2002.109(7): p. 887-900.
140. Liu, B.P. and S.M. Strittmatter, Semaphorin-mediated axonal guidance via Rho- 
related G proteins. Curr Opin Cell Biol, 2001.13(5): p. 619-26.
141. Mikule, K. et al., Eicosanoid activation of protein kinase C epsilon: involvement in 
growth cone repellent signaling. J Biol Chem, 2003. 278(23): p. 21168-77.
142. De Winter, F. et al., Injury-induced class 3 semaphorin expression in the rat spinal 
cord. Exp Neurol, 2002. 175(1): p. 61-75.
143. Manitt, C. et al., Widespread expression of netrin-1 by neurons and oligodendrocytes 
in the adult mammalian spinal cord. J Neurosci, 2001. 21(11): p. 3911-22.
144. Wehrle, R. et al., Expression of netrin-1, slit-1 and slit-3 but not of slit-2 after 
cerebellar and spinal cord lesions. Eur J Neurosci, 2005. 22(9): p. 2134-44.
145. Brose, K. et al., Slit proteins bind Robo receptors and have an evolutionarily 
conserved role in repulsive axon guidance. Cell, 1999. 96(6): p. 795-806.
146. Plump, A. S. et al., S litl and Slit2 cooperate to prevent premature midline crossing of 
retinal axons in the mouse visual system. Neuron, 2002. 33(2): p. 219-32.
278
147. Sundaresan, V. et al., Dynamic expression patterns of Robo (Robol and Robo2) in 
the developing murine central nervous system. J Comp Neurol, 2004. 468(4): p. 467-
81.
148. Berry, M. et al., Deposition of scar tissue in the central nervous system. Acta 
Neurochir Suppl (Wien), 1983. 32: p. 31-53.
149. Abnet, K. et al., Interactions between meningeal cells and astrocytes in vivo and in 
vitro. Brain Res Dev Brain Res, 1991. 59(2): p. 187-96.
150. Alonso, G. and A. Privat, Reactive astrocytes involved in the formation of lesional 
scars differ in the mediobasal hypothalamus and in other forebrain regions. J 
Neurosci Res, 1993. 34(5): p. 523-38.
151. Eagle, K. S. ef al., Axonal regeneration and limited functional recovery following 
hippocampal deafferentation. J Comp Neurol, 1995. 363(3): p. 377-88.
152. Kawaja, M.D. and F.H. Gage, Reactive astrocytes are substrates for the growth of 
adult CNS axons in the presence of elevated levels of nerve growth factor. Neuron,
1991. 7(6): p. 1019-30.
153. Saad, B. et al., Astrocyte-derived TGF-beta 2 and NGF differentially regulate neural 
recognition molecule expression by cultured astrocytes. J Cell Biol, 1991.115(2): p. 
473-84.
154. Privat, A. et al., Spinal cord injuries: comments on preventive and curative strategy. 
Agressologie, 1993. 34: p. 64.
155. Wilhelmsson, U. ef al., Absence of glial fibrillary acidic protein and vimentin prevents 
hypertrophy of astrocytic processes and improves post-traumatic regeneration. J 
Neurosci, 2004. 24(21): p. 5016-21.
156. Kalderon, N. and Z. Fuks, Structural recovery in lesioned adult mammalian spinal 
cord by x-irradiation o f the lesion site. Proc Natl Acad Sci USA, 1996. 93(20): p. 
11179-84.
157. Kalderon, N. and Z. Fuks, Severed corticospinal axons recover electrophysiologic 
control of muscle activity after x-ray therapy in lesioned adult spinal cord. Proc Natl 
Acad Sci U S A, 1996. 93(20): p. 11185-90.
158. Ridet, J. L. ef al., Effects o f spinal cord X-irradiation on the recovery of paraplegic rats. 
Exp Neurol, 2000.161(1): p. 1-14.
159. Brewer, K. L. ef al., Neuroprotective effects of interleukin-10 following excitotoxic 
spina! cord injury. Exp Neurol, 1999.159(2): p. 484-93.
160. Canning, D. R. ef al., A potent inhibitor of neurite outgrowth that predominates in the 
extracellular matrix of reactive astrocytes. Int J Dev Neurosci, 1996.14(3): p. 153-75.
161. McKeon, R. J. ef al., The Chondroitin Sulfate Proteoglycans Neurocan and 
Phosphacan Are Expressed by Reactive Astrocytes in the Chronic CNS Glial Scar. J. 
Neurosci., 1999. 19(24): p. 10778-10788.
279
162. Jones, L.L. et al., The chondroitin sulfate proteoglycans neurocan, brevican, 
phosphacan, and versican are differentially regulated following spinal cord injury. Exp 
Neurol, 2003. 182(2): p. 399-411.
163. Junghans, U. et al., Purification o f a meningeal cell-derived chondroitin sulphate 
proteoglycan with neurotrophic activity for brain neurons and its identification as 
biglycan. Eur J Neurosci, 1995. 7(11): p. 2341-50.
164. Davies, J.E. et al., Decorin suppresses neurocan, brevican, phosphacan and NG2 
expression and promotes axon growth across adult rat spinal cord injuries. Eur J 
Neurosci, 2004. 19(5): p. 1226-42.
165. Logan, A. et al., Decorin attenuates gliotic scar formation in the rat cerebral 
hemisphere. Exp Neurol, 1999.159(2): p. 504-10.
166. Hynds, D.L. and D.M. Snow, Neurite outgrowth inhibition by chondroitin sulfate 
proteoglycan: stalling/stopping exceeds turning in human neuroblastoma growth 
cones. Exp Neurol, 1999.160(1): p. 244-55.
167. McKeon, R. J. et al., Injury-induced proteoglycans inhibit the potential for laminin- 
mediated axon growth on astrocytic scars. Exp Neurol, 1995.136(1): p. 32-43.
168. Schmalfeldt, M. et al., Brain derived versican V2 is a potent inhibitor of axonal growth. 
J Cell Sci, 2000.113: p. 807-16.
169. Ughrin, Y.M. et al., Multiple regions of the NG2 proteoglycan inhibit neurite growth 
and induce growth cone collapse. J Neurosci, 2003. 23(1): p. 175-86.
170. Jones, L. L. ef al., NG2 is a major chondroitin sulfate proteoglycan produced after 
spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. 
J Neurosci, 2002. 22(7): p. 2792-803.
171. Moon, L. D. et al., Relationship between sprouting axons, proteoglycans and glial cells 
following unilateral nigrostriatal axotomy in the adult rat. Neuroscience, 2002.109(1): 
p. 101-17.
172. Dow, K. E. et al., Molecular correlates of spinal cord repair in the embryonic chick: 
heparan sulfate and chondroitin sulfate proteoglycans. Exp Neurol, 1994.128(2): p. 
233-8.
173. McKeon, R.J. et al., Reduction of neurite outgrowth in a model of glial scarring 
following CNS injury is correlated with the expression o f inhibitory molecules on 
reactive astrocytes. J Neurosci, 1991.11(11): p. 3398-411.
174. Rudge, J.S. and J. Silver, Inhibition of neurite outgrowth on astroglial scars in vitro. J 
Neurosci, 1990. 10(11): p. 3594-603.
175. Bahr, M. et al., Astrocytes from adult rat optic nerves are nonpermissive for 
regenerating retinal ganglion cell axons. Exp Neurol, 1995.131(2): p. 211-20.
176. Inman, D.M. and O. Steward, Ascending sensory, but not other long-tract axons, 
regenerate into the connective tissue matrix that forms at the site of a spinal cord 
injury in mice. J Comp Neurol, 2003. 462(4): p. 431-49.
280
177. Zhang, Y. et al., Correlation between putative inhibitory molecules at the dorsal root 
entry zone and failure of dorsal root axonal regeneration. Mol Cell Neurosci, 2001. 
17(3): p. 444-59.
178. Lemons, M. L. et al., Chondroitin sulfate proteoglycan immunoreactivity increases 
following spinal cord injury and transplantation. Exp Neurol, 1999.160(1): p. 51-65.
179. Bruckner, G. et al., Acute and long-lasting changes in extracellular-matrix chondroitin- 
sulphate proteoglycans induced by injection of chondroitinase ABC in the adult rat 
brain. Exp Brain Res, 1998.121(3): p. 300-10.
180. Pizzorusso, T. et al., Reactivation o f ocular dominance plasticity in the adult visual 
cortex. Science, 2002. 298(5596): p. 1248-51.
181. Bradbury, E. J .e t  al., Chondroitinase ABC promotes functional recovery after spinal 
cord injury. Nature, 2002. 416(6881): p. 636-640.
182. Moon, L. D. et al., Regeneration of CNS axons back to their target following treatment 
of adult rat brain with chondroitinase ABC. Nat Neurosci, 2001. 4(5): p. 465-6.
183. Yick, L.W. et ai., Axonal regeneration of Clarke's neurons beyond the spinal cord 
injury scar after treatment with chondroitinase ABC. Exp Neurol, 2003.182(1): p. 160-
8.
184. Yick, L. W. et al., Lithium chloride reinforces the regeneration-promoting effect of 
chondroitinase ABC on rubrospinal neurons after spinal cord injury. J Neurotrauma,
2004. 21(7): p. 932-43.
185. Yick, L. W. et al., Chondroitinase ABC promotes axonal regeneration of Clarke's 
neurons after spinal cord injury. Neuroreport, 2000.11(5): p. 1063-7.
186. Caggiano, A. 0. ef al., Chondroitinase ABCI improves locomotion and bladder 
function following contusion injury of the rat spinal cord. J Neurotrauma, 2005. 22(2): 
p. 226-39.
187. Lemons, M. L. et al., Intact aggrecan and chondroitin sulfate-depleted aggrecan core 
glycoprotein inhibit axon growth in the adult rat spinal cord. Exp Neurol, 2003.184(2): 
p. 981-90.
188. Grimpe, B. and J. Silver, A novel DNA enzyme reduces glycosaminoglycan chains in 
the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate 
beyond lesions in the spinal cord. J Neurosci, 2004. 24(6): p. 1393-7.
189. Gavazzi, I. et al., Growth responses of different subpopulations of adult sensory
neurons to neurotrophic factors in vitro. Eur J Neurosci, 1999.11(10): p. 3405-14.
190. Leclere, P. et al., Effects of glial cell line-derived neurotrophic factor on axonal growth 
and apoptosis in adult mammalian sensory neurons in vitro. Neuroscience, 1998. 
82(2): p. 545-58.
191. Cai, D. et al., Prior exposure to neurotrophins blocks inhibition of axonal regeneration 
by MAG and myelin via a cAMP-dependent mechanism. Neuron, 1999. 22(1): p. 89- 
Id .
281
192. Yamashita, T. et al., Neurotrophin binding to the p75 receptor modulates Rho activity
and axonal outgrowth. Neuron, 1999. 24(3): p. 585-93.
193. Yamashita, T. et al., The p75 receptor transduces the signal from myelin-associated
glycoprotein to Rho. J Cell Biol, 2002.157(4): p. 565-70.
194. Fu, S. Y. and T. Gordon, The cellular and molecular basis of peripheral nerve 
regeneration. Mol Neurobiol, 1997.14(1-2): p. 67-116.
195. Snider, W.D. et al., Signaling the pathway to regeneration. Neuron, 2002. 35(1): p. 
13-6.
196. Schwaiger, F.W. et al., Peripheral but not central axotomy induces changes in Janus 
kinases (JAK) and signal transducers and activators of transcription (STAT). Eur J 
Neurosci, 2000. 12(4): p. 1165-76.
197. Cafferty, W. B. et al., Leukemia inhibitory factor determines the growth status of
injured adult sensory neurons. J Neurosci, 2001. 21(18): p. 7161-70.
198. Zhong, J. et al., Sensory impairments and delayed regeneration of sensory axons in 
interleukin-6-deficient mice. J Neurosci, 1999.19(11): p. 4305-13.
199. Romero, M. I. et al., Functional regeneration o f chronically injured sensory afferents 
into adult spinal cord after neurotrophin gene therapy. J Neurosci, 2001. 21(21): p. 
8408-16.
200. Ramer, M.S. e ta i, Functional regeneration of sensory axons into the adult spinal 
cord. Nature, 2000. 403(6767): p. 312-6.
201. Iwaya, K. et al., Neurotrophic agents in fibrin glue mediate adult dorsal root 
regeneration into spinal cord. Neurosurgery, 1999. 44(3): p. 589-95; discussion 595-
6.
202. Ramer, M.S. e ta i,  Neurotrophin-3-mediated regeneration and recovery of 
proprioception following dorsal rhizotomy. Molecular and Cellular Neurosciences, 
2002. 19(2): p. 239-49.
203. Oudega, M. and T. Hagg, Neurotrophins promote regeneration of sensory axons in
the adult rat spinal cord. Brain Res, 1999. 818(2): p. 431-8.
204. Jelsma, T.N. and A.J. Aguayo, Trophic factors. Curr Opin Neurobiol, 1994. 4(5): p.
717-25.
205. Tuszynski, M.H. et al., NT-3 gene delivery elicits growth of chronically injured 
corticospinal axons and modestly improves functional deficits after chronic scar 
resection. Exp Neurol, 2003. 181(1): p. 47-56.
206. Blesch, A. and M.H. Tuszynski, GDNF gene delivery to injured adult CNS motor 
neurons promotes axonal growth, expression of the trophic neuropeptide CGRP, and 
cellular protection. J Comp Neurol, 2001. 436(4): p. 399-410.
207. Liu, Y. et al., Transplants of Fibroblasts Genetically Modified to Express BDNF 
Promote Regeneration of Adult Rat Rubrospinal Axons and Recovery of Forelimb 
Function. J. Neurosci., 1999. 19(11): p. 4370-4387.
282
208. Grill, R. J. et al., Robust Growth of Chronically Injured Spinal Cord Axons Induced by 
Grafts of Genetically Modified NGF-Secreting Cells. Experimental Neurology, 1997. 
148(2): p. 444-452.
209. Coumans, J.V. et al., Axonal regeneration and functional recovery after complete 
spinal cord transection in rats by delayed treatment with transplants and 
neurotrophins. The Journal of Neuroscience, 2001. 21(23): p. 9334-44.
210. Bregman, B. S. et al., Neurotrophic factors increase axonal growth after spinal cord 
injury and transplantation in the adult rat Exp Neurol, 1997.148(2): p. 475-94.
211. Chao, M. V., Neurotrophins and their receptors: a convergence point for many 
signalling pathways. Nat Rev Neurosci, 2003. 4(4): p. 299-309.
212. Plunet, W. et ai., Promoting axonal regeneration in the central nervous system by 
enhancing the cell body response to axotomy. J Neurosci Res, 2002. 68(1): p. 1-6.
213. Blesch, A. et al., Neurotrophic factors, gene therapy, and neural stem cells for spinal 
cord repair. Brain Research Bulletin, 2002. 57(6): p. 833-8.
214. Novikova, L.N. ef al., Survival effects of BDNF and NT-3 on axotomized rubrospinal 
neurons depend on the temporal pattern o f neurotrophin administration. Eur J 
Neurosci, 2000.12(2): p. 776-80.
215. Priestley, J.V. et al., Stimulating regeneration in the damaged spinal cord. Journal of 
Physiology, Paris, 2002. 96(1-2): p. 123-33.
216. Gautier, S.E. et al., Poly(alpha-hydroxyacids) for application in the spinal cord: 
resorbability and biocompatibility with adult rat Schwann cells and spinal cord. J 
Biomed Mater Res, 1998. 42(4): p. 642-54.
217. Li, Y. and G. Raisman, Schwann cells induce sprouting in motor and sensory axons 
in the adult rat spinal cord. J Neurosci, 1994.14(7): p. 4050-63.
218. Xu, X. M. et al., Regrowth o f axons into the distal spinal cord through a Schwann-cell- 
seeded mini-channel implanted into hemisected adult rat spinal cord. Eur J Neurosci, 
1999.11(5): p. 1723-40.
219. McDonald, J. W. et al., Repair of the injured spinal cord and the potential of embryonic 
stem cell transplantation. J Neurotrauma, 2004. 21(4): p. 383-93.
220. Horner, P. J .e ta i., Proliferation and differentiation of progenitor cells throughout the 
intact adult rat spinal cord. J Neurosci, 2000. 20(6): p. 2218-28.
221. Wichterle, H. et al., Directed differentiation of embryonic stem cells into motor 
neurons. Cell, 2002. 110(3): p. 385-97.
222. McDonald, J.W. et al., Transplanted embryonic stem cells survive, differentiate and 
promote recovery in injured rat spinal cord. Nat Med, 1999. 5(12): p. 1410-2.
223. Cao, Q. L. ef al., Pluripotent stem cells engrafted into the normal or lesioned adult rat 
spinal cord are restricted to a glial lineage. Exp Neurol, 2001.167(1): p. 48-58.
224. Ramon-Cueto, A. ef al., Functional recovery of paraplegic rats and motor axon 
regeneration in their spinal cords by olfactory ensheathing glia. Neuron, 2000. 25(2): 
p. 425-35.
283
225. Li, Y. et al., Repair of adult rat corticospinal tract by transplants of olfactory 
ensheathing cells. Science, 1997. 277(5334): p. 2000-2.
226. The Eph Nomenclature Committee, Nomenclature site for the Eph receptors and their 
ligands, the ephrins. 2003, http://ephmomenclature.med.harvard.edu/.
227. Dodelet, V.C. and E.B. Pasquale, Eph receptors and ephrin ligands: embryogenesis 
to tumorigenesis. Oncogene, 2000.19(49): p. 5614-9.
228. Flanagan, J.G. and P. Vanderhaeghen, The Ephrins and Eph Receptors in Neural 
Development. Annu. Rev. Neurosci., 1998. 21(1): p. 309-345.
229. Zhou, R., The Eph family receptors and ligands. Pharmacology & Therapeutics, 1998. 
77(3): p. 151-81.
230. Wilkinson, D.G., Multiple roles of EPH receptors and ephrins in neural development. 
Nat Rev Neurosci, 2001. 2(3): p. 155-64.
231. Pasquale, E.B., Eph-ephrin promiscuity is now crystal clear. Nat Neurosci, 2004. 7(5): 
p. 417-418.
232. Himanen, J.P. et al., Repelling class discrimination: ephrin-A5 binds to and activates 
EphB2 receptor signaling. Nat Neurosci, 2004. 7(5): p. 501-9.
233. Gale, N.W. et al., Elk-L3, a novel transmembrane ligand for the Eph family of receptor 
tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain 
segments. Oncogene, 1996. 13(6): p. 1343-52.
234. Dottori, M. et al., EphA4 (Sek1) receptor tyrosine kinase is required for the 
development of the corticospinal tract. Proc Natl Acad Sci U S A, 1998. 95(22): p. 
13248-53.
235. Kullander, K. et al., Ephrin-B3 is the midline barrier that prevents corticospinal tract 
axons from recrossing, allowing for unilateral motor control. Genes & Development, 
2001.15(7): p. 877-88.
236. Yokoyama, N. et al., Forward signaling mediated by ephrin-B3 prevents contralateral 
corticospinal axons from recrossing the spinal cord midline. Neuron, 2001. 29(1): p. 
85-97.
237. Schmucker, D. and S.L. Zipursky, Signaling downstream of Eph receptors and ephrin 
ligands. Cell, 2001. 105(6): p. 701-4.
238. Schlessinger, J., Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000.103(2): p. 
211-225.
239. Gille, H. et al., A repressor sequence in the juxtamembrane domain of Fit-1 (VEGFR- 
1) constitutively inhibits vascular endothelial growth factor-dependent 
phosphatidylinositol 3-kinase activation and endothelial cell migration. EMBO 
Journal, 2000. 19(15): p. 4064-4073.
240. Wybenga-Groot, L. E .e t  al., Structural Basis for Autoinhibition of the EphB2 Receptor 
Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region. Cell, 2001.
106(6): p. 745-757.
284
241. Kullander, K. et al., Kinase-Dependent and Kinase-Independent Functions of EphA4 
Receptors in Major Axon Tract Formation In Vivo. Neuron, 2001. 29(1): p. 73-84.
242. Davis, S. et al., Ligands for EPH-related receptor tyrosine kinases that require 
membrane attachment or clustering for activity. Science, 1994. 266(5186): p. 816-9.
243. Holland, S. J. et al., Bidirectional signalling through the EPH-family receptor Nuk and 
its transmembrane ligands. Nature, 1996. 383(6602): p. 722-725.
244. Bruckner, K. et al., Tyrosine phosphorylation of transmembrane ligands for Eph 
receptors. Science, 1997. 275(5306): p. 1640-3.
245. Stein, E. et al., Eph receptors discriminate specific ligand oligomers to determine 
alternative signaling complexes, attachment, and assembly responses. Genes and 
Development, 1998.12(5): p. 667-678.
246. Himanen, J.P. and D.B. Nikolov, Eph signaling: a structural view. Trends in 
Neurosciences, 2003. 26(1): p. 46-51.
247. Himanen, J.P. et al., Crystal structure of an Eph receptor-ephrin complex. Nature, 
2001.414(6866): p. 933-8.
248. Patel, B.N. and D.L. Van-Vactor, Axon guidance: the cytoplasmic tail. Current Opinion 
in Cell Biology, 2002.14(2): p. 221-9.
249. Noren, N.K. and E.B. Pasquale, Eph receptor-ephrin bidirectional signals that target 
Ras and Rho proteins. Cellular Signalling, 2004.16(6): p. 655-666.
250. Lehmann, M. et al., Inactivation of Rho Signaling Pathway Promotes CNS Axon 
Regeneration. J. Neurosci., 1999. 19(17): p. 7537-7547.
251. Meyer, G. and E.L. Feldman, Signaling mechanisms that regulate actin-based motility 
processes in the nervous system. Journal of Neurochemistry, 2002. 83(3): p. 490- 
503.
252. Giniger, E., How do Rho family GTPases direct axon growth and guidance? A 
proposal relating signaling pathways to growth cone mechanics. Differentiation; 
Research in Biological Diversity, 2002. 70(8): p. 385-96.
253. Holmberg, J. et al., Regulation of repulsion versus adhesion by different splice forms 
of an Eph receptor. Nature, 2000. 408(6809): p. 203-6.
254. Klein, R., Excitatory Eph receptors and adhesive ephrin ligands. Current Opinion in 
Cell Biology, 2001. 13(2): p. 196-203.
255. Cowan, C.A. and M. Henkemeyer, Ephrins in reverse, park and drive. Trends in Cell 
Biology, 2002. 12(7): p. 339-46.
256. Holmberg, J. and J. Frisen, Ephrins are not only unattractive. Trends in 
Neurosciences, 2002. 25(5): p. 239-43.
257. Knoll, B. and U. Drescher, Ephrin-As as receptors in topographic projections. Trends- 
Neurosci, 2002. 25(3): p. 145-9.
258. Kullander, K. and R. Klein, Mechanisms and functions of Eph and ephrin signalling. 
Nature Reviews Molecular Cell Biology, 2002. 3(7): p. 475-86.
285
259. Shamah, S.M. et al., EphA receptors regulate growth cone dynamics through the 
novel guanine nucleotide exchange factor ephexin. Cell, 2001.105(2): p. 233-44.
260. Bruckner, K. et al., EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft 
membrane microdomains. Neuron, 1999. 22(3): p. 511-24.
261. Kalo, M.S. and E.B. Pasquale, Signal transfer by Eph receptors. Cell and Tissue 
Research, 1999. 298(1): p. 1-9.
262. Lin, D. et al., The carboxyl terminus of B class ephrins constitutes a PDZ domain 
binding motif. J Biol Chem, 1999. 274(6): p. 3726-33.
263. Lu, Q. et al., Ephhn-B reverse signaling is mediated by a novel PDZ-RGS protein and 
selectively inhibits G protein-coupled chemoattraction. Cell, 2001.105(1): p. 69-79.
264. Takasu, M.A. et al., Modulation o f NMDA receptor-dependent calcium influx and gene 
expression through EphB receptors. Science, 2002. 295(5554): p. 491-5.
265. Murai, K.K. and E.B. Pasquale, Can Eph receptors stimulate the mind? Neuron,
2002. 33(2): p. 159-62.
266. KnOII, B. and U. Drescher, Src family kinases are involved in EphA receptor-mediated 
retinal axon guidance. Journal of Neuroscience, 2004. 24(28): p. 6248-6257.
267. Sahin, M. et al., Eph-dependent tyrosine phosphorylation o f ephexin 1 modulates 
growth cone collapse. Neuron, 2005. 46: p. 191-204.
268. Schmidt, A. and A. Hall, Guanine nucleotide exchange factors for Rho GTPases: 
turning on the switch. Genes Dev., 2002.16(13): p. 1587-1609.
269. Penzes, P. et al., Rapid Induction o f Dendritic Spine Morphogenesis by trans- 
Synaptic EphrinB-EphB Receptor Activation of the Rho-GEF Kalirin. Neuron, 2003. 
37(2): p. 263-274.
270. Irie, F. and Y. Yamaguchi, EphB receptors regulate dendritic spine development via 
intersectin, Cdc42 and N-WASP. Nat Neurosci, 2002. 5(11): p. 1117-8.
271. Mellitzer, G. et al., Eph receptors and ephrins restrict cell intermingling and 
communication. Nature, 1999. 400(6739): p. 77-81.
272. Kalo, M.S. et al., In Vivo Tyrosine Phosphorylation Sites of Activated Ephrin-B1 and 
EphB2 from Neural Tissue. J. Biol. Chem., 2001. 276(42): p. 38940-38948.
273. Palmer, A. et al., EphrinB phosphorylation and reverse signaling: regulation by Src 
kinases and PTP-BL phosphatase. Molecular Cell, 2002. 9(4): p. 725-37.
274. Davy, A. et al., Compartmentalized signaling by GPI-anchored ephrin-A5 requires the 
Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev, 1999.13(23): p. 3125-
35.
275. Knoll, B. etai., A role for the EphA family in the topographic targeting of vomeronasal 
axons. Development, 2001.128(6): p. 895-906.
276. Henkemeyer, M. et al., Nuk controls pathfinding of commissural axons in the 
mammalian central nervous system. Cell, 1996. 86(1): p. 35-46.
277. Homberger, M. R. et al., Modulation of EphA receptor function by coexpressed 
ephrinA ligands on retinal ganglion cell axons. Neuron, 1999. 22(4): p. 731-42.
286
278. Yin, Y. et al., EphA receptor tyrosine kinases interact with co-expressed ephrin-A 
ligands in cis. Neuroscience Research, 2004.48(3): p. 285-295.
279. Eberhart, J. et al., Expression of EphA4, ephrin-A2 and ephrin-A5 during axon 
outgrowth to the hindlimb indicates potential roles in pathfinding. Developmental 
Neuroscience, 2000. 22(3): p. 237-50.
280. Iwamasa, H. et al., Expression of Eph receptor tyrosine kinases and their ligands in 
chick embryonic motor neurons and hindlimb muscles. Dev Growth Differ, 1999. 
41(6): p. 685-98.
281. Battaglia, A. et al., EphB receptors and ephrin-B ligands regulate spinal sensory 
connectivity and modulate pain processing. Nat Neurosci, 2003. 6(4): p. 339-40.
282. Rodger, J. et al., EphA/ephrin-A interactions during optic nerve regeneration: 
restoration of topography and regulation of ephrin-A2 expression. Mol Cell Neurosci,
2004. 25(1): p. 56-68.
283. Pratt, R.L. and M.S. Kinch, Activation of the EphA2 tyrosine kinase stimulates the 
MAP/ERK kinase signaling cascade. Oncogene, 2002. 21(50): p. 7690-7699.
284. Tong, J. et al., Manipulation of EphB2 Regulatory Motifs and SH2 Binding Sites 
Switches MAPK Signaling and Biological Activity. J. Biol. Chem., 2003. 278(8): p. 
6111-6119.
285. Lawrenson, I.D. et al., Ephrin-A5 induces rounding, blebbing and de-adhesion of 
EphA3-expressing 293T and melanoma cells by Crkll and Rho-mediated signalling. J 
Cell Sci, 2002. 115(5): p. 1059-1072.
286. Miralles, F. et al., Actin Dynamics Control SRF Activity by Regulation of Its 
Coactivator MAL. Cell, 2003. 113(3): p. 329-342.
287. Egea, J. et al., Regulation of EphA4 Kinase Activity Is Required for a Subset of Axon 
Guidance Decisions Suggesting a Key Role for Receptor Clustering in Eph Function. 
Neuron, 2005. 47(4): p. 515-528.
288. Wimmer-Kleikamp, S.H. et al., Recruitment of Eph receptors into signaling clusters 
does not require ephrin contact. J Cell Biol, 2004. 164(5): p. 661-6.
289. Coonan, J. R. ef al., Development and reorganization of corticospinal projections in 
EphA4 deficient mice. J Comp Neurol, 2001. 436(2): p. 248-62.
290. Kullander, K. et al., Role of EphA4 and EphrinB3 in Local Neuronal Circuits That 
Control Walking. Science, 2003. 299(5614): p. 1889-1892.
291. Mackarehtschian, K. et al., Regional differences in the developing cerebral cortex 
revealed by ephrin-A5 expression. Cereb Cortex, 1999. 9(6): p. 601-10.
292. Vanderhaeghen, P. and F. Polleux, Developmental mechanisms patterning 
thalamocortical projections: intrinsic, extrinsic and in between. Trends in 
Neurosciences, 2004. 27(7): p. 384-391.
293. Dufour, A. et al., Area Specificity and Topography of Thalamocortical Projections Are 
Controlled by ephrin/Eph Genes. Neuron, 2003. 39(3): p. 453-465.
287
294. Gao, P.-P. et al., Regulation of topographic projection in the brain: Elf-1 in the 
hippocamposeptal system. PNAS, 1996. 93(20): p. 11161-11166.
295. Zhang, J. H. et al., Detection of ligands in regions anatomically connected to neurons 
expressing the Eph receptor Bsk: potential roles in neuron-target interaction. The 
Journal of Neuroscience, 1996. 16(22): p. 7182-92.
296. Helmbacher, F. et al., Targeting of the EphA4 tyrosine kinase receptor affects 
dorsal/ventral pathfinding of limb motor axons. Development, 2000.127(15): p. 3313- 
3324.
297. Eberhart, J. et al., Ephrin-A5 Exerts Positive or Inhibitory Effects on Distinct Subsets 
of EphA4-Posrtive Motor Neurons. J. Neurosci., 2004. 24(5): p. 1070-1078.
298. Kania, A. and T.M. Jessell, Topographic motor projections in the limb imposed by LIM  
homeodomain protein regulation of ephrin-A.EphA interactions. Neuron, 2003. 38(4): 
p. 581-96.
299. Donoghue, M. J. et al., The Eph kinase ligand AL-1 is expressed by rostral muscles 
and inhibits outgrowth from caudal neurons. Molecular and Cellular Neurosciences,
1996. 8(2-3): p. 185-98.
300. Feng, G. et al., Roles for ephrins in positionally selective synaptogenesis between 
motor neurons and muscle fibers. Neuron, 2000. 25(2): p. 295-306.
301. Wang, H. et al., Development of inhibition by ephrin-A5 on outgrowth of embryonic 
spinal motor neurites. Journal of Neurobiology, 2000. 47(3): p. 233-43.
302. Lai, K.O. ef al., Expression of Eph receptors in skeletal muscle and their localization 
at the neuromuscular junction. Mol Cell Neurosci, 2001.17(6): p. 1034-47.
303. Frisen, J. et al., Ephrin-A5 (AL-1/RAGS) is essential for proper retinal axon guidance 
and topographic mapping in the mammalian visual system. Neuron, 1998. 20(2): p. 
235-43.
304. Brennan, C. ef al., Two Eph receptor tyrosine kinase ligands control axon growth and 
may be involved in the creation of the retinotectal map in the zebrafish. Development 
(Cambridge, England), 1997.124(3): p. 655-64.
305. Mann, F. ef al., Topographic mapping in dorsoventral axis of the Xenopus retinotectal 
system depends on signaling through ephrin-B ligands. Neuron, 2002. 35(3): p. 461-
73.
306. Pittman, A. and C.B. Chien, Understanding dorsoventral topography: backwards and 
forwards. Neuron, 2002. 35(3): p. 409-11.
307. Holt, C.E. Axon guidance in the visual system, in Society for Neuroscience Annual 
Meeting. 2001. San Diego.
308. Wang, H.U. and D. J. Anderson, Eph family transmembrane ligands can mediate 
repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron,
1997. 18(3): p. 383-96.
309. Krull, C.E. ef al., Interactions of Eph-related receptors and ligands confer rostrocaudal 
pattern to trunk neural crest migration. Curr Biol, 1997. 7(8): p. 571-80.
288
310. Chen, Z. Y. et al., Abnormal hippocampal axon bundling in EphB receptor mutant 
mice. J Neurosci, 2004. 24(10): p. 2366-74.
311. Cowan, C. A. et al., Ephrin-B2 reverse signaling is required for axon pathfinding and 
cardiac valve formation but not early vascular development. Dev Biol, 2004. 271(2): 
p. 263-71.
312. Coonan, J. R. et al., Role of EphA4 in defining the position of a motoneuron pooI 
within the spinal cord. J Comp Neurol, 2003. 458(1): p. 98-111.
313. Kiehn, 0. and K. Kullander, Central Pattern Generators Deciphered by Molecular 
Genetics. Neuron, 2004. 41(3): p. 317-321.
314. Butt, S.J. and 0. Kiehn, Functional identification of interneurons responsible for left- 
right coordination of hindlimbs in mammals. Neuron, 2003. 38(6): p. 953-63.
315. Sobel, R. A., Ephrin A receptors and ligands in lesions and normal-appearing white 
matter in multiple sclerosis. Brain Pathology, 2005.15(1): p. 35-45.
316. Hafner, C. et al., Differential gene expression of Eph receptors and ephrins in benign 
human tissues and cancers. Clin Chem, 2004. 50(3): p. 490-9.
317. Xiao, D. et al., Ephrin/Eph receptor expression in brain of adult nonhuman primates: 
Implications for neuroadaptation. Brain Res, 2005.
318. Willson, C. A .e t  al., Upregulation o f EphA receptor expression in the injured adult rat 
spinal cord. Cell Transplantation, 2002.11(3): p. 229-39.
319. Greferath, U. ef al., Developmental expression of EphA4-tyroslne kinase receptor in 
the mouse brain and spinal cord. Gene Expr Patterns, 2002. 2(3-4): p. 267-74.
320. Karam, S.D. et al., EphA4 is not required for Purkinje cell compartmentation. 
Developmental Brain Research, 2002.135(1-2): p. 29-38.
321. Martone, M. E. et al., Immunolocalization o f the receptor tyrosine kinase EphA4 in the 
adult rat central nervous system. Brain Research, 1997. 771(2): p. 238-250.
322. Rogers, J.H. et al., Eph receptors and ephrins demarcate cerebellar lobules before 
and during their formation. Mech Dev, 1999. 87(1-2): p. 119-28.
323. Liebl, D. J. et al., mRNA expression of ephrins and Eph receptor tyrosine kinases in 
the neonatal and adult mouse central nervous system. Journal of Neuroscience 
Research, 2003. 71(1): p. 7-22.
324. Mori, T. et al., Differential expressions of the eph family of receptor tyrosine kinase 
genes (sek, elk, eck) in the developing nervous system of the mouse. Molecular Brain 
Research, 1995. 29(2): p. 325-335.
325. Yue, Y. et al., Specification of Distinct Dopaminergic Neural Pathways: Roles of the 
Eph Family Receptor EphB 1 and Ligand Ephrin-B2. J. Neurosci., 1999.19(6): p. 
2090-2101.
326. Lai, C. and G. Lemke, An extended family of protein-tyrosine kinase genes 
differentially expressed in the vertebrate nervous system. Neuron, 1991. 6(5): p. 691- 
704.
289
327. Mori, T. et al., Localization of novel receptor tyrosine kinase genes of the eph family, 
MDK1 and its splicing variant, in the developing mouse nervous system. Molecular 
Brain Research, 1995. 34(1): p. 154-160.
328. Taylor, V. et al., Expression and developmental regulation of Ehk-1, a neuronal Elk­
like receptor tyrosine kinase in brain. Neuroscience, 1994. 63(1): p. 163-78.
329. Zhou, R. et al., Isolation and characterization of Bsk, a growth factor receptor-like 
tyrosine kinase associated with the limbic system. Journal of Neuroscience Research,
1994. 37(1): p. 129-43.
330. Fabes, J. et al., Accumulation o f the inhibitory receptor EphA4 may prevent 
regeneration of corticospinal tract axons following lesion. Eur J Neurosci, 2006. 23(7): 
p. 1721-30.
331. Benson, M. D. et al., Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth.
PNAS, 2005.102(30): p. 10694-10699.
332. Wang, Y. ef al., Induction o f ephrin-B1 and EphB receptors during denervation- 
induced plasticity in the adult mouse hippocampus. European Journal of 
Neuroscience, 2005. 21(9): p. 2336-2346.
333. Klein, R., Eph/ephrin signaling in morphogenesis, neural development and plasticity. 
Current Opinion in Cell Biology, 2004.16(5): p. 580-9.
334. Grunwald, I.C. et al., Hippocampal plasticity requires postsynaptic ephrinBs. Nat 
Neurosci, 2004. 7(1): p. 33-40.
335. Murai, K. K. et al., Control o f hippocampal dendritic spine morphology through ephrin- 
A3/EphA4 signaling. Nature Neuroscience, 2003. 6(2): p. 153-160.
336. Ethell, I.M. et al., EphB/Syndecan-2 Signaling in Dendritic Spine Morphogenesis. 
Neuron, 2001. 31(6): p. 1001-1013.
337 Henkemeyer, M. et al., Multiple EphB receptor tyrosine kinases shape dendritic
spines in the hippocampus. J Cell Biol, 2003.163(6): p. 1313-26.
338. Murai, K.K. and E.B. Pasquale, Eph receptors, ephrins, and synaptic function. 
Neuroscientist, 2004.10(4): p. 304-314.
339. Contractor, A. et al., Trans-synaptic Eph receptor-ephrin signaling in hippocampal 
mossy fiber LTP. Science, 2002. 296(5574): p. 1864-9.
340. Gerlai, R. ef al., Regulation of learning by EphA receptors: a protein targeting study. 
Journal of Neuroscience, 1999.19(21): p. 9538-9549.
341. Wahl, S. ef al., Ephrin-A5 induces collapse of growth cones by activating Rho and 
Rho kinase. J Cell Biol, 2000. 149(2): p. 263-70.
342. Vanek, P. ef al., Increased lesion-induced sprouting of corticospinal fibres in the 
myelin-free rat spinal cord. Eur J Neurosci, 1998.10(1): p. 45-56.
343. Park, S. ef al., Aberrant axonal projections in mice lacking EphA8 (Eek) tyrosine 
protein kinase receptors. EMBO J., 1997.16(11): p. 3106-3114.
344. Conover, J. C. et al., Disruption of Eph/ephrin signaling affects migration and 
proliferation in the adult subventricular zone. Nat Neurosci, 2000. 3(11): p. 1091-7.
290
345. Gerlai, R., Eph receptors and neural plasticity. Nat Rev Neurosci, 2001. 2(3): p. 205-
9.
346. Xu, B. et al., EphA/ephrin-A interactions regulate epileptogenesis and activity- 
dependent axonal sprouting in adult rats. Mol Cell Neurosci, 2003. 24(4): p. 984-99.
347. Aasheim, H.C. et al., A splice variant of human ephrin-A4 encodes a soluble molecule 
that is secreted by activated human B lymphocytes. Blood, 2000. 95(1): p. 221-30.
348. Luo, H. et al., EphB6 crosslinking results in costimulation of T cells. J Clin Invest, 
2002.110(8): p. 1141-50.
349. Sharfe, N. etai., Ephrin stimulation modulates Tcell chemotaxis. Eur J Immunol,
2002. 32(12): p. 3745-55.
350. Huynh-Do, U. et al., Surface densities of ephrin-B1 determine EphB1-coupled 
activation of cell attachment through alpha-V-beta-3 and alpha-V-beta-1 integrins. 
EMBO J, 1999.18(8): p. 2165-73.
351. Zou, J.X. et al., An Eph receptor regulates integrin activity through R-Ras. PNAS, 
1999. 96(24): p. 13813-8.
352. Huai, J. and U. Drescher, An ephrin-A-dependent signaling pathway controls integrin 
function and is linked to the tyrosine phosphorylation of a 120-kDa protein. Journal of 
Biological Chemistry, 2001. 276(9): p. 6689-94.
353. Magal, E. et al., B61, a ligand for the Eck receptor protein-tyrosine kinase, exhibits 
neurotrophic activity in cultures of rat spinal cord neurons. Journal of Neuroscience 
Research, 1996. 43(6): p. 735-44.
354. Stichel, C.C. and H.W. Muller, The CNS lesion scar: new vistas on an old 
regeneration barrier. Cell Tissue Res, 1998. 294(1): p. 1-9.
355. Eng, L. F. et al., Astrocyte activation and fibrous gliosis: glial fibrillary acidic protein 
immunostaining of astrocytes following intraspinal cord grafting of fetal CNS tissue. 
Prog Brain Res, 1987. 71: p. 439-55.
356. Reier, P. J. and J.D. Houle, The glial scar: its bearing on axonal elongation and 
transplantation approaches to CNS repair. Adv Neurol, 1988. 47: p. 87-138.
357. Xu, Q. et al., In vivo cell sorting in complementary segmental domains mediated by 
Eph receptors and ephrins. Nature, 1999. 399(6733): p. 267-71.
358. Dubreuil, C. I. et al., Rho activation patterns after spinal cord injury and the role of 
activated Rho in apoptosis in the central nervous system. Journal of Cell Biology,
2003. 162(2): p. 233-243.
359. Miao, H. et al., Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK 
pathway. Nat Cell Biol, 2001. 3(5): p. 527-30.
360. Balasingam, V. and V.W. Yong, Attenuation of astroglial reactivity by interleukin-10. J 
Neurosci, 1996. 16(9): p. 2945-55.
361. Bechmann, I. and R. Nitsch, Astrocytes and microglial cells incorporate degenerating 
fibers following entorhinal lesion: a light, confocal, and electron microscopical study 
using a phagocytosis-dependent labeling technique. Glia, 1997. 20(2): p. 145-54.
291
362. Deller, T. et al., Up-regulation of astrocyte-derived tenascin-C correlates with neurite 
outgrowth in the rat dentate gyrus after unilateral entorhinal cortex lesion. 
Neuroscience, 1997. 81(3): p. 829-46.
363. Savaskan, N.E. et al., Myelin does not influence the choice behaviour of entorhinal 
axons but strongly inhibits their outgrowth length in vitro. The European Journal of 
Neuroscience, 1999.11(1): p. 316-26.
364. Haas, C. A. et al., Entorhinal cortex lesion in adult rats induces the expression of the 
neuronal chondroitin sulfate proteoglycan neurocan in reactive astrocytes. J 
Neurosci, 1999.19(22): p. 9953-63.
365. Deller, T. and M. Frotscher, Lesion-induced plasticity of central neurons: sprouting of 
single fibres in the rat hippocampus after unilateral entorhinal cortex lesion. Prog 
Neurobiol, 1997. 53(6): p. 687-727.
366. Wang, Y. et al., Semi-quantitative expression analysis of ephrin mRNAs in the 
deafferented hippocampus. Molecular Brain Research, 2003.120(1): p. 79-83.
367. Caron, E. and A. Hall, Identification of two distinct mechanisms of phagocytosis 
controlled by different Rho GTPases. Science, 1998. 282(5394): p. 1717-21.
368. Etienne-Manneville, S. and A. Hall, Rho GTPases in cell biology. Nature, 2002. 
420(6916): p. 629-35.
369. Bergemann, A. D. ef al., Ephrin-B3, a ligand for the receptor EphB3, expressed at the 
midline of the developing neural tube. Oncogene, 1998.16(4): p. 471-80.
370. Imondi, R. et al., Complementary expression of transmembrane ephrins and their 
receptors in the mouse spinal cord: a possible role in constraining the orientation of 
longitudinally projecting axons. Development (Cambridge, England), 2000.127(7): p. 
1397-410.
371. Dergham, P. et al., Rho signaling pathway targeted to promote spinal cord repair. J 
Neurosci, 2002. 22(15): p. 6570-7.
372. Ellezam, B. et al., Inactivation of intracellular Rho to stimulate axon growth and 
regeneration. Prog Brain Res, 2002.137: p. 371-80.
373. Gao, P.-P. et al., Ephrin-dependent growth and pruning of hippocampal axons. 
PNAS, 1999. 96(7): p. 4073-4077.
374. Castellani, V. et al., Dual action of a ligand for Eph receptor tyrosine kinases on 
specific populations of axons during the development of cortical circuits. J Neurosci,
1998. 18(12): p. 4663-72.
375. Gao, P. P. ef al., Ephrins stimulate or inhibit neurite outgrowth and survival as a 
function of neuronal cell type. Journal of Neuroscience Research, 2000. 60(4): p. 
427-36.
376. Moreno Flores, M.T. ef al., Ephrin-B1 promotes dendrite outgrowth on cerebellar 
granule neurons. Mol Cell Neurosci, 2002. 20(3): p. 429-46.
292
377. Hindges, R. et al., EphB forward signaling controls directional branch extension and 
arborization required for dorsal-ventral retinotopic mapping. Neuron, 2002. 35: p. 
475—487.
378. Holash, J. A. et al., Reciprocal expression of the Eph receptor Cek5 and its ligand(s) 
in the early retina. Dev Biol, 1997.182(2): p. 256-69.
379. King, C.E. et al., Transient up-regulation of retinal Eph A3 and EphA5, but not ephrin- 
A2, coincides with re-establishment of a topographic map during optic nerve 
regeneration in goldfish. Experimental Neurology, 2003.183(2): p. 593-599.
380. Biervert, C. et al., Semiquantitative expression analysis of ephrine-receptor tyrosine 
kinase mRNA's in a rat model of traumatic brain injury. Neuroscience Letters, 2001. 
315(1-2): p. 25-28.
381. Miranda, J. D .e ta i., Induction of Eph B3 after spinal cord injury. Experimental 
Neurology, 1999.156(1): p. 218-22.
382. Knoll, B. et al., Graded expression patterns ofephrin-As in the superior colliculus 
after lesion of the adult mouse optic nerve. Mechanisms of Development, 2001. 
106(1-2): p. 119-127.
383. Rodger, J. et al., Expression of ephrin-A2 in the superior colliculus and EphA5 in the 
retina following optic nerve section in adult rat Eur J Neurosci, 2001.14(12): p. 1929- 
1936.
384. Wang, A.G. et al., Change of gene expression profiles in the retina following optic 
nerve injury. Brain Res Mol Brain Res, 2002.101(1-2): p. 82-92.
385. Moreno-Flores, M.T. and F. Wandosell, Up-regulation of Eph tyrosine kinase 
receptors after excitotoxic injury in adult hippocampus. Neuroscience, 1999. 91(1): p. 
193-201.
386. Wohlfahrt, J.G. et al., Ephrin-A 1 suppresses Th2 cell activation and provides a 
regulatory link to lung epithelial cells. J Immunol, 2004.172(2): p. 843-50.
387. Smith, L.M. et al., Eph A3 is induced by CD28 and IGF-1 and regulates cell adhesion. 
Exp Cell Res, 2004. 292(2): p. 295-303.
388. Savaskan, N.E. and R. Nitsch, Molecules involved in reactive sprouting in the 
hippocampus. Rev Neurosci, 2001.12(3): p. 195-215.
389. Murai, K.K. et al., Targeting the EphA4 receptor in the nervous system with 
biologically active peptides. Mol Cell Neurosci, 2003. 24(4): p. 1000-11.
390. Guest, J.D. et al., Influence of IN-1 antibody and acidic FGF-fibrin glue on the 
response of injured corticospinal tract axons to human Schwann cell grafts. Journal of 
Neuroscience Research, 1997. 50(5): p. 888-905.
391. Silver, J. and J.H. Miller, Regeneration beyond the glial scar. Nat Rev Neurosci,
2004. 5(2): p. 146-56.
392. Fitch, M.T. and J. Silver, Glial cell extracellular matrix: boundaries for axon growth in 
development and regeneration. Cell Tissue Res, 1997. 290(2): p. 379-84.
293
393. Tang, B.L., Inhibitors of neuronal regeneration: mediators and signaling mechanisms. 
Neurochem Int, 2003. 42(3): p. 189-203.
394. Nystrom, B. and J.E. Berglund, Spinal cord restitution following compression injuries 
in rats. Acta Neurol Scand, 1988. 78(6): p. 467-72.
395. Paxinos, G. and C. Watson, The Rat Brain in Stereotaxic Coordinates. 1986: New 
York Academic Press.
396. Demaison, C. et al., High-level transduction and gene expression in hematopoietic 
repopulating cells using a human immunodeficiency [correction of imunodeficiency] 
virus type 1-based lentiviral vector containing an internal spleen focus forming virus 
promoter. Hum Gene Ther, 2002.13(7): p. 803-13.
397. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT- 
PCR. Nucl. Acids Res., 2001. 29(9): p. e45-.
398. Bartsch, S. et al., Expression oftenascin in the developing and adult cerebellar 
cortex. J. Neurosci., 1992. 12(3): p. 736-749.
399. Zhang, Y. et al., Molecular basis of interactions between regenerating adult rat 
thalamic axons and Schwann cells in peripheral nerve grafts I. Neural cell adhesion 
molecules. J Comp Neurol, 1995. 361(2): p. 193-209.
400. de Castro, R.C., Jr. et al., Metalloproteinase increases in the injured rat spinal cord. 
Neuroreport, 2000.11(16): p. 3551-4.
401. Duchossoy, Y. et al., MMP-related gelatinase activity is strongly induced in scar 
tissue of injured adult spinal cord and forms pathways for ingrowing neurites. Mol Cell 
Neurosci, 2001. 17(6): p. 945-56.
402. Carpenter, M. K. et al., Ligands for EPH-related tyrosine kinase receptors are 
developmental^ regulated in the CNS. Journal of Neuroscience Research, 1995. 
42(2): p. 199-206.
403. Parker, M. et al., Reverse endocytosis of transmembrane ephrin-B ligands via a 
clathrin-mediated pathway. Biochem Biophys Res Commun, 2004. 323(1): p. 17-23.
404. Zimmer, M. et al., EphB-ephrinB bi-directional endocytosis terminates adhesion 
allowing contact mediated repulsion. 2003. 5(10): p. 869-878.
405. Mann, F. et al., B-type Eph receptors and ephrins induce growth cone collapse 
through distinct intracellular pathways. J Neurobiol, 2003. 57(3): p. 323-36.
406. Moran, P. and I.W. Caras, Fusion of sequence elements from non-anchored proteins 
to generate a fully functional signal for glycophosphatidylinositol membrane anchor 
attachment. The Journal of Cell Biology, 1991.115(6): p. 1595-600.
407. Mizushima, S. and S. Nagata, pEF-BOS, a powerful mammalian expression vector. 
Nucleic Acids Research (Online), 1990.18(17): p. 5322.
408. Turner, D., pCS2+ Vector Resource. 2003, 
http://sitemaker.umich.edu/dltumer.vectors.
409. Flanagan, J.G. and P. Leder, The kit ligand: a cell surface molecule altered in steel 
mutant fibroblasts. Cell, 1990. 63(1): p. 185-94.
294
410. Cheng, H.J. and J.G. Flanagan, Identification and cloning of ELF-1, a 
developm ental expressed ligand for the Mek4 and Sek receptor tyrosine kinases. 
Cell, 1994. 79(1): p. 157-68.
411. Berger, J. et al., Secreted placental alkaline phosphatase: a powerful new 
quantitative indicator of gene expression in eukaryotic cells. Gene, 1988. 66(1): p. 1-
10.
412. Miska, W. and R. Geiger, Synthesis and characterization of luciferin derivatives for 
use in bioluminescence enhanced enzyme immunoassays. New ultrasensitive 
detection systems for enzyme immunoassays, I. Journal of Clinical Chemistry and 
Clinical Biochemistry, 1987. 25(1): p. 23-30.
413. Brennan, C. and J. Fabes, Alkaline phosphatase fusion proteins as affinity probes for 
protein localization studies. Science STKE, 2003(168).
414. Ciossek, T. et al., Eph receptor-ligand interactions are necessary for guidance of 
retinal ganglion cell axons in vitro. The European Journal of Neuroscience, 1998. 
10(5): p. 1574-80.
415. Klostermann, S. and F. Bonhoeffer, Investigations of signaling pathways in axon 
growth and guidance. Perspectives On Developmental Neurobiology, 1996. 4(2-3): p. 
237-52.
416. Yamada, T. et al., Analysis of ephhn-A2 in the chick retinotectal projection using a 
function-blocking monoclonal antibody. Journal of Neurobiology, 2001. 47(4): p. 245-
54.
417. Vielmetter, J. et al., In vitro assay to test differential substrate affinities of growing 
axons and migratory cells. Experimental Brain Research, 1990. 81(2): p. 283-7.
418. Chadbom, N. et al., Direct measurement of local raised subplasmalemmal calcium 
concentrations in growth cones advancing on an N-cadherin substrate. The European 
Journal of Neuroscience, 2002.15(12): p. 1891-8.
419. Vielmetter, J. and C.A. Stuermer, Goldfish retinal axons respond to position-specific 
properties of tectal cell membranes in vitro. Neuron, 1989. 2(4): p. 1331-9.
420. Walter, J. et al., Recognition of position-specific properties of tectal cell membranes 
by retinal axons in vitro. Development (Cambridge, England), 1987.101(4): p. 685-
96.
421. Dijkstra, S. et al., Selective stimulation of dendrite outgrowth from identified 
corticospinal neurons by homotopic astrocytes. Neuroscience, 1999. 92(4): p. 1331- 
1342.
422. Muir, E. et al., Increased axon growth through astrocyte cell lines transfected with 
urokinase. Glia, 1998. 23(1): p. 24-34.
423. Gallo, G. et al., Transient PKA activity is required for initiation but not maintenance of 
BDNF-mediated protection from nitric oxide-induced growth-cone collapse. J 
Neurosci, 2002. 22(12): p. 5016-23.
295
424. Myshkin, E. and B. Wang, Chemometrical Classification of Ephrin Ligands and Eph 
Kinases Using GRID/CPCA Approach. Journal of Chemical Information and 
Computer Sciences, 2003. 43(3): p. 1004-10.
425. Himanen, J. P. ef al., Crystal structure of the ligand-binding domain of the receptor 
tyrosine kinase EphB2. Nature, 1998. 396(6710): p. 486-91.
426. Chrencik, J. E .e ta i., Structure and thermodynamic characterization of the 
EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor 
specificity. Structure, 2006.14(2): p. 321-30.
427. Nikolov, D.B. et al., Crystal structure of the ephrin-B1 ectodomain: implications for 
receptor recognition and signaling. Biochemistry, 2005. 44(33): p. 10947-53.
428. Nathan, A. et al., Tissue Engineered Perivascular Endothelial Cell Implants Regulate 
Vascular Injury. PNAS, 1995. 92(18): p. 8130-8134.
429. Lu, P. et al., BDNF-expressing marrow stromal cells support extensive axonal growth 
at sites of spinal cord injury. Experimental Neurology, 2005.191(2): p. 344-360.
430. Cao, L. et al., Olfactory ensheathing cells genetically modified to secrete GDNF to 
promote spinal cord repair. Brain, 2003.
431. Jaeger, C. B .e t  al., Growth of tumour cell lines in polymer capsules: ultrastructure of 
encapsulated PC12 cells. Journal of Neurocytology, 1992. 21(7): p. 469-480.
432. Corpet, F., Multiple sequence alignment with hierarchical clustering. Nucleic Acids 
Res, 1988. 16(22): p. 10881-90.
433. Leenen, L.P. et al., A detailed morphometrical analysis of the pyramidal tract of the 
rat. Brain Res, 1985. 359(1-2): p. 65-80.
434. Harding, G.W. and A. L. Towe, Fiber analysis of the pyramidal tract of the laboratory 
rat. Exp Neurol, 1985. 87(3): p. 503-18.
435. Bass, N.H. and P. Lundborg, Postnatal development of bulk flow in the cerebrospinal 
fluid system of the albino rat: clearance of carboxyl-( 14 Cjinulin after intrathecal 
infusion. Brain Res, 1973. 52: p. 323-32.
436. Keyvan-Fouladi, N. et al., Delayed repair of corticospinal tract lesions as an assay for 
the effectiveness of transplantation of Schwann cells. Glia, 2005. 51(4): p. 306-11.
437. Schwab, J.M. et al., Differential Cellular Accumulation of Connective Tissue Growth 
Factor Defines a Subset of Reactive Astrocytes, Invading Fibroblasts, and Endothelial 
Cells Following Central Nervous System Injury in Rats and Humans. Journal of 
Neurotrauma, 2001. 18(4): p. 377-388.
438. Webb, A.A. and G.D. Muir, Unilateral dorsal column and rubrospinal tract injuries 
affect overground locomotion in the unrestrained rat. European Journal of 
Neuroscience, 2003.18(2): p. 412-422.
439. Weidner, N. et al., Spontaneous corticospinal axonal plasticity and functional 
recovery after adult central nervous system injury. Proc Natl Acad Sci U S A, 2001. 
98(6): p. 3513-8.
296
